BEFORE THE

INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATI ON:	CROWNE PLAZA HOTEL SFO
	1177 AI RPORT BOULEVARD
	BURLINGAME, CALIFORNIA

DATE: FRI DAY, JANUARY 30, 2009 9 A. M.

REPORTER: BETH C. DRAIN, CSR CSR. NO. 7152

BRS FILE NO.: 82458

INDEX

I TEM DESCRIPTION	PAGE NO.
CALL TO ORDER.	3
PLEDGE OF ALLEGIANCE.	3
ROLL CALL.	3
CONTINUATION OF DISCUSSION FROM 1/29	41
ACTION ITEMS:	
CONSIDERATION OF RECOMMENDATIONS FROM GRANTS WORKING GROUP ON BRIDGES TO STEM CEI RESEARCH AND TRAINING GRANT II APPLICATIONS	
CONSIDERATION OF RECOMMENDATIONS FROM GRANTS WORKING GROUP ON TOOLS & TECHNOLOGY APPLICATIONS.	135
REPORTS:	
PRESENTATION ON CIRM COLLABORATIVE FUNDING POLICY.	209
ACTION ITEMS:	
CONSIDERATION OF POLICIES AND IMPLEMENTATION PLAN/PROCESSES FOR CIRM LOAN PROGRAM, INCLUDING BUT NOT LIMITED TO THE LOAN ADMINISTRATION POLICY AND THE ROLE OF DELEGATED UNDERWRITERS/FINANCIAL SERVICE PROVIDERS.	151
CONSIDERATION OF LOAN-RELATED TERMS FOR DISEASE TEAMS RFA.	170
2	

I N D E X (CONT'D.)

CONSIDERATION OF NEW SCIENTIFIC MEMBERS FOR GRANTS WORKING GROUP.	177
CONSIDERATION OF A PUBLIC PROCESS FOR OBTAINING BOARD MEMBER, INDUSTRY, AND PUBLIC INPUT REGARDING AN UPDATE TO THE SCIENTIFIC STRATEGIC PLAN.	195
CONSIDERATION OF REGULATORY AMENDMENTS TO THE CIRM MEDICAL AND ETHICAL STANDARDS REGULATIONS, INCLUDING OVERSIGHT AND CONSE REQUIREMENTS FOR USE OF BLASTOCYSTS AND SO CELLS.	197 ENT DMATIC
CONSIDERATION OF SUPPLEMENTAL GRANT AWARDS FOR MEDICAL SCHOOL LOAN REPAYMENTS TO THOS PHYSICIAN-SCIENTISTS WHO WERE AWARDED NEW FACULTY I AND II RESEARCH GRANTS.	

	BARRISTERS' REPORTING SERVICE
1	SAN FRANCISCO, CALIFORNIA; FRIDAY, JANUARY 30, 2009
2	9 A.M.
3	
4	CHAIRMAN KLEIN: ALL RIGHT. WELCOME THIS
5	MORNING TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE
6	MEDICINE BOARD MEETING. THANK YOU ALL FOR COMING.
7	AND, MELISSA, IF YOU COULD PROCEED WITH THE PLEDGE
8	OF ALLEGIANCE AND ROLL CALL.
9	(THE PLEDGE OF ALLEGIANCE.)
10	MS. KING: RICARDO AZZIZ.
11	DR. AZZIZ: HERE.
12	MS. KING: ROBERT BIRGENEAU. FLOYD BLOOM.
13	GORDON GILL FOR DAVID BRENNER.
14	DR. GILL: PRESENT.
15	MS. KING: JACOB LEVIN FOR SUSAN BRYANT.
16	DR. LEVIN: PRESENT.
17	MS. KING: MARSHA CHANDLER. MARCY FEIT.
18	MS. FEIT: HERE.
19	MS. KING: MICHAEL FRIEDMAN.
20	DR. FRI EDMAN: HERE.
21	MS. KING: LEEZA GIBBONS. MICHAEL
22	GOLDBERG.
23	MR. GOLDBERG: HERE.
24	MS. KING: SAM HAWGOOD.
25	DR. HAWGOOD: HERE.
	4

		BARRISTERS' REPORTING SERVICE
1	MS	S. KING: BOB KLEIN.
2	CH	AIRMAN KLEIN: HERE.
3	MS	S. KING: SHERRY LANSING.
4	MS	S. LANSING: HERE.
5	MS	S. KING: GERALD LEVEY. TED LOVE. ED
6	PENHOET.	
7	DF	R. PENHOET: HERE.
8	MS	S. KING: PHIL PIZZO. CLAIRE POMEROY.
9	DF	R. POMEROY: HERE.
10	MS	S. KING: FRANCISCO PRIETO.
11	DF	R. PRI ETO: HERE.
12	MS	S. KING: CARMEN PULIAFITO.
13	DF	R. PULIAFITO: HERE.
14	MS	S. KING: ROBERT QUINT. JOHN REED.
15	DF	R. REED: HERE.
16	MS	S. KING: DUANE ROTH.
17	MF	R. ROTH: HERE.
18	MS	S. KING: JOAN SAMUELSON. DAVID
19	SERRANO-SEWE	ELL.
20	MF	R. SERRANO-SEWELL: HERE.
21	MS	S. KING: JEFF SHEEHY.
22	MF	R. SHEEHY: HERE.
23	MS	S. KING: JONATHAN SHESTACK. AND OSWALD
24	STEWARD.	
25	MS	S. KING: FOR THE RECORD, DR. BIRGENEAU
		_
		5

HAS JOINED THE MEETING.

1

CHAIRMAN KLEIN: THANK YOU VERY MUCH. 2 AND WHERE ARE WE, COUNSEL? WE HAVE ONE OR MORE. 3 WHILE WE'RE WAITING FOR DR. PIZZO, JUST TO TIE TOGETHER 4 LAST NIGHT'S MEETING WITH THIS MORNING'S MEETING, 5 I'D LIKE TO SAY THAT WE HAD A DISCUSSION LAST NIGHT 6 7 ON THE PATH TO DARKNESS AND THE PATH TO LIGHT, IN 8 DR. PIZZO'S WORDS. AS I SAID THIS MORNING AT THE 9 BEGINNING OF THE SPOTLIGHT, I VIEW IT AS THE PATH 10 THROUGH DARKNESS.

IMPORTANTLY, ONE OF THE TOOLS WE HAVE 11 POTENTIALLY OR RESOURCES WE HAVE POTENTIALLY IS IN 12 13 WORKING WITH THE FEDERAL GOVERNMENT WHICH HAS BEEN EXTRAORDINARILY SUPPORTIVE. WHILE WE'RE DEFERRING 14 TO THE NEXT MEETING A FULL DISCUSSION ON THE 15 16 INTERFACE WITH THE FEDERAL GOVERNMENT, IT'S 17 IMPORTANT TO NOTE THAT, WHILE THERE ARE A NUMBER OF GROUPS AROUND THE COUNTRY THAT ARE FOCUSED ON THE 18 19 NATIONAL INSTITUTES OF HEALTH AND INCREASING THAT FUNDING, AND CERTAINLY THAT IS ONE OF OUR EMPHASES 20 21 AS WELL, THERE IS A CONSTRAINT INHERENT IN THE 22 MATHEMATICS OF THE JOB CREATION BILL THAT 23 CONGRESSMAN OBEY EDUCATED ME ON WHEN I WAS IN 24 WASHINGTON A LITTLE OVER TWO WEEKS AGO. AND THAT 25 CONSTRAINT IS THAT WHEN YOU RAISE THE BASELINE FOR

6

1	THE NIH, YOU'RE CHARGED ON A BUDGETARY SYSTEM NOT
2	FOR ONE YEAR OF FUNDING, BUT FOR FOUR YEARS OF
3	FUNDI NG.
4	SO IF YOU'RE LOOKING AT THE JOB CREATIONS
5	IN THE FIRST YEAR FROM RAISING THE NIH, YOU HAVE A
6	NEGATIVE LEVERAGE BECAUSE THEY'RE COUNTING IT AS IF
7	YOU HAVE TO PUT OUT FOUR YEARS OF FUNDING TO ACHIEVE
8	THAT GOAL. IF, IN FACT, THEY DO THE MATH ON A
9	TWO-YEAR BASIS IN TERMS OF JOB CREATION, YOU STILL
10	HAVE TWO ADDITIONAL YEARS YOU'RE CHARGED WITH.
11	I SAW CONGRESSMAN OBEY, WHO'S CHAIRMAN OF
12	THE HOUSE APPROPRIATIONS, THREE HOURS BEFORE THE
13	MARKUP. HE WAS VERY GENEROUS AND SPENT AN HOUR WITH
14	ME DISCUSSING THE WHOLE ISSUE OF THE STATES BECAUSE
15	HE SAW THE STATES POTENTIALLY AS A WAY TO ADVANCE
16	MORE FUNDS TO BIOMEDICAL RESEARCH THAN HE COULD GET
17	CONSENSUS IN SUPPORTING FOR THE NIH. THE NIH FIGURE
18	HE WAS AT AT THAT MEETING WAS A BILLION. I
19	ENCOURAGED HIM TO INCREASE IT FURTHER.
20	THE SPEAKER PELOSI STRONGLY TOOK A
21	POSITION TO INCREASE NIH FUNDING. I HAD MET WITH
22	WENDALL PRIMUS, HER HEAD POLICYMAKER, AND THE
23	SPEAKER; AND, IN FACT, THE HOUSE DID COME UP IN THE
24	MARKUP THREE HOURS LATER WITH A HIGHER NIH FIGURE
25	BECAUSE OF A LOT OF DEDICATED EFFORTS BY SCIENTIFIC
	7

7

1	GROUPS, BY UNIVERSITIES, BY PATIENT GROUPS AROUND
2	THE COUNTRY.
3	BUT THERE ARE VERY FEW INDIVIDUALS, AN
4	EXTREMELY LIMITED GROUP, WHO ARE BACK IN WASHINGTON
5	DEALING WITH THE STATE'S POTENTIAL COMPLEMENTARY
6	ROLE IN THIS BIOMEDICAL RESEARCH. AND WE CERTAINLY
7	NEED AN AGGRESSIVE CRISIS LEVEL OF PRESENCE IN
8	WASHINGTON BECAUSE IT'S NOT REALLY WHAT HAPPENS OVER
9	THE PHONE. IT'S WHAT HAPPENS IN PERSON AND NOT JUST
10	WHAT HAPPENS AT THE STAFF LEVEL.
11	I'VE DISCUSSED WITH A COUPLE OF BOARD
12	MEMBERS THE FACT THAT THE STAFF IS IN THESE TIMES AN
13	EXTREME FILTER ON INFORMATION GETTING TO THE
14	CONGRESSMEN, CONGRESSWOMEN, AND THE SENATORS. IT IS
15	CRITICAL, AND I MAY ASK TO DRAFT A NUMBER OF THE
16	BOARD MEMBERS IN A COMPLEMENTARY IN A ROLE
17	SUPPORTING THE STATES IN A COMPLEMENTARY ROLE TO THE
18	NI H.
19	OUR EFFORTS IN WASHINGTON ARE NOT GOING TO
20	BE NECESSARILY LIMITED TO THE STIMULUS BILL, THE
21	OMNIBUS BILL, WHICH CARRIES THE BUDGET BEYOND THE
22	CONTINUING RESOLUTIONS THAT END IN MARCH THROUGH THE
23	REST OF THE FEDERAL FISCAL YEAR AND THE 2010 BUDGET.
24	OUR ROLE IN WASHINGTON IS GOING TO HAVE TO BE
25	CARRIED IF, IN FACT, THE STATES ARE GOING TO BENEFIT

8

1	EVEN THROUGH THEIR INSTITUTIONS DOWN TO THE LEVEL OF
2	THE AGENCIES THAT ADMINISTER AND IMPLEMENT THESE
3	FEDERAL PROGRAMS.
4	A SINGLE LINE CAN BE ABSOLUTELY CRITICAL.
5	IF THAT LINE IN THE CAPITAL RESEARCH PROGRAM
6	INCLUDES UNIVERSITIES AND NONPROFIT INSTITUTIONS FOR
7	CAPITAL FUNDING OF NEW CONSTRUCTION AND IT'S IN THE
8	COMMITTEE REPORTS WHICH EXPANDS ON THE BILL ITSELF,
9	THEN OUR INSTITUTIONS WHO NEED CAPITAL FUNDING FOR
10	RESEARCH FACILITIES CAN POTENTIALLY ACCESS THOSE
11	FUNDS. THAT LINE IS NOT IN THE BILL ITSELF. THAT
12	LINE IS PUT IN THE COMMITTEE REPORTS AT A VERY LATE
13	HOUR.
14	IT'S IMPORTANT FOR US TO UNDERSTAND THAT
15	IN THE COMPETITION FOR RESOURCES, WE HAVE A GREAT
16	STORY, BUT WE ARE GOING TO NEED TO SPEAK UP. THE
17	GOVERNOR OF THE STATE OF WISCONSIN, JIM DOYLE, IS A
18	GREAT ADVOCATE. THE INDIVIDUALS REPRESENTING
19	MASSACHUSETTS ARE GREAT ADVOCATES, BUT THERE ARE
20	VERY FEW STATES THAT ARE ACTUALLY FIELDING
21	INDIVIDUALS IN WASHINGTON DEALING WITH HOW THE
22	STATES CAN SERVE AS COMPLEMENTARY BIOMEDICAL OR IN
23	THIS CASE STEM CELL RESEARCH FUNDING PARTNERS.
24	THERE ARE 32 STATES THAT HAVE BIOMEDICAL
25	RESEARCH FUNDING PROGRAMS OF SOME KIND, EITHER LOAN
	9

i	
1	PROGRAMS OR GRANT PROGRAMS. THERE ARE ABOUT 18
2	STATES THAT HAVE SOME FORM, ALTHOUGH IN MANY CASES
3	NASCENT FORMS, OF STEM CELL RESEARCH PROGRAMS.
4	WHAT I WOULD LIKE TO EMPHASIZE ON THE
5	POSITIVE SIDE, DR. PIZZO'S PATH TO LIGHT, IS THAT
6	THE RECEPTION IN WASHINGTON FOR STATE FUNDING OF
7	BIOMEDICAL RESEARCH AND STEM CELL RESEARCH IN
8	PARTICULAR IS PHENOMENAL. WHEN I WAS BACK THERE TWO
9	WEEKS AGO, DESPITE VOTES GOING ON CONSTANTLY,
10	COMMITTEES MEETING, THE PREPARATIONS FOR THE
11	INAUGURATION THE FOLLOWING WEEK, I THINK IN A PERIOD
12	OF FOUR DAYS, I WAS ABLE TO SEE ABOUT 15 OR 20
13	SENATORS AND APPROXIMATELY TEN HOUSE MEMBERS,
14	INCLUDING THE LEADERSHIP OF THE KEY COMMITTEES IN
15	THE SENATE AND THE LEADERSHIP IN THE HOUSE.
16	THE AVAILABILITY IS THERE TO US, BUT WE
17	NEED TO BE THERE PHYSICALLY, AND WE'RE GOING TO NEED
18	TO HAVE A VERY MAJOR PRESENCE. HAVING LAWYERS
19	REPRESENT YOU IN WASHINGTON IS VALUABLE AS A
20	TECHNICAL AND AS A SUPPORT TOOL. IT IS NOT A
21	SUBSTITUTE FOR ADVOCACY, INCLUDING BOARD MEMBER
22	ADVOCACY. THE ATTITUDE OF SENATORS AND CONGRESSMEN
23	TO ADVOCATES AND BOARD MEMBERS OF BOARDS LIKE OUR
24	OWN IS THAT WE'RE HERE DEDICATED TO A MISSION. OUR
25	PRIMARY MISSION IS TO ADVANCE MEDICAL RESEARCH.

10

1	WE'RE HERE FOR PUBLIC SERVICE JUST LIKE THEY ARE
2	HERE IN PUBLIC SERVICE. WE HAVE A POWERFUL VOICE.
3	THE TECHNICAL SUPPORTING AND
4	ADMINISTRATIVE PROCESS THAT LAWYERS CAN HELP US WITH
5	IN WASHINGTON TO MOVE PROGRAMS DOWNSTREAM TO MAKE
6	SURE THAT THEY'RE GOING TO DELIVER FUNDS AS THE
7	REPRESENTATIVES INTENDED IS AN IMPORTANT SUPPORT
8	FUNCTION, BUT THERE IS NO SUBSTITUTE FOR THE ACTUAL
9	ADVOCACY OF INDIVIDUALS ON THIS BOARD AND/OR
10	SUPPORTING DISEASE GROUPS OR OTHER ORGANIZATIONS.
11	I'D LIKE TO SPECIFICALLY ASK THE BOARD
12	MEMBERS TO THINK ABOUT WHEN THEY CAN BE AVAILABLE.
13	THIS IS NOT A PROCESS OF JUST GETTING THE STIMULUS
14	BILL THROUGH. THIS IS NOT A PROCESS OF JUST GETTING
15	THE '09 BUDGET BILL THROUGH. THIS IS NOT A PROCESS
16	OF JUST GETTING THE 2010 BUDGET THROUGH. THERE'S
17	ALSO THE SUBSEQUENT YEAR BUDGET. TWENTY-FOUR HOURS
18	AGO I WAS ON THE PHONE WITH A SENIOR PERSON IN THE
19	WHITE HOUSE WHO I'VE KNOWN FOR A NUMBER OF YEARS.
20	HIS ADVICE TO ME WAS GO AFTER EVERY PROGRAM. YOU
21	HAVE ON THE MERITS AN EXTREMELY APPEALING AND
22	JUSTIFIED ARGUMENT WITHIN THE PUBLIC POLICY CONTEXT
23	OF THIS ADMINISTRATION. GO AFTER EVERY ONE OF THEM,
24	GO AFTER IT INTENSELY, AND REALIZE THAT YOU MAY GET
25	ONE OUT OF TWO OR THREE PROGRAMS WHERE YOU FINALLY

11

BARRISTERS' REPORTING SERVICE GET THE FUNDING THROUGH. 1 2 SO IT'S GOING TO BE A TOUGH PROCESS. IT'S GOING TO TAKE A TREMENDOUS AMOUNT OF EFFORT. AND 3 THE EFFORT WILL BE UNRELENTING IN THE NEXT TWO YEARS 4 BECAUSE, AS WE DISCUSSED LAST NIGHT, IT IS A PATH 5 THROUGH DARKNESS, AND IT WILL TAKE MORE THAN A FEW 6 7 HOURS OF EVERYONE'S TIME ON THIS BOARD. 8 WITH THAT, I THINK WE HAVE A -- I THINK WE 9 HAVE A QUORUM, BUT I'M GOING TO ASK DR. TROUNSON FOR 10 HIS COMMENT. DR. TROUNSON: THANK YOU, CHAIR. JUST ONE 11 12 CORRECTION FROM YESTERDAY. JUST ONE CORRECTION FROM 13 YESTERDAY. IN SCENARIO 1 IS INCLUDED THE FACILITIES COMMITMENTS TO THE LAST STAGE EXCEPT FOR A VERY 14 SMALL AMOUNT, EXCEPT FOR A VERY SMALL AMOUNT. AND 15 16 SO I'M NOT SURE WHY THAT SMALL AMOUNT IS NOT 17 INCLUDED, BUT IT'S ALL IN SCENARIO 1. SO ALL OUR COMMITMENTS ON THE FACILITIES, ON THE FACILITIES 18

19 PROGRAMS, ARE IN SCENARIO 1 AND, HENCE, WOULD BE IN20 SCENARIO 2 AND 3.

CHAIRMAN KLEIN: SO VERY SPECIFICALLY,
THOSE INSTITUTIONS THAT DID NOT GET FRONT-END
FUNDING ON A DISCOUNTED PROGRAM, THEY ARE IN THAT
SCENARIO 1 CASH FLOW THAT WE WERE DISCUSSING LAST
NIGHT.

12

1	DR. PIZZO: BOB, I JUST WANT TO FOLLOW UP
2	ON YOUR COMMENTS, WHICH ARE HELPFUL. I SUSPECT THAT
3	ACTUALLY THERE ARE MANY PEOPLE AT THIS TABLE WHO'VE
4	PERSONALLY SPENT A LOT OF TIME MEETING WITH MEMBERS
5	IN CONGRESS. IF MY EXPERIENCE IS REMINISCENT OF
6	ANYONE ELSE, I'VE BEEN ON A REGULAR BASIS OVER THE
7	PAST 15 YEARS AND EVEN LOTS MORE WHEN I WAS AT
8	BETHESDA. AND I THINK THAT ONE THING THAT HAS
9	CHANGED FOR SURE HAS BEEN, AND THIS BEGAN BACK IN
10	2006, IS THE INCREASED, AGAIN, SUPPORT FOR
11	BIOMEDICAL RESEARCH BY THE CONGRESS DESPITE THE
12	ANTISCIENCE MOOD THAT WAS STILL PERVASIVE IN
13	WASHINGTON.
14	BUT THAT SAID, I WANT TO JUST MAKE SURE
15	THAT WE THINK ABOUT WHAT WE'RE SEEKING VIS-A-VIS
16	STATE VERSUS FEDERAL GOVERNMENT. I DON'T THINK I
17	HAVE, NOR DO I SUSPECT ANYONE HERE DOES, ANY DOUBT
18	ABOUT THE IMPORTANCE OF WHAT PROP 71 HAS BROUGHT TO
19	THE AGENDA OF STEM CELL RESEARCH. SO I THINK THAT
20	GOES WITHOUT SAYING. I ALSO DON'T HAVE ANY DOUBT
21	ABOUT WHAT HAS MADE THE UNITED STATES THROUGH NOW
22	THE LEADER IN BIOMEDICAL RESEARCH IN THE WORLD,
23	WHICH HAS BEEN THE STRENGTH OF FEDERAL SUPPORT
24	THROUGH THE NIH, THE NSF, AND OTHER FEDERAL
25	AGENCI ES.

13

1	AND I ALSO, WHILE I'D LOVE TO THINK ABOUT
2	COMPLEMENTARY INTERACTIONS, I WANT TO JUST SHARE A
3	FEAR THAT IT WOULD BE VERY EASY FOR THE GOVERNMENT,
4	PARTICULARLY IN TIMES OF DIFFICULTY, TO SAY, WELL,
5	WE'LL JUST SHED SOME OF THIS WORK TO THE STATES.
6	LET THEM PICK UP THE BURDEN. SO IF WE TAKE ON AN
7	ARGUMENT THAT SAYS WE WANT TO EXPAND THE STATE
8	CONTRIBUTIONS TO BIOMEDICAL RESEARCH, WE MAY FIND A
9	VERY WELCOMING VOICE IN WASHINGTON; BUT IN THE LONG
10	RUN, THAT MAY INADVERTENTLY SABOTAGE THE STRENGTH OF
11	ORGANIZATIONS LIKE THE NIH, WHICH WILL HAVE
12	DISASTROUS COMPLICATIONS GOING FORWARD.
13	SO I WANT TO JUST BE SURE THAT WE THINK
14	MINDFULLY ABOUT WHAT WE'RE DOING. WE DO HAVE A
15	SHORT-TERM PROBLEM IN CALIFORNIA. WE DO HAVE WE
16	HAVE TAKEN A LEAD IN STEM CELL RESEARCH THAT'S
17	FILLED IN A VITAL GAP, BUT I THINK OUR GOALS AS
18	INDIVIDUALS HAS TO BE TO ECHO SUPPORT FOR WHAT HAS
19	MADE THIS NATION THE LEADER IN BIOSCIENCE, WHICH IS
20	THE STRENGTH AND INTEGRITY OF OUR NATIONAL
21	INSTITUTES OF HEALTH.
22	CHAIRMAN KLEIN: I THINK IT'S VERY
23	IMPORTANT TO EMPHASIZE YOUR POINT, THAT WE HAVE
24	EMPHASIZED THAT THE NIH IS THE BACKBONE OF THIS
25	COUNTRY'S BIOMEDICAL RESEARCH, AND WE NEED TO
	14

1	MAXIMIZE WHATEVER NIH FUNDING CAN BE ACHIEVED AND IN
2	AN ORDERLY FASHION, AS YOU'VE PREVIOUSLY EMPHASIZED.
3	WHAT WE'RE LOOKING AT HERE IS ALSO NOT
4	UNLIMITED ON THE STATE SIDE. IT HAS TO BE WHAT THE
5	STATES CAN CURRENTLY SHOW THAT THEY HAVE THE
6	INFRASTRUCTURE, THE PROVEN INFRASTRUCTURE, TO
7	HANDLE. OUTSIDE OF CALIFORNIA, WISCONSIN,
8	MASSACHUSETTS, AND A FEW OTHER STATES, THAT'S VERY
9	LIMITED. ON A RELATIVE SCALE TO THE NIH, IT'S
10	EXTREMELY LIMITED, BUT IT IS AN IMPORTANT
11	COMPLEMENTARY CONTRIBUTION.
12	SO IT'S VERY CLEAR WHAT OUR EMPHASIS IS
13	STRATEGICALLY FOR THE CONTINUITY OF OUR PROGRAM AND
14	FOR THE CONTINUITY OF OTHER STEM CELL PROGRAMS
15	AROUND THE COUNTRY. THE STATES' DOLLARS THAT ARE
16	NECESSARY FOR THAT CONTINUITY ARE RELATIVELY SMALL
17	DOLLARS IN THE SEVEN OR \$800 BILLION THAT ARE BEING
18	ADDRESSED.
19	MS. KING: EXCUSE ME. CAN I JUST CHECK,
20	SHERRY, BEFORE YOU START? DR. ROME, ARE YOU ON THE
21	LINE?
22	DR. ROME: I'M HERE, YES.
23	MS. KING: EXCELLENT. SO FOR THE RECORD,
24	DR. LEONARD ROME IS JOINING FOR DR. LEVEY FROM UCLA.
25	MS. LANSING: I THINK WE ALSO HAVE TO BE
	15

1	MINDFUL OF THE CHALLENGE THAT IS OUTLINED IN THE
2	ARTICLE AS WELL, WHICH IS THE PRESIDENT HAS STATED
3	THAT HE WILL LIFT THE BAN ON STEM CELL RESEARCH.
4	HE'S BEEN GOOD ON ALL OF HIS PROMISES SO FAR, SO I
5	HAVE NO REASON TO DOUBT THAT HE WILL NOT BE GOOD ON
6	THIS AS WELL. THEN THE FUNDING WILL BE LOOKED AT, I
7	THINK, I CAN'T PREDICT FOR SURE, BUT LOGICALLY WILL
8	BE LOOKED AT SOMETHING THAT COMES FROM THE NATIONAL
9	INSTITUTE OF HEALTH.

AND THEN I THINK WE, WRONGLY SO, WILL BE 10 11 QUESTIONED AS TO WHAT OUR PARTICULAR CIRM DOES. AND I THINK THAT IN OUR LOBBYING EFFORTS AND IN ALL OF 12 13 OUR PUBLIC COMMUNICATIONS, IT IS VERY IMPORTANT THAT OUR MISSION BE SEEN AS NEEDED AND STILL RELEVANT AND 14 NOT AS SOMETHING THAT HAS BEEN TAKEN CARE OF BY THE 15 16 NATIONAL GOVERNMENT. SO I THINK THAT IS SOMETHING 17 THAT WE ALL KNOW. AND THIS ARTICLE, YOU KNOW, ALSO STATES ONE OF THE WAYS THAT WE'RE HELPFUL, CERTAINLY 18 19 NOT THE ONLY WAY.

BUT I THINK THE VOTERS HAVE SPOKEN. THIS IS WHAT THE VOTERS OF CALIFORNIA WISH THEIR DOLLARS TO GO FOR. THAT HAS BEEN SOMETHING THEY HAVE MADE QUITE CLEAR, AND WE HAVE A MISSION THAT WE HAVE TO COMPLETE NO MATTER WHAT HAPPENS AT THE FEDERAL LEVEL, WHICH WILL ONLY BE GOOD NEWS FOR US.

16

1	CHAIRMAN KLEIN: DR. FRIEDMAN.
2	DR. FRIEDMAN: MR. CHAIRMAN, I DON'T WANT
3	TO PROLONG THIS, BUT JUST A COUPLE OF QUICK POINTS.
4	ONE IS THAT I REALLY ENDORSE WHAT THE PREVIOUS
5	SPEAKERS HAVE SAID, BUT WHAT I'D LIKE US TO DO IS TO
6	HAVE A VERY CLEARLY ARTICULATED SET OF SPEAKING
7	POINTS THAT WE ALL USE. YOUR POINT ABOUT MANY
8	PEOPLE WANTING TO PARTICIPATE I THINK IS GOOD. IT
9	MAGNIFIES THE EFFECT.
10	THE CHANCE FOR MISSTATEMENT AND
11	MISCOMMUNICATION AND MISUNDERSTANDING IS EXTREMELY
12	HIGH. WE ALL HAVE DIFFERENT VISIONS OF WHAT WE
13	WOULD LIKE. I ABSOLUTELY WOULD NOT LIKE US TO TRY
14	AND CRAFT THAT MESSAGE HERE. I THINK THIS IS THE
15	WRONG PLACE TO TRY AND DO IT. I DO ASK YOU TO
16	PLEASE, EITHER WITH A STANDING OR APPOINT SOME
17	SUBCOMMITTEE, VERY SIMPLE SET OF SPEAKING POINTS,
18	THE SIMPLER THE BETTER, AND THAT WILL BE THE BASIS
19	OF WHAT WE DO TO MAKE SURE THAT PHIL'S POINTS ABOUT
20	THE NIH AND SHERRY'S POINTS ABOUT THE INTEGRITY OF
21	OUR OWN SYSTEM ARE TAKEN CARE OF.
22	AND SO IT'S A GOOD CALL TO ARMS, BUT WE'RE
23	NOT READY TO GO NOBODY HERE IS READY TO GO TO
24	WASHINGTON TO TAKE A MESSAGE BECAUSE WE DON'T HAVE A
25	CLEARLY ARTICULATED MESSAGE AT THIS MOMENT, I THINK.
	17

17

1	CHAIRMAN KLEIN: I THINK WE HAVE A MESSAGE
2	ON CERTAIN POINTS. CERTAINLY SUPPORTING THE
3	BACKBONE OF THE NIH IS VERY CLEAR. AND I DO THINK
4	WE HAVE A MESSAGE THAT NEEDS TO BE CRAFTED AND PUT
5	INTO BULLET POINTS SO THAT WE HAVE A CONSISTENT
6	MESSAGE.
7	DR. FRIEDMAN: THAT'S ALL I'M ASKING.
8	CHAIRMAN KLEIN: RIGHT. SO WHAT WE HAVE
9	TODAY IS
10	DR. SIMPSON: ARE YOU TAKING PUBLIC
11	COMMENT ON THAT REPORT?
12	CHAIRMAN KLEIN: WHY DON'T WE TAKE A
13	MOMENT FOR A PUBLIC COMMENT ON THIS GENERAL POINT.
14	AND I WOULD ALSO SAY TO DR. FRIEDMAN, IN TERMS OF
15	MESSAGING, IN TERMS OF A COMPLEMENTARY RELATIONSHIP,
16	AS SHERRY HAS REFERENCED, TO THE NIH, ONE OF THE
17	THINGS THAT'S EXTREMELY ATTRACTIVE IN WASHINGTON IS
18	THAT WE'RE DOING THINGS LIKE DISEASE TEAMS, WHICH IS
19	NOT A STANDARD NIH PROGRAM, BUT VIEWED AS
20	COMPLEMENTARY TO THE NIH, THAT WE HAVE THE ABILITY
21	TO FUND PHASE I HUMAN TRIALS AND PHASE II HUMAN
22	TRIALS, WHICH IS A RARE OCCURRENCE THROUGH THE NIH.
23	AND THEIR FUNDING PROGRAMS AND FUTURE FUNDING
24	PROGRAMS AT THIS TIME DON'T ANTICIPATE A MAJOR
25	CHANGE IN THAT ROLE.

18

1	SO IN THE THERAPEUTIC AND TRANSLATIONAL
2	DEVELOPMENT AREA, WE HAVE A ROLE THAT IS A
3	COMPLEMENTARY ROLE THAT REALLY HELPS DRIVE TOWARDS
4	PATIENTS THAT IS VERY ATTRACTIVE AS A COMPLEMENTARY
5	ROLE IN THE EYES OF LEADERSHIP IN WASHINGTON.
6	PUBLIC COMMENT.
7	DR. SIMPSON: JOHN SIMPSON WITH CONSUMER
8	WATCHDOG. I THINK IT'S IMPORTANT THAT WE TRY AND
9	FORM APPROPRIATE COLLABORATIONS AT THE NATIONAL
10	LEVEL, AND THAT MAKES SENSE. BUT I HAVE TO SAY THAT
11	I'M VERY SKEPTICAL ABOUT THE NOTION OF THE NEED TO
12	HAVE A FULL-FLEDGED, FULL-PRESS LOBBYING EFFORT
13	THERE. AND I'M TROUBLED BY THE FACT THAT WHAT
14	APPEARS TO BE AN RFP OUT FOR A \$200,000 LOBBYIST, I
15	THINK THAT THE VOTERS OF CALIFORNIA WANTED THIS TO
16	HAPPEN IN CALIFORNIA AND THAT THE EMPHASIS SHOULD BE
17	HERE, NOT PLAYING ON NOW THE NATIONAL STAGE.
18	I THINK IT'S IMPORTANT THAT AT THE LEVEL
19	OF THE WORKING SCIENTISTS THAT PERHAPS THE PRESIDENT
20	HAVE GOOD RELATIONSHIPS WITH THE NIH, BUT I'M VERY
21	SKEPTICAL ABOUT THE WISDOM OF TRYING TO INFLUENCE
22	THE FEDERAL STIMULUS PACKAGE AND ALL THOSE SORTS OF
23	THINGS. IT DIVERTS YOU FROM WHAT SHOULD BE YOUR
24	SIMPLE, PRIMARY GOAL OF FIGURING OUT, IN THE CONTEXT
25	OF WHAT WENT ON LAST NIGHT, WHERE TO GET THE MONEY

19

1	TO FUND THE COMMITMENTS HERE. THAT'S PRIMARILY, I
2	THINK, THROUGH A VERY CREATIVE EFFORT OF PRIVATE
3	BOND PLACEMENT.
4	AND IT WOULD SEEM TO ME THAT A LOT OF THIS
5	OTHER STUFF IS DIVERSIONARY, ADDS COSTS, AND I'M
6	HIGHLY SKEPTICAL. I JUST WANTED TO GET THAT ON THE
7	RECORD. THANK YOU.
8	CHAIRMAN KLEIN: SURE. THERE IS AN RFP
9	OUT. THE DOLLAR AMOUNT OF THAT IS COMPLETELY
10	UNKNOWN AT THIS TIME. IT'S IN ORDER TO ATTRACT
11	PROPOSALS AND SEE WHAT WE HAVE AND WHAT RESOURCES WE
12	NEED. SO WE'RE IN AN INVESTIGATION STAGE OF THAT.
13	DR. PENHOET: JUST A QUICK COMMENT. I'VE
14	BEEN A STRONG ADVOCATE OF YOUR POINT OF VIEW, WHICH
15	IS WE SHOULD STICK WITH OUR KNITTING IN CALIFORNIA
16	AND DO OUR JOB WELL. HOWEVER, IN DOING SO, WE HAVE
17	BECOME THE WORLD'S LEADING AUTHORITIES ON THIS
18	FIELD. AND I DO THINK WE HAVE SOME OBLIGATION TO
19	SHARE OUR EXPERIENCE, OUR KNOWLEDGE OF THE FIELD,
20	ETC., WITH OTHERS BECAUSE IT TURNS OUT WE ARE THE
21	WORLD LEADERS. WE'RE CERTAINLY THE LEADERS IN THE
22	UNITED STATES, AND I THINK WE'RE THE LEADERS
23	WORLDWIDE IN TERMS OF THE TOTAL QUANTITY AND QUALITY
24	OF THE PROGRAMS THAT WE'VE FUNDED, THE INFORMATION
25	WE'RE GETTING BACK, JUST THE MASS OF WHAT WE'VE

20

DONE. 1 SO AT SOME LEVEL I THINK WE HAVE AN 2 3 OBLIGATION BEYOND THE BORDERS OF OUR STATE TO SHARE WHAT WE'VE LEARNED HERE AND TO CONTINUE TO PLAY A 4 5 LEADERSHIP ROLE. HAVING SAID THAT, WE OBVIOUSLY STILL NEED 6 7 TO STICK WITH OUR KNITTING IF WE WANT TO MAINTAIN 8 THAT LEADERSHIP ROLE. 9 CHAIRMAN KLEIN: I'D ALSO POINT OUT THE 10 INITIATIVE SPECIFICALLY SPEAKS AND ADDRESSES AND 11 INTENDS THIS AGENCY TO HAVE AN ACTIVE ROLE WITH CONGRESS. THAT IS SPECIFICALLY ADDRESSED IN THE 12 13 INITIATIVE. SO LET'S GO FORWARD AND DEAL WITH THE 14 FIRST ITEM ON TODAY'S AGENDA, WHICH I BELIEVE WOULD 15 16 BE ITEM 5. THIS IS THE CARRY-OVER -- EXCUSE ME --17 ITEM 4, WHICH ARE THE GRANTS WORKING GROUP ON BRIDGES TO STEM CELL AND TRAINING GRANT NO. II 18 19 APPLI CATI ONS. 20 MS. KING: AND I BELIEVE WE'LL BE STARTING 21 WITH TRAINING GRANTS. 22 DR. SAMBRANO: MR. CHAIR --23 CHAIRMAN KLEIN: SHERRY LANSING. 24 MS. LANSING: I WANT TO BE CLEAR THAT --25 WELL, WE HAVEN'T COME TO THIS CONCLUSION YET

21

1	ACTUALLY BECAUSE ARE WE NOW LOOKING I WOULD LIKE
2	TO RECOMMEND THAT WE LOOK AT ALL OF THE, NOT JUST
3	THESE GRANTS, BUT ALL OF THE GRANTS AND PROPOSALS
4	THAT ARE UP FOR CONSIDERATION AND THAT WE MAKE OUR
5	DECISIONS BASED ON THEIR SCIENTIFIC MERIT, BUT THAT
6	WE ALWAYS ADD AT THE END OF THEM "SUBJECT TO FUNDING
7	BEING AVAILABLE." BUT I DON'T THINK WE ACTUALLY
8	HAVE TAKEN A CONSENSUS TO BE SURE EVERYBODY IS OKAY.
9	CHAIRMAN KLEIN: I THINK IT'S A GOOD
10	OPENING POSITION. AND AS WE GO THROUGH, AFTER THE
11	PRESENTATION, I THINK IT'S IN ORDER TO HAVE A
12	MOTI ON.
13	MR. ROTH: MR. CHAIRMAN, I SORT OF THINK
14	WE OUGHT TO DO THAT FIRST. THERE WAS DISCUSSION
15	LAST NIGHT WHERE PEOPLE WERE NOT IN FAVOR OF DOING
16	THE REVIEW HERE AND PUTTING IT OFF. BUT IF WE COULD
17	SETTLE THAT FIRST, I THINK THAT WOULD SAVE POTENTIAL
18	TIME IN GOING THROUGH THE MERITS OF THESE PROPOSALS.
19	CHAIRMAN KLEIN: WE'RE STILL GOING THROUGH
20	THE MERITS OF THESE OF WHAT'S BEING PROPOSED; BUT
21	AS A POLICY STATEMENT, IF WE'D LIKE TO OPEN AND
22	ESTABLISH A FRAMEWORK FOR THIS DISCUSSION, I THINK
23	THAT'S ENTIRELY APPROPRIATE. SO IF WE LIKE, SHERRY,
24	WOULD YOU LIKE TO MAKE A MOTION?
25	MS. LANSING: YES. I MOVE THAT ALL OF THE
	22

	BARRISTERS' REPORTING SERVICE
1	GRANTS, TOOLS, TECHNOLOGY, EVERYTHING THAT IS
2	SCHEDULED FOR TODAY
3	CHAIRMAN KLEIN: SHERRY, WHAT WE NEED TO
4	DO IS CONFINE IT TO WHAT WE HAVE AGENDIZED TODAY IN
5	TERMS OF THIS MOTION.
6	MS. LANSING: THAT'S WHAT I SAID, BUT
7	THEY' RE ALL AGENDI ZED.
8	CHAIRMAN KLEIN: WHAT THE AGENDA ITEM WE
9	HAVE THAT WE CAN CONSIDER RIGHT NOW IS BRIDGES AND
10	TRAINING. THE TOOLS ARE UNDER A SEPARATE AGENDA
11	I TEM.
12	MS. LANSING: OKAY. I RECOMMEND THEN, AND
13	I WILL COME BACK THEN, AND IT'S CALLED TOOLS
14	CHAIRMAN KLEIN: AND THE ISSUE, I THINK,
15	WITH COUNSEL IS THAT WE NEED SOMEONE WITH NO
16	CONFLICTS TO MAKE THAT MOTION.
17	MS. LANSING: THAT SURE ISN'T ME.
18	MR. ROTH: I'LL MAKE A MOTION. YOU WANT
19	TO DEAL WITH THESE SEPARATELY? YOU DON'T WANT TO
20	DEAL WITH ALL THREE?
21	CHAIRMAN KLEIN: WE HAVE TWO DIFFERENT
22	AGENDIZED ITEMS, SO WE CAN DEAL WITH BOTH BRIDGES
23	AND TRAINING UNDER THIS MOTION.
24	MR. ROTH: SO THIS ONE IS TRAINING. I'LL
25	MAKE A MOTION THAT WE CONSIDER BRIDGES AND TRAINING
	23

-	
1	WITH THE CAVEAT THAT WE WOULD APPROVE AND THEN
2	LEDGER WHEN FUNDS WHEN AND IF FUNDS ARE
3	AVAI LABLE.
4	CHAIRMAN KLEIN: IF I CAN ASSIST WITH THAT
5	WORDING, PERHAPS INSTEAD OF THE WORD "LEDGER," IF WE
6	CAN APPROVE THEM FOR FUNDING SUBJECT TO THE
7	AVAILABILITY OF FUNDING.
8	MR. ROTH: THAT'S CORRECT.
9	DR. REED: SECOND.
10	CHAIRMAN KLEIN: IT'S BEEN MOVED AND
11	SECONDED.
12	(SIMULTANEOUS DI SCUSSION.)
13	CHAIRMAN KLEIN: IS THERE A SECOND TO THE
14	MOTION FROM SOMEONE WITH NO CONFLICTS?
15	MS. LANSING: DON'T WE HAVE A SECOND?
16	CHAIRMAN KLEIN: I CAN SECOND. I WILL
17	SECOND FOR PURPOSES OF THIS DISCUSSION.
18	MR. HARRISON: MR. CHAIR, COULD I ASK FOR
19	ONE CLARIFICATION WITH RESPECT TO THE MOTION? IS
20	THE DETERMINATION AS TO WHETHER SUFFICIENT FUNDS ARE
21	AVAILABLE INTENDED TO BE LEFT IN THE HANDS OF STAFF,
22	OR IS THAT A MATTER TO BE BROUGHT BACK TO THE BOARD?
23	MR. ROTH: MATTER TO BE BROUGHT BACK TO
24	THE BOARD.
25	CHAIRMAN KLEIN: DR. PULIAFITO.
	24

-	
1	DR. PULIAFITO: THIS IS A QUESTION. OKAY.
2	I AGREE WITH THE APPROACH HERE, BUT WE DON'T KNOW
3	WHAT OUR FINANCIAL FUTURE IS. SO I THINK THAT IT'S
4	IMPORTANT THAT WE HAVE THE ABILITY, WE MAY WISH
5	IF WE HAVE LIMITED FUNDS, WE MAY WISH TO NOT FUND
6	THESE AND FUND SOMETHING ELSE. SO IN OTHER WORDS,
7	IT CAN'T BE THAT THE NEXT TIME WE GET A DOLLAR THAT
8	WE'RE GOING TO GIVE IT AUTOMATICALLY TO THIS. IS
9	THAT
10	CHAIRMAN KLEIN: WELL, THAT'S NOT IN THIS
11	CURRENT MOTION. THIS MOTION AS CURRENTLY STATED
12	MR. SERRANO-SEWELL: IT'S A FAIR QUESTION
13	THOUGH. IS THE INTENT BEHIND THE MOTION
14	CHAIRMAN KLEIN: I'M GOING TO ASK THE
15	MAKER OF THE MOTION.
16	MR. ROTH: MY INTENT WOULD BE THAT IT COME
17	BACK TO THIS BOARD TO MAKE THAT DETERMINATION AS THE
18	FUNDS ARE AVAI LABLE.
19	DR. POMEROY: I HAVE A POINT OF ORDER FOR
20	JAMES.
21	CHAIRMAN KLEIN: DR. POMEROY.
22	DR. POMEROY: I'M NOT ALLOWED TO SPEAK TO
23	THIS MOTION PER SE BECAUSE I'M CONFLICTED ON THE
24	TRAINING GRANTS. I FEEL THAT THAT SHUTS OUT MY
25	VOICE ABOUT THE DECISION THAT WE'RE REALLY MAKING,
	25

1	WHICH IS HOW TO PRIORITIZE OUR FINANCES. AND I,
2	THEREFORE, AM TROUBLED BY THE FACT THAT I WON'T BE,
3	BY VIRTUE OF HOW THIS IS BEING FRAMED, I WON'T BE
4	ABLE TO HAVE INPUT INTO THE REAL ISSUE OF BEING
5	FI SCALLY RESPONSI BLE.
6	CHAIRMAN KLEIN: OKAY. LET ME ADDRESS
7	DR. POMEROY: MY QUESTION WAS TO JAMES, SO
8	MAYBE HE COULD ANSWER THAT.
9	MR. HARRISON: I SYMPATHIZE WITH YOUR
10	POSITION. UNFORTUNATELY ONE OF THE CHALLENGES WE
11	FACE IS THAT WHEN WE CONSIDER OMNIBUS MOTIONS LIKE
12	THIS THAT DEAL AT LARGE WITH AN ENTIRE GRANT
13	PROGRAM, IT EFFECTIVELY PRECLUDES THOSE MEMBERS WHO
14	HAVE AN INTEREST IN AN APPLICATION WITHIN THAT ROUND
15	FROM PARTICIPATING IN THE DISCUSSION OF THE OMNIBUS
16	MOTI ON.
17	WE'VE DEVELOPED A TOOL TO LET YOU
18	PARTICIPATE IN A VOTE THROUGH THE MECHANISM OF
19	VOTING FOR THE MOTION OR AGAINST IT WITH THE
20	EXCEPTION OF THOSE APPLICATIONS IN WHICH YOU HAVE AN
21	INTEREST, WHICH I ADMIT IT DOES NOT SOLVE THE
22	PROBLEM. BUT THUS FAR, WE HAVEN'T BEEN ABLE TO
23	DEVELOP AN ALTERNATIVE THAT ADDRESSES YOUR CONCERN
24	WHEN WE HAVE AN OMNIBUS MOTION LIKE THIS.
25	CHAIRMAN KLEIN: I WOULD SUPPLEMENT THOSE
	26
	20

1	COMMENTS, DR. POMEROY, BY STATING THAT WE'VE ALREADY
2	INDICATED IN MARCH WE'RE COMING BACK TO SPECIFICALLY
3	ADDRESS ON A POLICY LEVEL, NOT RELATED TO ANY
4	SPECIFIC APPLICATION, OUR POLICY POSITION, WHICH WE
5	CERTAINLY WILL REVISIT IN APRIL AND PROBABLY
6	FREQUENTLY THEREAFTER, ON FUNDING. SO THIS IS NOT
7	THE ONLY CHANCE TO HAVE A FULL DISCUSSION. WE PUT
8	INFORMATION ON THE TABLE IN THE DISCUSSIONS LAST
9	NIGHT, BUT
10	DR. POMEROY: I APPRECIATE THAT, BUT THIS
11	IS A POLICY DECISION BY DEFAULT THROUGH A DIFFERENT
12	MECHANISM. SO I JUST WANT TO GO ON THE RECORD WITH
13	MY DISCOMFORT WITH THAT.
14	CHAIRMAN KLEIN: ALL RIGHT. THANK YOU.
15	DR. PI ZZO.
16	DR. PIZZO: WELL, CERTAINLY BEING
17	SYMPATHETIC TO CLAIRE'S POINT AND DISCOMFORT, AND I
18	WON'T TALK ABOUT THE CURRENT PROPOSAL, BUT I JUST
19	WILL BY REFLECTION SAY THAT AT AN EARLIER TIME WHEN
20	WE DID NOT HAVE FUNDS AVAILABLE, WE AS A GROUP
21	APPROVED THE TRAINING GRANTS. AND WE DID SO FOR A
22	SPECIFIC REASON. WE DID SO IN ANTICIPATION, HOPEFUL
23	ANTICIPATION, OF BOND ADVANCEMENT NOTES AT THAT
24	TIME, AND WE DID SO TACTICALLY BECAUSE WE FELT THAT
25	BY HAVING SOMETHING CONCRETE IN OUR PORTFOLIO, IT

1	WOULD ENABLE US TO MAKE THE CASE EVEN MORE STRONGLY
2	TO THOSE WHO MAY BE SUPPORTING THE PROGRAM.
3	SO I THINK THAT IN A SENSE WE DO HAVE A
4	HISTORY IN THIS AREA OF COMING FORWARD IN
5	ANTICIPATION OF SOMETHING WITH CONCRETE PROPOSALS
6	THAT A DONOR COMMUNITY, IF YOU WILL, MIGHT SEE AS
7	MERI TORI OUS.
8	CHAIRMAN KLEIN: I WOULD ALSO SAY IT
9	ADDRESSES THE DONOR COMMUNITY. IT ALSO IS HELPFUL
10	IN TRYING TO ACCOMPLISH PRIVATE PLACEMENTS TO HAVE
11	CONCRETE OBJECTIVES THAT HAVE BEEN IDENTIFIED BY
12	THIS BOARD AS WORTHWHILE OF FUNDING SO THAT WE CAN
13	SHOW THEM THAT WE HAVE A REAL ISSUE IN FUNDING WHERE
14	WE NEED IMMEDIATE ACTION, NOT ACTION ON A LONG-TERM
15	BASIS, BUT IMMEDIATE ACTION FOR THIS PROBLEM IF
16	WE'RE GOING TO CONTINUE TO HAVE OUR MOMENTUM.
17	DR. TROUNSON: CHAIR, I'D JUST MAYBE POINT
18	OUT TO THE BOARD YOU NEED TO BE CAREFUL ABOUT THE
19	WORDS BECAUSE WE ACTUALLY DO HAVE FUNDING AVAILABLE
20	RIGHT AT THE MOMENT. IS IT ADDITIONAL FUNDING, OR
21	IS IT FUNDING AVAILABLE? AND SO I THINK IT WOULD BE
22	IMPORTANT TO CRAFT THE WORDS APPROPRIATELY.
23	CHAIRMAN KLEIN: SO
24	MR. ROTH: THAT IS MY MOTION, THAT IT
25	WOULD COME BACK TO THIS BOARD TO MAKE THAT
	28

	BARRISTERS' REPORTING SERVICE
1	DETERMINATION WHEN FUNDS ARE AVAILABLE.
2	CHAIRMAN KLEIN: I THINK, IF WE CAN JUST
3	COORDINATE THIS DISCUSSION.
4	MR. ROTH: TO FUND THESE SPECIFIC GRANTS,
5	IT HAS TO COME BACK HERE, AND WE'LL MAKE THAT
6	DETERMINATION THAT WE
7	CHAIRMAN KLEIN: ON FUNDS BEING AVAILABLE.
8	MR. ROTH: THAT'S RIGHT.
9	CHAIRMAN KLEIN: BUT AS I UNDERSTOOD THIS
10	IN CONTEXT, WE'RE LOOKING FOR ADDITIONAL SOURCES OF
11	FUNDING BEYOND THE FUNDS WE HAVE CURRENTLY
12	AVAILABLE. IS THAT A CORRECT STATEMENT?
13	MR. ROTH: AND THAT THAT DETERMINATION
14	WOULD BE MADE BY THIS BOARD AT A FUTURE MEETING.
15	CHAIRMAN KLEIN: RIGHT. OKAY. SO DR.
16	AZZI Z.
17	DR. AZZIZ: LET ME ASK JAMES. CAN I
18	JAMES, CAN WE SPEAK TO THIS MOTION AND, IN FACT, I
19	NEED A CLARIFICATION IN THE END OF THIS OMNIBUS
20	MOTION. OF COURSE, WE ALL WILL EXEMPT OURSELVES
21	FROM THOSE THAT WE HAVE CONFLICT, BUT CAN WE VOTE,
22	OR ARE WE ACTUALLY LIMITING VOTING TO THREE PEOPLE?
23	MR. HARRISON: NO. YOU WILL ALL HAVE THE
24	RIGHT TO VOTE SIMILAR TO WHAT WE DID WITH TIER 2 OF
25	THE TOOLS AND TECHNOLOGY APPLICATIONS WHERE THE

29

1	BOARD MADE A DECISION AS TO ALL OF THOSE
2	APPLICATIONS TO DEFER THEM FOR FUTURE CONSIDERATION.
3	AND YOU VOTED YES OR NO ON THE MOTION WITH THE
4	EXCEPTION OF ANY APPLICATION IN WHICH YOU HAD AN
5	INTEREST.
6	DR. POMEROY: BUT FOR CLARIFICATION, WE'RE
7	NOT ALLOWED TO COMMENT.
8	MR. HARRISON: CORRECT.
9	CHAIRMAN KLEIN: YOU'RE NOT ALLOWED TO
10	COMMENT IF, IN FACT, BECAUSE IT IS ADDRESSING BOTH
11	TRAINING AND BRIDGES, IF YOUR INSTITUTION IS
12	INVOLVED IN EITHER OF THOSE.
13	DR. AZZIZ: YOU'RE NOT ALLOWED TO COMMENT.
14	CAN YOU CLARIFY THAT? I THINK THIS IS WHERE RUBBER
15	IS HITTING THE ROAD HERE.
16	MR. HARRISON: ONE OF THE CHALLENGES WE
17	FACE IS THAT UNDER STATE LAW AND UNDER THE ICOC'S
18	OWN POLICIES, WHEN YOU HAVE AN INTEREST IN AN
19	APPLICATION THAT'S PENDING BEFORE THE BOARD, AND A
20	MOTION ENCOMPASSES THAT APPLICATION, YOU'RE
21	PROHIBITED FROM PARTICIPATING IN THE DISCUSSION OF
22	THAT MOTION.
23	DR. AZZIZ: SO MY QUESTION TO YOU AGAIN IS
24	IF I HAVE ONE CONFLICT, DOESN'T MATTER HOW MANY, IF
25	I HAVE A CONFLICT WITH ONE OF THESE GRANTS, I CAN'T
	30
	30

	BARRISTERS' REPORTING SERVICE
1	DI SCUSS, I CANNOT SPEAK?
2	MR. HARRISON: THAT'S CORRECT. YOU CANNOT
3	TRY TO INFLUENCE THE OUTCOME OF THE MOTION.
4	DR. POMEROY: PERHAPS YOU COULD CLARIFY
5	THIS, JAMES, BY STATING WHO'S
6	DR. AZZIZ: OTHERWISE, WE'RE NOT GOING TO
7	HAVE ANY DISCUSSION.
8	DR. POMEROY: ALLOWED TO COMMENT AND
9	WHO IS ALLOWED TO VOTE.
10	MR. HARRISON: I UNDERSTAND THE
11	DI FFI CULTY.
12	(SIMULTANEOUS VOICES.)
13	MR. SERRANO-SEWELL: THAT'S A GOOD POINT
14	OF ORDER QUESTION, CLAIRE'S. CAN YOU INFORM THE
15	BOARD, BASED ON HOW YOU DEFINE THE OMNIBUS NATURE OF
16	DUANE'S MOTION, WHICH ENCOMPASSES EVERYTHING THAT
17	YOU JUST ARTICULATED, CAN YOU TELL US NOW, AS I
18	THINK CLAIRE JUST ASKED, WHO CAN TALK, WHO CAN SPEAK
19	TO THE MOTION AS IT CURRENTLY STANDS AND OBVIOUSLY
20	THEN WHO CAN VOTE ON IT?
21	MR. HARRISON: I CAN IF YOU GIVE ME A
22	MINUTE TO DOUBLE-CHECK TO VERIFY SO THAT WE DON'T
23	MAKE ANY MISTAKES. I WILL DO THAT.
24	CHAIRMAN KLEIN: I'D LIKE TO SUSPEND THESE
25	COMMENTS FOR JUST A COUPLE MINUTES SO COUNSEL CAN
	31

1	BOTH LOOK AT THIS LIST AND CROSS-VERIFY IT BECAUSE
2	WE TRY AND HAVE TWO COUNSEL ALWAYS VERIFY THESE
3	DECI SI ONS.
4	(PAUSE IN PROCEEDINGS.)
5	CHAIRMAN KLEIN: DR. PRIETO.
6	DR. PRIETO: MAYBE A QUESTION FOR COUNSEL.
7	WOULD IT BE POSSIBLE FOR THE MAKER TO WITHDRAW THE
8	MOTION AND PERHAPS CRAFT A DIFFERENT ONE THAT WOULD
9	OR PERHAPS SEVERAL DIFFERENT ONES THAT WOULD GET US
10	AROUND SOME OF THESE RESTRICTIONS? IT'S REALLY NOT
11	FEASIBLE FOR US TO FUNCTION AS A BOARD IF WE CAN'T
12	DISCUSS THE KEY ISSUES IN FRONT OF US.
13	MS. LANSING: WELL, I HAVE A SUGGESTION.
14	I THINK WHAT CLAIRE AND SOME OF MY COLLEAGUES ARE
15	QUESTIONING IS WHETHER WE SHOULD FUND ANYTHING AT
16	ALL. SO I THINK IT IS PERFECTLY ACCEPTABLE TO MAKE
17	A GENERAL MOTION THAT STATES I WANT TO BE VERY
18	CAREFUL THAT TODAY ANY FURTHER THIS WOULD NOT
19	BE SOMETHING ANYONE WAS CONFLICTED FROM, ANY FURTHER
20	GRANTS THAT WE MAKE IN ANY AREA WILL ALL BE SUBJECT
21	TO FUNDING DEEMED AVAILABLE BY THIS BOARD. THAT WE
22	WILL THIS IS A GENERAL SITUATION THAT WE'RE
23	TALKING ABOUT, AND MAYBE YOU CAN HELP ME, JAMES.
24	I'M GENERALLY RECOMMENDING THAT, DUE TO
25	THE ECONOMIC CRISIS THAT WE ARE FACING, THAT WE LOOK
	32

1	AT ALL THE FUTURE GRANTS THAT COME BEFORE US TODAY,
2	JUST ASKING FOR TODAY, BASED ON THEIR SCIENTIFIC
3	MERIT AND RECOMMEND WHETHER WE SHOULD FUND THEM
4	PURELY ON THAT, AND ALL FUNDING FOR TODAY'S GRANTS
5	BE SUBJECT TO WHETHER OR NOT FUNDING IS AVAILABLE
6	AND WE PRIORITIZE WHAT WE FUND, AND IT COMES BACK TO
7	THE BOARD BECAUSE THERE IS CERTAINLY FUNDING
8	AVAILABLE. JAMES, YOU CAN HELP ME WITH THIS.
9	CHAIRMAN KLEIN: SO, SHERRY, BY OPERATION
10	OF LAW, THE AGENDAS AND TIMING, IN FACT, THAT'S
11	WHAT'S GOING TO HAPPEN BECAUSE IN MARCH WE DO NOT
12	HAVE ANYTHING UP FOR FUNDING, AND WE WILL, IN FACT,
13	SPECIFICALLY ADDRESS THIS IN A SITUATION WHERE WE DO
14	NOT HAVE CONFLICTS. BUT THE ISSUE I HAVE THE
15	ONLY QUESTION I HAVE, JAMES, I HAVE NO ISSUE WITH
16	CLAIRE'S WITH SHERRY'S INTENT. THE QUESTION IS
17	CAN WE, AS AGENDIZED, JUSTIFY THAT THE BROADER
18	MOTION CAN BE SUBSUMED UNDER THE SPECIFIC AGENDA
19	ITEM THAT WE HAVE BEFORE US?
20	MS. LANSING: SEE, WHAT I'M REALLY TRYING
21	TO DO IS ALLOW PEOPLE TO TALK.
22	MR. HARRISON: I UNDERSTAND. AND WHAT
23	SHERRY IS SUGGESTING IS THAT WE, IN ESSENCE, ADOPT A
24	STANDARD WHICH IS A SPECIFIC EXCEPTION IN THE LAW
25	WHICH WOULD PERMIT ALL OF YOU TO PARTICIPATE. AND
	22
	33

-	
1	IT'S A STANDARD WHICH WOULD APPLY TO ALL FUTURE
2	GRANT AWARDS SUBJECT TO A DECISION BY THIS BOARD TO
3	CHANGE THE STANDARD. AND THAT WOULD PERMIT
4	PARTICIPATION. I THINK WE NEED A MINUTE TO CONFER
5	ABOUT WHETHER, BASED ON OUR CURRENT AGENDA, WE HAVE
6	THE ABILITY TO CONSIDER THAT MOTION.
7	CHAIRMAN KLEIN: AND WE CERTAINLY CAN AND
8	WOULD INTEND TO CONSIDER THAT MOTION AT THE MARCH
9	MEETING.
10	MR. SERRANO-SEWELL: TO SHERRY'S
11	SUGGESTION, I THINK SOMETHING WE GOT TO KEEP IN MIND
12	IS, AND I HEAR THIS REPEATEDLY FROM MY COLLEAGUES,
13	AND THAT IS THE PERCEPTION WE HAVE IN THE PUBLIC.
14	NOW, WE HAVE GONE THROUGH EXTRAORDINARY EFFORTS TO
15	ENSURE TRANSPARENCY AND NO ONE HAS A CONFLICT. WE
16	PRIDE OURSELF IN THAT. I THINK, AS A STATE AGENCY,
17	WE DO VERY WELL IN THAT CATEGORY.
18	AND THE PERFECT EXAMPLE IS THE
19	POPULATION POPULATING THE GRANTS WORKING GROUP.
20	WE APPOINTED OUT-OF-STATE REVIEWERS. WE DIDN'T HAVE
21	TO, AND WE DO THAT AT GREAT EXPENSE BECAUSE WE
22	WANTED TO ENSURE THAT THE PUBLIC HAD CONFIDENCE IN
23	WHAT WE'RE DOING.
24	SHERRY, MY CONCERN WITH YOUR MOTION IS I
25	TOO SHARE THE DESIRE TO GET AS MUCH COMMENT FROM MY
	34

-	
1	COLLEAGUES AS POSSIBLE, BUT WE'RE USING POSSIBLY
2	THAT MOTION, YOUR MOTION, YOUR SUGGESTION, AS A
3	MECHANISM TO DO THAT BECAUSE, YOU KNOW, IT'S LIKE
4	WE'RE MAKING AN EXCEPTION TO THE RULE. WE HAVE
5	THESE CONFLICT ISSUES; WE'VE ADOPTED THEM; THE
6	PUBLIC HAS APPLAUDED US. THE PRICE WE PAY
7	SOMETIMES, UNFORTUNATELY, IS WE DON'T GET FULL
8	PARTICIPATION. BUT THAT'S THE PRICE YOU PAY FOR IF
9	YOU WANT TO ENSURE THAT WE GET THAT WE ENSURE WE
10	MAKE THE HIGHEST ETHICAL STANDARDS, TRANSPARENCY,
11	CONFLICT OF INTEREST. IF WE WANT TO LOWER THOSE
12	STANDARDS, WE CAN CHANGE OUR RULES AND DO SO.
13	MS. LANSING: BUT I DON'T WANT TO LOWER
14	THOSE STANDARDS. WHAT WE'RE FACING IS A CRISIS THAT
15	NONE OF US COULD HAVE ANTICIPATED, THAT WE DON'T
16	HAVE, PERHAPS LOOK, I WANT TO MOVE FORWARD. I
17	THINK I MADE MY POSITION CLEAR. BUT WHAT WE'RE
18	FACING IS A CRISIS WHERE WE MAY RUN OUT OF MONEY.
19	WE'VE BEEN FULLY TRANSPARENT IN THAT. SO AND WE'RE
20	NOT ALONE IN THAT SITUATION.
21	SO THE QUESTION IS TODAY, AND IT'S BEEN A
22	CONTINUAL DISCUSSION SINCE LAST NIGHT, IS DO WE MOVE
23	AHEAD AND FUND THESE? WE HAVE THREE CHOICES. WE
24	CAN MOVE AHEAD AND FUND THEM WITH THE MONEY THAT WE
25	HAVE, AND THAT WAS STAFF'S RECOMMENDATION, AND THEN

1	WE CANNOT POSSIBLY HAVE ANY MORE MONEY TO FUND
2	ANYTHING ELSE. THAT'S ONE POSSIBLE CONCLUSION. WE
3	CAN MOVE AHEAD AND JUDGE EVERYTHING BASED ON ITS
4	SCIENTIFIC MERIT; AND THEN WHEN WE HAVE A CLEARER
5	VIEW OF HOW MUCH MONEY WE WILL HAVE IN THE NEXT
6	EIGHT WEEKS
7	DR. PENHOET: SHERRY, WE HAVE A MOTION ON
8	THE FLOOR. YOU'RE BEGINNING TO SPEAK TO THE MOTION.
9	IF DUANE WITHDRAWS HIS MOTION FOR A MOMENT, MAYBE
10	MS. LANSING: CAN I JUST FINISH MY
11	SENTENCE? THEN WE CAN FUND THAT WAY, OR CANNOT FUND
12	ANYTHING. THAT IS SOMETHING THAT SOME PEOPLE FEEL
13	STRONGLY ABOUT.
14	DR. PENHOET: COULD I SUGGEST A CLARIFYING
15	DEFINITION OF FUNDING AVAILABLE? FUNDING AVAILABLE
16	WOULD MEAN THE FUNDS WERE AVAILABLE GENERALLY TO THE
17	CIRM AND APPROVED BY THIS BOARD FOR THIS PURPOSE.
18	IF THAT WAS THE DEFINITION OF AVAILABLE FUNDING
19	CHAIRMAN KLEIN: THAT IS WHAT DUANE HAS
20	SAID. AND SO I THINK THAT'S IMPORTANT, ED, TO
21	EMPHASIZE THAT. I'M GOING TO
22	DR. PIZZO: CAN I JUST BE SURE THAT I
23	CLARIFY SOMETHING THAT SHERRY SAID?
24	CHAIRMAN KLEIN: CAN I IT LOOKS LIKE
25	THE ATTORNEYS ARE STILL WORKING.
	36

	BARRISTERS' REPORTING SERVICE
1	DR. PIZZO: JUST A CLARIFICATION.
2	CHAIRMAN KLEIN: YOUR COMMENT AND THEN DR.
3	AZZIZ' COMMENT.
4	DR. PIZZO: I JUST WANT TO, SHERRY, BE
5	SURE. YOU'RE NOT SAYING, AT LEAST I DON'T THINK YOU
6	ARE, THAT WE WOULD NOT FULFILL OUR EXISTING
7	COMMITMENTS? WHEN WE TALK ABOUT MONEY ON THE
8	TABLE
9	MS. LANSING: NO, I'M NOT.
10	DR. PIZZO: OKAY. JUST TO BE CLEAR, WHEN
11	YOU SAY WE CAN MAKE DECISIONS, YOU KNOW, WE HAVE A
12	POT OF MONEY, BUT A LOT OF IT IS COMMITTED. WE'RE
13	TALKING ABOUT INCREMENTAL.
14	CHAIRMAN KLEIN: LET ME SAY, NOT ONLY
15	COMMITTED, WE HAVE CONTRACTS. SO THESE ARE
16	SOVEREI GN CONTRACTS.
17	MR. ROTH: MR. CHAIRMAN
18	CHAIRMAN KLEIN: WE HAVE DR. AZZIZ AND
19	THEN DUANE ROTH. AND I'D LIKE TO REMIND EVERYONE
20	IT'S VERY CLEAR WE'RE NOT SETTING A PRECEDENT IN THE
21	FUTURE. I THINK, IN PART, THIS IS AN ARTIFICIAL
22	DISCUSSION BECAUSE WE'RE GOING TO HAVE A CLEAR
23	DISCUSSION ON POLICIES AND STANDARDS IN MARCH. THIS
24	IS NOT IN ANY WAY GOING TO BE MISINTERPRETED AS A
25	GENERAL POLICY OR A LACK OF AS A GENERAL POLICY.
	27

1	WE WILL HAVE THE ABILITY TO HAVE GENERAL POLICY
2	DISCUSSIONS. WHICHEVER SIDE CLAIRE OR ANYONE ELSE
3	ARE ON ON A GENERAL POLICY, WE WILL HAVE A FULL
4	DISCUSSION, AGENDIZED ISSUES ON GENERAL POLICIES,
5	AND FULL ABILITY AS A GENERAL STANDARD AND A POLICY
6	FOR EVERYONE ON THIS BOARD TO DEBATE IT IN MARCH.
7	FOLLOW ME? WE CAN CRAFT IN MARCH THE ABILITY TO
8	HAVE A GENERAL DISCUSSION OF ALL THE MEMBERS ON THIS
9	BOARD.

10 DR. AZZIZ: I DID WANT TO COMMENT, NOT IN 11 GENERAL TO THE MOTION, SINCE I MAY NOT BE ABLE TO SPEAK TO THE MOTION, BUT I DO THINK THAT THE LAST 12 13 TEN MINUTES WE HAVE BEGUN TO SLIDE INTO A POSITION WHERE THERE IS A SENSE THAT OTHERS MAY PERCEIVE THAT 14 THINGS ARE BEING RAILROADED IN THE BOARD AND THAT 15 16 THE BOARD IS RELEASING ITS FIDUCIARY RESPONSIBILITY. 17 AND SO I WOULD PLEAD WITH THE CHAIR TO BE VERY CAREFUL HOW THIS DISCUSSION IS DIRECTED. 18 BECAUSE 19 OTHERWISE THERE MAY BE A PERCEPTION THAT THE BOARD 20 IS BEING DISENFRANCHISED AT A TIME WHEN THE ECONOMY 21 ISN'T GOING TO ALLOW US TO DO THAT.

22 SO THIS ENTIRE DISCUSSION REALLY HAS 23 REVOLVED AROUND REVIEWING GRANTS THAT ARE ON THE 24 AGENDA WHEN THE ISSUE INITIALLY SHOULD HAVE BEEN 25 DISCUSSED AS TO WHETHER WE WANT TO ACTUALLY EVEN

38

1REVIEW THEM AT ALL OR EVEN BEGIN TO THINK OF FUNDING2OR SHOULD WE REVISIT THIS AS A CORPORATION WOULD AND3SO ON FOR THE FOUR OR THREE OR TWO MONTHS.4I JUST WANT TO GO ON THE RECORD WITH THAT5BECAUSE I'M BEGINNING TO BE VERY UNCOMFORTABLE WITH6THE ENTIRE DIRECTION OF THE DISCUSSION THAT WE'RE7HAVING.8CHAIRMAN KLEIN: DR. AZZIZ, I'D LIKE TO9POINT OUT THAT THE CHAIR ON THE CHAIR'S OWN10INITIATIVE BROUGHT A FULL DISCUSSION OF THE11ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE12BOARD'S REQUEST, BUT AT THE BOARD AT THE13INITIATION OF THE BOARD, INCLUDING GOING OUT TO142010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER15STATE AGENCY.16DR. AZZIZ: YOU SHOULD BE COMMENDED FOR17IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU18SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY,19THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 1020OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO21CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR23DI SCUSSION.24DR. AZZIZ: I THINK WE NEED TO PROBABLY25WAIT.26		
3SO ON FOR THE FOUR OR THREE OR TWO MONTHS.4I JUST WANT TO GO ON THE RECORD WITH THAT5BECAUSE I'M BEGINNING TO BE VERY UNCOMFORTABLE WITH6THE ENTIRE DIRECTION OF THE DISCUSSION THAT WE'RE7HAVING.8CHAIRMAN KLEIN: DR. AZZIZ, I'D LIKE TO9POINT OUT THAT THE CHAIR ON THE CHAIR'S OWN10INITIATIVE BROUGHT A FULL DISCUSSION OF THE11ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE12BOARD'S REQUEST, BUT AT THE BOARD AT THE13INITIATION OF THE BOARD, INCLUDING GOING OUT TO142010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER15STATE AGENCY.16DR. AZZIZ: YOU SHOULD BE COMMENDED FOR17IT. SO, IN FACT, YOU SHOULD BE COMMENDED FOR18SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY,19THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 1020OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO21CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR23DI SCUSSION.24DR. AZZIZ: I THINK WE NEED TO PROBABLY25WAIT.	1	REVIEW THEM AT ALL OR EVEN BEGIN TO THINK OF FUNDING
4I JUST WANT TO GO ON THE RECORD WITH THAT5BECAUSE I'M BEGINNING TO BE VERY UNCOMFORTABLE WITH6THE ENTIRE DIRECTION OF THE DISCUSSION THAT WE'RE7HAVING.8CHAIRMAN KLEIN: DR. AZZIZ, I'D LIKE TO9POINT OUT THAT THE CHAIR ON THE CHAIR'S OWN10INITIATIVE BROUGHT A FULL DISCUSSION OF THE11ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE12BOARD'S REQUEST, BUT AT THE BOARD AT THE13INITIATION OF THE BOARD, INCLUDING GOING OUT TO142010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER15STATE AGENCY.16DR. AZZIZ: YOU SHOULD BE COMMENDED FOR17IT. SO, IN FACT, YOU SHOULD BE COMMENDED FOR17IT. SO, IN FACT, YOU SHOULD BE COMMENDED FOR18HOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY,19THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 1020OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO21CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR23DI SCUSSION.24DR. AZZIZ: I THINK WE NEED TO PROBABLY25WAIT.	2	OR SHOULD WE REVISIT THIS AS A CORPORATION WOULD AND
5BECAUSE I'M BEGINNING TO BE VERY UNCOMFORTABLE WITH THE ENTIRE DIRECTION OF THE DISCUSSION THAT WE'RE HAVING.8CHAIRMAN KLEIN: DR. AZZIZ, I'D LIKE TO POINT OUT THAT THE CHAIR ON THE CHAIR'S OWN INITIATIVE BROUGHT A FULL DISCUSSION OF THE10INITIATIVE BROUGHT A FULL DISCUSSION OF THE11ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE BOARD'S REQUEST, BUT AT THE BOARD AT THE INITIATION OF THE BOARD, INCLUDING GOING OUT TO 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER STATE AGENCY.16DR. AZZIZ: YOU SHOULD BE COMMENDED FOR IT. SO, IN FACT, YOU SHOULD BE COMMENDED FOR IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION.24DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT.	3	SO ON FOR THE FOUR OR THREE OR TWO MONTHS.
 6 THE ENTIRE DIRECTION OF THE DISCUSSION THAT WE'RE HAVING. 8 CHAIRMAN KLEIN: DR. AZZIZ, I'D LIKE TO 9 POINT OUT THAT THE CHAIR ON THE CHAIR'S OWN 10 INITIATIVE BROUGHT A FULL DISCUSSION OF THE 11 ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE 12 BOARD'S REQUEST, BUT AT THE BOARD AT THE 13 INITIATION OF THE BOARD, INCLUDING GOING OUT TO 14 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER 15 STATE AGENCY. 16 DR. AZZIZ: YOU SHOULD BE COMMENDED FOR 17 IT. SO, IN FACT, YOU SHOULD BE COMMENDED FOR 18 SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, 19 THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 10 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO 21 CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR 22 IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST 23 DISCUSSION. 24 DR. AZZIZ: I THINK WE NEED TO PROBABLY 25 WAIT. 	4	I JUST WANT TO GO ON THE RECORD WITH THAT
 HAVING. CHAIRMAN KLEIN: DR. AZZIZ, I'D LIKE TO POINT OUT THAT THE CHAIR ON THE CHAIR'S OWN INITIATIVE BROUGHT A FULL DISCUSSION OF THE ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE BOARD'S REQUEST, BUT AT THE BOARD AT THE INITIATION OF THE BOARD, INCLUDING GOING OUT TO 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER STATE AGENCY. DR. AZZIZ: YOU SHOULD BE COMMENDED FOR IT. SO, IN FACT, YOU SHOULD BE COMMENDED FOR SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT. 	5	BECAUSE I'M BEGINNING TO BE VERY UNCOMFORTABLE WITH
 CHAIRMAN KLEIN: DR. AZZIZ, I'D LIKE TO POINT OUT THAT THE CHAIR ON THE CHAIR'S OWN INITIATIVE BROUGHT A FULL DI SCUSSION OF THE ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE BOARD'S REQUEST, BUT AT THE BOARD AT THE INITIATION OF THE BOARD, INCLUDING GOING OUT TO 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER STATE AGENCY. DR. AZZIZ: YOU SHOULD BE COMMENDED FOR IT. SO, IN FACT, YOU SHOULD BE COMMENDED FOR SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT. 	6	THE ENTIRE DIRECTION OF THE DISCUSSION THAT WE'RE
 POINT OUT THAT THE CHAIR ON THE CHAIR'S OWN INITIATIVE BROUGHT A FULL DISCUSSION OF THE ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE BOARD'S REQUEST, BUT AT THE BOARD AT THE INITIATION OF THE BOARD, INCLUDING GOING OUT TO 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER STATE AGENCY. DR. AZZIZ: YOU SHOULD BE COMMENDED FOR IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT. 	7	HAVI NG.
 INITIATIVE BROUGHT A FULL DISCUSSION OF THE ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE BOARD'S REQUEST, BUT AT THE BOARD AT THE INITIATION OF THE BOARD, INCLUDING GOING OUT TO 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER STATE AGENCY. DR. AZZIZ: YOU SHOULD BE COMMENDED FOR IT. SO, IN FACT, YOU SHOULD BE COMMENDED FOR SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT. 	8	CHAIRMAN KLEIN: DR. AZZIZ, I'D LIKE TO
 ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE BOARD'S REQUEST, BUT AT THE BOARD AT THE INITIATION OF THE BOARD, INCLUDING GOING OUT TO 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER STATE AGENCY. DR. AZZIZ: YOU SHOULD BE COMMENDED FOR IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT. 	9	POINT OUT THAT THE CHAIR ON THE CHAIR'S OWN
 BOARD'S REQUEST, BUT AT THE BOARD AT THE INITIATION OF THE BOARD, INCLUDING GOING OUT TO 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER STATE AGENCY. DR. AZZIZ: YOU SHOULD BE COMMENDED FOR IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT. 	10	INITIATIVE BROUGHT A FULL DISCUSSION OF THE
 13 INITIATION OF THE BOARD, INCLUDING GOING OUT TO 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER 15 STATE AGENCY. 16 DR. AZZIZ: YOU SHOULD BE COMMENDED FOR 17 IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU 18 SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, 19 THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 20 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO 21 CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR 22 IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST 23 DISCUSSION. 24 DR. AZZIZ: I THINK WE NEED TO PROBABLY 25 WAIT. 	11	ECONOMICS TO THE BOARD AT THIS MEETING, NOT AT THE
 14 2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER 15 STATE AGENCY. 16 DR. AZZIZ: YOU SHOULD BE COMMENDED FOR 17 IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU 18 SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, 19 THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 20 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO 21 CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR 22 IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST 23 DI SCUSSION. 24 DR. AZZIZ: I THINK WE NEED TO PROBABLY 25 WAIT. 	12	BOARD'S REQUEST, BUT AT THE BOARD AT THE
 STATE AGENCY. DR. AZZI Z: YOU SHOULD BE COMMENDED FOR IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZI Z: I THINK WE NEED TO PROBABLY WAIT. 	13	INITIATION OF THE BOARD, INCLUDING GOING OUT TO
16DR. AZZI Z: YOU SHOULD BE COMMENDED FOR17I.T. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU18SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY,19THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 1020OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO21CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR22IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST23DI SCUSSION.24DR. AZZI Z: I THINK WE NEED TO PROBABLY25WAIT.	14	2010, WHICH, IN FACT, WE DON'T SEE IN ANY OTHER
 17 IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU 18 SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, 19 THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 20 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO 21 CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR 22 IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST 23 DI SCUSSION. 24 DR. AZZIZ: I THINK WE NEED TO PROBABLY 25 WAIT. 	15	STATE AGENCY.
 18 SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY, 19 THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 20 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO 21 CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR 22 IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST 23 DI SCUSSION. 24 DR. AZZIZ: I THINK WE NEED TO PROBABLY 25 WAIT. 	16	DR. AZZIZ: YOU SHOULD BE COMMENDED FOR
 19 THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10 20 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO 21 CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR 22 IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST 23 DI SCUSSION. 24 DR. AZZIZ: I THINK WE NEED TO PROBABLY 25 WAIT. 	17	IT. SO, IN FACT, YOU SHOULD BE COMMENDED AND YOU
 OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT. 	18	SHOULD CONTINUE IN THAT VEIN, NOT YOU PERSONALLY,
 CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT. 	19	THE BOARD. I'M JUST SIMPLY STATING THAT THE LAST 10
 IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST DI SCUSSION. DR. AZZIZ: I THINK WE NEED TO PROBABLY WAIT. 	20	OR 15 MINUTES BECAUSE HAS BECOME A SLIDE TO
23 DI SCUSSI ON. 24 DR. AZZI Z: I THINK WE NEED TO PROBABLY 25 WAI T.	21	CHAIRMAN KLEIN: WHAT WE'RE SEARCHING FOR
24DR. AZZIZ: I THINK WE NEED TO PROBABLY25WAIT.	22	IS A WAY TO ACCOMMODATE THE GREATEST AND BROADEST
25 WAIT.	23	DI SCUSSI ON.
	24	DR. AZZIZ: I THINK WE NEED TO PROBABLY
39	25	WALT.
39		
		39

1	MR. ROTH: SO, JAMES, CAN I ASK IF I WERE
2	TO WITHDRAW MY MOTION AND WE RETURN TO THE
3	DISCUSSION WE HAD LAST NIGHT THAT WAS AGENDIZED
4	UNDER THE CHAIRMAN'S REPORT, HAVE A GENERAL
5	DISCUSSION, NOT ABOUT THESE SPECIFIC GRANTS, BUT HOW
6	WE GET A SENSE OF THE BOARD, NO MOTIONS, NO ACTION,
7	THEN WE CAN RETURN AFTER WE HAVE THAT DISCUSSION TO
8	THE ACTIONS AND THEN PEOPLE CAN VOTE.
9	CHAIRMAN KLEIN: WE HAVE TWO SEPARATE DAYS
10	UNDER TWO SEPARATE AGENDAS.
11	MR. ROTH: IT CAN BE A CONTINUATION.
12	CHAIRMAN KLEIN: I UNDERSTAND. I'M OPEN
13	TO ANY SOLUTION. I'M INTENSELY AWARE OF THE
14	INTRICACIES OF THE SITUATION. SO I'M ASKING VERY
15	SPECIFIC QUESTIONS.
16	MR. HARRISON: WE HAVE TWO SEPARATE
17	AGENDAS FOR THIS MEETING. THE MORE GENERAL ITEM WAS
18	ON YESTERDAY'S AGENDA. IT'S NOT ON TODAY'S AGENDA;
19	HOWEVER, IT'S INTENDED FOR DISCUSSION ONLY, NOT FOR
20	ACTION. SO IN OTHER WORDS, THERE WOULD BE NOTHING
21	TO UNDO IF SOMEONE WERE TO EXPRESS A CONCERN ABOUT
22	THE FACT THAT THERE WERE A DISCUSSION.
23	FURTHERMORE, IT, AS THIS CONVERSATION HAS
24	DEMONSTRATED, IS OF OBVIOUS RELEVANCE TO THE ISSUES
25	THAT ARE AGENDIZED FOR TODAY; NAMELY, THE
	40
	40

1	CONSIDERATION OF THREE ROUNDS OF GRANT APPLICATIONS.
2	MR. ROTH: SO I THINK THE BEST WAY MAYBE
3	IS FOR ME IS TO WITHDRAW MY MOTION AND RETURN TO THE
4	DISCUSSION WE DID NOT FINISH LAST NIGHT. THERE WERE
5	A LOT OF COMMENTS, BUT MAYBE WE CAN GET A SENSE OF
6	THE BOARD, LET EVERYBODY SPEAK, AND THEN WE CAN
7	DECIDE. I CAN MAKE THE MOTION AGAIN AND WE CAN
8	REVIEW.
9	CHAIRMAN KLEIN: I'D BE HAPPY TO WITHDRAW
10	MY SECOND.
11	MR. ROTH: WITHDRAW MY MOTION.
12	CHAIRMAN KLEIN: SO I'M GOING TO LEAVE
13	THIS AGENDA ITEM, AND WE'RE GOING TO GO INTO A
14	GENERAL POLICY DISCUSSION WHICH WE HAD AN IN-DEPTH
15	DISCUSSION ON LAST NIGHT. AND IN THAT DISCUSSION,
16	SHERRY, WOULD YOU LIKE TO START THE DISCUSSION, AND
17	THEN I WILL CALL ON ANYONE ELSE AS TO A POTENTIAL
18	GENERAL STANDARD THAT WE WILL ACT ON HOPEFULLY IN
19	MARCH, BUT A DISCUSSION OF THAT POTENTIAL GENERAL
20	STANDARD.
21	MS. LANSING: I FEEL VERY, VERY STRONGLY
22	THAT, THOUGH THESE ARE DIFFICULT ECONOMIC TIMES, WE
23	HAVE FACED CRISES BEFORE. AND I FEEL VERY, VERY
24	STRONGLY THAT WE MUST MOVE FORWARD WITH THE HOPE AND
25	THE ANTICIPATION THAT WE WILL GET THE MONEY TO FUND
	41

41

1	THESE GRANTS. WE DON'T KNOW WHAT THE FUTURE HOLDS
2	FOR US. WE DON'T KNOW WHAT'S GOING TO HAPPEN IN THE
3	ECONOMY. AND SO I THINK TO STOP WOULD HAVE BEEN
4	LIKE STOPPING WHEN WE HAD THE LAWSUITS AGAINST US.
5	SO IT IS MY BELIEF THAT WE SHOULD REVIEW
6	EVERY GRANT SUBJECT TO FUNDING BEING AVAILABLE AND
7	APPROVE OR DISAPPROVE THEM IN THE NORMAL COURSE OF
8	BUSINESS. I THINK THAT WE ARE FULLY TRANSPARENT.
9	WE HAVE BEEN MORE THAN HONEST TO ANYBODY WHO HAS
10	SUBMITTED ANYTHING. AND WHEN THESE MATTERS BECOME
11	CLEARER TO US, WHICH THEY WILL WHEN WE KNOW WHAT
12	HAPPENS WHEN WE GO OUT FOR NONCONVENTIONAL BONDINGS,
13	WE KNOW WHAT HAPPENS WHEN WE GO TO FOUNDATIONS AND
14	INDIVIDUALS, WE WILL HAVE A BETTER DETERMINATION.
15	BUT TO STOP THIS, I THINK, IS A DIRE MISTAKE AND
16	WILL ONLY PUT US BEHIND. SO I URGE THAT WE MOVE
17	FORWARD.
18	DR. REED: I SHARE SHERRY'S SENTIMENTS IN
19	TERMS OF HOW WE SHOULD PROCEED AS A BOARD. I THINK
20	THE ONLY SUGGESTION I HAVE TO OFFER REALLY THOUGH IS
21	THE USE OF THE TERM "SUBJECT TO AVAILABILITY" WITH
22	RESPECT TO FUNDS. I THINK IT'S REALLY WHERE WE'RE
23	TALKING. BECAUSE THAT CAN BE INTERPRETED BY
24	DIFFERENT PEOPLE TO MEAN DIFFERENT THINGS, I THINK
25	WHAT WE REALLY ARE TALKING ABOUT IS HOLDING IN

42

1	ABEYANCE ANY FUNDING. SO WHAT WE'RE REALLY TALKING
2	ABOUT IS APPROVING FOR FUNDING, BUT NOT ACTUALLY
3	FUNDING. AND WHAT WE'RE TALKING ABOUT ESSENTIALLY
4	IS A HOLDING IN ABEYANCE OF THE FUNDING UNTIL SUCH
5	TIME AS THIS BOARD AGREES THAT IT'S PRUDENT TO DO SO
6	AND THAT IT HAS THE RESOURCES TO DO AND THAT IT CAN
7	THEN THE BOARD CAN ALSO EXERCISE ITS DISCRETION
8	IN TERMS OF WHICH OF THESE APPROVED GRANTS WOULD
9	ACTUALLY BE FUNDED SUBJECT TO OUR PRIORITIZATION OF
10	THOSE GRANTS IN TERMS OF THE DIFFERENT TYPES OF
11	PROGRAMS I'M THINKING OF HERE AND THE AVAILABILITY
12	OF FUNDS, HOW MUCH FUNDS DO WE HAVE.
13	CHAIRMAN KLEIN: THIS IS A GENERAL POLICY
14	STATEMENT NOT RELATED TO ANY PARTICULAR PROGRAM, BUT
15	EVERYTHING WE'RE CONSIDERING AS AN AGENCY.
16	DR. BIRGENEAU: I WOULD PERSONALLY LIKE TO
17	ADD I AGREE WITH EVERYTHING THAT'S BEEN SAID EXCEPT
18	I WOULD LIKE TO ADD THE ADDITIONAL CAVEAT THAT I
19	THINK WE MUST GIVE PRIORITY TO PREVIOUSLY APPROVED
20	GRANTS. PEOPLE HAVE MADE DETAILED PLANS BASED ON
21	THE ASSUMPTION THAT THOSE RESOURCES WOULD COME.
22	CHAIRMAN KLEIN: LET ME TRY AND REFOCUS US
23	ALL ON THAT. THOSE ARE ACTUALLY CONTRACT
24	OBLIGATIONS, SO THEY'RE NOT SUBJECT TO NEW FUNDING
25	DECISIONS. THEY HAVE SOVEREIGNTY UNDER THE FEDERAL
	13

1	AND STATE CONTRACT LAW THAT MUST BE HONORED AS
2	EXISTING OBLIGATIONS. IF WE DID NOTHING, BY
3	OPERATION OF LAW OF THE STATE OF CALIFORNIA, PUBLIC
4	BONDS WOULD EVENTUALLY BE SOLD TO FUND THOSE GRANTS.
5	BY US TAKING AN AFFIRMATIVE POSITION AND
6	RAISING FUNDS POTENTIALLY THROUGH PRIVATE PLACEMENTS
7	OR STIMULUS BILLS OR ANY OTHER RESOURCE, WE CAN
8	ACCELERATE THE AVAILABILITY OF FUNDS FOR EXISTING
9	AND NEW PROGRAMS, BUT THOSE NEW PROGRAMS UNDER
10	OPERATION OF LAW WILL BE FUNDED BY PUBLIC BONDS
11	OF THOSE EXISTING ONES BY PUBLIC BONDS OF THE
12	STATE IF WE DID NOTHING AT SOME POINT, HOPEFULLY ON
13	TIME. IN FACT, THE LAW WOULD REQUIRE THEM TO FUND
14	IT ON TIME.
15	DR. FRIEDMAN: SO AT THE RISK OF PILING
16	ON, I TOO AGREE. LET ME MAKE SURE THAT WE'RE CLEAR
17	ABOUT WHAT WAS JUST SAID BECAUSE I THINK IT'S
18	CRUCIAL. WHEN ALAN SAYS THAT WE HAVE SUFFICIENT
19	FUNDS TO THINK ABOUT DOING CERTAIN THINGS, I'M NOT
20	SPEAKING TO A SPECIFIC PROGRAM, I'M TALKING IN
21	GENERAL, IN FACT, IF WE LOOK OUT TO THE EXTENT OF
22	OUR OBLIGATION FOR THE THINGS THAT WE'VE PREVIOUSLY
23	COMMITTED, IT'S NOT AT ALL CLEAR TO ME THAT WE HAVE
24	SUFFICIENT FUNDS IF WE TAKE ON THE TWO-, THREE-, OR
25	WHATEVER-YEAR OBLIGATION THAT WE'VE COMMITTED TO IN

44

1	THE CONTRACTUAL SENSE THAT YOU' VE JUST SAID.
2	ESTABLISHING THE PRIMACY OF THE
3	COMMITMENTS WE'VE ALREADY MADE, I THINK, IS EXACTLY
4	THE RIGHT THING TO DO. I ALSO AGREE WITH EVERYONE
5	WHO HAS SPOKEN ABOUT THE VALUE OF REVIEWING THESE
6	GRANTS NOW AND ASSIGNING SOME AN APPROVED PRIORITY,
7	NOT JUST TO SHOW THAT THERE'S DYNAMISM IN THE
8	PROGRAM, ALSO TO GIVE FEEDBACK TO THOSE
9	INVESTIGATORS WHO WANT TO CONTINUE TO CRAFT THEIR
10	PROPOSALS TO MAKE THEM BETTER, BUT ALSO SO THEY
11	COULD USE THOSE PROPOSALS IN GOING TO OTHER
12	AGENCI ES.
13	NOW, I UNDERSTAND IT'S LARGELY SYMBOLIC,
14	BUT WE COULD, EITHER OURSELVES OR HAVE THESE
15	INVESTIGATORS, PROVIDE TO NIH OUR REVIEWS OF THESE
16	PROGRAMS AND SAY WE DON'T HAVE THE RESOURCES,
17	PERHAPS, FOR A FUTURE ACTIVITY TO FUND THEM RIGHT
18	NOW, BUT WE THINK THESE ARE HIGHLY MERITORIOUS, AND
19	WE JUST WANT TO MAKE YOU ARE AWARE OF THIS. THERE
20	MAY BE PRIVATE ORGANIZATIONS, DISEASE-FOCUSED
21	ORGANIZATIONS THAT WOULD BE INTERESTED IN FUNDING
22	THESE. AND, AGAIN, BY GIVING OUR STAMP OF REVIEW,
23	IT MIGHT HELP THOSE INVESTIGATORS IN THEIR
24	ACTI VI TI ES.
25	AND SO I THINK IT'S STRONGLY TO EVERYONE'S
	45

45

1	ADVANTAGE TO MOVE AHEAD, BUT I REALLY DO WANT TO
2	HAVE A VERY CONSERVATIVE FINANCIAL PERSPECTIVE ON
3	THIS. AND I'M GLAD THAT EVERYONE'S SAYING IT WILL
4	COME BACK TO THIS BOARD BEFORE ANY DECISIONS ABOUT
5	FUNDING ANY OF THE POSSIBLE RFA'S THAT WE'RE TALKING
6	ABOUT OVER THE NEXT PERIOD OF TIME. THANK YOU.
7	CHAIRMAN KLEIN: OKAY.
8	MS. FEIT: IS IT POSSIBLE, AND I THINK
9	THAT I GAVE THIS A LOT OF THOUGHT LAST NIGHT AFTER
10	THE MEETING, WE'RE TRYING TOO HARD TO PREDICT THE
11	FUTURE. AND I THINK AS A STATE AGENCY WE SHOULD DO
12	WHAT OTHER AGENCIES DO, JUST CONTINUE OUR WORK. AND
13	TAKE THESE THINGS SEPARATELY. WE HAVE IN FRONT OF
14	US GRANTS THAT HAVE BEEN REVIEWED, HAVE GONE THROUGH
15	A PROCESS, AND I THINK WE NEED TO CONCLUDE THAT
16	PROCESS AS ONE ACTION THAT WE TAKE.
17	THE SECOND ACTION WOULD BE THEN FOR THE
18	BOARD TO CONSIDER ITS FUTURE FINANCING AND NOT TRY
19	TO LUMP EVERYTHING TOGETHER AND PREDICT WHAT THE
20	STATE IS GOING TO DO, BUT TO SIMPLY DO THE WORK OF
21	THIS AGENCY AND MOVE FORWARD.
22	I THINK THAT THAT IS THE CLEAREST WAY TO
23	ADDRESS THIS. I WOULD THINK WE'D BE REMISS IN
24	LEAVING THIS STUFF ON THE TABLE AFTER ALL WE'VE DONE
25	TO GET THE WORK HERE. AND I THINK THAT EVERYBODY
	16

46

1	UNDERSTANDS THE PREDICAMENT OF THE ECONOMIC CLIMATE.
2	WE DON'T HAVE TO RESTATE IT. EVERYBODY, EVERYBODY
3	IN THE WORLD NOW KNOWS WHERE WE STAND.
4	SO I THINK THIS AGENCY NEEDS TO COMPLETE
5	ITS WORK, MOVE FORWARD, BUT I THINK WE SHOULD
6	SEPARATE THE WORK AND KEEP IT CLEAN. I THINK WE
7	SHOULD LOOK AT THE WORK IN FRONT OF US, COMPLETE THE
8	PROCESS OF THESE GRANTS THAT HAVE BEEN SUBMITTED TO
9	US, AND THEN TAKE UP THE ISSUE AROUND FUTURE
10	FINANCING OF THIS AGENCY AS A SEPARATE ISSUE GOING
11	FORWARD.
12	CHAIRMAN KLEIN: I HAVE DAVID, DEAN PIZZO,
13	CLAIRE POMEROY, DR. AZZIZ, DR. GILL.
14	MR. SERRANO-SEWELL: I'M GLAD WE FOUND A
15	MECHANISM TO HAVE A BROADER DISCUSSION BECAUSE IT
16	WILL INFORM MY DECISION WHEN WE GET INTO THE
17	SPECIFICS. SO I'LL GIVE YOU MY BROAD SENSE OF
18	THINGS. AND THAT IS WE SHOULD PROCEED, BUT I'M
19	UNCOMFORTABLE WITH THE PROCEED WHEN FUNDING
20	AVAILABLE BECAUSE IT DIVERTS FROM THE RECOMMENDATION
21	FROM STAFF, WHICH WE HEARD LAST NIGHT AND WE HAVE
22	MATERIALS IN FRONT OF US. AND I DO BELIEVE THE
23	RECOMMENDATION FROM STAFF EMBODIES OUR SCIENTIFIC
24	MISSION, OUR CORE MISSION, OUR CORE VALUES, AND TO
25	DIVERT FROM THAT WOULD CAUSE GREAT HARM TO OUR

47

1	MISSION. I BELIEVE THAT. AND WE DO HAVE, WE CAN
2	FUND CERTAIN PROPOSALS THAT ARE IN FRONT OF US
3	TODAY. WE CAN DO THAT, AND WE OUGHT TO DO THAT.
4	PERHAPS IT HAS TO BE AUGMENTED AND AMENDED
5	IN SOME WAY, BUT I BELIEVE WE CAN. I BELIEVE THE
6	MONEY IS THERE. AND WE HEARD FROM STAFF THAT THE
7	MONEY IS THERE. SO YOU CAN WE'RE WELCOME TO
8	REJECT STAFF'S ASSESSMENT OF THINGS, BUT I HAPPEN TO
9	THINK IT HAS SOME VALIDITY.
10	CHAIRMAN KLEIN: OKAY. DR. POMEROY.
11	DR. POMEROY: I THINK THIS CONVERSATION
12	HAS BEEN VERY HELPFUL. I WOULD SAY THIS. I THINK
13	THAT THE DECISION WE MAKE ABOUT THIS WILL SEND AN
14	IMPORTANT MESSAGE, AND THE MESSAGE THAT WE WERE
15	SENDING BEFORE WHEN WE PROCEEDED WITH OUR WORK WHEN
16	WE WERE BEING SUED WAS ABOUT AN EXTERNAL THREAT AND
17	GOING FORWARD DESPITE AN EXTERNAL THREAT. THIS IS A
18	MESSAGE ABOUT WHETHER WE'RE GOING TO BE FISCALLY
19	RESPONSIBLE INTERNALLY WITH OUR OWN FUNDS.
20	SO I THINK THE DECISIONS ARE VERY DISTINCT
21	AND VERY DIFFERENT, AND WE ARE SENDING A MESSAGE
22	BOTH ABOUT THE MISSION AND ALSO ABOUT OUR ABILITY TO
23	BE FISCALLY RESPONSIBLE. I PERSONALLY THINK THAT
24	THE ALL OF THESE PROGRAMS, NOT TO SPEAK TO A
25	PARTICULAR ONE, ARE VERY IMPORTANT; HOWEVER, I THINK

48

1	IT IS MOST IMPORTANT TO GET OUR FINANCIAL HOUSE IN
2	ORDER BEFORE WE PROCEED AS IF THERE'S PLENTY OF
3	MONEY AROUND. AND I WOULD LIKE TO SEE I DO NOT
4	BELIEVE THAT A SIX-WEEK DELAY WILL HURT OUR MISSION
5	WHILE WE GATHER FURTHER DATA ABOUT THE FINANCIAL
6	REALITIES AND ABOUT OUR ABILITY TO GET MORE BONDS.
7	SO WE HAVE TO COME UP FIRST WITH WE HEARD
8	\$112 MILLION IN BONDS TO MEET OUR EXISTING
9	OBLIGATIONS THROUGH 2010, ASSUMING THAT EVERYTHING
10	IS ALL CLEANED UP BY THEN. AND I WOULD LIKE TO KNOW
11	THAT THERE'S A SOLUTION FOR THAT \$112 MILLION GAP
12	BEFORE I IMPLY THAT IT IS ACCEPTABLE TO GO ON WITH
13	SPENDING OR EVEN CONSIDERING THE SPENDING OF
14	ADDITIONAL MONEY.
15	CHAIRMAN KLEIN: THANK YOU. DR. AZZIZ,
16	AND THEN DR. GILL.
17	DR. AZZIZ: I DO WANT TO THANK DUANE AND
18	BOB FOR ALLOWING A BROADER DISCUSSION. I THINK IT'S
19	VERY IMPORTANT.
20	I HAVE TO SAY THAT I AGREE WITH PARTS OF
21	EVERYTHING THAT'S BEEN SAID. CERTAINLY I AGREE WITH
22	DR. POMEROY AND WITH DAVID'S POINT OF VIEW. I FEEL
23	THE ISSUE THAT WE NEED TO RESOLVE, AND I'M LESS
24	CONCERNED ABOUT THE REVIEW OF THE GRANT THAN THE
25	SIGNAL WE ARE GIVING, AND THE SIGNAL OF HOPE IS
	10

1	GREAT, BUT THE SIGNAL OF FIDUCIARY LACK OF
2	FIDUCIARY CAUTION IS ANOTHER ONE THAT I'M CONCERNED
3	ABOUT. AND I AM CONCERNED ABOUT, AS DAVID SAID, THE
4	ISSUE OF WHEN FUNDS ARE AVAILABLE.
5	THIS TERMINOLOGY NEEDS TO BE THOUGHT
6	THROUGH VERY WELL. ARE WE IMPLYING A CONTRACT? ARE
7	WE MEANING THAT ANY MONIES THAT COME IN FIRST GO TO
8	THIS PROGRAM? DO WE ACTUALLY FUND THIS AFTER WE
9	SATISFY THAT WE HAVE THE MONIES TO PAY OUR ALREADY
10	PRIOR OBLIGATIONS? DO EXPOSE OURSELVES TO SUITS OF
11	SOME SORT OR ANOTHER? DO WE ACTUALLY HAVE SOME
12	RAISED EXPECTATIONS THAT ACTUALLY MAY NOT BE
13	FULFI LLED?
14	THESE ARE ALL QUESTIONS THAT SIMPLY WE
15	CAN'T ANSWER IN A SHORT TERM. THE CRAFTING OF THE
16	MESSAGE REGARDING THE MONIES AVAILABLE, WHICH CAN
17	RANGE FROM THIS IS YOUR SCORE, THERE ARE TODAY NO
18	MONIES.
19	CHAIRMAN KLEIN: DR. PULIAFITO, IF WE
20	COULD FOCUS ON DR. AZZIZ, PLEASE.
21	DR. AZZIZ: THANK YOU. THERE ARE NO
22	MONIES IN THE PROGRAM, BUT WE WILL LET YOU KNOW IF
23	THERE ARE; AND IF YOU HAVEN'T HEARD OF US BY JUNE,
24	THERE WILL BE NO MONEY OR SOMETHING VERY SPECIFIC
25	LIKE THAT TO SOMETHING VAGUE AS, WELL, IT WILL BE
	50

FUNDED IF MONIES ARE AVAILABLE HAS TO BE THOUGHT
 THROUGH BECAUSE THEY ARE IMPLICATIONS FOR THE
 GRANTEES. AND THERE ARE IMPLICATIONS FOR HOW WE
 MANAGE THIS.

SO I AM JUST SIMPLY SUGGESTING THAT WE 5 NEED MORE INFORMATION. AND WHILE SOME ARE VERY 6 7 SAVVY, LIKE YOURSELF AND OTHER PEOPLE, ABOUT THE 8 BOND MARKETS AND SO ON AND SO FORTH, I'M NOT SURE THAT WE WOULD DO OUR BEST JOB IF WE JUST PUT A 9 10 LITTLE SENTENCE AT THE END OF EVERY RESPONSE LETTER AND THEN FOUND OUT ACTUALLY THAT WE DON'T EVEN KNOW 11 12 WHAT THAT MEANS.

13 CHAIRMAN KLEIN: SO WE WILL BE ABLE, AND IT IS OUR INTENTION, IN MARCH TO HAVE SOME VERY 14 DETAILED ALTERNATIVE POSITIONS THAT COULD BE TAKEN 15 16 ON A FULLY AGENDIZED ITEM. BUT THE PROPOSITION 71 17 WAS APPROVED BY SEVEN MILLION VOTERS WHO SPECIFICALLY AUTHORIZED THIS MONEY. WE ACTUALLY 18 19 HAVE THE AUTHORITY. WE ARE TRYING TO EXERT DI SCI PLI NE HERE EVEN THOUGH WE HAVE AUTHORIZED 20 21 SPENDING BECAUSE WE WANT TO MAKE SURE THAT WHEN WE 22 MAKE A COMMITMENT TO A GRANTEE ORGANIZATION, THE FUNDS ARRIVE AND ARRIVE ON TIME. THEIR ECONOMIC 23 24 PLANNING DURING THIS PERIOD WILL BE VERY CRITICAL. 25 PART OF THE EXERCISE TODAY IS, AS YOU' VE

51

1SAID, TO BE VERY TRANSPARENT AND TO INFORM THEM SO2THAT THEY' RE MAKING INDEPENDENT DECISIONS. WE'RE3NOT MAKING ANY ASSUMPTIONS FOR THEM. WE'RE BEING4COMPLETELY OPEN ABOUT THE CHALLENGES WE HAVE IN5ENSURING THAT THOSE FUNDS ARRIVE ON TIME.6BUT WE CAN CERTAINLY, AS HAS BEEN7SUGGESTED, DECOUPLE THESE QUESTIONS AND APPROVE FOR8FUNDING, MAKING IT CLEAR WE'RE NOT MAKING A FUNDING9APPROPRIATION, AND MAKE AND REFINE IN MARCH DECISION10AVAILABILITY OF FUNDING AND WHAT IT MEANS.11DR. AZZIZ: CAN YOU CLARIFY? YOU JUST12SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER13THAN THE REVIEWS?14CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR15FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE16EUNDING DECISION ON TIMING DECAUSE THAT WILL RE	
 NOT MAKING ANY ASSUMPTIONS FOR THEM. WE'RE BEING COMPLETELY OPEN ABOUT THE CHALLENGES WE HAVE IN ENSURING THAT THOSE FUNDS ARRIVE ON TIME. BUT WE CAN CERTAINLY, AS HAS BEEN SUGGESTED, DECOUPLE THESE QUESTIONS AND APPROVE FOR FUNDING, MAKING IT CLEAR WE'RE NOT MAKING A FUNDING APPROPRIATION, AND MAKE AND REFINE IN MARCH DECISION AVAILABILITY OF FUNDING AND WHAT IT MEANS. DR. AZZIZ: CAN YOU CLARIFY? YOU JUST SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER THAN THE REVIEWS? CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE 	
 COMPLETELY OPEN ABOUT THE CHALLENGES WE HAVE IN ENSURING THAT THOSE FUNDS ARRIVE ON TIME. BUT WE CAN CERTAINLY, AS HAS BEEN SUGGESTED, DECOUPLE THESE QUESTIONS AND APPROVE FOR FUNDING, MAKING IT CLEAR WE'RE NOT MAKING A FUNDING APPROPRIATION, AND MAKE AND REFINE IN MARCH DECISION AVAILABILITY OF FUNDING AND WHAT IT MEANS. DR. AZZIZ: CAN YOU CLARIFY? YOU JUST SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER THAN THE REVIEWS? CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE 	
 ENSURI NG THAT THOSE FUNDS ARRI VE ON TIME. BUT WE CAN CERTAINLY, AS HAS BEEN SUGGESTED, DECOUPLE THESE QUESTIONS AND APPROVE FOR FUNDI NG, MAKI NG IT CLEAR WE'RE NOT MAKI NG A FUNDI NG APPROPRI ATI ON, AND MAKE AND REFI NE IN MARCH DECISION AVAI LABI LI TY OF FUNDI NG AND WHAT IT MEANS. DR. AZZI Z: CAN YOU CLARI FY? YOU JUST SAI D SOMETHI NG. WHAT WOULD WE BE APPROVI NG OTHER THAN THE REVI EWS? CHAI RMAN KLEI N: WE WOULD APPROVE THEM FOR FUNDI NG, MAKI NG IT CLEAR WE ARE NOT MAKI NG THE 	
 BUT WE CAN CERTAINLY, AS HAS BEEN SUGGESTED, DECOUPLE THESE QUESTIONS AND APPROVE FOR FUNDING, MAKING IT CLEAR WE'RE NOT MAKING A FUNDING APPROPRIATION, AND MAKE AND REFINE IN MARCH DECISION AVAILABILITY OF FUNDING AND WHAT IT MEANS. DR. AZZIZ: CAN YOU CLARIFY? YOU JUST SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER THAN THE REVIEWS? CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE 	
 SUGGESTED, DECOUPLE THESE QUESTIONS AND APPROVE FOR FUNDING, MAKING IT CLEAR WE'RE NOT MAKING A FUNDING APPROPRIATION, AND MAKE AND REFINE IN MARCH DECISION AVAILABILITY OF FUNDING AND WHAT IT MEANS. DR. AZZIZ: CAN YOU CLARIFY? YOU JUST SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER THAN THE REVIEWS? CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE 	
 FUNDING, MAKING IT CLEAR WE'RE NOT MAKING A FUNDING APPROPRIATION, AND MAKE AND REFINE IN MARCH DECISION AVAILABILITY OF FUNDING AND WHAT IT MEANS. DR. AZZIZ: CAN YOU CLARIFY? YOU JUST SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER THAN THE REVIEWS? CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE 	
 APPROPRIATION, AND MAKE AND REFINE IN MARCH DECISION AVAILABILITY OF FUNDING AND WHAT IT MEANS. DR. AZZIZ: CAN YOU CLARIFY? YOU JUST SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER THAN THE REVIEWS? CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE 	
 AVAILABILITY OF FUNDING AND WHAT IT MEANS. DR. AZZIZ: CAN YOU CLARIFY? YOU JUST SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER THAN THE REVIEWS? CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE 	
11DR. AZZIZ: CAN YOU CLARIFY? YOU JUST12SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER13THAN THE REVIEWS?14CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR15FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE	
 SAID SOMETHING. WHAT WOULD WE BE APPROVING OTHER THAN THE REVIEWS? CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE 	
 13 THAN THE REVIEWS? 14 CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR 15 FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE 	
14CHAIRMAN KLEIN: WE WOULD APPROVE THEM FOR15FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE	
15 FUNDING, MAKING IT CLEAR WE ARE NOT MAKING THE	
16 FUNDING DECISION ON TIMING BECAUSE THAT WILL BE	
17 DI SCUSSED I N MARCH.	
18 NOW, WE CAN IN SPEAKING GENERALLY, WE	
19 COULD FOLLOW THAT APPROACH WITH ANY RFA.	
20 DR. GILL: I THINK WHAT DR. POMEROY SAID	
21 IS WHAT'S BEEN TROUBLING ME. AND THAT IS THAT IF WE	
22 ARE IN A VERY DIFFICULT FINANCIAL TIME, ONE MIGHT	
23 WISH TO REEVALUATE SOMEWHAT THE PREVIOUSLY SET	
24 PRIORITIES IN ORDER TO BE FINANCIALLY RESPONSIBLE.	
25 AND BY THAT I MEAN, I THINK JEFF ADDRESSED THIS LAST	
52	

52

1	NIGHT, THAT AMONG THE GRANTS WE'RE GOING TO LOOK AT
2	ON THE AGENDA, NONE OF THESE ADDRESS THE CORE
3	MISSION OF RESEARCH AND TRANSLATION INTO PATIENTS.
4	RATHER, THEY WOULD, SAY, PREPARE A WORKFORCE FOR AN
5	INDUSTRY WHICH MIGHT NOT EXIST.
6	SO IT SEEMS TO ME THAT THE MOST PRUDENT
7	THING WOULD BE TO CONSIDER THESE AT A MARCH OR APRIL
8	MEETING, TO POSTPONE A DECISION ON THIS TYPE OF
9	GRANT EVEN THOUGH THEY HAVE BEEN REVIEWED, TO WAIT
10	UNTIL IT'S CLARIFIED.
11	CHAIRMAN KLEIN: I DON'T THINK YOU WANT TO
12	ADDRESS THE ISSUE OF THE GRANTS WE HAVE BEFORE US.
13	YOU ARE TALKING ABOUT A GENERAL POLICY.
14	DR. GILL: A GENERAL POLICY OF DECIDING
15	WHERE THE PRIORITIES REEVALUATION OF THE
16	PRIORITIES FOR FUNDING GIVEN A DIFFERENT FINANCIAL
17	CLIMATE. THAT IS CORRECT.
18	CHAIRMAN KLEIN: IT'S IMPORTANT AS A PRIOR
19	REFERENCE THAT, AS A NUMBER OF SPEAKERS HAVE SAID,
20	THERE'S A TREMENDOUS AMOUNT OF WORK THAT'S GONE INTO
21	THESE. IN SOME CASES INSTITUTIONS HAVE, ACTUALLY IN
22	MANY CASES INSTITUTIONS HAVE ACTUALLY SELECTED THE
23	INDIVIDUALS TO BE IN THE PROGRAM. AND THEY HAVE IN
24	SOME CASES FUNDED PART OF THIS WORK ALREADY. SO
25	PROVIDING A CLEAR MESSAGE I REALIZE I DO NOT HAVE

1	ANY CONFLICTS, SO I CAN ADDRESS THIS ISSUE
2	PROVIDING A CLEAR MESSAGE ABOUT OUR DESIRE TO FUND
3	THESE ON WHICH PEOPLE REASONABLY RELIED IN DOING THE
4	WORK AND BRINGING THEM HERE AND GOING THROUGH PEER
5	REVIEW HAS MAYBE AN INDEPENDENT VALUE SEPARATE FROM
6	OTHER GRANTS WHERE THOSE EXPECTATIONS AND THE WORK
7	HAS NOT YET BEEN ACCOMPLISHED.
8	THE BAYBIO HAS JUST ISSUED A REPORT SAYING
9	THE CRITICAL SHORTFALL IS NOT JUST FOR INDUSTRY,
10	BUT, IN FACT, FOR THE EXPANSION IN THE NONPROFIT
11	SECTOR FOR RESEARCH TO HAVE THESE HIGHLY TRAINED
12	TECHNICIANS. SO ONE COULD CERTAINLY ARGUE THAT THIS
13	IS PART OF OUR CORE MISSION TO MAKE SURE THAT OUR
14	SCIENTISTS HAVE EXTREMELY WELL-TRAINED INDIVIDUALS.
15	DR. PRI ETO.
16	DR. PRIETO: I GUESS I'D RESPECTFULLY HAVE
17	TO DISAGREE WITH DR. GILL ABOUT THE IMPORTANCE OF
18	CERTAIN TYPES OF INVESTMENTS, IF YOU WILL, THAT WE
19	MIGHT MAKE. I THINK YOU CAN ARGUE THAT
20	STRATEGICALLY INVESTING IN A WORKFORCE AND TOOLS
21	THAT WOULD HAVE APPLICABILITY ACROSS MANY, MANY
22	DIFFERENT PARTICULAR LOCATIONS AND PARTICULAR GRANTS
23	AND PARTICULAR, YOU KNOW, AVENUES OF RESEARCH MIGHT
24	BE MORE IMPORTANT THAN ANY INDIVIDUAL SCIENTIFIC
25	GRANT OR EVEN POOL OF SCIENTIFIC GRANTS.

54

1	AND IN TERMS OF THIS INDUSTRY DOES
2	EXIST IN CALIFORNIA NOW. AND WHETHER IT GROWS AND
3	REALLY TAKES ROOT AND DEVELOPS HERE VERSUS SOMEWHERE
4	ELSE I THINK WILL DEPEND IN PART ON WHAT STRATEGIC
5	DECISIONS WE MAKE. AND I THINK STRATEGICALLY THAT
6	SOME OF THE THINGS WE'RE LOOKING AT ARE GOING TO BE
7	VERY IMPORTANT FOR THE FUTURE OF STEM CELL RESEARCH
8	HERE.
9	CHAIRMAN KLEIN: DR. PIZZO AND THEN DR.
10	PULI AFI TO.
11	DR. PIZZO: THIS IS OBVIOUSLY A VERY
12	HELPFUL, IMPORTANT DISCUSSION. I THINK I WANT TO
13	FRAME IT IN A SLIGHTLY DIFFERENT WAY. WE HAVE OUR
14	WORDS BEFORE US AND THE RECOGNITION THAT THEY'RE
15	GOING TO BE HEARD QUITE DIFFERENTLY BY DIFFERENT
16	POPULATIONS OF INDIVIDUALS WHO WILL BE AFFECTED BY
17	THEM BECAUSE WE HAVE SO MANY DIFFERENT
18	CONSTITUENCIES. WHAT WE DO IS GOING TO BE HEARD BY
19	THE CITIZENS OF CALIFORNIA WHO VOTED FOR PROP 71.
20	IT WILL BE HEARD BY GOVERNMENT OFFICIALS WHO HAVE
21	HAD POSITIVE AND/OR NEGATIVE FEELINGS ABOUT CIRM AND
22	WHAT WE HAVE BEEN DOING AND THOSE WHO IN THE PAST
23	HAVE HAD AS PART OF THEIR GOAL AN OBJECTIVE TO
24	INTERFERE WITH THE ACTIVITIES THAT WE'RE CARRYING
25	FORTH. THEY WILL CLEARLY HAVE AN IMPACT ON THOSE

55

1	WHO HAVE BEEN RECIPIENTS OF PAST AWARDS OR WHO MIGHT
2	APPLY TO FUTURE ONES BOTH IN ACADEMIA AS WELL AS IN
3	INDUSTRY. AND THEY ARE CLEARLY IMPACTING ALL OF US
4	AS THE INDIVIDUALS WHO OVERSEE WHAT WE'RE DOING.
5	SO I THINK IT'S VERY IMPORTANT, AS WE ARE
6	CARRYING ON THIS DISCUSSION, TO BE COGNIZANT OF HOW
7	THIS IS GOING TO FEEL TO THOSE INDIVIDUALS. AND
8	WHAT WE DO IS NOT SIMPLY GOING TO BE A REFLECTION OF
9	SOME INTERIM ACTIVITY TODAY, BUT WILL HAVE FAIRLY
10	LONG-TERM IN THE SIGNIFICANCE IN TERMS OF THOSE WHO
11	ARE IN TRAINING OR THOSE WHO ARE TRYING TO CARRY OUT
12	THEIR RESEARCH AND THOSE WHO'D LIKE TO SEE US BE
13	SUCCESSFUL AND THOSE WHO WOULD NOT.
14	SO I BREAK THINGS DOWN INTO SORT OF THREE
15	CATEGORIES, GETTING VERY PRACTICAL. I THINK WE'VE
16	ALL SAID AND AGREED THAT WE MUST SUPPORT THOSE
17	GRANTS AND CONTRACTS THAT WE'VE ALREADY AGREED TO.
18	AND, THEREFORE, AS FIDUCIARIES, WE NEED TO BE
19	RESPONSI VE TO THOSE.
20	THE SECOND IS I THINK THAT WE HAVE A, I
21	FEEL, AN OBLIGATION TO OFFER SOME COMMENTARY TO
22	THOSE WHO'VE ALREADY IN GOOD FAITH APPLIED FOR RFA'S
23	OR PROGRAMS THAT WE'VE PUT FORTH. AND WE SHOULD LET
24	THEM KNOW EITHER TODAY OR BY MARCH THAT WE'RE GOING
25	TO TAKE SOME ACTION ON THEM. AND THE ACTION COULD
	E 4

56

1	BE THAT WE HAVE REVIEWED THEIR PROPOSALS AND THAT
2	ANY FUNDING WILL BE CONTINGENT UPON THE AVAILABILITY
3	OF RESOURCES. CLEARLY WE DON'T WANT TO STRETCH
4	BEYOND OUR PIPELINE OF FUNDING.

BUT I ALSO THINK WE HAVE A THIRD GROUP, 5 AND THAT THIRD GROUP ARE THOSE WHO ARE ACTIVELY 6 7 ANTICIPATING OR HOPING THAT SOME PROJECTS ARE GOING 8 TO COME FORTH BECAUSE WE'VE TALKED A LOT ABOUT 9 THESE, TRANSLATIONAL AWARDS, THE DISEASE AWARDS. 10 AND I THINK WE NEED TO COMMUNICATE VERY CLEARLY THAT THOSE MAY BE ON HOLD FOR NOW SO THAT WE DON'T GET 11 INTO A SITUATION WHERE PEOPLE ARE FRUSTRATED BY OUR 12 13 INACTION.

AND IF WE DO THAT, I THINK WE HAVE TO BE, 14 THEN, MINDFUL OF THE CONSEQUENCES. THE CONSEQUENCES 15 16 WILL BE RECEIVED VERY DIFFERENTLY BY THE CITIZENS 17 WHO VOTED FOR US, BY THE INVESTIGATORS WHO ARE DEPENDENT UPON US, BY THOSE WHO WOULD SEEK TO PUT US 18 19 OUT OF BUSINESS, AND THOSE WHO MAY FUND US GOING 20 FORWARD. EACH OF THESE THREE AREAS DOES HAVE AN 21 IMPORTANT SET OF COMPONENTS ASSOCIATED WITH THEM. 22 CHAIRMAN KLEIN: AND I'D LIKE TO SAY THIS 23 LAST POINT, DR. PIZZO, IS VERY IMPORTANT. I'M GOING 24 TO ASK FOR A COMMENT FROM STAFF BECAUSE MY 25 UNDERSTANDING OF THE PROCESS, FOR EXAMPLE, FOR

57

1	DISEASE TEAMS, WHICH IS VERY, VERY IMPORTANT TO
2	MOTIVATING PRIVATE-PLACED G.O. BOND SALES, IS THAT
3	OUR FIRST PART OF THAT PROCESS IS TRIAGE, WHICH FOR
4	THE INDIVIDUALS THAT ARE ALREADY IN THIS PROCESS, IT
5	IS A LIMITED APPLICATION. AND I WOULD ABSOLUTELY,
6	FROM AN INDIVIDUAL POINT OF VIEW, I'D LIKE TO HEAR
7	THE OTHER BOARD MEMBERS, ENCOURAGE THEM TO AT LEAST
8	GO THROUGH THE TRIAGE PROCESS BECAUSE IT BUYS US THE
9	TIME TO TRY AND RAISE THAT ADDITIONAL CAPITAL WHICH
10	I PERSONALLY AM DEDICATED TO ACHIEVING. BUT IF THEY
11	DON'T GO THROUGH THE TRIAGE PROCESS, WE DON'T HAVE
12	THE PIPELINE. WE DON'T HAVE THE ARGUMENT FOR
13	URGENCY FOR THE PRIVATE PLACEMENT OF THE G.O. BONDS.
14	SO, DR. TROUNSON OR DR. CSETE, COULD YOU
15	COMMENT ON HOW DETAILED THE APPLICATION IS FOR
16	TRIAGE, FOR EXAMPLE, FOR DISEASE TEAMS?
17	DR. CSETE: I WAS GOING TO USE THE TIME
18	LATER WHEN I TALKED ABOUT AGENDA ITEM 8 TO BRING
19	THIS UP. BUT ONE THING THAT GOT LOST A LITTLE BIT
20	IN ALL OF THE STRINGS LAST NIGHT WAS THE FACT THAT
21	STAFF HAS CONSCIOUSLY GOTTEN TOGETHER OVER THE LAST
22	FEW WEEKS TO TRY TO RECOMMEND TO YOU WHAT OUR
23	PRIORITIES SHOULD BE. AND I WILL SAY THIS IN THE
24	CONTEXT OF SOMEONE WHO, LIKE JOHN AND ALAN, SHUTTLED
25	SUCCESSFUL CAREERS TO COME HERE TO SHEPHERD THROUGH

58

1	THE TRANSLATIONAL PROGRAMS OF CIRM.
2	AND I THINK THAT OUR STRONG RECOMMENDATION
3	INTERNALLY, ALL OF THE STAFF, WAS THAT WE FIGURE OUT
4	A WAY TO MOVE FORWARD WITH THE UNIQUE DISEASE TEAM
5	PROGRAMS AND THE EARLY TRANSLATION PROGRAM THAT
6	REALLY IS ITS UNDERPINNING THE FUEL FOR THE FUTURE
7	DISEASE TEAM PROGRAMS. THE TIME IS RIGHT IN STEM
8	CELL BIOLOGY FOR THIS. YOU' VE PUT TOGETHER A STAFF,
9	A REMARKABLY TALENTED STAFF AT CIRM THAT'S READY TO
10	SHEPHERD THESE THROUGH. AND IT'S OUR STRONG IT
11	WAS OUR STRONG RECOMMENDATION, AND YOU SAW THEM IN
12	JOHN'S SLIDES, THAT DISEASE TEAMS AND EARLY
13	TRANSLATION, AND THEN OUR THIRD ONE WAS THE BRIDGES
14	PROGRAM BE GIVEN STRONG PRIORITY.
15	IN THAT CONTEXT, THE SPECIFIC QUESTION
16	THAT CHAIRMAN KLEIN ASKED WAS ABOUT THE
17	PREAPPLICATION SCREENING PROCESS. SO OUR PLAN IS TO
18	HAVE A FOUR-PAGE PREAPPLICATION THAT WILL BE
19	REVIEWED BY A COMBINATION OF EXTERNAL REVIEWERS AND
20	INTERNALLY BY CIRM STAFF, AND WE WENT THROUGH THAT
21	PROCESS IN SOME DETAIL OVER THE LAST TWO BOARD
22	MEETINGS, THAT WILL ASK THE INVESTIGATORS TO
23	DESCRIBE THEIR TARGET MOLECULE OR TARGET CELL
24	POPULATION, HOW IT WILL BE ADMINISTERED, WHAT THE
25	TARGET POPULATION IS, AND THE BASIC OUTLINES OF

59

1	THEIR RESEARCH PLAN THAT GETS THEM, AND THIS IS
2	ACKNOWLEDGEDLY AGGRESSIVE, TO AN IND APPLICATION
3	WITHIN A FOUR-YEAR TIMEFRAME.
4	AND AS DR. PIZZO HAS SAID, THIS
5	APPLICATION HAS THE IDEA OF THIS PROGRAM HAS
6	GENERATED ENORMOUS BUZZ IN THE STATE. THERE'S BEEN
7	REMARKABLE EFFORT ON FORMING MULTIDISCIPLINARY
8	PRIVATE-PUBLIC PARTNERSHIP TEAMS THAT REPRESENT
9	REALLY THE BEST SCIENCE IN CALIFORNIA, AND AS YOU
10	WILL HEAR LATER WHEN WE GET TO AGENDA ITEM 8, SOME
11	OF THE BEST SCIENTISTS FROM AROUND THE WORLD.
12	THE PREAPPLICATION WILL, WE HOPE, ALLOW US
13	TO RECOMMEND THAT ABOUT 50 OR 60 TEAMS' APPLICATIONS
14	BE RECEIVED IN FULL TO BE REVIEWED BY THE DISEASE
15	BY THE GRANTS WORKING GROUP. AND ORIGINALLY, AT THE
16	TIME OF CONCEPT APPROVAL, THE BOARD RECOMMENDED
17	SETTING ASIDE ABOUT \$250 MILLION FOR THE POSSIBILITY
18	THAT ABOUT TEN OF THESE TEAMS WOULD BE FUNDED.
19	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
20	NOW, MR. HARRISON, MY UNDERSTANDING IS, AND I
21	SPECIFICALLY CHOSE DISEASE TEAMS HOPEFULLY FOR THIS
22	REASON, IS THAT SINCE NO APPLICATIONS HAVE BEEN
23	RECEIVED, THAT ANY MEMBER OF THE BOARD CAN DISCUSS
24	THIS. IS THAT A CORRECT STATEMENT? THERE'S BEEN A
25	CONCEPTUAL APPROVAL, BUT NO APPLICATIONS HAVE BEEN

60

	BARRISTERS' REPORTING SERVICE
1	RECEI VED.
2	MR. HARRISON: THAT'S RIGHT.
3	CHAIRMAN KLEIN: I KNOW THAT I CAN TALK
4	ABOUT IT, BUT I'M TRYING TO BROADEN THE ABILITY OF
5	BOARD MEMBERS TO TALK.
6	MR. HARRISON: TO TALK GENERALLY ABOUT THE
7	DI SEASE TEAMS PROGRAMS? YES.
8	CHAIRMAN KLEIN: THANK YOU. JEFF AND THEN
9	DR. HAWGOOD.
10	MR. SHEEHY: WHAT I'M TRYING TO FIGURE OUT
11	IS WHAT OUR DECISION POINTS ARE, ESPECIALLY SINCE
12	WE'RE NOT GOING TO BE ABLE TO ADDRESS THEM DIRECTLY,
13	BUT RATHER HOW WE DISPOSE OF THESE THREE GRANT
14	ROUNDS TODAY. IT SEEMS LIKE WE STARTED OFF I WAS
15	HEARING TWO THINGS. ONE IS LET'S PROCEED MORE OR
16	LESS LIKE WE'RE STILL IN BUSINESS; AND WHEN FUNDS
17	BECOME AVAILABLE, WE'LL FUND THESE.
18	THE OTHER I'M HEARING IS LET'S PUT
19	EVERYTHING ON HOLD UNTIL WE HAVE MORE INFORMATION.
20	BUT BOTH OF THOSE TO ME DON'T SEEM TO REALLY PROVIDE
21	ENOUGH INFORMATION PER WHAT THE STAFF IS DISCUSSING
22	WHICH IS SOME SENSE OF PRIORITY. I DO THINK THAT
23	THE OPTION TO JUST STOP EVERYTHING IS ONE OPTION;
24	BUT I THINK FOR THE OTHER OPTION, WE SHOULDN'T MAKE
25	DECISIONS ABOUT ALL THE GRANT ROUNDS THAT ARE IN

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

61

FRONT OF US.

1

WE SHOULD SOMEHOW INDICATE, AS WE DISCUSS 2 THE AGENDA ITEMS BEFORE US, SOME SENSE OF PRIORITY. 3 AND THAT WILL SEND SIGNALS TO THOSE INDIVIDUALS WHO 4 ARE AND GROUPS OF INDIVIDUALS WHO ARE PREPARING 5 GRANT APPLICATIONS IN OUR UPCOMING ROUNDS THAT WE DO 6 7 INTEND TO VIGOROUSLY PURSUE OUR PRIORITIES. BUT I 8 THINK OUR EITHER/ORS OUGHT TO BE EITHER/OR OR 9 BECAUSE I DO THINK THAT WE NEED TO SEND A CLEAR 10 SIGNAL THAT SOME THINGS ARE GOING TO BE ATTENDED TO FIRST AS WE MOVE IF WE DECIDE WE'RE GOING TO MOVE 11 12 FORWARD. 13 THERE IS STILL THAT OPTION JUST TO SAY WE

DON'T KNOW ENOUGH, YOU KNOW, WE'RE VERY PRUDENT. 14 BUT I REALLY WOULD PREFER THAT THE OTHER OPTION NOT 15 16 BE LET'S JUST PUT EVERYTHING AND JUST START PILING STUFF BACK, START PILING AIRPLANES UP UNTIL THE 17 LANDING IS OPEN, BUT ACTUALLY SAY THESE ARE THE ONES 18 19 THAT ARE GOING TO GO FORWARD, AND WE'RE GOING TO DO WHAT WE CAN TO GET THOSE FUNDED, FOR ME PERSONALLY. 20 21 DR. HAWGOOD: I THINK I WOULD LARGELY ECHO 22 WHAT JEFF JUST SAID AND APPRECIATE WHAT DR. CSETE 23 JUST TOLD US. I THINK THE ONE POINT OF CONSENSUS 24 THAT WE CAN ALL AGREE TO IS THAT WE ARE FISCALLY 25 CONSTRAINED, AND I THINK THAT SPEAKS TO STRATEGY.

62

1	AND I AM RELUCTANT TO BOX US IN ON A GIVEN STRATEGY
2	UNTIL WE'VE ALIGNED ALL OF OUR PRIORITIES. I THINK
3	WE HAVE VERY EXCITING THINGS COMING DOWN THE PIKE,
4	BUT WE'RE GOING TO BE CONSTRAINED. WE'RE GOING TO
5	HAVE TO MAKE HARD CHOICES. AND I WOULD AS SOON MAKE
6	THOSE CHOICES SIMULTANEOUSLY VERSUS SEQUENTIALLY AND
7	FIND OURSELVES BOXED IN AND NOT ABLE TO DO SOMETHING
8	THAT WE WOULD ALL AGREE IS ABSOLUTELY MISSION
9	CRITICAL.
10	CHAIRMAN KLEIN: OKAY. I THINK WE'VE HAD
11	A VERY GOOD DISCUSSION ON THIS ITEM COMPLEMENTING
12	THE DISCUSSION FROM LAST NIGHT. DUANE, DID YOU HAVE
13	A COMMENT?
14	MR. ROTH: IF WE'RE COMPLETED, I THINK I'M
15	READY TO ATTEMPT A MOTION.
16	CHAIRMAN KLEIN: SO I'D LIKE TO GO FROM
17	THIS ITEM OF GENERAL DISCUSSION, REEMPHASIZING THAT
18	WITH THE PREPARATION OF THESE DISCUSSIONS AND THE
19	INPUT FROM THE BOARD, WE'RE GOING TO BE ABLE TO COME
20	BACK IN MARCH WITH SOME POLICY OPTIONS THAT ARE WELL
21	DEVELOPED AND TAKE INTO ACCOUNT THE INPUT FROM THE
22	BOARD, WHICH IS, OF COURSE, AN ESSENTIAL PART OF THE
23	PROCESS TO REALLY BRING ANYTHING REASONABLE HERE FOR
24	CONSIDERATION ON STANDARDS.
25	WE ARE NOW GOING BACK TO ITEM 4. AND CAN
	63

1	I ASK YOU, DUANE, MAYBE TO ENHANCE PARTICIPATION, WE
2	COULD HANDLE EACH OF THESE SEPARATELY?
3	MR. HARRISON: MR. CHAIR, THAT ACTUALLY
4	DOESN'T MAKE A DIFFERENCE IN TERMS OF THE ABILITY OF
5	MEMBERS TO PARTICIPATE.
6	CHAIRMAN KLEIN: BECAUSE THEY'RE ALL IN
7	BOTH. OKAY. FINE. I'M JUST TRYING TO SEARCH FOR
8	OPPORTUNITIES FOR PARTICIPATION.
9	MR. ROTH: BEFORE I MAKE MY MOTION, JUST
10	THERE WERE A NUMBER OF VERY, VERY PROFOUND
11	SUGGESTIONS AND COMMENTS MADE IN THIS LAST SESSION.
12	AND I'M PERSUADED BY MARCY'S CONCERN THAT WE
13	CONTINUE OUR WORK. I THINK THAT'S IMPORTANT. I
14	THINK RICARDO, WORDS MATTER, AND THEN DR. PIZZO AND
15	OTHERS THAT WE'VE MADE COMMITMENTS HERE THAT ARE
16	REALLY HARD TO GO BACK AND SECOND-GUESS. PERHAPS IF
17	WE HAD DONE THIS BEFORE THE RFA'S WENT OUT, THAT
18	WOULD BE APPROPRIATE. BUT I THINK THE INTEGRITY OF
19	OUR PROCESS IS VERY IMPORTANT, THAT WE TRY TO
20	MAINTAIN THE INTEGRITY THERE.
21	SO WITH THAT, I'M GOING TO MAKE THIS
22	MOTION WITH A LITTLE HELP FROM JAMES. I MOVE THAT
23	WE CONSIDER AND APPROVE FOR FUNDING THE BRIDGES AND
24	TRAINING GRANT II APPLICATIONS WITH CAVEAT, WITH THE
25	CAVEAT THAT FUNDING OF APPROVAL OF THE GRANTS IS
	4.4

64

1	SUBJECT TO THE ICOC'S DETERMINATION, IN ITS SOLE
2	DISCRETION, THAT CIRM HAS SUFFICIENT FUNDS,
3	EXCLUDING FUNDS AVAILABLE TO MEET EXISTING
4	COMMITMENTS, TO FUND THE GRANT APPLICATIONS.
5	CHAIRMAN KLEIN: I'D SECOND THAT. I
6	THINK, JAMES, IT APPEARS TO ME TO BE SUFFICIENT ON
7	ITS FACE?
8	MR. HARRISON: YES.
9	DR. PENHOET: CLARIFYING POINT. I THINK
10	THE CURRENT DR. AZZIZ MADE A PLEA FOR A VERY
11	ROBUST DEFINITION OF THE TERM "FUNDS BEING
12	AVAILABLE." I BELIEVE THAT THE CURRENT PROPOSAL
13	DOES NOT INCLUDE THAT THE FUNDS AVAILABLE WOULD BE
14	AT THE DISCRETION OF THE BOARD, IRRESPECTIVE OF
15	FUNDS ARE GENERALLY AVAILABLE TO THIS BOARD, AND
16	COULD INCLUDE A DECISION THAT THE FUNDS WOULD NOT BE
17	AVAILABLE FOR REASON OF REPRIORITIZING FUNDS WITHIN
18	CIRM BY THE BOARD. I THINK THAT, DUANE, I THINK
19	THAT'S WHAT YOU MEANT BY YOUR FIRST ONE.
20	SO FUNDS AVAILABLE WOULD MEAN FUNDS
21	GENERALLY AVAILABLE TO CIRM AS A RESULT OF BOND
22	SALES, ETC., AND THAT THIS BOARD HAD CONCLUDED THAT
23	THE FUNDS WERE AVAILABLE TO THESE SPECIFIC, WHATEVER
24	THEY ARE, THESE TWO OR ANY OTHERS, BASED ON CURRENT
25	UNDERSTANDING OF THE PRIORITIES OF THE CIRM. BOTH

65

1	OF THOSE WOULD BE INCLUDED IN THE DEFINITION.
2	CHAIRMAN KLEIN: I'D LIKE TO POTENTIALLY
3	DISTINGUISH THESE, TAKING YOUR COMMENT, DR. PENHOET.
4	STAFF HAS IDENTIFIED BRIDGES AS A MISSION CRITICAL
5	OBJECTIVE. AND I'D LIKE TO SEPARATE THEM. IT IS
6	OUR OPTION, SO I'D LIKE TO ASK IF WE FIRST WOULD
7	CONSIDER THIS MOTION, DUANE, AS TO THE TRAINING
8	PROGRAM AND THEN SEPARATELY CONSIDER, INCLUDING DR.
9	PENHOET'S ADDITIONAL LANGUAGE, AND THEN SEPARATELY
10	CONSIDER IT AS TO THE BRIDGES PROGRAM WITH THE
11	UNDERSTANDING HERE THAT DUANE ALREADY HAS IN THE
12	LANGUAGE THAT IT'S THE SOLE DISCRETION OF THE BOARD
13	WHETHER TO FUND. SO IT DOES NOT MEAN THAT WE'RE
14	COMMITTED TO ACTUALLY ADVANCE THE FUNDS, BUT I'M
15	TRYING TO RECOGNIZE THAT THERE IS A POTENTIAL
16	DIFFERENCE IN THESE TWO PROGRAMS.
17	I WOULD LIKE TO RECOGNIZE DR. OLSON.
18	DR. OLSON: I JUST WANTED TO THANK YOU,
19	MR. CHAIRMAN. I JUST WANTED TO MAKE SURE THAT
20	THERE'S A FURTHER CLARIFICATION REGARDING THIS "IF
21	FUNDS AVAILABLE. " RECOGNIZE THAT YOU' VE ALL BEEN
22	TALKING ABOUT THROUGH DECEMBER 31ST OF 2010. WE
23	HAVE COMMITMENTS EXTENDING BEYOND THAT. SO I WANT
24	TO MAKE IT VERY CLEAR WHAT YOU'RE TALKING ABOUT WHEN
25	YOU'RE TALKING ABOUT FUNDS AVAILABLE, AND I JUST ASK

66

1	YOU TO TAKE THAT INTO CONSIDERATION.
2	CHAIRMAN KLEIN: AND THE INTENT IS AT THE
3	MARCH MEETING TO ADDRESS THOSE ISSUES VERY
4	SPECIFICALLY. AND REMEMBER WHAT DUANE HAS SUGGESTED
5	IS IT'S THE SOLE DISCRETION OF THE BOARD ON THE
6	ACTUAL FUNDING.
7	DR. AZZIZ: JUST A PROCEDURAL QUESTION.
8	ED, WAS THAT A FRIENDLY AMENDMENT?
9	DR. PENHOET: I CAN'T MAKE AN AMENDMENT.
10	I WAS TRYING TO CLARIFY THE DEFINITION.
11	CHAIRMAN KLEIN: I WAS ASKING IF THERE
12	COULD BE A FRIENDLY AMENDMENT. SO THAT WAS THE FORM
13	OF MY QUESTION.
14	MR. ROTH: LET ME LISTEN TO THE LANGUAGE.
15	MR. HARRISON: IF YOU'D GIVE ME JUST ONE
16	MINUTE, I THINK I CAN SOLVE THE QUANDARY.
17	DR. PIZZO: WHILE HE'S GETTING THE
18	LANGUAGE, THERE'S AMONG THE MANY ARTICLES THAT ARE
19	OUT THERE TODAY, WON'T TALK ABOUT THE ONE, BUT THE
20	OTHER IS STEM CELL FACILITY MIGHT NOT GET BUILT.
21	THIS IS THE SAN DIEGO TRIBUNE, AND IT'S A BIG STORY.
22	IT ALSO ALLUDES TO OUR DISCUSSION OF LAST NIGHT.
23	AND I THINK WE CERTAINLY CAN ENVISION THAT SOME OF
24	THE DIALOGUE WE'RE HAVING HERE TODAY IS GOING TO BE
25	OUT THERE, WHICH IS WHY, GOING BACK TO MY EARLIER

67

1	COMMENTS, THE MESSAGES WE CONVEY ARE EITHER GOING TO
2	PROVIDE DARKNESS OR HOPE.
3	CHAIRMAN KLEIN: LET'S GO THROUGH THE
4	STEPS HERE. WE HAVE MARCY AND THEN SHERRY LANSING.
5	AND I WAS ON THE PHONE WITH ED HOLMES AT 10:30 LAST
6	NIGHT GOING THROUGH THE CONSTITUTIONAL PROTECTIONS
7	FOR EXISTING COMMITMENTS AND DISCUSSING THE WORK
8	THAT JAMES HAS BEEN DOING AT MY REQUEST FOR THE LAST
9	FIVE WEEKS ON DEVELOPING SOMETHING FOR THE BANKS SO
10	THEY COULD UNDERSTAND THAT THEY COULD RELY UPON
11	CONSTITUTIONAL PROTECTIONS AND THE FUNDING
12	AUTHORIZATION WE HAVE IN PLACE ON EXISTING
13	CONTRACTS.
14	MS. FEIT: JUST HAVE TWO QUICK POINTS I
15	WANTED TO MAKE. ONE IS, AGAIN, TO RESTATE
16	CONTINUING THE WORK OF THIS AGENCY GOING FORWARD,
17	BUT ALSO BEING CLEAR THAT THE BOARD HAS SERIOUS
18	FIDUCIARY RESPONSIBILITIES RIGHT NOW.
19	THE SECOND POINT IS FOR FUTURE AGENDAS,
20	I'D LIKE FOR MARCH FOR THE BOARD TO CONSIDER AS A
21	TOPIC OF DISCUSSION THAT QUARTERLY PAYMENTS IN THE
22	FUTURE BECOME A POLICY SINCE FIDUCIARILY WE SHOULD
23	DO EVERYTHING TO CONSERVE CAPITAL NOW AND IN THE
24	FUTURE FOR CIRM'S MISSION.
25	CHAIRMAN KLEIN: DUANE, IF I COULD GET
	68
	UO

1	SHERRY'S COMMENTS AND THEN WE'LL GO BACK TO YOU.
2	MS. LANSING: YOU KNOW, I'VE BEEN SITTING
3	AND LISTENING. AND THE ONE GROUP THAT WE HAVE SORT
4	OF SKIRTED AROUND, AND PHIL WAS VERY ELOQUENT IN
5	GOING THROUGH THE GROUPS, IS THE PATIENTS
6	THEMSELVES. DO YOU KNOW? AND THAT IS PERHAPS THE
7	GROUP THAT WE REPRESENT THE MOST, WHICH IS ACTUALLY
8	ALL THE CITIZENS OF CALIFORNIA. AND WE MUST
9	REMEMBER THAT THEY VOTED FOR THIS, AND THEY ARE THE
10	MOST POWERFUL GROUP. THEY ARE THE CITIZENS. THEY
11	ARE THE CITIZENS THAT GET PEOPLE ELECTED.
12	AND THERE ARE WAYS THAT OUR GOVERNMENT,
13	OUR LEGISLATURE CAN SOLVE THESE PROBLEMS. THEY MAY
14	BE UNPLEASANT WAYS, THEY MAY BE DIFFICULT, BUT I
15	REALLY BELIEVE THAT IF WE MOVE FORWARD AND IF THERE
16	IS NO FUNDING TO FUND THESE, YOU ARE GOING TO HAVE A
17	GROUP, TO QUOTE A MOVIE, THAT'S MAD AS HELL AND NOT
18	GOING TO TAKE ANY MORE AND IS GOING TO FIND A WAY TO
19	UNITE THE DIVISIVE, YOU KNOW, PEOPLE AND UNITE THE
20	LEGISLATURE. AND WE WILL FIND A WAY TO GET THE
21	MONEY. AND IN MY OPINION, THAT IS WHY I FEEL SO
22	STRONGLY THAT REPRESENTING THE PATIENTS, WHICH IS
23	REALLY BASICALLY EVERY CITIZEN, IS REALLY THE
24	OVERRIDING CONCERN THAT WE SHOULD HAVE. AND WE MUST
25	MOVE FORWARD.

69

	BARRISTERS' REPORTING SERVICE
1	(APPLAUSE.)
2	MR. ROTH: SO, JAMES, COULD YOU GIVE ME
3	YOUR THOUGHTS ON HOW TO CRAFT THIS MOTION?
4	MR. HARRISON: LET'S SEE IF THIS WORKS.
5	APPROVED TRAINING II GRANTS AND BRIDGES GRANTS WOULD
6	BE SUBJECT FUNDING OF BRIDGES AND TRAINING II
7	GRANTS WOULD BE SUBJECT TO THE ICOC'S DETERMINATION,
8	IN ITS SOLE DISCRETION, THAT CIRM HAS SUFFICIENT
9	FUNDS, EXCLUDING FUNDS AVAILABLE TO MEET EXISTING
10	COMMITMENTS, AND THAT FUNDING THE GRANTS IS
11	CONSISTENT WITH CIRM'S PRIORITIES.
12	CHAIRMAN KLEIN: OKAY.
13	MR. ROTH: SO I WILL ACCEPT THAT AS AN
14	AMENDMENT TO THE ORIGINAL MOTION.
15	CHAIRMAN KLEIN: I ACCEPT IT AS THE
16	SECOND. ALL RIGHT. SO THAT IS THE MOTION. WE'VE
17	HAD A THOUGHTFUL DISCUSSION. I'D LIKE PUBLIC
18	COMMENT. SEEING NO PUBLIC COMMENT
19	MR. NUNN: MIKE NUNN FROM THE SALK
20	INSTITUTE. I'M THE DIRECTOR OF GRANTS DEVELOPMENT
21	THERE. AND I GUESS I'M NOT CONFLICTED BECAUSE I'M
22	NOT ON THE BOARD, SO I CAN SAY WHAT I THINK.
23	AS FAR AS THE TRAINING GRANTS GOES AND
24	BRIDGES TO STEM CELLS, WE HAVE INVOLVEMENT WITH BOTH
25	PROGRAMS. AND WITH THE TRAINING GRANTS IN
	70

1	PARTICULAR, WE HAVE AN EXISTING PROGRAM THAT WOULD
2	BE CONTINUING. AND PRIOR TO COMING TO THE SALK
3	INSTITUTE, I WAS A PROGRAM DIRECTOR AT THE NATIONAL
4	INSTITUTES OF HEALTH, THE NEUROLOGY INSTITUTE, FOR
5	QUITE A WHILE, FIVE YEARS.
6	AND THERE IN TRAINING GRANTS YOU ALWAYS
7	HAD A CONTINUATION PHASE BECAUSE YOU'RE TALKING
8	ABOUT PEOPLE WHO ARE ON FUNDING WHERE IF YOU MAKE A
9	DECISION TO STOP FUNDING, ESSENTIALLY THEY HAVE NO
10	JOB, AND THESE ARE STUDENTS, YOUNG PEOPLE.
11	SO I WOULD HOPE THAT IN YOUR PROVISION FOR
12	THESE KINDS OF AWARDS, ESPECIALLY IN A CONTINUATION
13	SITUATION, THAT YOU CONSIDER PEOPLE, IT'S NOT THE
14	DOLE, BUT ON THE DOLE, WHO IF YOU TAKE THEM OFF THE
15	DOLE, THEY WOULD COMPLETELY FALL OUT OF THIS LINE OF
16	WORK.
17	CHAIRMAN KLEIN: WE HAVE DEDICATED
18	STUDENTS WHO ARE COMMITTING THEIR LIFE TO THIS FIELD
19	WHO ARE BEING SUPPORTED IN THEIR LEARNING THIS VERY
20	SPECIFIC AND SPECIALIZED NEW AREA OF MEDICINE.
21	MR. NUNN: I THINK THAT IT'S IMPORTANT TO
22	CONSIDER THOSE PEOPLE.
23	IN ADDITION, PUTTING ON MY FORMER NIH HAT,
24	IT MAY BE, I DON'T KNOW IF THIS IS BAD LANGUAGE
25	HERE, BUT NIH ROUTINELY USES THE PHRASE "PENDING
	71
	/ 1

1	AVAILABILITY OF FUNDS, " AND ALL INSTITUTIONS FUNDED
2	BY NIH ARE USED TO WHAT THAT MEANS, WHICH IS WHEN
3	THE CONGRESS GETS THEIR BUDGET ACT TOGETHER, YOU
4	WILL GET AN AWARD AS SOON AS WE FIGURE OUT HOW TO DO
5	IT. AND I THINK MOST OF THE INSTITUTIONS RECEIVING
6	AWARDS FROM THIS AGENCY WOULD BE QUITE FAMILIAR WITH
7	THAT.
8	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
9	DR. SIMPSON: JOHN SIMPSON FROM CONSUMER
10	WATCHDOG. IT STRIKES ME SPECIFICALLY ON THE MOTION
11	THAT IT HITS THE APPROPRIATE BALANCE OF FIDUCIARY
12	RESPONSIBILITY AND HOPE THAT WILL CARRY YOU FORWARD
13	AND SEND THE BEST MESSAGE THAT YOU CAN SEND TO ALL
14	FOLKS RIGHT NOW, SO I WOULD NOW ENDORSE THE MOTION.
15	CHAIRMAN KLEIN: THANK YOU.
16	MR. ROTH: CALL THE QUESTION.
17	CHAIRMAN KLEIN: CALL THE QUESTION.
18	MS. KING: MAYBE COUNSEL WANTS TO TELL
19	MEMBERS HOW TO RESPOND, PLEASE.
20	MR. HARRISON: JUST REMINDER, AS IF YOU
21	NEED IT, BECAUSE THIS IS AN OMNIBUS MOTION THAT
22	COVERS TWO DIFFERENT GRANT ROUNDS, YOU SHOULD STATE
23	YOUR VOTE WITH THE CAVEAT THAT YOU ARE NOT VOTING AS
24	TO THOSE APPLICATIONS IN WHICH YOU HAVE A CONFLICT
25	OF INTEREST.

72

1	MS. KING: RICARDO AZZIZ.
2	DR. AZZIZ: FOR, EXCEPT FOR THOSE
3	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
4	MS. KING: ROBERT BIRGENEAU.
5	DR. BIRGENEAU: FOR, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MS. KING: GORDON GILL.
8	DR. GILL: AGAINST, EXCEPT FOR THOSE
9	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
10	MS. KING: JACOB LEVIN.
11	DR. LEVIN: FOR, EXCEPT FOR THOSE
12	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
13	MS. KING: MARCY FEIT.
14	MS. FEIT: YES, EXCEPT FOR THOSE
15	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
16	MS. KING: MICHAEL FRIEDMAN.
17	DR. FRIEDMAN: FOR, EXCEPT FOR THOSE
18	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
19	MS. KING: MICHAEL GOLDBERG.
20	MR. GOLDBERG: YES, EXCEPT FOR THOSE
21	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
22	MS. KING: SAM HAWGOOD.
23	DR. HAWGOOD: YES, EXCEPT FOR THOSE
24	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
25	MS. KING: BOB KLEIN.
	73

	BARRISTERS' REPORTING SERVICE
1	CHAIRMAN KLEIN: YES, EXCEPT FOR THOSE
2	APPLICATIONS WITH WHICH I HAVE A CONFLICT. I DON'T
3	HAVE ANY CONFLICTS. I'M GETTING TIRED.
4	MS. KING: SHERRY LANSING.
5	MS. LANSING: YES, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MS. KING: LEONARD ROME.
8	DR. ROME: YES, EXCEPT FOR THOSE
9	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
10	MS. KING: ED PENHOET.
11	DR. PENHOET: YES, EXCEPT FOR THOSE
12	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
13	MS. KING: PHIL PIZZO.
14	DR. PIZZO: YES, EXCEPT FOR THOSE
15	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
16	MS. KING: CLAIRE POMEROY.
17	DR. POMEROY: NO, EXCEPT FOR THOSE
18	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
19	MS. KING: FRANCISCO PRIETO.
20	DR. PRIETO: YES, EXCEPT FOR THOSE
21	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
22	MS. KING: CARMEN PULIAFITO.
23	DR. PULIAFITO: YES, EXCEPT FOR THOSE
24	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
25	MS. KING: JOHN REED.
	74

74

	BARRISTERS' REPORTING SERVICE
1	DR. REED: YES, EXCEPT FOR THOSE
2	APPLICATIONS WITH WHICH I HAVE A CONFLICT, IF THERE
3	ARE ANY SUCH GRANTS WITH WHICH I HAVE A CONFLICT
4	BECAUSE I DON'T KNOW.
5	MS. KING: DUANE ROTH.
6	MR. ROTH: YES.
7	MS. KING: DAVID SERRANO-SEWELL.
8	MR. SERRANO-SEWELL: NO.
9	MS. KING: JEFF SHEEHY.
10	MR. SHEEHY: NO, EXCEPT FOR THOSE
11	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
12	CHAIRMAN KLEIN: OKAY. THANK YOU.
13	MS. KING: IT APPEARS THAT THAT MOTION
14	CARRIES FOR THE RECORD; IS THAT CORRECT, COUNSEL?
15	CHAIRMAN KLEIN: THAT WOULD CERTAINLY BE
16	CORRECT. THANK YOU. ALL RIGHT.
17	SO AT THIS POINT I'D LIKE TO, I THINK,
18	PROCEED ON ITEM 4 AND ASK FOR A BREAK AT THE REQUEST
19	OF THE PUBLIC AND OUR DEDICATED TRANSCRIPTIONIST.
20	THANK YOU. FIVE-MINUTE BREAK.
21	(A RECESS WAS TAKEN.)
22	(DR. PRICE IS NOW IN FOR DR.
23	BI RGENEAU.)
24	CHAIRMAN KLEIN: IF WE COULD RECONVENE,
25	PLEASE. STAFF, IF YOU COULD HELP FIND MEMBERS. IF
	75

_	
1	STAFF WOULD PLEASE RAID THE RESTROOMS. THERE IS NO
2	PLACE SAFE FROM STEM CELL RESEARCH. STAFF, HOW WE
3	DOING? OKAY. WE REALLY DO NEED TO RESCUE WHATEVER
4	BOARD MEMBERS ARE IN THE HALL. WE NEED TO PROCEED
5	HERE.
6	WHILE THE BOARD IS ASSEMBLING, I'D LIKE TO
7	CALL EVERYONE'S ATTENTION TO THE NEW TIME MAGAZINE
8	COVER, WHICH IS JUST OUT, HAS ON THE COVER A VERY
9	VIBRANT STEM CELL PICTURE, AND IT STATES, "HOW THE
10	COMING REVOLUTION IN STEM CELLS COULD SAVE YOUR
11	LIFE. " THAT'S THE COVER OF TIME MAGAZINE.
12	DR. PIZZO: IS THAT WITH YOUR PICTURE,
13	BOB? WHAT KIND OF STEM CELL IS IT?
14	CHAIRMAN KLEIN: I WAS GOING TO PASS IT TO
15	YOU TO IDENTIFY FOR ME.
16	THE SUBSET IS DIABETES, HEART DISEASE,
17	PARKI NSON' S.
18	MS. KING: IF I COULD JUST REMIND ALL THE
19	BOARD MEMBERS TO REFER TO THE SHEETS THAT I'VE
20	HANDED YOU THAT LIST THE APPLICATIONS WITH WHICH YOU
21	HAVE CONFLICTS FOR BOTH THE TRAINING PROGRAM AND
22	THEN ON A SEPARATE SHEET THE BRIDGES PROGRAM DURING
23	THESE CONVERSATIONS, THAT WOULD BE GREAT. THANK
24	YOU.
25	CHAIRMAN KLEIN: ALL RIGHT. MR. SIMPSON,
	77
	76

1	YOU HAVE A QUESTION?
2	DR. SIMPSON: VERY QUICK POINT OF
3	HOUSEKEEPING SORT OF THINGS. I'VE GOT A COUPLE OF
4	E-MAILS FROM PEOPLE WHO ARE TRYING TO FOLLOW IN ON
5	THE WEBCAST. IT'S SIMPLY THAT WHEN YOU ARE
6	ADDRESSING SLIDES AND SO ON, THEY DON'T HAVE ACCESS
7	TO THEM. SO IF YOU CAN REFER TO NUMBERS AND FIGURES
8	AND SO ON, THE PEOPLE WHO ARE LISTENING, AND THERE
9	ARE A LOT OF THEM, AND IT'S COMMENDABLE THAT YOU'RE
10	DOING THIS, WOULD BENEFIT MORE SIMPLY BY HAVING THAT
11	REFERENCE TO FIGURES.
12	CHAIRMAN KLEIN: THANK YOU VERY MUCH. WE
13	WILL DO IT TO THE EXTENT POSSIBLE.
14	MR. GOLDBERG: MR. SIMPSON, PERHAPS IN THE
15	SPIRIT OF THAT, IS THERE ANY CHANCE THE CONSUMER
16	WATCHDOG COULD PROVIDE THE VIDEO SERVICES THAT COULD
17	ALLOW THIS TO BE SIMULTANEOUSLY WEBCAST IN VIDEO AS
18	WELL AS AUDIO? JUST FOR YOUR CONSIDERATION, SIR.
19	CHAIRMAN KLEIN: WE'LL LOOK FOR MONEY
20	EVERYWHERE, JOHN. ALL RIGHT.
21	WE NEED TO MOVE, AND WE'RE GOING I'D
22	ASK THE BOARD TO CONSIDER TIME. WE HAVE AN AGENDA
23	WITH A NUMBER OF ITEMS WE HAVE TO GET THROUGH. I'D
24	LIKE TO MOVE EXPEDITIOUSLY. AND IF WE COULD PLEASE
25	CONSIDER THAT.

77

1	WE ARE GOING TO ASK THE STAFF, GIL
2	SAMBRANO. DR. SAMBRANO IS GOING TO BEGIN, AND I
3	BELIEVE YOU'RE BEGINNING ON TRAINING GRANTS II; IS
4	THAT CORRECT?
5	DR. SAMBRANO: THAT'S CORRECT.
6	CHAIRMAN KLEIN: PLEASE LET'S MAKE THE
7	COMMENTS IN A MORE SUMMARY, BOTTOM-LINE FASHION WITH
8	A SHORT INTRODUCTION IF WE COULD.
9	DR. SAMBRANO: I WILL DO MY BEST. SO MR.
10	CHAIR, MEMBERS OF THE BOARD, AND MEMBERS OF THE
11	PUBLIC, I'M PLEASED TO BRING TO YOU THE
12	RECOMMENDATIONS FROM THE GRANTS WORKING GROUP
13	REGARDING THE RESEARCH TRAINING PROGRAM II. AND AS
14	YOU WILL NOTE, THIS PROGRAM IS A REISSUANCE OF AN
15	RFA THAT WE ISSUED THE VERY FIRST TIME FOR TRAINING
16	GRANTS TO TRAIN PREDOCTORAL, POSTDOCTORAL, AND
17	CLINICAL FELLOWS AND TO LEAD THEM TO DEVELOP
18	PRODUCTIVE PROGRAMS IN STEM CELL RESEARCH.
19	THE AWARDS THEMSELVES PROVIDE SUPPORT FOR
20	TRAINEES, INCLUDING STIPENDS, TUITION, AND FEES FOR
21	STUDENTS, HEALTH INSURANCE, AND AN ALLOWANCE FOR
22	RESEARCH AND TRAVEL. IT ALSO PROVIDES SUPPORT FOR
23	PROGRAM ADMINISTRATION, INCLUDING THE DEVELOPMENT OF
24	COURSES, SEMINARS, AND PARTIAL SALARY FOR THE
25	PROGRAM DI RECTOR.

78

1	THE PROGRAM IS AVAILABLE IN THREE TYPES.
2	THE TYPE 1 ARE COMPREHENSIVE PROGRAMS THAT WILL
3	SUPPORT UP TO 16 TRAINEES AT ALL THREE TRAINING
4	LEVELS. THE TYPE 2 ARE INTERMEDIATE PROGRAMS WHICH
5	WOULD SUPPORT UP TO TEN TRAINEES AT TWO LEVELS AT
6	840,000 PER YEAR. AND THE TYPE 3, WHICH ARE MORE
7	FOCUSED OR SPECIALIZED PROGRAMS, WHICH WOULD SUPPORT
8	UP TO SIX TRAINEES AT ONE OR TWO TRAINING LEVELS AT
9	525, 000 PER YEAR.
10	AND JUST TO REMIND YOU, THE CONCEPT WHICH
11	YOU APPROVED FOR THIS PROGRAM WOULD ALLOW FUNDING OF
12	UP TO 18 PROGRAMS FOR THREE YEARS WITH A TOTAL
13	PROGRAM COST OF ABOUT \$48 MILLION.
14	THE REVIEW CRITERIA THAT WAS UTILIZED BY
15	THE GRANTS WORKING GROUP TO DETERMINE THE MERIT OF
16	THESE APPLICATIONS ARE THOSE THAT ARE SHOWN ON THE
17	SLIDE. THEY ARE ALSO THE ONES THAT WERE APPROVED BY
18	THE BOARD AND EXIST IN THE GRANTS ADMINISTRATION
19	POLICY AND INCLUDE THE OVERALL QUALITY OF THE
20	PROGRAM, THE PROGRAM LEADERSHIP, OBVIOUSLY THE
21	RESEARCH AND TRAINING STRENGTH OF THE MENTORS THAT
22	ARE PROPOSED, THE QUALITY AND DIVERSITY OF ANY
23	EXISTING TRAINING PROGRAMS, WHETHER THEY ARE CIRM
24	PREVIOUS TRAINING PROGRAMS OR NIH TRAINING PROGRAMS,
25	FOR EXAMPLE, AND THE STRENGTH OF STEM CELL RESEARCH

79

1	AT THE INSTITUTION.
2	I WANT TO JUST POINT OUT TO YOU THAT THE
3	REVIEWERS, IN MAKING THEIR SCORES AND
4	RECOMMENDATIONS, HAD THE OPTION TO RECOMMEND A
5	DECREASE IN THE NUMBER OF TRAINEE SLOTS THAT WERE
6	REQUESTED BY THE APPLICANT. THEY ALSO HAD THE
7	OPTION TO RECOMMEND A CHANGE TO A MORE FOCUSED
8	PROGRAM CATEGORY. FOR EXAMPLE, IF AN APPLICANT CAME
9	IN WITH AN APPLICATION FOR A TYPE 1 PROGRAM,
10	REVIEWERS, IF THEY FELT APPROPRIATE, COULD RECOMMEND
11	A CHANGE TO A TYPE 2 PROGRAM.
12	YOU SHOULD ALSO NOTE THAT, FOR EXISTING
13	TRAINING PROGRAMS, REVIEWERS WERE PRESENTED WITH
14	FACTUAL DATA ON THE NUMBER OF PUBLICATIONS THAT WERE
15	REPORTED FROM TRAINEES FOR THAT PROGRAM, THE NUMBER
16	OF SLOTS THAT THEY WERE ABLE TO SUCCESSFULLY FILL,
17	AND THE TIMELINESS OF THE PROGRESS REPORTS.
18	SHOWN HERE IS JUST THE HISTOGRAM OF THE
19	SCORE DISTRIBUTION OF THE INITIAL SCIENTIFIC SCORE
20	GIVEN BY THE WORKING GROUP. ALONG THE BOTTOM AXIS
21	ARE THE SCORES FROM ONE TO A HUNDRED WITH A HUNDRED
22	BEING THE BEST POSSIBLE SCORE AND AGAINST THE NUMBER
23	OF APPLICATIONS. THE GRANTS WORKING GROUP INITIALLY
24	DREW A LINE AT ABOUT 75 TO DEFINE TIER 1 OR THOSE
25	THAT THEY WOULD RECOMMEND FOR FUNDING BEING ABOVE

80

1	THAT LINE. THOSE THAT WERE NOT DEEMED MERITORIOUS
2	OR RECOMMENDED FOR FUNDING WERE UNDER A SCORE OF 60.
3	THOSE IN BETWEEN WERE RECOMMENDED IF FUNDS
4	AVAI LABLE.
5	IN THE NEXT SLIDE WE HAVE A SUMMARY TABLE
6	OF THE FINAL RECOMMENDATIONS OF THE WORKING GROUP,
7	WHICH TOTAL TO 15 APPLICATIONS WITH A TOTAL AMOUNT
8	REQUESTED OF 40.6 MILLION, AND THAT WOULD CONSTITUTE
9	TIER 1. AND IN TIER 2 THERE ARE TWO ADDITIONAL
10	APPLICATIONS THAT TOTAL 4.6 MILLION THAT WOULD BE
11	RECOMMENDED IF FUNDS AVAILABLE.
12	AND SO I THINK WE CAN GO TO THE LISTING OF
13	THE APPLICATIONS. SO SHOWN HERE ARE THE
14	APPLICATIONS IN RANK ORDER AND THE RECOMMENDATIONS.
15	THEY SHOW THE APPLICATION NUMBER, THE SCORE
16	RECEIVED, A REDACTED TITLE, WHICH DEIDENTIFIES IT,
17	AND THEN THE NUMBER OF SLOTS REQUESTED FOR
18	PREDOCTORAL, POSTDOCTORAL, OR CLINICAL FELLOWS
19	SLOTS.
20	CHAIRMAN KLEIN: OKAY. THANK YOU VERY
21	MUCH. SO JEFF SHEEHY, WOULD YOU LIKE TO LOOK AT THE
22	COMPARISON OF THE RECOMMENDATION TOTALS TO THE
23	BUDGET TOTAL?
24	MR. SHEEHY: WELL, IT IS I BELIEVE IT'S
25	A LITTLE BIT UNDER BUDGET, ISN'T IT? DIDN'T WE
	01
	81

1	BUDGET
2	DR. SAMBRANO: THAT'S CORRECT.
3	MR. SHEEHY: SO WE DID COME IN UNDER.
4	DR. SAMBRANO: SO TIER 1 REPRESENTS,
5	AGAIN, ABOUT 40 MILLION, AND THE ALLOCATED BUDGET
6	FOR THE OVERALL PROGRAM WAS 48 MILLION.
7	CHAIRMAN KLEIN: CAN I SEE THE GRAY AREA
8	ON THIS, PLEASE?
9	DR. SAMBRANO: THE COLOR DOESN'T SHOW UP
10	WELL ON THIS ONE, BUT THE GRAY ZONE ARE APPLICATIONS
11	115 AND I'M SORRY 1155 AND 1161.
12	CHAIRMAN KLEIN: I WOULD JUST LIKE TO
13	STATE THAT THE TRAINING PROGRAM HAS TURNED OUT TO BE
14	HIGHLY PRODUCTIVE IN TERMS OF PUBLICATIONS AND IN
15	TERMS OF OUR EFFECTIVE RESULTS FROM THE PHASE ON THE
16	TRAINING PROGRAM I. I BELIEVE, IF I CAN SEE THE
17	NUMBERS, 161, IS THAT THE SECOND ONE IN THE GRAY
18	AREA, IS AN INSTITUTION THAT HAD A HISTORY OF HIGH
19	PRODUCTIVITY IN PUBLICATIONS.
20	AND IN THE PEER REVIEW AT THE END OF THE
21	PEER REVIEW, THE LEAD PEER REVIEWER MADE A STATEMENT
22	THAT NOW THAT HE HAD GONE THROUGH THE WHOLE SYSTEM,
23	THAT HE REALIZED THAT, IN FACT, HIS COMMENTS ON A
24	RELATIVE BASIS HAD RESULTED IN IT BEING IN THE GRAY
25	AREA WHERE HE REALLY THOUGHT IT, SOLIDLY BELIEVED IT

82

SHOULD HAVE BEEN IN THE FUNDED AREA. 1 IT'S IMPORTANT THAT IN ANY PROCESS, WHEN 2 YOU START AT THE BEGINNING AND YOU END UP AT THE 3 END, YOU' VE GOT THE WHOLE SPECTRUM AND IT GIVES YOU 4 SOME CONTEXT FOR THE EVALUATION. BUT ALSO DURING 5 THE EVALUATION PROGRAM, WE LEARNED THAT A NUMBER OF 6 7 THESE INSTITUTIONS HAVE DEVELOPED COURSES THAT ARE 8 TAUGHT THROUGH VIDEO CONFERENCING TO BRING IN 9 SPECIALISTS FROM OTHER AREAS. AND EARLY ON IN THE 10 DISCUSSION, IT WASN'T CLEAR WHAT THE VARIOUS INDIVIDUALS IN THE PEER REVIEW THOUGHT ABOUT THE 11 VALUE OF SOME OF THOSE COURSES. LATER ON THERE WERE 12 13 SOME VERY STRONGLY POSITIVE COMMENTS MADE ABOUT THE VALUE OF THOSE COURSES, WHICH I THINK WOULD HAVE 14 15 RESULTED, BASED ON MY INDIVIDUAL PERCEPTION, IN SOME 16 HIGHER SCORES. 17 BUT I WOULD LIKE TO EMPHASIZE THAT IN BUILDING OUR CORE ENTRY GATEWAY FOR INDIVIDUALS INTO 18 19 THIS FIELD, THAT THIS HAS BEEN A VERY PRODUCTIVE PROGRAM IN TERMS OF PUBLICATIONS FOR US, THE 20 21 PUBLICATIONS OF THE INDIVIDUAL PARTICIPANTS, AND I 22 BELIEVE THAT STATISTICALLY FROM MY MEMORY IS THAT THE SECOND ITEM DOWN IN THE GRAY AREA RESULTED IN 23 24 SEVEN DIFFERENT PUBLICATIONS, WHICH, GIVEN THE 25 NUMBER OF INDIVIDUALS AND THE SHORT TIME PERIOD,

83

1	THAT WAS A VERY GOOD PERFORMANCE.
2	BUT MOST IMPORTANTLY, I THINK WE HAVE A
3	STRONG DISCIPLINE, EVEN IF WE HAVE FUTURE FUNDING,
4	TO REMAIN IN THE BUDGET. AND MY UNDERSTANDING IS
5	THAT EVEN WITH THE APPLICATIONS IN THE GRAY AREA, WE
6	WOULD BE IN THE BUDGET; IS THAT CORRECT?
7	DR. SAMBRANO: THAT IS CORRECT.
8	CHAIRMAN KLEIN: DR. PIZZO, DID YOU WANT
9	TO ADDRESS THI S?
10	DR. PIZZO: WELL, ORDINARILY I WOULD BE,
11	IN LIGHT OF ALL OF OUR DISCUSSIONS HERETOFORE, BE
12	ARGUING TO RAISE THE BAR RATHER THAN TO LOWER THE
13	BAR. IN TRAINING GRANTS I THINK THE BAR COULD BE
14	MODIFIED BECAUSE WE ALL RECOGNIZE THAT THE PIPELINE
15	IS REALLY KEY TO CALIFORNIA'S AND OUR NATION'S
16	FUTURE, BUT WE HAVE JUST ON THIS ALREADY 15 OUT OF
17	20 OF THE TRAINING GRANTS ALREADY BEING APPROVED.
18	AND I WOULD HAVE SIGNIFICANT DIFFICULTY IN SEEING
19	ANY OTHERS COME UP TO THE FUNDABLE LEVEL.
20	THERE IS A DISPARITY IN SCORES. THERE'S A
21	BREAKOFF. THESE ARE BELOW 80. ALL THE OTHER ONES
22	ARE FAIRLY AT OR ABOVE. SO I THINK THAT WE
23	SHOULDN'T, IN LIGHT OF EVERYTHING WE SPENT LAST
24	NIGHT AND TODAY TALKING ABOUT, GOING BACK TO OLD
25	POLICY, AND TRYING TO GIVE MORE, I THINK WE SHOULD

84

	BARRISTERS' REPORTING SERVICE
1	BE WORKING ON GETTING AND MAKING THE BAR AS HIGH AS
2	WE CAN. AND I THINK THIS IS ALREADY APPROPRIATELY
3	SET FOR TRAINING GRANTS.
4	CHAIRMAN KLEIN: OKAY.
5	DR. POMEROY: JAMES, CAN YOU CLARIFY WHO
6	CAN TALK?
7	MR. HARRISON: YES. THE ONLY MEMBER WHO
8	CANNOT PARTICIPATE IN THE DISCUSSION OF THESE TWO
9	GRANTS, WHICH ARE 1168 EXCUSE ME 1155 AND
10	1161, IS DR. PULIAFITO.
11	CHAIRMAN KLEIN: AS TO THESE TWO GRANTS.
12	DR. AZZIZ.
13	DR. AZZIZ: JUST A POINT, A QUESTION
14	ACTUALLY PROBABLY FOR STAFF. BOB, YOU MENTIONED
15	THAT THE SENIOR LEAD REVIEWER FOR 61, AFTER GOING
16	THROUGH IT, FELT THAT HIS OR HER SCORE WE OFTEN
17	RUN INTO THAT IN OTHER REVIEWS THERE IS NO
18	OPPORTUNITY TO SAY WE'VE GONE THROUGH THESE. NOW
19	LET ME REASSESS. IS THERE NOT A SCORING SHEET WHERE
20	YOU CAN CHANGE YOUR NUMBER?
21	CHAIRMAN KLEIN: HIS COMMENT WAS MADE
22	AFTER PROGRAMMATIC REVIEW.
23	DR. AZZIZ: AFTER PROGRAMMATIC. I'M
24	SORRY. NOT DURING THE REVIEW.
25	CHAIRMAN KLEIN: AND THE PROBLEM WAS THAT
	85

1	THEY HAVE AN ABILITY TO RESCORE. THIS IS SOMETHING
2	THAT HE ACTUALLY THOUGHT ABOUT VERY SERIOUSLY AND
3	ACTUALLY WROTE A FOLLOW-UP LETTER MAKING THIS POINT.
4	SO IT'S SOMETHING HE MUST HAVE WRESTLED WITH AND
5	THEN MADE THE COMMENT AT THE END OF THE PROGRAMMATIC
6	REVIEW.
7	DR. TROUNSON: SO, I MEAN, CHAIR, IN
8	RESPECT TO THAT, THERE ARE 15 REVIEWERS THERE.
9	THERE ARE TWO OTHER SUBSIDIARY REVIEWERS. AND SO,
10	YOU KNOW, I THINK WE HAVE TO TAKE, YOU KNOW, SOME
11	REGARD TO THAT. AND THERE WERE DEFICIENCIES IN
12	THOSE TWO. PERHAPS THEY WERE IN THE WRITING, BUT
13	THERE WERE THE DEFICIENCIES, AND THEY WERE
14	RECOGNI ZED.
15	NORMALLY I WOULD I THINK I'D BE VERY
16	SUPPORTIVE OF GETTING THESE KIND OF THINGS UP,
17	PERHAPS IF THERE WAS DOUBT ABOUT IT, TO GET THEM IN;
18	BUT THESE WERE WELL AND TRULY BELOW THE MARKS THAT
19	ARE RECOMMENDED TO YOU.
20	SO FROM THE POINT OF THE GRANTS WORKING
21	GROUP, THERE ARE 15 REVIEWERS THAT MARK THEM AND
22	THEN PATIENT ADVOCATES WHO WERE THERE. THEY ALL HAD
23	THE OPPORTUNITY TO MAKE ADJUSTMENTS. SO I THINK THE
24	THOUGHTS FROM THAT REVIEWER HAVE COME AFTER THE TIME
25	OF THE MEETING.

86

1	CHAIRMAN KLEIN: OKAY. JEFF SHEEHY.
2	MR. SHEEHY: I WANT TO SECOND DR. PIZZO'S
3	COMMENT. AND EVEN THOUGH WE'RE FUNDING THESE FOR
4	WHEN WE MIGHT ACTUALLY HAVE MONEY, I THINK WE NEED
5	TO BE VERY CONSCIOUS OF THESE ARE NOT GOING TO GO IN
6	WITH ANY PRIORITY, I DON'T BELIEVE. AND WE MIGHT
7	HAVE TO START RAISING OUR BAR. I THINK THAT'S WHERE
8	WE ARE. AND THIS IS NOT I'M NOT CERTAIN THAT
9	WHEN WE PUT EVERYTHING INTO PERSPECTIVE, THIS IS
10	GOING TO BE THE HIGHEST PRIORITY RFA THAT WE DO THIS
11	YEAR.
12	AND I HAD DISCUSSIONS WITH STAFF PRIOR TO
13	TRYING TO THINK ABOUT PROGRAMMATIC REVIEW ABOUT AN
14	ISSUE THAT CAME UP IN THE REVIEW OF THE FIRST
15	TRAINING GRANTS, WHICH WAS A PHILOSOPHICAL ISSUE
16	THAT DIDN'T GET RESOLVED BECAUSE WE WERE BUILDING
17	CAPACITY. BUT HOW MANY TRAINING PROGRAMS DO YOU
18	NEED? DO YOU WANT TO CREATE KIND OF A CORE SET OF
19	SUPERB TRAINING PROGRAMS, OR DO YOU WANT TO HAVE A
20	GREAT NUMBER OF TRAINING PROGRAMS THAT RANGE IN
21	QUALITY FAIRLY BROADLY?
22	AND STAFF HAS NOT GOTTEN ENOUGH FEEDBACK
23	FROM THE FIRST ROUND TO REALLY ALLOW THAT TO BE A
24	REALLY EVIDENCE-BASED DECISION IN THE WAY THAT WE
25	WOULD REALLY WANT TO DO IT AS AN AGENCY AND SAY WE
	07

87

1	HAVE A NUMBER OF PROGRAMS THAT HAVE BEEN VERY
2	SUCCESSFUL WITH PUBLICATIONS AND OTHER SORTS OF
3	METRICS TO REALLY HIGHLIGHT THE FRONT-RUNNERS AND
4	START TO MAYBE HONE OUR TRAINING PROGRAM INTO
5	SOMETHING THAT'S A LITTLE TIGHTER AND SMALLER.
6	UNFORTUNATELY, THOUGH, I THINK OUR HAND
7	MAY HAVE BEEN OUR HANDS MAY HAVE BEEN FORCED IN
8	THIS GIVEN OUR REALITY. AND GIVEN THAT WE ARE KIND
9	OF APPROVING GRANTS ON A KIND OF PROMISSORY BASIS, I
10	THINK WE SHOULD TRY TO BE AS REALISTIC AND AS
11	HARD-NOSED ABOUT THIS AS WE CAN BECAUSE I DON'T
12	THINK WE'RE GOING TO BE ABLE TO FUND EVERYTHING THAT
13	WE SAY WE'RE GOING TO FUND.
14	CHAIRMAN KLEIN: AND DUANE. AFTER DUANE,
15	I'D LIKE THE STAFF TO COMMENT. ONE OF THE THINGS
16	I'M CONCERNED ABOUT IS, SINCE THE GRAY AREA
17	REPRESENTS EXISTING TRAINING PROGRAMS, ARE THEY
18	LOCKED IN AS AN ESSENTIAL PART OF ANY OF THE BRIDGES
19	PROPOSALS THAT WE WILL SEE? I THINK MARIE IS SAYING
20	NO, WHICH WOULD BE A GOOD ANSWER.
21	MR. ROTH: I WAS GOING TO MAKE A MOTION
22	THAT WE MOVE TO FUND THE RECOMMENDED FOR FUNDING
23	AREA, HOPEFULLY GET A SECOND ON THAT, AND THEN WE
24	CAN MOVE, IF THERE NEEDS TO BE A DISCUSSION ON THOSE
25	TWO GRANTS AND TAKE THEM INDIVIDUALLY, IF SOMEBODY
	88
	00

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626

1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	WANTS TO DO THAT. IF IT'S APPROPRIATE, I'D LIKE TO
2	MAKE A MOTION THAT, WITH THE CAVEAT OF THE PREVIOUS
3	MOTION THAT WE PASSED, THAT WE APPROVE THESE
4	RECOMMENDED FOR FUNDING IN THE WHITE AREA.
5	CHAIRMAN KLEIN: OKAY. SECOND BY DAVID
6	SERRANO-SEWELL. DI SCUSSI ON?
7	MR. SHEEHY: I THINK WE HAVE A CONFLICTS
8	ISSUE HERE, DON'T WE?
9	CHAIRMAN KLEIN: WE DO HAVE EVERYONE
10	HAS IN FRONT OF THEM A LIST OF THEIR CONFLICTS. IF
11	ANYONE WOULD LIKE CLARIFICATION
12	MR. SHEEHY: I JUST THINK IT'D BE MORE
13	PRUDENT TO START GOING GRANT BY GRANT MYSELF AT THE
14	POINT WE'RE AT WITH THE MONEY. I'M JUST NOT I
15	JUST FEEL LIKE NOW I DON'T HAVE ANY CHOICES. EVEN
16	THESE IN THE WHITE AREA, WE ARE NOT GOING TO FUND
17	ALL THOSE EVEN IF WE SAY WE'RE GOING TO.
18	CHAIRMAN KLEIN: DR. REED, YOU'RE GOING TO
19	ADDRESS THE GENERAL POLICY ISSUE, NOT ANY INDIVIDUAL
20	GRANT?
21	DR. REED: I WAS GOING TO ADDRESS THE
22	PRIOR STATEMENT ABOUT GOING GRANT BY GRANT, IF I
23	MAY. AND THAT IS THAT IN READING THE MATERIALS
24	SUPPLIED TO US, THEY ALL SOUND THE SAME. I DON'T
25	KNOW HOW WE'RE GOING TO GO THROUGH WHAT WE HAVE AND
	89

_	BARRISTERS' REPORTING SERVICE
1	FIGURE OUT WHICH OF THESE IS MORE MERITORIOUS THAN
2	ANOTHER.
3	CHAIRMAN KLEIN: THEY'RE ALL CONSISTENTLY
4	VERY HIGH QUALITY.
5	DR. REED: THEY ALL TALK ABOUT THE SAME
6	THING. THEY'VE GOT A TRAINING PROGRAM AND CLASSES
7	AND LAB WORK.
8	MR. SHEEHY: WHEN WE COME BACK SIX MONTHS
9	FROM NOW AND WE REALIZE THAT WE DIDN'T GET ALL THE
10	MONEY TO DO SCENARIO 3 AND WE HAVE TO START CULLING,
11	WE'RE GOING TO HAVE ALL THESE APPROVED. WHEN ARE WE
12	GOING TO START FACING THAT WE DON'T HAVE ENOUGH
13	MONEY TO DO EVERYTHING?
14	CHAIRMAN KLEIN: SO JEFF, I THINK THAT
15	YOUR POINT HAS BEEN MADE. DR. AZZIZ.
16	DR. AZZIZ: I DID WANT TO SPEAK TO JEFF'S
17	POINT, AND I VERY MUCH, AS YOU ALL KNOW, AM
18	CONCERNED ABOUT FUNDING. HOWEVER, WE'RE PAST THAT
19	ROAD. I MEAN WE'RE NOW IN THE STAGE OF HAVING TO
20	DECIDE WHAT WE THINK OF THE PRIORITIZATION THAT THE
21	STAFF HAS ALREADY COME THROUGH. SO WE GIVE THE
22	STAFF A JOB TO DO. THEY BRING THE BEST SCIENCE AS
23	POSSIBLE, THEY GIVE US THEIR RANKING. WE DO NEED TO
24	BE CAREFUL THAT WE ON ONE SIDE DON'T SECOND-GUESS
25	THEM ON THE OTHER SIDE, DO OUR FIDUCIARY

90

1	RESPONSI BI LI TY.
2	SO ALL I'M SAYING TO JEFF IS I DON'T THINK
3	GOING GRANT BY GRANT BY GRANT AT THIS POINT IS THE
4	REASONABLE THING NOW THAT WE'RE IN THIS PROCESS OF
5	HAVING TO DO THIS.
6	AS I SAID BEFORE, IF WE WANTED TO CHANGE
7	THE PAY LINES OR THESE KIND OF THINGS, WE PROBABLY
8	SHOULD DELAY THE ENTIRE REVIEW. SO I SPEAK TO THE
9	FACT THAT WE ACCEPT THE RECOMMENDATION.
10	CHAIRMAN KLEIN: I THINK JEFF IS SPEAKING
11	TO THE FACT THAT WE DO HAVE AN OBLIGATION TO MAKE
12	SURE THAT IF ANY GRANT IN THIS GROUP STOOD OUT AS
13	BEING INAPPROPRIATE, WE WOULD QUESTION IT AND PULL
14	IT OUT OF THE FUNDING IN TERMS OF OUR STATUTORY
15	OBLI GATI ON.
16	DR. PIZZO: I THINK THAT TWO THINGS. ONE,
17	I THINK JEFF IS ALSO SAYING, AND WE ALL AGREE WITH,
18	I THINK, THAT WE'RE GOING TO HAVE TO BE MORE RATHER
19	THAN LESS STRINGENT. THAT, I THINK, IS CLEAR.
20	THE SECOND PART OF IT IS THAT I THINK MY
21	INTERPRETATION OF THE MOTION PASSED IS THAT WE'LL
22	HAVE AN OPPORTUNITY TO STILL DO THAT. SO THAT WHAT
23	WE'RE DOING NOW IS WE'RE APPROVING THE
24	RECOMMENDATIONS. IF WE TURN OUT TO HAVE A TENTH OF
25	THE DOLLARS THAT WE THOUGHT WE WERE GOING TO HAVE,

1	
1	WE CAN COME BACK AT THAT POINT AND REVISIT THIS IN
2	COMPARISON TO OTHER THINGS. SO I THINK WE'RE NOT
3	CUTTING OUT THAT FLEXIBILITY THAT YOU'VE
4	ARTI CULATED.
5	MR. SHEEHY: I JUST THINK THAT THE WORKING
6	GROUP MIGHT HAVE DRAWN THE LINES DIFFERENTLY IF THEY
7	WERE OPERATING IN THE SAME BUDGET ENVIRONMENT. I
8	THINK THERE MIGHT HAVE BEEN A LARGER GRAY AREA.
9	DR. PIZZO: IT'S POSSIBLE, BUT THEN WE'RE
10	BEING REVISIONIST. I DON'T KNOW THAT WE CAN.
11	CHAIRMAN KLEIN: WE DO HAVE AN OBLIGATION
12	TO MAKE THOSE INDIVIDUAL DECISIONS.
13	DR. PIZZO: I UNDERSTAND THAT. BUT WHAT
14	I'M SAYING BY THAT COMMENT IS WE'RE BEING
15	REVISIONIST IN A QUALIFIER, NOT THE DECISION, BUT
16	HOW THE ECONOMIC CLIMATE WILL INFLUENCE IT. THERE'S
17	NO DOUBT THAT WE'RE ALL THINKING DIFFERENTLY TODAY
18	THAN WE WERE YESTERDAY OR MONTHS AGO.
19	DR. REED: ANOTHER POINT OF CLARIFICATION.
20	DID THE RFA ACTUALLY SPECIFY HOW MANY FUNDS WERE
21	GOING TO BE ADMINISTERED VIA THIS PROGRAM?
22	CHAIRMAN KLEIN: IT DID SET THE RFA DID
23	SET OUT A
24	DR. REED: SORT OF SET AN EXPECTATION.
25	CHAIRMAN KLEIN: PROGRAM BUDGET, AND WE
	92

BARRISTERS' REPORTING SERVICE ARE 20 PERCENT BELOW THAT BUDGET. 1 2 MR. ROTH: COULD WE CALL THE QUESTION? CHAIRMAN KLEIN: IF WE CAN -- I'D LIKE TO 3 GET ANY PUBLIC COMMENT. 4 5 MS. MARTINS-GREEN: MR. CHAIR, MEMBERS OF THE BOARD, THANK YOU FOR GIVING ME THIS OPPORTUNITY 6 7 TO SPEAK. MY NAME IS MANUELA MARTINS-GREEN. I'M A 8 PROFESSOR AT THE UNIVERSITY OF CALIFORNIA RIVERSIDE. 9 AND I'M HERE TODAY TO ADVOCATE FOR FUNDING OF OUR 10 PROPOSAL, WHICH IS THE VERY FIRST ONE IN THE GREEN THERE. 11 I HEAR YOUR CONCERNS, BUT I ACTUALLY HOPE 12 13 THAT YOU HEAR MY CONCERNS AS WELL. LET ME PUT IT 14 FORTH. I'M NOT A PI ON THE GRANT, BUT I AM A 15 RESEARCHER. I AM AN EDUCATOR. I REALLY CARE FOR 16 17 THE QUALITY OF THE EDUCATION WE PRODUCE AT UCR TO OUR STUDENTS, AND I CAME HERE TODAY BECAUSE OF THAT. 18 19 I PERSONALLY MENTOR MANY UNDERREPRESENTED STUDENTS AND CAN SPEAK FOR THE IMPORTANCE OF A 20 21 CAMPUS WHERE MINORITY STUDENTS CAN SEE OPPORTUNITIES 22 FOR EDUCATION AND FOR SUCCEEDING AND COMPETING AFTER THEY LEAVE. 23 24 JUST THE DAY BEFORE YESTERDAY, I AND A 25 HANDFUL OF COLLEAGUES WERE RECOGNIZED FOR OUR 93

1	MENTORSHIP OF UNDERREPRESENTED MINORITIES. MY
2	STUDENT, WHOSE NAME GOES BY DAVID, FOR EXAMPLE, CAME
3	IN WITH A NUMBER OF DEFICIENCIES. WE COACHED HIM.
4	AND HE'S GRADUATING IN JUNE, HAS APPLIED FOR MEDICAL
5	SCHOOLS AROUND THE COUNTRY, HAS BEEN ACCEPTED IN SIX
6	MEDICAL SCHOOLS, AND HE HAS CHOSEN TO GO TO JOHN
7	HOPKINS. AND I WAS VERY PROUD OF HIM.
8	SO THE OTHER REASON WHY I'M HERE IS
9	BECAUSE I ACTUALLY, NOT BEING ON THE GRANT, LOOKING
10	AT IT, I ASKED MYSELF WHY IS IT THAT THE GRANT THREE
11	YEARS AGO THAT WAS SUBMITTED TO THIS BOARD AND
12	RECOMMENDED BY THE REVIEWERS FOR FUNDING AND
13	ACTUALLY HIGHLY MERITORIOUS, AND NOW THREE YEARS
14	LATER, WHEN WE HAVE A HUGE DIFFERENCE IN WHAT WE
15	HAVE ACHIEVED IN RIVERSIDE, IT'S NOT RECOMMENDED FOR
16	FUNDI NG.
17	SO LET ME JUST READ A FEW THINGS THAT WE
18	HAVE IN MEANTIME, WITHOUT FUNDING FROM CIRM, WITH
19	OUR FUNDING WE HAVE ESTABLISHED AT RIVERSIDE RELATED
20	TO STEM CELL RESEARCH. SO WE HAVE HIRED TWO NEW
21	FACULTY. WE HAVE NINE UCR FACULTY WORKING ON STEM
22	CELL RESEARCH. WE HAVE BEEN FUNDED BY CIRM FOR A
23	STEM CELL CORE FACILITY. THERE ARE THREE
24	INVESTIGATORS IN OUR GROUP WHO ARE FUNDED BY CIRM.
25	WE HAVE HAD FACULTY AND STUDENTS GOING TO MEETINGS

94

1	PRESENTING THEIR RESEARCH. WE HAVE HAD PUBLICATIONS
2	COMING OUT OF OUR GROUP. WE HAVE ALREADY TWO
3	COURSES, TWO FULL COURSES, ONE ON ETHICS AND ONE ON
4	STEM CELL BIOLOGY, GOING RIGHT NOW. WE HAVE WE
5	ARE ORGANIZING FOUR MORE COURSES. WE HAVE HAD
6	TRAINING OF ELEVEN GRADUATE STUDENTS AND THREE POST
7	DOCS AND INTERFACED WITH A NUMBER OF COMPANIES. WE
8	HAVE WORKED WITH OUR SISTER UNIVERSITY, UC IRVINE,
9	TO IMPROVE AND ENHANCE OUR ABILITY TO EDUCATE AND DO
10	RESEARCH IN STEM CELL.
11	SO WE NOW HAVE CURRENTLY A REQUEST FOR 30
12	STUDENTS TO ENGAGE IN STEM CELL RESEARCH AND
13	TRAINING. IF WE DO NOT GET THIS GRANT, IT REALLY
14	WILL BE A HUGE BLOW ON OUR EFFORTS TO EDUCATE OUR
15	UNDERREPRESENTED MINORITY. I TEACH LARGE CLASSES,
16	MEDIUM SIZE CLASSES, SMALL CLASSES. I CAN GUARANTEE
17	YOU THAT IF YOU WALK IN THOSE CLASSES, WHAT YOU SEE
18	IS A MULTIPLE-COLORED CLASS.
19	LAST YEAR I SPENT A YEAR ON SABBATICAL
20	LEAVE AT STANFORD. ON THE OTHER HAND, THOSE
21	STUDENTS ARE NOT OF THE SAME COLOR. AND YOU JUST
22	WALK ON THE COMMONS ON THE CAFETERIA TO SEE THE
23	DI FFERENCE.
24	SO THE THIRD REASON WHY I'M HERE IS
25	BECAUSE I DON'T KNOW HOW MANY MEMBERS OF THE BOARD
	95

1	KNOW THAT WE ARE RANKED THIRD NATIONALWIDE IN ETHNIC
-	
2	DIVERSITY. AND THIS CAME OUT OF THE U.S. NEWS AND
3	WORLD REPORT. WE HAVE 19,000 STUDENTS ON CAMPUS:
4	50 PERCENT ARE WOMEN, 33 PERCENT ARE
5	UNDERREPRESENTED MINORITIES, 25 PERCENT ARE
6	HISPANIC. IN FACT, THE DEPARTMENT OF EDUCATION HAS
7	NAMED US AS AN HISPANIC-SERVING INSTITUTION. AND WE
8	ARE THE NO. 1 MOST THE MOST RESEARCH INTENSE
9	INSTITUTION THAT'S CLASSIFIED AS HISPANIC.
10	FOR EXAMPLE, OUR PROGRAM IN CELL MOLECULAR
11	AND DEVELOPMENTAL BIOLOGY HAS 29 PERCENT MINORITIES,
12	50 PERCENT WOMEN, AND THIS WOULD BE A PROGRAM WHERE
13	WE WOULD BE DRAWING A LOT OF OUR TRAINEES FOR THE
14	STEM CELL. WE HAVE ANOTHER GRANT FROM GANN, WHICH
15	IS IN CHEMICAL ENGINEERING, 75 PERCENT
16	UNDERREPRESENTED MINORITIES AND 50 PERCENT WOMEN.
17	SO AT UCR, VERY MUCH LIKE CIRM, WE ARE
18	COMMITTED TO AND, I QUOTE, INCREASING THE CHANNELS
19	FOR SUCCESS AND TO ENSURE THAT ALL CALIFORNIANS CAN
20	BENEFIT FROM STEM CELL RESEARCH. I REALIZE WE'RE
21	NOT THE STANFORDS, THE UCLA'S, THE BERKELEYS OF THE
22	WORLD. AND THOSE PEOPLE, THOSE TRAINED PEOPLE THAT
23	GO ALL OVER THE WORLD IN A NUMBER OF THINGS, AND WE
24	APPLAUD. WE ARE A UNIVERSITY THAT TRAINS PEOPLE WHO
25	GO BACK TO THEIR COMMUNITIES WHO ENHANCE THE

96

1 EDUCATION OF THEIR COMMUNITIES, WHO RAISE THE 2 STANDARD OF LIVING. SO I'D LIKE TO FINISH BY JUST SAYING WHEN 3 OUR FIRST APPLICATION THAT WAS RECOMMENDED FOR 4 FUNDING WAS NOT AWARDED, IT PUT OUR CAMPUS AND OUR 5 STUDENTS AT SERIOUS DISADVANTAGE. IN SPITE OF THAT 6 7 SETBACK, UC RIVERSIDE USED ITS OWN RESOURCES TO RAMP 8 UP ITS STEM CELL PROGRAM IN SIGNIFICANT WAYS. THESE 9 POINTS WERE ALL PRESENTED IN THE LETTER THAT YOU 10 HAVE BEFORE YOU, THE PETITION. I HOPE THAT YOU CONSIDER THIS PROGRAMMATIC APPEAL AND WILL VOTE 11 TODAY TO FUND A NEW CIRM STEM CELL TRAINING PROGRAM 12 13 AT UCR. BY DOING SO, YOU WILL ALLOW US TO REALLY BE SUCCESSFUL IN DELIVERING STEM CELL TRAINING FOR A 14 GROWING POPULATION OF UNDERREPRESENTED MINORITY 15 16 STUDENTS IN THE MOST UNDERREPRESENTED REGION OF 17 CALI FORNI A. AND LET ME JUST LEAVE YOU WITH THIS 18 19 THOUGHT. IF WE DID ALL THIS WITHOUT CIRM MONEY, WHAT DO YOU THINK WE WOULD HAVE DONE WITH THE CIRM 20 21 MONEY? A LOT MORE. WE WOULD HAVE A FULLY BLOWN 22 PROGRAM. CHAIRMAN KLEIN: I THINK YOU' VE MADE AN 23 OUTSTANDING PRESENTATION. YOU' RE TO BE COMMENDED 24 25 FOR YOUR COMMITMENT AT UC RIVERSIDE. IT IS 97

1	EXTRAORDINARY TO BE RANKED THIRD IN ETHNIC MINORITY
2	DIVERSIFICATION. AND WHILE STANFORD HAS A GREAT
3	OUTREACH PROGRAM, YOU HAVE TREMENDOUS DIVERSITY EVEN
4	COMPARED ON A NATIONAL STANDARD. SO IT'S BUT
5	THIS OBVIOUSLY HAS BEEN AN HISTORIC COMMITMENT OF
6	OURS TO TRY AND GET DIVERSITY.
7	THE FIRST MOTION THAT WILL BE UP FOR VOTE,
8	AS I UNDERSTAND IT, DUANE, IS FOR THE TOP CATEGORY.
9	MS. FEIT: YES. I JUST WANTED TO COMMENT
10	DR. SUSAN BRYANT CALLED ME YESTERDAY, AND I'M JUST
11	SPEAKING FOR HER. I PROMISED HER I WOULD. THAT SHE
12	WANTED THE BOARD TO KNOW SHE WAS IN SUPPORT OF THIS
13	PROPOSAL.
14	MS. KING: I JUST WANTED TO LET BOARD
15	MEMBERS KNOW THAT TO REFER TO THE LETTER BEING
16	TALKED ABOUT, IT'S IN THE BACK OF YOUR BINDER WITH
17	THE GRANT SUMMARIES. THERE'S A TAB THAT SAYS
18	EXTRAORDINARY PETITIONS. THIS DOCUMENT IS BEHIND
19	THAT TAB.
20	MS. MARTINS-GREEN: THANK YOU FOR THE
21	TIME. AND I HOPE YOU SEND US OUT WITH A SIGN OF
22	HOPE, NOT A SIGN OF DISCOURAGEMENT AND FEAR.
23	CHAIRMAN KLEIN: THANK YOU.
24	MR. REED: KNOWING WHAT A DIFFICULT TIME
25	AND STRESS THIS IS, IF THIS WAS THE LAST DAY OF OUR
	98

1	EXISTENCE, I THINK THIS WOULD BE A TREMENDOUS DEED
2	TO ACCOMPLISH. IF WE TAKE CARE OF THE BASE, IF WE
3	PROVIDE FOR THE STUDENTS, THE FUTURE OF THE FIELD IS
4	SECURE. I THINK THIS IS AN AREA, IF WE'RE GOING TO
5	MAKE A MISTAKE, LET'S ERR ON THE SIDE OF TOO MANY
6	EDUCATIONAL PROGRAMS. I'D MUCH RATHER HAVE TOO MANY
7	QUALIFIED AND TRAINED STUDENTS THAN NOT ENOUGH.
8	CHAIRMAN KLEIN: THANK YOU. DOES THE
9	STAFF HAVE ANY COMMENT ON THE EXTRAORDINARY
10	PETITION? I THINK IT'S APPROPRIATE. DUANE HAS
11	CALLED THE POINT THAT THIS EXTRAORDINARY PETITION IS
12	NOT ADDRESSED BY THIS PARTICULAR MOTION. LET'S MOVE
13	ON THIS MOTION. I THINK WE'VE HAD DISCUSSION ON
14	THIS MOTION. AND IN THE INTEREST OF TIME, I'D LIKE
15	TO SEE IF WE COULD CALL THE QUESTION. AND DO WE
16	HAVE QUORUM THAT'S JUST RETURNED?
17	MR. HARRISON: MR. CHAIR, WE'RE TRYING TO
18	LOCATE A COUPLE OF BOARD MEMBERS. AS SOON AS THEY
19	RETURN, WE WILL HAVE A QUORUM.
20	CHAIRMAN KLEIN: OKAY. I WAS THINKING
21	THAT THAT MIGHT BE THE SITUATION. DUANE, GIVEN
22	THAT, AS I SUSPECTED, WE'RE TRYING TO LOCATE A
23	COUPLE, COULD WE HAVE THAT COMMENT AT THIS TIME. IS
24	THERE A STAFF COMMENT ON THE EXTRAORDINARY PETITION
25	WHILE WE'RE WAITING? DO WE NOW HAVE A QUORUM? WE
	00

99

1	HAVE A QUORUM. WE WILL RETURN TO THE INTENT TO HAVE
2	A VOTE ON THIS ITEM. AND CAN WE CALL THE QUESTION,
3	PLEASE.
4	MR. HARRISON: AGAIN, MR. CHAIR, REMINDER
5	TO MEMBERS TO VOTE FOR OR AGAINST THE MOTION WITH
6	THE EXCEPTION OF THOSE APPLICATIONS IN WHICH THEY
7	HAVE AN INTEREST.
8	CHAIRMAN KLEIN: THANK YOU.
9	MS. KING: RICARDO AZZIZ.
10	DR. AZZIZ: FOR, EXCEPT FOR THOSE
11	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
12	MS. KING: ROBERT PRICE.
13	DR. PRICE: YES, EXCEPT FOR THOSE
14	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
15	MS. KING: GORDON GILL.
16	DR. GILL: YES, EXCEPT FOR THOSE
17	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
18	MS. KING: JACOB LEVIN.
19	DR. LEVIN: YES, EXCEPT FOR THOSE
20	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
21	MS. KING: MARCY FEIT.
22	MS. FEIT: YES, EXCEPT FOR THOSE
23	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
24	MS. KING: MICHAEL FRIEDMAN.
25	DR. FRIEDMAN: YES, EXCEPT FOR THOSE
	100
	100

1	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
2	MS. KING: MICHAEL GOLDBERG.
3	MR. GOLDBERG: YES, EXCEPT FOR THOSE
4	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
5	MS. KING: SAM HAWGOOD.
6	DR. HAWGOOD: YES, EXCEPT FOR THOSE
7	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
8	MS. KING: BOB KLEIN.
9	CHAIRMAN KLEIN: YES.
10	MS. KING: SHERRY LANSING.
11	MS. LANSING: YES, EXCEPT FOR THOSE
12	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
13	MS. KING: LEONARD ROME.
14	DR. ROME: YES, EXCEPT FOR THOSE
15	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
16	MS. KING: ED PENHOET.
17	DR. PENHOET: ABSTAIN.
18	MS. KING: PHIL PIZZO.
19	DR. PIZZO: YES, EXCEPT FOR THOSE
20	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
21	MS. KING: CLAIRE POMEROY.
22	DR. POMEROY: YES, EXCEPT FOR THOSE
23	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
24	MS. KING: FRANCISCO PRIETO.
25	DR. PRI ETO: ABSTAI N.
	101

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

BARRISTERS' REPORTING SERVICE
MS. KING: CARMEN PULIAFITO.
DR. PULIAFITO: YES, EXCEPT FOR THOSE
APPLICATIONS WITH WHICH I HAVE A CONFLICT.
MS. KING: JOHN REED.
DR. REED: YES, EXCEPT FOR THOSE
APPLICATIONS WITH WHICH I HAVE A CONFLICT.
MS. KING: DUANE ROTH.

8 MR. ROTH: YES.

1

2

3

4

5

6

7

10

9 MS. KING: DAVID SERRANO-SEWELL.

MR. SERRANO-SEWELL: YES.

11 MS. KING: JEFF SHEEHY.

12 MR. SHEEHY: NO, EXCEPT FOR THOSE

13 APPLICATIONS WITH WHICH I HAVE A CONFLICT.

MS. KING: AND FOR THE RECORD, THAT MOTIONCARRIES.

MR. HARRISON: MR. CHAIRMAN, JUST TO
CORRECT ONE THING. BECAUSE OF THE VARYING QUORUM
LEVELS, WE WILL HAVE TO DO A CALCULATION TO
DETERMINE WHETHER THERE ARE ANY APPLICATIONS FOR
WHICH WE DIDN'T HAVE AN ADEQUATE QUORUM WITH THIS
VOTE.

CHAIRMAN KLEIN: THANK YOU. SO WE'RE
GOING TO MOVE ON TO THE NEXT ITEM, AND WE'RE GOING
TO MAINTAIN THE OPTION OF COMING BACK TO THIS ITEM
IF WE NEED TO BREAK IT DOWN TO A SUBITEM.

102

	BARRISTERS' REPORTING SERVICE
1	SO GIL, DR. SAMBRANO, COULD YOU ADDRESS
2	THE BRIDGES PROGRAM, PLEASE.
3	DR. AZZIZ: TIER 2 AND THEN TIER 3.
4	CHAIRMAN KLEIN: WE WILL CONSIDER ANY
5	MOTIONS ON TIER 2 OR TIER 3 AT THIS POINT. ARE
6	THERE ANY MOTIONS ON TIER 2 OR TIER 3 FOR FUNDING?
7	LET ME ASK THIS QUESTION. DOES ANYONE
8	HAVE ANY INTEREST IN CARRYING FORWARD TIER 2 TO A
9	FUTURE DATE TO SEE IF MORE FUNDS BECOME AVAILABLE?
10	OKAY. SO IS THERE A
11	MR. HARRISON: MR. CHAIR, I JUST WANTED TO
12	REPORT BACK THAT WE DID HAVE A SUFFICIENT QUORUM AS
13	TO EACH OF THE APPLICATIONS COVERED BY THAT MOTION.
14	CHAIRMAN KLEIN: SO LET US DEAL WITH TIER
15	2 AND TIER 3.
16	DR. TROUNSON: SORRY, BOB. I THINK YOU
17	DID ASK US TO COMMENT ON THE EXTRAORDINARY PETITION.
18	CAN WE DO THAT JUST FOR COMPLETENESS?
19	MR. SHEEHY: ACTUALLY IN TERMS OF THE
20	PROCESS OF EXTRAORDINARY PETITION, WHAT WE WERE
21	TRYING TO DO IS NOT GET INTO A DISCUSSION OF IT
22	UNLESS THE BOARD BROUGHT IT UP SO AS NOT TO
23	ENCOURAGE EXTRAORDINARY PETITIONS AND HAVE THE
24	BOARD'S TIME BE TAKEN UP BY IT. UNLESS THERE'S A
25	MOTION TO CONSIDER THAT APPLICATION, I WOULD I

103

1	READ THE DOCUMENT. I APPLAUD STAFF FOR THE
2	DILIGENCE WITH WHICH THEY DID IT; BUT IF WE TAKE UP
3	EVERY EXTRAORDINARY PETITION, WE MIGHT CEASE TO
4	FUNCTION AND ENCOURAGE EXTRAORDINARY PETITIONS TO
5	COME IN GREATER QUANTITY.
6	CHAIRMAN KLEIN: ALL RIGHT. IS THERE A
7	STAFF IS THERE A BOARD MEMBER WHO WOULD LIKE THE
8	REPORT ON THE EXTRAORDINARY PETITION? OKAY. THERE
9	IS NOT.
10	IS THERE A MOTION ON TIER 2 AND TIER 3?
11	AND, MR. HARRISON, IT WOULD BE NOT TO CONSIDER FOR
12	FUTURE NOT TO CONSIDER FOR FUNDING?
13	MR. HARRI SON: CORRECT.
14	MR. SHEEHY: SO MOVE.
15	CHAIRMAN KLEIN: IS THERE A SECOND? HE
16	DOES NOT HAVE A CONFLICT. IS THERE A SECOND?
17	MR. ROTH: SECOND.
18	CHAIRMAN KLEIN: SECOND FROM DUANE.
19	COMMENT FROM THE BOARD? COMMENT FROM THE AUDIENCE?
20	CALL THE QUESTION.
21	MR. SHEEHY: TO NOT FUND TIER 2 OR TIER 3.
22	CHAIRMAN KLEIN: MR. HARRISON, COULD YOU
23	REPEAT THE MOTION, PLEASE.
24	MR. HARRISON: THE MOTION, AS I UNDERSTOOD
25	IT, IS NOT TO FUND THE APPLICATIONS THAT REMAIN,
	104
	104

	BARRISTERS' REPORTING SERVICE
1	THOSE IN TIER 2 AND TIER 3.
2	MS. KING: RICARDO AZZIZ.
3	DR. AZZIZ: FOR, EXCEPT FOR THOSE
4	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
5	MS. KING: ROBERT PRICE.
6	DR. PRICE: FOR, EXCEPT FOR THOSE
7	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
8	MS. KING: GORDON GILL.
9	DR. GILL: YES, EXCEPT FOR THOSE
10	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
11	MS. KING: JACOB LEVIN.
12	DR. LEVIN: YES, EXCEPT FOR THOSE
13	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
14	MS. KING: MARCY FEIT.
15	MS. FEIT: YES, EXCEPT FOR THOSE
16	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
17	MS. KING: MICHAEL FRIEDMAN.
18	DR. FRIEDMAN: FOR, EXCEPT FOR THOSE
19	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
20	MS. KING: MICHAEL GOLDBERG.
21	MR. GOLDBERG: YES, EXCEPT FOR THOSE
22	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
23	MS. KING: SAM HAWGOOD.
24	DR. HAWGOOD: YES, EXCEPT FOR THOSE
25	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
	105

105

1	MS. KING: BOB KLEIN.
2	CHAIRMAN KLEIN: YES.
3	MS. KING: SHERRY LANSING.
4	MS. LANSING: YES, EXCEPT FOR THOSE
5	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
6	MS. KING: LEONARD ROME.
7	DR. ROME: YES, EXCEPT FOR THOSE
8	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
9	MS. KING: ED PENHOET.
10	DR. PENHOET: YES.
11	MS. KING: PHIL PIZZO.
12	DR. PIZZO: YES, EXCEPT FOR THOSE
13	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
14	MS. KING: CLAIRE POMEROY.
15	DR. POMEROY: YES.
16	MS. KING: FRANCISCO PRIETO.
17	DR. PRI ETO: YES.
18	MS. KING: CARMEN PULIAFITO.
19	DR. PULIAFITO: YES, EXCEPT FOR THOSE
20	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
21	MS. KING: JOHN REED.
22	DR. REED: YES, EXCEPT FOR THOSE
23	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
24	MS. KING: DUANE ROTH.
25	MR. ROTH: YES.
	106

-	BARRISTERS REFORTING SERVICE
1	MS. KING: DAVID SERRANO-SEWELL.
2	MR. SERRANO-SEWELL: YES.
3	MS. KING: JEFF SHEEHY.
4	MR. SHEEHY: YES.
5	MS. KING: AND I THINK I CAN SAFELY SAY
6	THAT MOTION CARRIES.
7	CHAIRMAN KLEIN: OKAY. THANK YOU.
8	DR. YAFFE.
9	DR. YAFFE: MR. CHAIRMAN AND MEMBERS OF
10	THE COMMITTEE, IT'S MY PLEASURE TO BRING TO YOU THE
11	CONSIDERATION FOR YOUR CONSIDERATION THE
12	RECOMMENDATIONS OF THE GRANTS WORKING GROUP ON THE
13	BRIDGES TO STEM CELL RESEARCH AWARD APPLICATIONS.
14	MAY I JUST REMIND YOU THAT THE GOALS OF
15	THIS INITIATIVE ARE TO EXPAND CALIFORNIA'S WORKFORCE
16	IN STEM CELL SCIENCE AND REGENERATIVE MEDICINE AND
17	TO PROVIDE RESEARCH AND TRAINING OPPORTUNITIES FOR
18	STUDENTS REPRESENTING THE DIVERSITY OF CALIFORNIA'S
19	POPULATION, AND IN PARTICULAR TO PROVIDE THOSE
20	OPPORTUNITIES FOR STUDENTS WHO ARE MATRICULATING AT
21	COLLEGES OTHER THAN OUR RESEARCH INTENSIVE
22	UNI VERSI TI ES.
23	KEY FEATURES OF THE BRIDGES PROGRAM ARE
24	AND CENTER AROUND STUDENT RESEARCH INTERNSHIPS IN
25	STEM CELL LABORATORIES. IN ADDITION, THERE ARE
	107
	107

1	TECHNIQUES COURSES AT CIRM-FUNDED SHARED LAB OR
2	EQUIVALENT FACILITIES, AND AN INTEGRATION OF
3	INTERNSHIPS WITH NEW OR PREEXISTING UNDERGRADUATE OR
4	MASTER'S PROGRAMS AT HOME INSTITUTIONS.
5	WITH REGARD TO THIS FEATURE, I JUST WANT
6	TO ALERT THE COMMITTEE TO THE FACT THAT VIRTUALLY
7	ALL OF THESE PROPOSED PROGRAMS ARE LINKED TO THE
8	ACADEMIC SCHOOL YEAR. SO THERE WILL BE AN IMPACT IF
9	YOU CHOOSE TO DELAY A PROGRAM MUCH BEYOND THE
10	INITIATION OF THIS SUMMER.
11	FURTHER, THESE PROGRAMS FEATURE SUPPORTIVE
12	AND COMPLEMENTARY EDUCATIONAL ACTIVITIES, INCLUDING
13	COURSES, SEMINARS, AND APPROPRIATE ADVISING. THE
14	PROPOSALS WERE DEVELOPED AND SUBMITTED BY APPLICANT
15	OR HOME INSTITUTIONS WHICH ARE PUBLIC AND PRIVATE
16	CALIFORNIA EDUCATIONAL INSTITUTIONS WHICH DO NOT
17	HAVE A CIRM-FUNDED SHARED LAB FACILITY. THESE ARE
18	PRIMARILY THE CALIFORNIA STATE UNIVERSITY CAMPUSES,
19	CALIFORNIA COMMUNITY COLLEGES, AND PRIVATE COLLEGES
20	WITHIN CALIFORNIA.
21	THIS PROGRAM ALSO INVOLVES PARTNER OR
22	INTERNSHIP HOST INSTITUTIONS WHICH ARE CALIFORNIA'S
23	RESEARCH INTENSIVE UNIVERSITIES, RESEARCH
24	INSTITUTES, AND PRIVATE SECTOR COMPANIES ENGAGED IN
25	STEM CELL RESEARCH. AND THESE ORGANIZATIONS PROVIDE
	108

1	THE SITES OF THE INTERNSHIP RESEARCH OPPORTUNITIES.
2	IN TERMS OF THE SCOPE OF THE PROGRAM, EACH
3	AWARD WILL SUPPORT UP TO TEN INTERN TRAINEES PER
4	YEAR FOR INTERNSHIPS OF SIX TO 12 MONTHS' DURATION.
5	PROGRAMS WILL BE FUNDED FOR UP TO THREE YEARS. CIRM
6	ORIGINALLY INDICATED THAT WE WOULD FUND UP TO TEN
7	PROGRAMS WITH AN OVERALL PROGRAM COST, WHICH YOU
8	APPROVED IN THE CONCEPT PROPOSAL, OF UP TO \$18
9	MILLION.
10	THE PROGRAM RESULTED IN THE SUBMISSION OF
11	22 APPLICATIONS, AND THESE WERE REVIEWED BY THE
12	GRANTS WORKING GROUP AT THEIR NOVEMBER MEETING. THE
13	GRANTS WORKING GROUP USED THE FOLLOWING KEY CRITERIA
14	IN THEIR EVALUATION OF THESE PROPOSALS.
15	THEY EVALUATED THE TRAINING PROGRAM AND,
16	IN PARTICULAR, THE QUALITY AND AVAILABILITY OF
17	INTERNSHIPS, THE EDUCATIONAL ENHANCEMENT ACTIVITIES,
18	AND THE EDUCATIONAL INTEGRATION; THAT IS, THE
19	INTEGRATION OF THE INTERNSHIP PROGRAM INTO THEIR
20	OVERALL EDUCATIONAL DEGREE OR CERTIFICATE PROGRAMS.
21	IN ADDITION, THE GRANTS WORKING GROUP
22	EVALUATED THE CONSTITUTIONAL COMMITMENT AND
23	PARTNERING ARRANGEMENTS AND THE PROGRAM
24	ADMINISTRATION AND, IN PARTICULAR, THE
25	QUALIFICATIONS OF THE PROGRAM DIRECTOR.
	100

109

1	THE GRANTS WORKING GROUP SCORED THESE
2	PROGRAMS ON A SCALE OF ONE TO ONE HUNDRED. HERE YOU
3	SEE THE DISTRIBUTION OF THE SCORES OF THE PROGRAMS.
4	THE GRANTS WORKING GROUP ALSO DREW A LINE AT 75,
5	DEFINING TIER 1, THOSE APPLICATIONS RECOMMENDED FOR
6	FUNDING, AND DREW A SECOND LINE AT 55. THE
7	APPLICATIONS BELOW THIS LINE ARE IN TIER 3, NOT
8	RECOMMENDED, WITH THE APPLICATIONS BETWEEN THE LINES
9	IN TIER 2 RECOMMENDED IF FUNDS ARE AVAILABLE.
10	HERE YOU SEE THE SUMMARY OF THESE
11	RECOMMENDATIONS. TIER 1, RECOMMENDED FOR FUNDING,
12	11 APPLICATIONS, FOR A TOTAL OF REQUESTED BUDGET
13	\$17.5 MILLION. FOR YOUR REFERENCE, AT THE BOTTOM IS
14	THE ORIGINAL ALLOCATED APPROVED BUDGET, \$18 MILLION.
15	TIER 2, THERE ARE FIVE APPLICATIONS
16	RECOMMENDED IF FUNDS ARE AVAILABLE. TO FUND THESE
17	APPLICATIONS WOULD REQUIRE AN ADDITIONAL \$6.2
18	MILLION, AND TIER 3, NOT RECOMMENDED, THERE ARE SIX
19	APPLI CATI ONS.
20	AT THIS POINT PERHAPS MR. SHEEHY HAS
21	COMMENTS, OR WE COULD LOOK AT THE SCORES IN THE
22	DI FFERENT CATEGORI ES.
23	MR. SHEEHY: THE ONE COMMENT I'D LIKE TO
24	MAKE IS TO COMMEND THE SCIENTIFIC STAFF. THIS WAS
25	REALLY A UNIQUE RFA THAT WENT OUTSIDE THE BOUNDS OF
	110

1	OUR USUAL REVIEWERS. AND THE ASSEMBLY OF REVIEWERS
2	WHO WERE CAPABLE OF REALLY GIVING THE TYPE OF
3	RIGOROUS EVALUATION THAT WE TYPICALLY HAVE FOR OUR
4	GRANTS, WE SHOULD REALLY WE OWE STAFF A HAND FOR
5	THIS. THEY WERE VERY, VERY THOUGHTFULLY REVIEWED BY
6	PEOPLE WHO REALLY KNEW WHAT THEY WERE TALKING ABOUT.
7	AND GETTING THOSE FOLKS IN THE ROOM IS NOT AS EASY
8	AS PEOPLE MAY THINK.
9	(APPLAUSE.)
10	DR. YAFFE: MR. SHEEHY, I DON'T KNOW
11	MR. SHEEHY: I THINK YOU WANT TO TAKE ANY
12	MOTIONS NOW.
13	CHAIRMAN KLEIN: SO ARE THERE MY
14	UNDERSTANDING IS, AGAIN, TO REPEAT, IS THAT THE
15	RECOMMENDED GROUP IS WITHIN THE BUDGET CATEGORY?
16	DR. YAFFE: YES, IT IS. IT'S UNDER BUDGET
17	BY HALF A MILLION.
18	CHAIRMAN KLEIN: OKAY. I WILL TAKE
19	MOTIONS AND THEN TAKE BOARD DISCUSSION AND COMMENTS
20	ON THE MOTION BECAUSE I KNOW THERE ARE PEOPLE IN THE
21	AUDIENCE WHO WOULD LIKE TO ADDRESS THIS ITEM.
22	MR. ROTH: I WOULD LIKE TO MAKE A MOTION
23	TO FUND TIER 1 UNDER THE CAVEAT OF OUR PREVIOUS
24	DI SCUSSI ON.
25	CHAIRMAN KLEIN: ALL RIGHT. SECOND. I'M
	111

1	GOING TO OPEN THIS FIRST TO ACTUALLY I'D LIKE TO,
2	BECAUSE I KNOW THERE'S SOMEONE WHO WOULD LIKE TO
3	ADDRESS TIER 1 IN THE AUDIENCE, GIVE THEM THE
4	BENEFIT OF ADDRESSING THIS, AND THEN WE'LL HAVE THE
5	GENERAL BOARD DI SCUSSI ON.
6	MR. ROTH: CHAIRMAN KLEIN, IS IT IN TIER 1
7	THIS PUBLIC COMMENT?
8	CHAIRMAN KLEIN: THEIR COMMENT GOES TO THE
9	ISSUE OF WHETHER MOVING IT TO TIER 1, AND I'M TRYING
10	TO ANTICIPATE THE TIME WE HAVE FOR THIS OVERALL
11	DISCUSSION SO THEY CAN TAKE THIS INTO CONSIDERATION
12	IN ACTING BECAUSE THEN WE DON'T HAVE TO GO THROUGH
13	THIS TWICE. YES.
14	DR. COOK: GOOD MORNING. THANK YOU FOR
15	GIVING US A CHANCE TO PRESENT OUR CONCEPTS TO YOU.
16	I'M BOB COOK. I'M THE CHAIR OF THE BIOLOGY
17	DEPARTMENT AT CALIFORNIA STATE UNIVERSITY FULLERTON.
18	CHAIRMAN KLEIN: IF YOU COULD SPEAK A
19	LITTLE CLOSER TO THE MICROPHONE, PLEASE.
20	DR. COOK: I'M BOB COOK. I'M THE CHAIR OF
21	THE BIOLOGY DEPARTMENT AT CALIFORNIA STATE
22	UNIVERSITY FULLERTON, AND I'M HERE TO SPEAK TO YOU
23	ABOUT THE PROPOSAL THAT IS AT THE TOP OF THE GRAY
24	BARRIER, AND HOPING TO CONVINCE YOU TO FUND IT
25	PARTIALLY.

1	OUR PROGRAM, OUR GOAL IN THIS PROGRAM IS
2	TO PREPARE SCHOLARS IN THE ESSENTIALS OF STEM CELL
3	BIOLOGY AT THE HOME CAMPUS AND TO SEND THEM TO THE
4	HOST CAMPUS SO THAT THEY CAN ADVANCE THEIR RESEARCH
5	AND GAIN EXPERIENCE IN HUMAN STEM CELL BIOLOGY.
6	WE HAVE CREATED FOUR COURSES IN STEM CELL
7	BIOLOGY PRIOR TO THE CALL FOR THESE PROPOSALS. TWO
8	OF THESE COURSES DEAL WITH STEM CELL BIOLOGY
9	DIRECTLY, ONE OF WHICH IS A STEM CELL BIOLOGY
10	LABORATORY WHICH IS CURRENTLY FUNDED BY A GRANT FROM
11	NSF AND BY CAMPUS FUNDING.
12	IT'S ON THE BASIS OF THESE FOUR COURSES
13	THAT OUR ACADEMIC COMPONENT OF THIS GRANT PROPOSAL
14	RESTS. TO THIS POINT WE HAVE ALREADY TRAINED 28
15	STUDENTS IN THE BASIC SKILLS OF STEM CELL BIOLOGY,
16	BUT THEY HAVE NOT HAD THE ADVANTAGE OF BEING ABLE TO
17	BE IN A HUMAN STEM CELL BIOLOGY LAB YET. AND HAVING
18	THIS PROGRAM FUNDED WOULD ALLOW US TO MOVE OUR
19	STUDENTS FROM OUR LABS WHERE THEY DO MOUSE STEM CELL
20	WORK TO THE LABS OF OUR COLLABORATING HOST
21	INSTITUTIONS WHERE THEY WOULD DO HUMAN STEM CELL
22	BI OLOGY.
23	IT'S BASICALLY AGREED, I THINK, IF YOU
24	LOOK AT THE REVIEWS, THAT WE HAVE A STRONG
25	CURRICULUM IN PLACE ON OUR CAMPUS. WE HAVE FOUR
	113
	113

1	STRONG AND WELL-PREPARED FACULTY WHO CAN WORK WITH
2	STUDENTS TO GIVE THEM THE BASIC BACKGROUND IN STEM
3	CELL BIOLOGY AND TO PREPARE THE STUDENTS TO MOVE TO
4	OUR HOST CAMPUSES WHERE WE HAVE A CADRE OF EXCELLENT
5	HUMAN STEM CELL BIOLOGY RESEARCHERS PREPARED TO TAKE
6	THEM INTO THE PROGRAM.
7	WE HAVE AN ENERGETIC AND COMMITTED PROGRAM
8	DIRECTOR. WE HAVE A LARGE GROUP OF STUDENTS
9	PREPARED TO ENTER THE PROGRAM.
10	CAL STATE FULLERTON REPRESENTS OR SERVES,
11	RATHER, A DIVERSE MINORITY POPULATION IN NORTH
12	ORANGE COUNTY, A DIVERSE SOCIOECONOMIC POPULATION IN
13	NORTH ORANGE COUNTY, AND A GROUP OF FIRST-GENERATION
14	FAMILIES WHO HAVE NOT BEEN TO COLLEGE BEFORE.
15	HAVING A PROGRAM SUCH AS THIS WOULD GIVE THEM
16	OPPORTUNITIES THAT ARE UNAVAILABLE TO THEM AND WOULD
17	REMAIN UNAVAILABLE IF WE ARE NOT FUNDED.
18	WE HAVE WE WOULD ASK THAT YOU NOT, BY
19	MOVING US TO TIER 1, NOT BUMP ANY OF THE PREVIOUSLY
20	RECOMMENDED CANDIDATES, BUT RATHER ADD US TO THE
21	MIX, GIVE US PARTIAL FUNDING. TRAINING PROGRAMS BY
22	THEIR VERY NATURE ARE MODULAR IN COMPONENT. WE CAN
23	DO VERY WELL WITH FUNDS THAT REMAIN FROM THE
24	ORIGINAL 18 MILLION THAT HAVE BEEN ALLOCATED, AND
25	THAT WE WOULD BE HAPPY TO TAKE THE 500,000 THAT

114

-	
1	REMAIN, WORK WITH A SMALLER GROUP OF STUDENTS, MOVE
2	THEM THROUGH, AND AT LEAST HAVE SOME STUDENTS FROM
3	NORTH ORANGE COUNTY WHO CAN PARTICIPATE IN THIS
4	FANTASTIC PROGRAM THAT YOU' VE CREATED RATHER THAN
5	HAVING NO ORANGE COUNTY REPRESENTATION. THANK YOU
6	VERY MUCH.
7	CHAIRMAN KLEIN: SO THAT WE CAN GET THE
8	PUBLIC COMMENT ON THIS, MR. SIMPSON, DID YOU WANT TO
9	MAKE A PUBLIC COMMENT?
10	MR. SIMPSON: I'M CONFUSED AS TO WHETHER
11	YOU'RE TAKING COMMENT ON TIER 2, OR IS IT JUST ON
12	THE MOTION OF PUTTING INTO TIER 1?
13	CHAIRMAN KLEIN: JUST ON THE MOTION OF
14	PUTTING IT IN TIER 1.
15	MR. SIMPSON: I WOULD SUPPORT TIER 1 AS IT
16	IS NOW CONSTITUTED, BUT WITH THE CAVEAT THAT I WOULD
17	HOPE THAT TIER 2 GETS DISCUSSED AND THERE IS
18	APPROPRIATE COMMENT ON TIER 2.
19	CHAIRMAN KLEIN: ALL RIGHT. SO BOARD
20	DI SCUSSI ON. JEFF SHEEHY.
21	MR. SHEEHY: COULD I ASK A QUESTION OF
22	STAFF? YOU MADE A COMMENT ABOUT THERE'S A TIME
23	FACTOR RELATED, THAT WHILE WE'RE KICKING THIS DOWN
24	THE ROAD TO DECIDE WHETHER, YOU KNOW, WHEN WE
25	ACTUALLY FUND THIS, CAN YOU KIND OF ELABORATE?
	115
	115

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

_	
1	DR. YAFFE: WELL, VIRTUALLY ALL THE
2	PROPOSED PROGRAMS ARE LINKED TO THE ACADEMIC YEAR,
3	WHICH WOULD INVOLVE RECRUITMENT OF THEIR STUDENTS
4	DURING THE SUMMER OR IN EARLY FALL AND THEN
5	FOLLOWING IN THE ACADEMIC CALENDAR. IF A PROGRAM IS
6	NOT GIVEN THE GO-AHEAD OR FUNDED BY A CERTAIN DATE,
7	I DON'T KNOW WHAT THAT DATE MIGHT BE, BUT CERTAINLY
8	BY THE SUMMER OR BEGINNING OF THE FALL, THE PROGRAM
9	IS UNLIKELY TO BE ABLE TO START UP IN THE WINTER OR
10	LATE SPRING. THEY MAY HAVE TO WAIT FOR AN ENTIRE
11	YEAR BEFORE THEY CAN THEN INITIATE THE PROGRAM, AT
12	LEAST DESIGNED, DESCRIBED, AND RECOMMENDED BY THE
13	GRANTS WORKING GROUP.
14	MR. SHEEHY: THIS IS A PRIORITY PROGRAM OF
15	THE SCIENTIFIC STAFF, I BELIEVE, AS WE'VE HEARD. I
16	CAN'T OFFER AN AMENDMENT TO THE MOTION OR ANYTHING,
17	BUT DO WE WANT TO SOMEHOW ON THIS MOTION MAKE I
18	WOULD NOT LIKE THIS DECISION TO BE MADE BY DEFAULT.
19	I WONDER IF WE WANT TO SET A POINT SO THAT WE CAN
20	CLEARLY COMMUNICATE. JUST AS A PHILOSOPHICAL
21	QUESTION, DO WE WANT TO SAY IN MARCH OR APRIL THAT
22	WE'RE DEFINITELY GOING TO MAKE A GO OR NO GO SO THAT
23	THESE INSTITUTIONS CAN HAVE SOME CERTAINTY AS TO
24	WHETHER OR NOT THEY'RE GOING TO GO FORWARD?
25	CHAIRMAN KLEIN: LET ME ASK THE MAKER OF
	116

116

1	THE MOTION. DUANE, WOULD YOU BE WILLING TO INCLUDE
2	IN YOUR MOTION, BECAUSE I WOULD AS A SECOND, THAT WE
3	RECOGNIZE THAT THE STAFF HAS RECOMMENDED THIS AS A
4	MISSION CRITICAL PROGRAM?
5	MR. ROTH: YOU KNOW, I'M NOT SURE IT NEEDS
6	TO BE IN THE MOTION, BUT I WOULD HATE TO GIVE THE
7	IMPRESSION THAT SOMEHOW THIS IS GOING TO TAKE
8	PRIORITY OVER SOMETHING ELSE WHEN WE'VE ALREADY HAD
9	THAT DI SCUSSI ON.
10	CHAIRMAN KLEIN: THAT'S FINE.
11	MR. ROTH: THAT'S AT OUR SOLE DISCRETION
12	TO DO THAT.
13	MS. LANSING: I WOULD JUST LIKE TO SUGGEST
14	THAT WHEN WE COME TO OUR NEXT MEETING, THAT ALAN
15	PRESENT TO US STAFF'S RECOMMENDATION AS TO HOW WE
16	SHOULD PRIORITIZE THE GRANTS THAT WE'VE APPROVED
17	BECAUSE, DON'T FORGET, WE HAVE THE DISEASE TEAMS
18	YET. WE HAVE A LOT OF THE OTHER THINGS THAT ARE
19	GOING TO COME FORWARD, SO I DON'T THINK WE CAN
20	ANSWER THOSE QUESTIONS.
21	MR. ROTH: THAT'S THE POINT. I DON'T
22	THINK WE WANT TO LOSE OUR FLEXIBILITY AND TO CHANGE
23	THIS MOTION AND MAKE IT SOMEHOW DIFFERENT THAN THE
24	PREVIOUS ONES WE JUST APPROVED.
25	CHAIRMAN KLEIN: THAT'S EXACTLY THE
	117
	117

BARRISTERS' REPORTING SERVICE QUESTION I WAS ASKING. 1 2 MR. SHEEHY: SO WE'RE JUST NOT GOING TO 3 SET ANY PRIORITIES AT THIS MEETING. MR. SERRANO-SEWELL: I WAS GOING TO SPEAK 4 TO THAT. I THINK THAT CLARIFICATION IS REALLY 5 IMPORTANT. I THINK, BOB, IT'S WORTH REPEATING, 6 7 ESPECIALLY TO THE PEOPLE OR WHATEVER IT IS WE'RE 8 DOING FOR THEM IN THE FIRST YEAR. THE BOARD HAS 9 DECIDED TO RETAIN ITS SOLE DISCRETION, MEANING, 10 YEAH, WE APPROVED YOU, BUT YOU MIGHT NOT GET ANYTHING IN MARCH. YOU GET ZERO. 11 12 NOW, I DON'T KNOW HOW YOU -- AS AN 13 INSTITUTION, I DON'T KNOW HOW YOU REALLY RELY ON THAT AND GO BACK TO YOUR. I DON'T THINK YOU CAN, 14 BUT I'LL LEAVE IT TO THOSE INSTITUTIONS TO FIGURE IT 15 16 OUT. 17 MR. ROTH: MY HOPE IS THAT THROUGH ALL THIS DISCUSSION PEOPLE WILL WATCH WHAT'S HAPPENING 18 19 ON THE BUDGET AND WATCH WHAT HAPPENS WHEN WE GO AND START TALKING TO PEOPLE. AND I THINK THAT GIVES 20 21 THEM SOME SENSE OF WHETHER THIS IS GOING TO HAPPEN 22 OR NOT. CHAIRMAN KLEIN: YEAH. DR. PRIETO. 23 24 DR. PRIETO: WOULD IT BE APPROPRIATE TO 25 MAKE A SEPARATE -- TO REQUEST A SEPARATE AMENDMENT

118

1	TO THIS MOTION TO PARTIALLY FUND THE APPLICATION
2	FROM TIER 2?
3	CHAIRMAN KLEIN: AMENDMENTS ARE IN ORDER
4	IN DISCUSSION OF THE MOTION AS LONG AS YOU DON'T
5	HAVE ANY CONFLICTS.
6	DR. PRIETO: I DON'T HAVE ANY CONFLICT
7	WITH THIS APPLICATION.
8	CHAIRMAN KLEIN: MR. HARRISON, DO YOU HAVE
9	A QUESTION ABOUT THE RIGHT TO MAKE AN AMENDMENT TO
10	THIS MOTION?
11	MR. HARRISON: NO. UNDER THE BOARD'S
12	EXCEPTION TO ROBERTS RULES OF ORDER, IF THE MAKER
13	AND THE SECOND ACCEPT A FRIENDLY AMENDMENT, THEN IT
14	CAN BE CONSIDERED. OTHERWISE, IT COULD BE
15	CONSIDERED IN A SUBSEQUENT MOTION.
16	MR. ROTH: I WOULD PREFER NOT TO AND TO
17	DEAL WITH THAT IN THE SECOND DISCUSSION ABOUT
18	WHETHER WE WANT TO DO THAT AND THEN TALK ABOUT THAT.
19	CHAIRMAN KLEIN: THANK YOU.
20	DR. PIZZO: AS A MATTER OF PRINCIPLE, I
21	WOULD NOT LIKE TO SEE US GET INTO THE SITUATION
22	WHERE LEFTOVER MONEY THAT'S NOT APPLIED IS BEING
23	USED AS A SOURCE FOR FUNDING OTHER PROPOSALS THAT
24	DIDN'T MEET A CUTOFF. I THINK THAT CONFUSES WHAT
25	WE'RE TRYING TO DO.

1	CHAIRMAN KLEIN: I THINK WHAT YOU'RE
2	SAYING IS IT NEEDS TO BE ON THE MERITS RATHER THAN
3	WHETHER THERE'S LEFTOVER MONEY.
4	DR. PIZZO: BECAUSE OTHERWISE WE WILL NEED
5	TO GO CONTINUE TO GO BACK AND SEE IF WE HAVEN'T
6	FILLED IT. IT IS ON THE MERITS.
7	THE OTHER THING I'LL JUST QUICKLY SAY IS
8	SINCE WORDS MATTER, JUST GIVEN OUR LAST COMMENT, WE
9	MAY USE THE TERM "MISSION CRITICAL," BUT I'D LIKE TO
10	THINK THAT ALMOST EVERYTHING WE DO IS MISSION
11	CRITICAL. THERE MAY BE SOME PROPOSALS THAT ARE TIME
12	SENSITIVE, AND MAYBE THAT'S AN IMPORTANT CAVEAT THAT
13	WE WANT TO OFFER.
14	CHAIRMAN KLEIN: YEAH. I WAS SPECIFICALLY
15	RECOGNIZING THE STAFF'S POSITION THAT THIS IS A
16	MISSION CRITICAL OBJECTIVE, WHICH I THINK IS
17	RELEVANT INFORMATION FOR US TO CONSIDER AT THE NEXT
18	MEETING.
19	DR. REED: YOU SAID THE COMMENT ON THE
20	SPECIFIC SUGGESTED AMENDMENT, IF WE STILL ARE
21	DISCUSSING THAT, OR IS THAT NOW OFF THE TABLE?
22	CHAIRMAN KLEIN: BECAUSE IT HAS TO BE A
23	VOLUNTARY ACCEPTANCE OF THE MAKER OF THE MOTION AND
24	THE SECOND, THAT HAS TO NOW BE HANDLED AS A SEPARATE
25	I TEM.

120

	BARRISTERS' REPORTING SERVICE
1	DR. REED: ALL RIGHT. I'LL WAIT TILL
2	THEN.
3	CHAIRMAN KLEIN: ADDITIONAL BOARD
4	COMMENTS? I'D LIKE TO CALL THE QUESTION ON THIS
5	MOTI ON.
6	DR. POMEROY: CAN YOU REPEAT THE MOTION,
7	PLEASE?
8	MR. HARRISON: THE MOTION IS TO APPROVE
9	THOSE APPLICATIONS FOR BRIDGES GRANTS THAT ARE IN
10	TIER 1.
11	MS. KING: RICARDO AZZIZ.
12	DR. AZZIZ: FOR, EXCEPT FOR THOSE
13	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
14	MS. KING: ROBERT PRICE.
15	DR. PRICE: APPROVE, EXCEPT FOR THOSE I
16	HAD NO CONFLICTS.
17	MS. KING: GORDON GILL.
18	DR. GILL: YES, EXCEPT FOR THOSE
19	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
20	MS. KING: JACOB LEVIN.
21	DR. LEVIN: YES, EXCEPT FOR THOSE
22	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
23	MS. KING: MARCY FEIT.
24	MS. FEIT: YES, EXCEPT FOR THOSE
25	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
	121

1	MS. KING: MICHAEL FRIEDMAN.
2	DR. FRIEDMAN: FOR, EXCEPT FOR THOSE
3	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
4	MS. KING: MICHAEL GOLDBERG.
5	MR. GOLDBERG: YES, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MS. KING: SAM HAWGOOD.
8	DR. HAWGOOD: YES, EXCEPT FOR THOSE
9	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
10	MS. KING: BOB KLEIN.
11	CHAIRMAN KLEIN: YES.
12	MS. KING: SHERRY LANSING.
13	MS. LANSING: YES, EXCEPT FOR THOSE
14	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
15	MS. KING: LEONARD ROME.
16	DR. ROME: YES, EXCEPT FOR THOSE
17	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
18	MS. KING: ED PENHOET.
19	DR. PENHOET: YES, EXCEPT FOR THOSE
20	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
21	MS. KING: PHIL PIZZO.
22	DR. PIZZO: YES, EXCEPT FOR THOSE
23	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
24	MS. KING: CLAIRE POMEROY.
25	DR. POMEROY: YES, EXCEPT FOR THOSE
	122
	166

1	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
2	MS. KING: FRANCISCO PRIETO.
3	DR. PRIETO: YES, EXCEPT FOR THOSE
4	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
5	MS. KING: CARMEN PULIAFITO.
6	DR. PULIAFITO: YES, EXCEPT FOR THOSE
7	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
8	MS. KING: JOHN REED.
9	DR. REED: YES, EXCEPT FOR THOSE
10	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
11	MS. KING: DUANE ROTH.
12	MR. ROTH: YES.
13	MS. KING: DAVID SERRANO-SEWELL.
14	MR. SERRANO-SEWELL: YES.
15	MS. KING: JEFF SHEEHY.
16	MR. SHEEHY: YES, EXCEPT FOR THOSE
17	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
18	CHAIRMAN KLEIN: AND I'D LIKE TO SAY MY
19	UNDERSTANDING, DR. PRICE, OF WHAT YOU SAID IS EXCEPT
20	FOR THOSE WITH WHICH
21	DR. PRICE: YES. I WAS ABOUT TO MODIFY MY
22	VOTE.
23	MR. HARRISON: MR. CHAIR, COULD I MAKE ONE
24	SUGGESTION. BECAUSE OF THE QUORUM REQUIREMENTS FOR
25	TWO OF THE APPLICATIONS, I WOULD RECOMMEND THAT WE
	100
	123

1	LEAVE THIS VOTE OPEN. LEEZA GIBBONS PLANS TO JOIN
2	US AFTER LUNCH; AND AT THAT POINT IN TIME, SHE CAN
3	VOTE. WE CAN CLOSE THE VOTE AND WE WILL HAVE HAD A
4	SUFFICIENT QUORUM FOR EACH OF THE APPLICATIONS IN
5	TIER 1.
6	CHAIRMAN KLEIN: WITHOUT OBJECTION, I'M
7	GOING TO LEAVE THE VOTE OPEN. COULD YOU TELL ME THE
8	I TEMS, PLEASE?
9	MR. HARRISON: YES. THEY ARE APPLICATION
10	NOS. 1194 AND APPLICATION 1190.
11	CHAIRMAN KLEIN: THANK YOU. THOSE ITEMS
12	WILL BE LEFT OPEN. THE VOTE IS OTHERWISE LOGGED FOR
13	THOSE OTHER APPLICATIONS THAT WE JUST CONSIDERED.
14	AS TO THE GRAY AREA, IS THERE ANY MOTION
15	AS TO THE GRAY AREA?
16	DR. PULIAFITO: ONLY POINT OF INFORMATION.
17	ONLY NONCONFLICTED INDIVIDUALS CAN MAKE A MOTION?
18	CHAIRMAN KLEIN: ONLY NONCONFLICTED
19	INDIVIDUALS CAN MAKE A MOTION.
20	MR. ROTH: ON ANY INDIVIDUAL GRANT.
21	CHAIRMAN KLEIN: ON ANY INDIVIDUAL GRANT.
22	DR. PULIAFITO: WHAT ABOUT A MOTION AS A
23	GLOBAL MOTION?
24	CHAIRMAN KLEIN: THEY CAN MAKE A GLOBAL
25	MOTION ON THE GRAY AREA IF YOU'RE NOT CONFLICTED
	124

1	WITH ANY ITEMS IN THE GRAY AREA.
2	SO QUESTIONS? IS THERE ANYONE WHO, ON A
3	PROGRAMMATIC BASIS, WHICH IS OBVIOUSLY A CRITERIA
4	FOR CONSIDERATION AS WELL AS A STRAIGHT SCIENTIFIC
5	SCORE, WANTS TO PICK UP THE PROPOSAL, AS I
6	UNDERSTAND IT FROM THE COMMENT PREVIOUSLY MADE, THAT
7	THERE BE A \$600,000 AWARD TO FULLERTON INSTEAD OF
8	THE FULL AWARD SUGGESTED, WHICH WOULD KEEP US IN
9	BUDGET? MY UNDERSTANDING OF THE PROGRAMMATIC
10	REQUEST IS THIS IS AN UNDERREPRESENTED AREA WITH
11	TREMENDOUS POTENTIAL IN THE STATE WITH A PROGRAM
12	THAT IS IN THE GRAY AREA.
13	IS THERE ANYONE THAT WOULD LIKE TO ADDRESS
14	THAT REQUEST? ALL RIGHT. SEEING NO ONE. IS THERE
15	ANYONE THAT WOULD LIKE TO MAKE ANY MOTION AS TO THE
16	GRAY AREA? DR. REED.
17	DR. REED: I'D LIKE TO MOVE THAT NO
18	FURTHER GRANTS IN THIS CATEGORY ARE APPROVED FOR
19	FUNDING AT THIS TIME.
20	CHAIRMAN KLEIN: OKAY. THE WORDING OF
21	THAT MOTION IS INTERESTING, BUT LET ME ASK A
22	QUESTION OF COUNSEL. BECAUSE IT ADDRESSES THE
23	CATEGORY, IS THIS A MOTION THAT DR. REED SHOULD BE
24	MAKING?
25	MR. HARRISON: WITH ONE CLARIFICATION.
	125

	BARRISTERS' REPORTING SERVICE
1	THE QUESTION DR. REED CAN MAKE A MOTION AS TO
2	TIER 2. HE CANNOT MAKE A MOTION AS TO TIER 2 AND
3	TIER 3.
4	CHAIRMAN KLEIN: MY UNDERSTANDING IS HE
5	WAS ONLY ADDRESSING TIER 2; IS THAT CORRECT, DR.
6	REED?
7	DR. REED: I WOULD ADDRESS BOTH IF I'M
8	ALLOWED.
9	CHAIRMAN KLEIN: MY UNDERSTANDING, DR.
10	REED, IS YOU ARE INTENDING TO ADDRESS TIER 2; IS
11	THAT CORRECT?
12	DR. REED: I'LL WITHDRAW THE MOTION AND
13	ALLOW DUANE ROTH TO REPHRASE.
14	MR. ROTH: I WILL MAKE A MOTION NOT TO
15	FUND ANYTHING IN TIER 2 AND TIER 3 AT THIS TIME.
16	CHAIRMAN KLEIN: SO I'M INTERESTED IN THE
17	WORDING. IS THE WORDING "AT THIS TIME"? IS THERE
18	INTENT TO CARRY ANY OF THESE FORWARD, OR IS THIS AT
19	ANY TIME?
20	MR. ROTH: I'LL EXPLAIN MY MOTION. I
21	DON'T WANT TO GIVE ANYONE THE IMPRESSION THAT IT'S
22	LIKELY WE'RE GOING TO COME BACK AND VISIT THIS
23	BECAUSE I DON'T THINK THAT'S GOING TO HAPPEN. I
24	THINK THAT'S THE SENSE OF THE BOARD.
25	SECONDLY, WHILE I'M SYMPATHETIC TO THE
	126

1	PRESENTATION THAT WAS MADE, I THINK FROM A PRECEDENT
2	STANDPOINT, ONCE WE START GOING IN AND MODIFYING
3	BASED ON RECOMMENDATIONS FOR PARTIAL FUNDING, WE
4	SHOULD OPEN IT UP TO EVERYBODY WHO WOULD HAVE THE
5	CHANCE TO COME AND ARGUE FOR PARTIAL FUNDING OF
6	THEIR GRANT. THEREFORE, ON THE BASIS OF THAT, JUST
7	THE INTEGRITY OF THE PROCESS, I THINK I'LL STAY WITH
8	MY MOTION.
9	CHAIRMAN KLEIN: I THINK ANYONE CAN ARGUE
10	FOR PARTIAL FUNDING. I THINK YOU'RE JUST TAKING THE
11	POSITION THAT YOU DON'T WANT TO MAKE THAT DECISION.
12	SO ANY ADDITIONAL DISCUSSION? DO WE HAVE
13	A SECOND? WE DO NOT HAVE A SECOND.
14	DR. PRICE: SECOND.
15	CHAIRMAN KLEIN: LET US CHECK. WE NEED TO
16	CHECK THAT.
17	CHAIRMAN KLEIN: DR. GILL IS ASKING THE
18	QUESTI ON.
19	MR. SERRANO-SEWELL: I'LL MAKE THE SECOND.
20	CHAIRMAN KLEIN: DAVID SERRANO-SEWELL WILL
21	MAKE THE SECOND. THANK YOU. OKAY. DR. GILL ASKED
22	FIRST. YOU'D LIKE TO MAKE A SECOND?
23	DR. GILL: I SECOND.
24	CHAIRMAN KLEIN: I WILL RECOGNIZE THE
25	FIRST SECOND OF DR. GILL. IF I COULD ASK FOR PUBLIC
	127

COMMENT ON THIS.

1

2 DR. SIMPSON: JOHN SIMPSON FROM CONSUMER WATCHDOG. I'M DI SAPPOINTED THAT YOU ARE MAKING THIS 3 MOTION. I WOULD HAVE SUGGESTED THAT THE MOTION IN 4 THIS PARTICULAR CASE, BECAUSE OF THE UNIQUE NATURE 5 OF THIS PROGRAM AND BECAUSE, IF I CAN BE SO CRASS AS 6 7 TO SAY, ALL THE REPRESENTATIVES OF THE BIG FAT 8 UNIVERSITIES HAVE GOTTEN THEIRS ALREADY, AND THESE 9 GUYS HAVEN' T. AND YOU MANAGED TO SAVE ENOUGH TO 10 SUBSTANTIALLY FUND ALL THROUGH THE GRAY AREA. ____I WOULD HAVE, BECAUSE OF THE VERY SPECIAL CASE IN THIS 11 FIRST OPPORTUNITY TO OPEN IT UP TO MANY MORE PEOPLE 12 13 IN THE STATE OF CALIFORNIA AND UNSERVED MINORITIES, I WOULD STRONGLY RECOMMEND THAT YOU DEFEAT THIS 14 MOTION AND THAT A NEW MOTION BE ENTERED THAT WOULD 15 16 MOVE UP ALL OF THE GRAY AREA. THANK YOU. 17 CHAIRMAN KLEIN: OKAY. DR. GILL: CAN I EXPLAIN THE REASON I 18 19 SECONDED IT? I FEEL THAT THERE SHOULD BE EQUAL ACCESS FOR EACH PERSON IN AN AREA TO SPEAK IF WE 20 21 WERE GOING TO GO IN ONE BY ONE. IN OTHER WORDS, I 22 CERTAINLY APPRECIATE THE VALUE OF THE FULLERTON 23 PROGRAM, BUT WE HAVE NOT BEEN ABLE TO HEAR FROM THE 24 OTHER PROGRAMS, ONE OF WHICH HAS EXACTLY THE SAME 25 SCORE. SO I FIND IT IMPOSSIBLE TO JUDGE BASED ONLY

128

1	ON THE PRESENCE OF AN ADVOCATE HERE.
2	CHAIRMAN KLEIN: SO, DR. GILL, EVERYONE
3	HAS THE OPPORTUNITY TO SPEAK. THE FULLERTON
4	REPRESENTATIVE MADE THE EFFORT TO COME HERE AND
5	SPEAK. AND, IN FACT, THE SYSTEM REWARDS THE THE
6	SYSTEM PERMITS THAT THOSE WHO WILL MAKE THE EXTRA
7	EFFORT CAN PROVIDE A FOCUS ON THEIR CASE AND
8	CONSIDERATION. AND THEY ARE THE FULLERTON IS ONE
9	OF THE TOP TWO IN THIS CATEGORY.
10	DR. FRIEDMAN: I'M TRYING TO DECIDE
11	WHETHER TO MAKE A COMMENT OR NOT, AND I THINK I
12	WILL. I DON'T MEAN TO BE PROVOCATIVE, AND I DON'T
13	MEAN TO BE TRUCULENT. I TAKE STRONG EXCEPTION TO
14	YOUR COMMENTS. NOBODY KNOWS WHICH UNIVERSITIES ARE
15	GETTING WHAT. YOUR COMMENT ABOUT FAT UNIVERSITIES
16	GETTING FATTER IS ENTIRELY INAPPROPRIATE. YOUR
17	COMMENTS SHOULD HAVE BEEN RESTRICTED, I SUGGEST, TO
18	WHAT WOULD BE GOOD FOR THE BEST TRAINING FOR THE
19	BEST STUDENTS IN THE STATE TO HELP THE PROGRAM. AND
20	I FIND THAT REALLY AN INAPPROPRIATE COMMENT TO MAKE
21	AT THIS TIME.
22	MR. SIMPSON: I'M SORRY YOU TOOK IT THAT
23	WAY.
24	CHAIRMAN KLEIN: ADDITIONAL DISCUSSION?
25	DR. LEVIN: I JUST WANT TO CLARIFY WHAT
	129

1	THE MOTION IS ON THE FLOOR. ARE WE VOTING NOT TO
2	FUND THESE, OR TO PUSH THEM TO THE MARCH MEETING?
3	CHAIRMAN KLEIN: NOT TO FUND.
4	DR. PENHOET: WE'RE NOT FUNDING ANYTHING.
5	RECOMMEND FOR FUNDING.
6	DR. LEVIN: THERE WILL BE NO FURTHER
7	DISCUSSION OF THESE.
8	CHAIRMAN KLEIN: IF THIS PASSES, THERE
9	WILL BE NO FURTHER DISCUSSION OF THESE AT THE MARCH
10	MEETING OR ANY OTHER MEETING.
11	MR. ROTH: AGAIN, AS THE MAKER OF THE
12	MOTION, I JUST WANT TO COMMENT AGAIN. THE REASON I
13	THINK THIS IS PRUDENT IS IN LIGHT OF ALL THE
14	DISCUSSION WE'VE HAD, THAT, YOU KNOW, WE'RE TRYING
15	TO GO THE EXTRA MILE HERE IN MAKING SURE WE GIVE
16	PEOPLE EXPECTATIONS THAT WE POTENTIALLY CAN LIVE UP
17	TO. AND I THINK THE FACT THAT THINGS ARE GOING TO
18	CHANGE SIGNIFICANTLY ENOUGH THAT IN APRIL, MAY, JUNE
19	WE COULD DECIDE TO THROW ANOTHER FOUR OR \$5 MILLION
20	HERE IS NOT GOING TO HAPPEN. THEREFORE, I DO NOT
21	WANT TO GIVE ANY FALSE HOPE. I'D RATHER THEY KNOW
22	TODAY AND NOT HOLD ON.
23	CHAIRMAN KLEIN: OKAY. ADDITIONAL
24	DISCUSSION? CALL THE QUESTION.
25	MS. KING: RICARDO AZZIZ.
	130

	BARRISTERS' REPORTING SERVICE
1	DR. AZZIZ: FOR, EXCEPT FOR THOSE
2	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
3	MS. KING: ROBERT PRICE.
4	DR. PRICE: YES, EXCEPT FOR THOSE
5	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
6	MS. KING: GORDON GILL.
7	DR. GILL: YES, EXCEPT FOR THOSE
8	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
9	MS. KING: JACOB LEVIN.
10	DR. LEVIN: YES, EXCEPT FOR THOSE
11	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
12	MS. KING: MARCY FEIT.
13	MS. FEIT: YES, EXCEPT FOR THOSE
14	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
15	MS. KING: MICHAEL FRIEDMAN.
16	DR. FRIEDMAN: YES, EXCEPT FOR THOSE
17	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
18	MS. KING: MICHAEL GOLDBERG.
19	MR. GOLDBERG: YES, EXCEPT FOR THOSE
20	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
21	MS. KING: SAM HAWGOOD.
22	DR. HAWGOOD: YES, EXCEPT FOR THOSE
23	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
24	MS. KING: BOB KLEIN.
25	CHAIRMAN KLEIN: YES.
	131

-	
1	MS. KING: SHERRY LANSING.
2	MS. LANSING: YES, EXCEPT FOR THOSE
3	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
4	MS. KING: LEONARD ROME.
5	DR. ROME: YES, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MS. KING: ED PENHOET.
8	DR. PENHOET: YES, EXCEPT FOR THE ONE WITH
9	WHICH I HAVE A CONFLICT.
10	MS. KING: PHIL PIZZO.
11	DR. PIZZO: YES, EXCEPT FOR THOSE
12	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
13	MS. KING: CLAIRE POMEROY.
14	DR. POMEROY: YES, EXCEPT FOR THOSE
15	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
16	MS. KING: FRANCISCO PRIETO.
17	DR. PRIETO: NO, EXCEPT FOR THOSE
18	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
19	MS. KING: CARMEN PULIAFITO.
20	DR. PULIAFITO: YES, EXCEPT FOR THOSE
21	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
22	MS. KING: JOHN REED.
23	DR. REED: YES, EXCEPT FOR THOSE
24	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
25	MS. KING: DUANE ROTH.
	132

1	MR. ROTH: YES.
2	MS. KING: DAVID SERRANO-SEWELL.
3	MR. SERRANO-SEWELL: YES.
4	MS. KING: JEFF SHEEHY.
5	MR. SHEEHY: YES, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MR. HARRISON: MR. CHAIR, CAN I ONCE AGAIN
8	RECOMMEND THAT WE KEEP THE VOTE OPEN ON THIS MOTION
9	AS THERE'S ONE APPLICATION IN THIS CATEGORY, 1187,
10	FOR WHICH WE NEED MEMBER GIBBONS' VOTE.
11	DR. PENHOET: AS EMBARRASSED AS I AM, NOT
12	BEING ABLE TO COUNT, I HAVE TO CHANGE MY VOTE TO YES
13	EXCEPT FOR THOSE WITH WHICH I HAVE CONFLICTS.
14	CHAIRMAN KLEIN: ON THE ADVICE OF COUNSEL,
15	WITHOUT OBJECTION, I'M GOING TO KEEP 1187 OPEN. IS
16	THAT THE CORRECT NUMBER?
17	MR. HARRI SON: THAT' S CORRECT.
18	CHAIRMAN KLEIN: ALL THE OTHER VOTES WILL
19	BE LOGGED AS FINAL VOTES.
20	QUESTION AT THIS POINT. DR. YAFFE, DID
21	YOU HAVE ADDITIONAL?
22	DR. YAFFE: I DON'T.
23	MS. KING: TIER 3 IS DONE AS WELL, SO
24	WE'RE DONE WITH AGENDA ITEM 4, BRIDGES AND TRAINING.
25	CHAIRMAN KLEIN: THANK YOU. SO LET ME
	122
	133

-	
1	ASK, MELISSA, ARE WE AT A POINT WHERE IT WOULD BE
2	APPROPRIATE TO ADJOURN FOR THE LUNCH DISCUSSION?
3	MS. KING: WE ARE. THE ONLY THING YOU
4	MIGHT WANT TO CONSIDER IS ADDRESSING ITEM 5, TOOLS
5	AND TECHNOLOGY, TIER 2, THAT WAS CARRIED OVER FROM
6	THE LAST MEETING IF IT WAS THE SENSE OF THE BOARD
7	THAT THAT WOULD BE A BRIEF ENOUGH DISCUSSION, OR YOU
8	COULD GO TO LUNCH.
9	CHAIRMAN KLEIN: OKAY. THANK YOU FOR YOUR
10	ADVICE. LET ME ASK THE BOARD HERE. WHAT IS THE
11	SENSE OF THE BOARD? SHOULD WE TRY AND TACKLE THIS
12	ITEM OR ADJOURN FOR LUNCH?
13	DR. PULIAFITO: DO IT NOW.
14	MS. FEIT: DO WE HAVE A QUORUM TO TAKE
15	ACTION ON THAT?
16	DR. PULIAFITO: YOU MAY NOT HAVE IT AFTER
17	LUNCH.
18	CHAIRMAN KLEIN: LEEZA GIBBONS IS COMING
19	BACK AFTER LUNCH.
20	MS. KING: WE COULD JUST HOLD IT, BUT
21	WE'RE ALSO GOING TO LOSE DR. ROME.
22	CHAIRMAN KLEIN: WE HAVE A QUORUM WITH DR.
23	ROME OTHER THAN THOSE THAT HAVE WALKED OUT FOR JUST
24	A MOMENT.
25	MR. HARRISON: YES.
	134

	BARRISTERS' REPORTING SERVICE
1	CHAIRMAN KLEIN: WE DO. ALL RIGHT. YOU
2	KNOW YOU'RE IN A CRISIS WHERE BATHROOM PASSES COME
3	AT A PREMIUM.
4	DR. PENHOET: WE COULD RAISE MONEY FOR
5	THIS INSTITUTION BY SELLING THEM.
6	CHAIRMAN KLEIN: LET'S KEEP IT GOING FOR
7	TWO OR THREE MORE HOURS.
8	MS. KING: I'M GOING TO SUGGEST, WHILE DR.
9	AZZIZ IS OUT OF THE ROOM, THAT WE HAVE DR. TALIB
10	JUST BRIEFLY TAKE US THROUGH HIS SLIDES ON TOOLS AND
11	TECHNOLOGI ES.
12	CHAIRMAN KLEIN: YES. DR. TALIB, COULD
13	YOU BRING UP, AS I SUPPOSE YOU WILL, IMMEDIATELY THE
14	SCORING CHART TO SHOW US WHAT THE RELATIVE SCORES
15	ARE IN THE GRAY AREA?
16	DR. POMEROY: MELISSA, DO YOU HAVE
17	CONFLICT SHEETS?
18	MS. KING: I DO. I'M GOING TO NEED JUST A
19	MOMENT. I'VE GOT TO GET THIS SPREADSHEET UP AND I
20	WILL HAND THEM OUT TO YOU.
21	DR. TALIB: MR. CHAIRMAN AND MEMBERS OF
22	THE BOARD, WHAT I'D LIKE TO DO IS JUST PROVIDE YOU
23	THE TABLE IN WHICH THE TOOLS AND TECHNOLOGY AWARDS
24	WHICH WERE DISCUSSED IN THE LAST ICOC MEETING. IN
25	THE LAST ICOC MEETING, YOU APPROVED 23 APPLICATIONS,
	135

1	WHICH ARE SHOWN IN THE FIRST COLUMN AND THESE 23
2	APPLICATIONS WHICH WERE PLACED BY THE GRANTS WORKING
3	GROUP IN THE TIER 1.
4	SO THESE 23 APPLICATIONS WITH A TOTAL
5	AMOUNT OF THE FUNDING OF \$19.8 MILLION, WHICH IS
6	VERY CLOSE TO THE TARGET OF THE ICOC WHICH WAS
7	RECOMMENDED, AND THAT WAS \$20 MILLION.
8	YOU ALSO PLACED SOME OF THE APPLICATIONS
9	IN TIER 2, AND THOSE WERE TOTAL OF 17 APPLICATIONS
10	WHICH WERE PLACED IN TIER 2, AND THEY'RE UP FOR
11	DISCUSSION TODAY FOR CONSIDERATION. THESE 17
12	APPLICATIONS WOULD AMOUNT TO ADDITIONAL FUNDING OF
13	ABOUT \$16 MILLION.
14	IN THE NEXT SLIDE, JUST FOR YOUR
15	INFORMATION, I WANT TO EMPHASIZE THAT IN TIER 1,
16	WHICH YOU HAVE APPROVED, CONTAINS ALL THE
17	APPLICATIONS WHICH WERE RECOMMENDED OR WHICH WERE
18	CONSIDERED TO BE IMPORTANT IN TERMS OF THE AREAS
19	WHICH ARE IMPORTANT FOR FUNDING. THAT IS, ALL THE
20	SUBJECT AREAS WHICH ARE CONSIDERED TO BE IMPORTANT
21	IN WHICH THERE IS SOME ROADBLOCKS TO MOVE THE FIELDS
22	TOWARDS THE CLINIC.
23	THESE FIVE CATEGORIES ARE BIOMARKERS, GENE
24	MANIPULATION, BIOASSAYS, STEM CELL DIFFERENTIATION,
25	SCALE UP, AND BIOENGINEERING. SO ALL SUBJECT AREAS
	10/
	136

1	APPEARS TO BE EQUALLY REPRESENTED IN THE TIER 1
2	WHICH YOU HAVE ALREADY APPROVED FOR FUNDING.
3	AND I WILL NOW HAND OVER TO DR. SAMBRANO,
4	WHO CAN SHOW YOU MORE INFORMATION ABOUT THESE
5	APPLI CATI ONS.
6	CHAIRMAN KLEIN: I SPECIFICALLY WANT TO
7	SEE THE SCORING SHEET SHOWING US THE SCORES IN THE
8	GRAY AREA AS COMPARED TO THE APPROVED AREA.
9	DR. SAMBRANO: IT'S SHOWN UP HERE AND YOU
10	SHOULD NOTE THAT THEY ARE SEPARATED BY THE SESSIONS
11	IN WHICH THEY WERE REVIEWED. SO THERE WAS SESSION
12	1, WHICH IS SHOWN AT THE TOP, AND THEN THOSE ARE
13	SHOWN IN RANK ORDER OF SCORE, AND THEN BELOW THAT IS
14	SESSION 2, AGAIN, THOSE APPLICATIONS IN RANK ORDER.
15	THERE ARE TWO OF THEM, ONE IN EACH OF THE
16	SESSIONS, THAT ARE HIGHLIGHTED IN RED, APPLICATION
17	1050 AND APPLICATION 1062, WHICH WERE ORIGINALLY
18	RECOMMENDED BY THE GRANTS WORKING GROUP TO BE IN
19	TIER 1 AND WERE BROUGHT DOWN BY THE BOARD INTO TIER
20	2. SO THOSE ARE INCLUDED WITHIN THE OVERALL TIER 2
21	CATEGORY SHOWN HERE.
22	CHAIRMAN KLEIN: AND THE SCORING FOR TIER
23	1 IN BOTH SESSIONS ENDED AT WHAT SCORES? TIER 1
24	SCORING, WHAT WAS THE BOTTOM SCORE IN TIER 1?
25	DR. SAMBRANO: GIVE ME A SECOND.
	137
	157

1	CHAIRMAN KLEIN: WHILE THIS INFORMATION IS
2	BEING OBTAINED, THIS WAS A PARTICULARLY HIGH SCORING
3	ROUND, IF YOU RECALL, QUALITATIVELY. AND I THINK
4	WE'RE GOING TO SEE THAT IN TIER 1 WE HAVE SOME BEING
5	FUNDED WHERE WE HAVE HIGHER SCORES ACTUALLY IN TIER
6	2.
7	A SEPARATE CONSIDERATION IS WHILE EVERY
8	SUBJECT AREA WAS COVERED, I WOULD LIKE TO KNOW AT
9	THE MARCH MEETING IF THERE ARE SUBAREAS WHICH ARE
10	OBSTACLES TO CRITICAL PROGRESS THAT WERE NOT FUNDED
11	THAT ARE IN TIER 2 THAT HAVE HIGH SCORES.
12	THE ISSUE IS NOT I'M NOT ASKING THAT WE
13	TAKE ACTION ON RECOMMENDING FOR FUNDING AT THIS
14	TIME, JUST THAT WE CARRY OVER TIER 2 TO THE MARCH
15	MEETING SO THAT WE CAN SURGICALLY, GIVEN SCARCE
16	RESOURCES, LOOK AND SEE IF THERE'S ANY ITEMS IN TIER
17	2 THAT WOULD HAVE PARTICULAR SIGNIFICANCE BECAUSE
18	THEY'RE SUBAREAS OF A REPRESENTED AREA THAT STILL
19	REPRESENT POTENTIAL OBSTACLES.
20	DR. PIZZO: COULD YOU DEFINE WHAT YOU MEAN
21	BY HIGH SCORE BECAUSE NONE OF THOSE LOOK HIKE HIGH
22	SCORES TO ME.
23	CHAIRMAN KLEIN: WELL, LET'S LOOK AT THE
24	SCORES FOR THE FUNDED CATEGORY.
25	DR. SAMBRANO: SO THE ORIGINAL LINE THAT
	100
	138

1	WAS DRAWN BY THE GRANTS WORKING GROUP THAT
2	ORIGINALLY DEFINED TIER 1 WAS A SCORE OF 80 OR
3	ABOVE. BUT AFTER PROGRAMMATIC REVIEW, THERE WERE
4	APPLICATIONS THAT SCORED 77, 76 THAT WERE ALSO
5	INCLUDED IN TIER 1 THAT YOU MOVED FORWARD FOR
6	FUNDI NG.
7	DR. PIZZO: WHAT WAS THE MEDIAN SCORE FOR
8	TIER 1, THE MEDIAN?
9	DR. SAMBRANO: WELL, THE HIGHEST SCORE WAS
10	A 90.
11	CHAIRMAN KLEIN: MY COMMENT IS MADE, DR.
12	PIZZO, THAT WE HAVE FUNDED IN THE FUNDING
13	CATEGORY, WE HAVE SCORES THAT ARE, IN FACT, EQUAL TO
14	THE TOP FUNDED AREA OF TIER 2. AND THESE SCORES ARE
15	STILL, ON A COMPARATIVE WITH OTHER REVIEWS, STRONG
16	SCORES AT THE TOP OF THIS LIST. AND, AGAIN, BECAUSE
17	THIS ADDRESSES TOOLS WHICH MAY HAVE A SPECIFIC
18	SIGNIFICANCE TO A CRITICAL AREA, I KNOW THAT THERE
19	ARE DISAGREEMENTS OVER THE SUBJECT, BUT I'D JUST
20	LIKE TO RETAIN THE OPTION, IF POSSIBLE, FOR
21	CONSIDERATION OF THE BOARD.
22	DR. TROUNSON: SORRY, CHAIR. JUST TO
23	REMIND THE BOARD THAT IT WAS THE STAFF
24	RECOMMENDATION NOT TO FUND ANY MORE IN TOOLS AND
25	TECHNOLOGY. JUST TO REMIND YOU OF THAT
	139

	BARKISTERS' REPORTING SERVICE
1	RECOMMENDATI ON.
2	MR. ROTH: MR. CHAIRMAN, CAN I ASK A
3	QUESTI ON?
4	CHAIRMAN KLEIN: YES.
5	MR. ROTH: CAN YOU PUT THE SLIDE BACK UP
6	WITH THE DISTRIBUTION? THESE ARE BOTH IN THE
7	SCALE-UP CATEGORY, THESE TWO IN RED.
8	CHAIRMAN KLEIN: JEFF SHEEHY, WHILE WE'RE
9	PUTTING THIS SLIDE UP, I THINK, HAS A COMMENT, AND
10	THEN WE'RE GOING TO HAVE DR. CSETE'S COMMENT.
11	MR. SHEEHY: I WOULD SUPPORT THE CHAIR'S
12	SUGGESTION THAT WE PUT THIS OFF AND WE REALLY DRILL
13	DOWN ON THIS. I THOUGHT THAT THIS WAS A TRUE GRAY
14	AREA IN THE CONTEXT OF THE WORKING GROUP IN THAT
15	THERE WAS A SUGGESTION THAT WE FUND IF FUNDS ARE
16	AVAILABLE. AND WE DID NOT REALLY GET INTO DETAIL ON
17	THESE AT THE LAST MEETING BECAUSE IT WAS OUR FIRST
18	RECOGNITION THAT WE DID NOT HAVE THE FUNDING
19	AVAILABLE THAT WE TYPICALLY HAVE.
20	BUT I BELIEVE THERE'S VALUE IN HERE AND
21	THAT IT WOULD BE WORTHWHILE FOR US TO LOOK CAREFULLY
22	AT THESE. YOU KNOW, THE NOBEL IN BIOCHEMISTRY THIS
23	YEAR WENT TO A TOOL, BIOFLUORESCENCE. THESE ARE
24	REAL THINGS, REAL PRODUCTS, THAT WE'RE ACTUALLY
25	THIS IS A FIRST APPLIED SCIENCE GRANT THAT WE'VE

140

1	DONE. WE'RE ACTUALLY GOING TO HAVE SOMETHING AT THE
2	END OF THE DAY. AND I WOULD STRONGLY URGE THAT WE
3	HOLD IT OVER. AND IF THE CHAIR WITH SCIENTIFIC
4	STAFF CAN REALLY LOOK AND SEE IF THERE'S ANYTHING IN
5	HERE THAT MIGHT HAVE PARTICULAR VALUE.
6	CHAIRMAN KLEIN: SO DR. CSETE.
7	DR. CSETE: OUR RECOMMENDATION IN PART TO
8	FUND TIER 1 AND NOT BELOW WAS A RECOGNITION OF THE
9	SUCCESS OF THIS PROGRAM IN THAT THE TIER 1
10	APPLICATIONS REPRESENT ENORMOUSLY EXCITING SCIENCE.
11	AND WE'D LIKE A CHANCE TO EVALUATE THAT BUT I THINK
12	AFTER WE'RE INTO THE PROGRAM FOR A LITTLE WHILE TO
13	DETERMINE WHERE THE HOLES ARE DOWN THE ROAD. AND I
14	THINK WE SHOULD LOOK AT THIS AS A REAL SUCCESS.
15	ANOTHER THING ABOUT THE RELATIVELY HIGH
16	SCORES WAS MENTIONED. I THINK IT MAY BE PARTLY A
17	FUNCTION OF THE UNIQUE NATURE OF THIS RFA AS THE
18	ONLY TOOLS AND TECHNOLOGY THAT WE'VE DONE, BUT I
19	THINK WE'RE GOING TO SEE THIS INCREASINGLY WITH THE
20	MATURATION OF OUR PROGRAMS. EACH ROUND OF REVIEWS
21	GETS MORE COMPETITIVE, AND SO WE'RE GOING TO HAVE TO
22	BE SAYING NO TO THINGS THAT WE MAYBE A YEAR TWO OR
23	PRIOR TO THAT HAD NOT.
24	CHAIRMAN KLEIN: AND UNDERSTANDING THAT
25	FROM THE COMMENTS AT PEER REVIEW, IT IS NOT CLEAR TO
	141

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	ME THAT THERE ARE NOT SOME SUBPOINTS THAT MAY BE
2	CRITICAL TO OUR MISSION THAT ARE WITHIN CATEGORIES
3	THAT ARE OTHERWISE REPRESENTED. AND I'M JUST ASKING
4	THE BOARD TO CONSIDER THAT WE MAY WANT STAFF TO LOOK
5	AT THESE INDIVIDUAL AND COME BACK, NOT WITH A
6	CATEGORICAL RECOMMENDATION, BUT MAKE SURE THAT
7	THERE'S NOT SOME INDIVIDUAL APPLICATION IN THIS
8	CATEGORY THAT WOULD BE MISSION CRITICAL.
9	DR. PIZZO: ALONG THAT LINE, I WAS GOING
10	TO ASK A QUESTION THAT WAS SIMILAR TO WHAT WAS JUST
11	ANSWERED BY MARIE, AND JUST AM MAKING THE
12	ASSUMPTION, BASED UPON WHAT YOU SAID AND WHAT ALAN
13	SAID, THAT IN MAKING THE RECOMMENDATIONS NOT TO FUND
14	THOSE THAT WERE IN TIER 2, YOU'VE IN A SENSE ALREADY
15	LOOKED AT THESE AND YOU ALREADY CARRIED OUT THAT
16	WORK.
17	DR. CSETE: YES. AND OUR USUAL PRACTICE
18	IS TO DIVIDE THE POTENTIALLY DISCUSSED GRANTS AT THE
19	BOARD MEETING AMONG THE SCIENCE OFFICERS. IF THERE
20	ARE INDIVIDUAL QUESTIONS ABOUT TIER 2, THAT WE ARE
21	ALL PREPARED TO DISCUSS THAT, AND PERHAPS THAT COULD
22	BE DONE IN CLOSED SESSION.
23	DR. TROUNSON: IT'S A BIT PHILOSOPHICAL,
24	BUT I THINK WE WOULD BE BETTER OFF IF WE WAITED FOR,
25	YOU KNOW, A YEAR TO SEE WHAT WAS GOING TO BE REALLY
	142

1	CRITICALLY IMPORTANT COMING UP OVER THIS NEXT 12
2	MONTHS. AND I DON'T THINK THERE WAS ANY MEMBER OF
3	STAFF THAT FELT THAT THOSE THAT ARE IN THIS GRAY
4	AREA WOULD BE SOMETHING THAT WE COULD ABSOLUTELY
5	IT WOULDN'T HAVE A MAJOR IMPACT.
6	NOW, HAVING SAID THAT, SOME OF THESE
7	THINGS ARE UNPREDICTABLE, AS YOU KNOW, IN RESEARCH.
8	SO OFTEN I'M AWARE OF NOBEL PRIZES FROM PEOPLE WHO
9	NEVER GOT A GRANT. SO, YOU KNOW, GIVEN THAT'S NOT
10	THE SYSTEM THAT WE USE, IT IS ON THE RANKING, IT IS
11	ON THE BEST ESTIMATE, I WOULD ACTUALLY THINK, YOU
12	KNOW, WE WERE PHILOSOPHICALLY SMARTER TO SAY, OKAY,
13	IF WE GOT THE FUNDS, LET'S RETHINK ABOUT TOOLS AND
14	TECHNOLOGY WITHIN 12 MONTHS OR IN 12 MONTHS' TIME
15	BECAUSE I THINK THERE WILL BE SOME SAVAGELY
16	IMPORTANT ONES THAT WILL DEMONSTRATE THEMSELVES IN
17	THAT TIME.
18	CHAIRMAN KLEIN: SO I WOULD AMEND MY
19	STATEMENT TO SAY THAT THE SUGGESTION OF DR.
20	TROUNSON, THAT WE COULD EXAMINE WHETHER A SUBSEQUENT
21	TOOLS AND TECHNOLOGY ROUND COULD BE MISSION CRITICAL
22	WITHIN THE NEXT 12 MONTHS WOULD APPROPRIATELY
23	ADDRESS THE ISSUE THAT I WAS CONCERNED WITH.
24	DR. PIZZO: SO THEN CAN WE HAVE
25	DR. POMEROY: IS THERE A MOTION ON THE
	143

	BARRISTERS' REPORTING SERVICE
1	FLOOR?
2	DR. PIZZO: I WAS GOING TO MAKE A MOTION.
3	CHAIRMAN KLEIN: CAN YOU MAKE A MOTION IN
4	THIS CATEGORY?
5	DR. PIZZO: CAN I? PROBABLY NOT.
6	MR. ROTH: NO, BUT I CAN, AND I'LL MAKE
7	THE MOTION THAT WE NOT RECONSIDER THESE FOR A NUMBER
8	OF REASONS. NO. 1, I'M PERSUADED, LOOKING AT THIS
9	CHART, THAT WE HAVE A GOOD MIX. THERE'S NOT
10	ANYTHING THERE THAT'S GLARINGLY UNDERREPRESENTED,
11	NO. 1. NO. 2, BACK TO THIS FISCAL DISCIPLINE AND
12	THESE ARE JUST DIFFERENT TIMES, AND I DON'T WANT
13	TO I DON'T THINK WE WANT TO BE INCONSISTENT WITH
14	WHAT WE JUST DID AND GIVE PEOPLE FALSE HOPE. I
15	THOROUGHLY, THOROUGHLY SUPPORT THIS CATEGORY, AND I
16	AGREE THAT IF WE COME BACK WITHIN A YEAR WITH
17	ANOTHER RFA, THAT WOULD EVEN BE MORE POWERFUL.
18	SO I'LL MAKE THE MOTION WE DO NOT CONSIDER
19	ANY OF THESE GRANTS FURTHER.
20	MR. SHEEHY: I JUST I WOULD LIKE TO
21	THINK ABOUT MAYBE KEEPING ALIVE 1050, WHICH WAS
22	RECOMMENDED FOR FUNDING BY THE WORKING GROUP IN
23	PROGRAMMATIC REVIEW. THERE WERE TWO THAT WERE NOT.
24	I ACTUALLY THINK WE COVERED THE SCIENTIST IN 1062.
25	BUT THE 1050, THAT WAS RECOMMENDED BY THE WORKING
	144

144

1	GROUP. AND IF WE CAN PUT THAT IN THE SAME CATEGORY
2	THAT WE PUT THE OTHER GRANTS THAT WE PUT FORWARD, AT
3	LEAST WE'D BE CONSISTENT. AND SCALE-UP DOES SEEM
4	IMPORTANT SINCE WE'RE IN CLINICAL TRIALS. BUT
5	PEOPLE DIDN'T RECOMMEND THINGS FOR FUNDING UNLESS
6	THEY THOUGHT THAT THEY WERE GOING TO USE THEM. AND
7	FOR SOMEONE TO PULL UP A SCORE, THERE WAS THE SENSE
8	THAT THAT WAS A VALUABLE APPLICATION.
9	CHAIRMAN KLEIN: DISCUSSION?
10	MR. ROTH: IS THERE A SECOND? I DON'T
11	THINK YOU HAVE A SECOND.
12	DR. POMEROY: I'LL SECOND IT IN THE GLORY
13	OF HAVING A MOTION THAT I'M NOT CONFLICTED WITH.
14	CHAIRMAN KLEIN: THANK YOU, DR. POMEROY.
15	THIS WILL BE A VERY FAMOUS MOTION.
16	SO THERE'S A MOTION AND A SECOND. AND
17	THERE'S A REQUEST FOR AN AMENDMENT TO THE MOTION.
18	AND THE MAKER HE CAN ASK THE MAKER OF THE
19	MOTION YOU CAN'T.
20	MR. SHEEHY: I HAVE CONFLICTS, NOT WITH
21	THIS PARTICULAR APPLICATION I REFERENCED, BUT WITHIN
22	THIS GROUP.
23	CHAIRMAN KLEIN: HE CAN ASK FOR AN
24	AMENDMENT THAT ADDRESSES THIS INDIVIDUAL
25	APPLICATION; IS THAT CORRECT?
	145

	BARRISTERS' REPORTING SERVICE
1	MR. SHEEHY: 1050. I'M NOT CONFLICTED ON
2	THE APPLICATION, BUT I'M CONFLICTED ON APPLICATIONS
3	IN THE GROUP.
4	MR. HARRISON: RIGHT. IF YOUR QUESTION OR
5	REQUEST IS JUST RELATED TO APPLICATION 1050, THAT'S
6	FINE.
7	CHAIRMAN KLEIN: THE QUESTION GOES TO THE
8	MAKER OF THE MOTION.
9	MR. ROTH: JEFF, I'M GOING TO STICK TO
10	WHAT I SAID LAST TIME. I THINK WE JUST I WOULD
11	LOVE TO CONSIDER TWO OR THREE OF THESE, BUT I THINK
12	WE JUST CANNOT DO IT.
13	MR. SHEEHY: WELL, WE'RE JUST DOING TIER 1
14	ACROSS THE BOARD TODAY, AND I JUST FELT LIKE THIS
15	ONE PROBABLY WOULD HAVE SURVIVED.
16	MR. ROTH: I KNOW, BUT THINGS ARE
17	DIFFERENT. AND I THINK I HATE THIS STUFF AND I
18	KNOW ALL OF YOU DO, BUT I THINK WE'VE GOT TO STICK
19	TO OUR
20	CHAIRMAN KLEIN: OKAY. THANK YOU. THE
21	AMENDMENT IS NOT ADOPTED BY THE MAKER OR THE SECOND.
22	SO I'D ASK FOR PUBLIC COMMENT. SEEING NO PUBLIC
23	COMMENT, I'D LIKE TO CALL THE QUESTION.
24	MS. KING: COULD I ASK FOR THE ASSISTANCE
25	OF A COLLEAGUE TO STEP OUTSIDE THE DOOR AND ASK DR.
	146

1	
1	GILL TO REJOIN US, PLEASE?
2	DR. PRIETO: COULD YOU RESTATE THE MOTION?
3	CHAIRMAN KLEIN: MR. HARRISON, IF YOU
4	WOULD RESTATE THE MOTION, AND THEN WE WILL CONFIRM
5	THAT WE HAVE ALL THE VOTES WE NEED IN THE ROOM.
6	MR. HARRISON: THE MOTION MADE BY DUANE
7	ROTH AND SECONDED BY CLAIRE POMEROY IS NOT TO FUND
8	THE APPLICATIONS IN TIER 2 OF TOOLS AND TECHNOLOGY.
9	MS. KING: I JUST WANTED TO CHECK IN. DR.
10	ROME, ARE YOU STILL WITH US?
11	DR. ROME: YES.
12	MS. KING: EXCELLENT. THANK YOU. I KNOW
13	YOU STAYED LONGER THAN YOU HAD THOUGHT YOU WERE ABLE
14	TO, AND I REALLY APPRECIATE THAT. WE'RE JUST ABOUT
15	DONE AND ABOUT TO BREAK FOR LUNCH, SO THANK YOU.
16	CHAIRMAN KLEIN: SHE CAN BEGIN THE ROLL
17	CALL WHILE WE'RE WAITING?
18	MR. HARRISON: YES.
19	MS. KING: RICARDO AZZIZ.
20	DR. AZZIZ: FOR, EXCEPT FOR THOSE
21	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
22	MS. KING: ROBERT PRICE.
23	DR. PRICE: FOR, EXCEPT FOR THOSE
24	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
25	MS. KING: I WILL SKIP DR. GILL AND RETURN
	147

	BARRISTERS' REPORTING SERVICE
1	TO HIM. JACOB LEVIN.
2	DR. LEVIN: YES, EXCEPT FOR THOSE
3	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
4	MS. KING: MARCY FEIT.
5	MS. FEIT: YES, EXCEPT FOR THOSE
6	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
7	MS. KING: MICHAEL FRIEDMAN.
8	DR. FRI EDMAN: YES, EXCEPT FOR THOSE
9	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
10	MS. KING: MICHAEL GOLDBERG.
11	MR. GOLDBERG: YES, EXCEPT FOR THOSE
12	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
13	MS. KING: SAM HAWGOOD.
14	DR. HAWGOOD: YES, EXCEPT FOR THOSE
15	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
16	MS. KING: BOB KLEIN.
17	CHAIRMAN KLEIN: YES.
18	MS. KING: RETURNING TO DR. GILL.
19	DR. GILL: THIS IS DUANE'S MOTION, YES.
20	THE ANSWER IS YES, EXCEPT FOR THOSE APPLICATIONS
21	WITH WHICH I HAVE A CONFLICT.
22	MS. KING: JAMES, COULD I ASK YOU TO
23	REPEAT THE MOTION FOR SHERRY LANSING?
24	MR. HARRISON: YES. THE MOTION IS NOT TO
25	FUND THOSE APPLICATIONS IN TIER 2 OF TOOLS AND
	148

	BARRISTERS' REPORTING SERVICE
1	TECHNOLOGY.
2	MS. LANSING: NOT TO FUND THE ONES IN TIER
3	2. I BETTER ABSTAIN BECAUSE I WASN'T HERE FOR THE
4	DI SCUSSI ON.
5	MS. KING: LEONARD ROME.
6	DR. ROME: YES, EXCEPT FOR THOSE
7	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
8	MS. KING: ED PENHOET.
9	DR. PENHOET: YES, EXCEPT FOR THOSE WITH
10	WHICH I HAVE A CONFLICT.
11	MS. KING: PHIL PIZZO.
12	DR. PIZZO: YES, EXCEPT FOR THOSE
13	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
14	MS. KING: CLAIRE POMEROY.
15	DR. POMEROY: YES.
16	MS. KING: FRANCISCO PRIETO.
17	DR. PRI ETO: NO.
18	MS. KING: CARMEN PULIAFITO.
19	DR. PULIAFITO: YES, EXCEPT FOR THOSE
20	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
21	MS. KING: JOHN REED.
22	DR. REED: YES, EXCEPT FOR THOSE
23	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
24	MS. KING: DUANE ROTH.
25	MR. ROTH: YES.
	149
	147

	BARRISTERS' REPORTING SERVICE
1	MS. KING: JEFF SHEEHY.
2	MR. SHEEHY: NO, EXCEPT FOR THOSE
3	APPLICATIONS WITH WHICH I HAVE A CONFLICT.
4	MS. KING: I'M SORRY. I FORGOT YOU WERE
5	BACK THERE. DAVID SERRANO-SEWELL.
6	MR. SERRANO-SEWELL: NO.
7	MS. KING: THAT MOTION CARRIES AND WE
8	DON'T NEED TO HOLD IT OPEN.
9	CHAIRMAN KLEIN: OKAY. MOTION CARRIES.
10	CAN YOU TELL US WHERE TO ADJOURN FOR
11	LUNCH?
12	MS. KING: YES. LUNCH WILL BE IN THE
13	PENINSULA ROOM, WHICH IS WHERE YOU HAD BREAKFAST
14	THIS MORNING. IT'S AT THE OTHER END OF THE HOTEL
15	BEYOND THE RESTAURANT.
16	CHAIRMAN KLEIN: FOR THE QUORUM PURPOSES,
17	LEEZA GIBBONS IS RETURNING. WHAT TIME?
18	MS. KING: SHE'S RETURNING RIGHT AROUND
19	NOW. SHE'S GOING TO TRY TO JOIN US FOR LUNCH AND
20	THEN COME BACK INTO THE MEETING RIGHT AFTER LUNCH.
21	NOBODY ELSE CAN LEAVE BECAUSE WE ALSO LOST DR. ROME.
22	SO I CAN'T HAVE ANYONE ELSE LEAVE DURING LUNCHTIME.
23	CHAIRMAN KLEIN: WE'RE GOING TO TRY AND
24	HOLD THIS AT 35 MINUTES BECAUSE WE'VE GOT A LOT OF
25	THINGS TO COVER.

150

1	(A RECESS WAS TAKEN.)
2	CHAIRMAN KLEIN: ALL RIGHT. I THINK WE'RE
3	GOING TO RECONVENE. WE HAVE ONE MEMBER OR SO COMING
4	BACK IN. WE'RE GOING TO RECONVENE. WE HAVE A LOT
5	TO COVER. I'M GOING TO GO DIRECTLY TO AN ACTION
6	ITEM, ITEM 10. AND I'M GOING TO TURN THIS OVER TO
7	MI CHAEL GOLDBERG.
8	MR. GOLDBERG: THANK YOU, CHAIRMAN KLEIN.
9	IAN, ITEM.
10	CHAIRMAN KLEIN: WE'RE GOING TO GO TO NO.
11	10 FIRST. IS THE LAP UNDER 9 OR 10? WE'RE GOING TO
12	9.
13	MR. GOLDBERG: AND IAN IS GOING TO LEAD US
14	THROUGH THE CHANGES WE DI SCUSSED AND HAVE
15	INCORPORATED SINCE OUR LAST CONVERSATION ON THIS
16	POI NT.
17	MR. SWEEDLER: GOOD AFTERNOON. I'M HAPPY
18	TO BE HERE TODAY TO PRESENT TO YOU THE LOAN
19	ADMINISTRATION POLICY, WHICH IS THE CULMINATION OF
20	MANY MONTHS, OVER A YEAR OF WORK BY A LOT OF
21	DIFFERENT PEOPLE.
22	THE LOAN ADMINISTRATION POLICY DEFINES THE
23	TERMS AND PROCEDURES THAT WILL APPLY TO CIRM LOAN
24	FUNDING. AND IT'S BEFORE YOU AS SOMETHING WE NEED
25	TO IMPLEMENT TO HAVE LOAN FUNDING. WE WANT IT
	151

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	PASSED THIS MONTH IN PARTICULAR BECAUSE WE INTEND TO
2	DEBUT LOAN FUNDING WITH THE DISEASE TEAMS RFA, WHICH
3	IS SCHEDULED TO BE RELEASED NEXT MONTH.
4	THE WAY WE GOT HERE, YOU APPOINTED A LOAN
5	TASK FORCE WHICH WAS CHAIRED BY DUANE ROTH. THERE
6	WAS EXTENSIVE RESEARCH THAT WENT INTO THEIR WORK, A
7	NUMBER OF PUBLIC HEARINGS. THEY BROUGHT THAT TO THE
8	FINANCE SUBCOMMITTEE WHICH WORKED WITH THAT FURTHER
9	AND EVENTUALLY PRODUCED A POLICY DOCUMENT THAT YOU
10	APPROVED IN SEPTEMBER. AND WE'VE BEEN WORKING SINCE
11	THEN WITH THE FINANCE SUBCOMMITTEE TO TURN THAT
12	POLICY DOCUMENT INTO REGULATIONS.
13	FOR THE MOST PART, LOANS WILL WORK JUST
14	LIKE GRANTS, AND THEY WILL BE GOVERNED BY OUR
15	STANDARD GRANTS ADMINISTRATION POLICY. SO THE LOAN
16	ADMINISTRATION POLICY IS NOT A COMPREHENSIVE SET OF
17	RULES. WHAT IT IS IS A COLLECTION OF THE SPECIFIC
18	RULES THAT APPLY JUST TO LOANS, AND THAT'S WHAT
19	WE'RE HERE TO GO OVER TODAY.
20	AND WHAT I'D LIKE TO DO IS JUST GO THROUGH
21	THE BASIC TERMS, AND THEN I'D BE HAPPY TO TAKE ANY
22	QUESTI ONS.
23	THERE ARE TWO TYPES OF LOANS AVAILABLE. A
24	RECOURSE LOAN IS THE SIMPLE KIND OF LOAN THAT WE'RE
25	ALL FAMILIAR WITH. YOU BORROW THE MONEY AND THEN
	152

WHEN IT'S DUE, YOU PAY IT BACK WITH INTEREST. A
 NONRECOURSE LOAN IS MORE CLOSELY TIED TO THE FATE OF
 THE PARTICULAR PROJECT OR PRODUCTS THAT THE CIRM
 LOAN IS FUNDING. A NONRECOURSE LOAN, THE BORROWER
 MAY BE ABLE TO CANCEL THAT LOAN IF THE PROJECT IS
 ABANDONED.

7 SOME OF THE BASIC TERMS OF THE LOAN, THE 8 INTEREST RATE WILL BE DETERMINED ON AN RFA-BY-RFA 9 BASIS. THE LOAN TERMS ARE GENERALLY FOR SIX OR TEN 10 YEARS WITH THE COMPANIES HAVING THE OPTION OF CHOOSING WHICH TERM WORKS BEST FOR THEM. AND THEN 11 THERE ARE A VARIETY OF CIRCUMSTANCES RELATED TO 12 13 BUSINESS CONDITIONS THAT WOULD ACCELERATE THE REPAYMENT OBLIGATION, BRING IT FORWARD. AND WHAT 14 THOSE TRIGGERS RECOGNIZE IS THAT THESE LOANS ARE 15 16 THERE, IN PART, TO MAKE IT POSSIBLE FOR COMPANIES TO 17 MOVE ON TO THE NEXT STAGE IN THEIR FINANCIAL DEVELOPMENT AND THE POINT COMES WHEN THEY DON'T 18 19 REALLY NEED THE MONEY ANYMORE. WE HAVE OTHER USES FOR IT. 20

AN IMPORTANT PART OF HOW THIS PROGRAM
WORKS IS THAT CIRM GETS STOCK WARRANTS AS PART OF
THE LOAN. A STOCK WARRANT IS BASICALLY A STOCK
OPTION. FOR A RECOURSE LOAN, WE RECEIVE 10 PERCENT.
THE WARRANT'S WORTH 10 PERCENT OF THE AMOUNT OF THE

153

1	LOAN. FOR A NONRECOURSE LOAN, WE RECEIVE WARRANTS
2	EQUIVALENT TO A HUNDRED PERCENT OF THE VALUE OF THE
3	LOAN.
4	THE WAY IT'S BEEN PROPOSED IN THE POLICY,
5	WE THINK THIS IS WHAT WORKS BEST, FOR RFA'S WHERE
6	WE'RE TARGETING SMALLER AWARDS, BELOW \$3 MILLION, WE
7	BELIEVE IT'S BEST JUST TO PROCEED WITH GRANTS FOR
8	THOSE RFA'S. FOR LARGER AWARD RFA'S, IT'S SOMETHING
9	THAT WILL BE DECIDED FOR EACH RFA BY THE ICOC AT THE
10	TIME OF CONCEPT APPROVAL.
11	WE ALSO PROPOSE THAT LOANS NOT ALWAYS BE
12	OPTIONAL. IN FACT, THE FIRST OPTION UNDER THERE IS
13	THE ONE THAT WOULD PROBABLY BE THE MOST COMMON, ONE
14	IN WHICH NONPROFIT APPLICANTS GET GRANTS AND
15	FOR-PROFIT APPLICANTS GET LOANS. BUT THERE ARE
16	OTHER OPTIONS THAT YOU COULD ADOPT FOR ANY
17	PARTICULAR RFA. ONE WOULD BE GRANTS TO NONPROFITS,
18	AND FOR-PROFIT APPLICANTS COULD CHOOSE GRANTS OR
19	LOANS. FINALLY, EVEN FOR A LARGER RFA, YOU WOULD
20	RETAIN THE OPTION TO MAKE IT GRANTS ONLY.
21	WITH DISEASE TEAMS AND OTHERS, WE ARE
22	ENCOURAGING PARTNERSHIPS, COLLABORATIONS BETWEEN
23	FOR-PROFIT AND NONPROFIT INSTITUTIONS. IF A
24	NONPROFIT IS THE LEAD APPLICANT ORGANIZATION, WE'VE
25	WORKED OUT A WAY THAT THEY COULD STILL GET THEIR
	154

154

1	FUNDING IN THE FORM OF A LOAN. AND THE WAY THAT
2	WOULD WORK IS THAT THE FUNDING GOES TO THE NONPROFIT
3	AS THE LEAD INSTITUTION. THEY ADMINISTER IT. AND
4	FOR ALL INTENTS AND PURPOSES, FOR THE NONPROFIT, IT
5	WORKS JUST LIKE A GRANT. THE FOR-PROFIT PARTNER IN
6	THAT COLLABORATION AGREES TO ASSUME THE REPAYMENT
7	OBLIGATION AND TO PROVIDE THE WARRANTS.
8	SO THE FOR-PROFIT IS WHAT'S PROVIDING THE
9	REVENUE BACK TO CIRM. THE NONPROFIT ADMINISTERS THE
10	FUNDING JUST AS IT WOULD WITH AN ORDINARY GRANT.
11	ONE OPTION THAT EXISTS IN THE POLICY IS TO RECOGNIZE
12	THAT THERE MAY BE TIMES WHERE THE LEAD APPLICANT IS
13	A NONPROFIT ORGANIZATION, BUT THE FOR-PROFIT STILL
14	IS A VERY SUBSTANTIAL PARTICIPANT IN THAT PROJECT.
15	AND THE ICOC HAS THE OPTION IN AN RFA OF SAYING THAT
16	IF THE FOR-PROFIT RECEIVES MORE THAN A THRESHOLD
17	AMOUNT OF THE FUNDING, THEN THAT COLLABORATION
18	SHOULD BE REQUIRED TO APPLY FOR A LOAN.
19	AND WHAT WE ARE ASKING YOU TO DO TODAY IS
20	TO ADOPT THIS POLICY AS AN INTERIM REGULATION WITH
21	EFFECTIVE DATE OF JUNE 15, 2009, WHICH IS WHEN WE
22	NEED IT TO ACTUALLY TAKE EFFECT, AND TO AUTHORIZE
23	STAFF TO INITIATE A FORMAL RULEMAKING, WHICH WILL
24	ALLOW US TO TURN THIS INTO AN OFFICE OF
25	ADMINISTRATIVE LAW APPROVED LONG-TERM REGULATION.

155

1	SO WITH THOSE BASICS OUT THERE, I'M HAPPY
2	TO ADDRESS ANY QUESTIONS YOU HAVE.
3	MR. GOLDBERG: BEFORE THERE ARE QUESTIONS,
4	I WANT TO THANK IAN FOR YEOMAN'S WORK IN CONNECTION
5	WITH THE LOAN ADMINISTRATION POLICY AND LYNN
6	HARWELL, WHO FACILITATED ALL THE INTERACTIONS OF THE
7	FINANCE SUBCOMMITTEE.
8	AND NOW TO DUANE ROTH, WHO CHAIRED THE
9	LOAN TASK FORCE AND SERVES ON THE FINANCE
10	SUBCOMMITTEE, WHO WOULD LIKE TO MAKE A COUPLE OF
11	MODIFICATIONS TO WHAT YOU HAVE IN YOUR BOOK.
12	MR. ROTH: SO I READ THROUGH THIS AGAIN,
13	AND WE'VE BEEN THIS HAS BEEN AN ITERATIVE PROCESS
14	TO MAKE SURE WE GET THE POLICY RIGHT. SO THE LAST
15	TWO ITERATIONS THAT I WOULD LIKE TO LOOK AT ARE ON
16	PAGE 11 AT THE TOP.
17	WE TALK ABOUT WHAT HAPPENS IF A PROGRAM IS
18	SUSPENDED AND THEN RESUMES. IN OTHER WORDS, IT'S A
19	NONRECOURSE LOAN. THEY NOTICED BY US THEY'VE
20	ABANDONED THE PROGRAM AND IT GOES INTO SUSPENSION,
21	BUT SOMETHING HAPPENS A YEAR OR TWO DOWN THE ROAD
22	AND THE PROGRAM GETS RESUMED EITHER BY THEM OR BY
23	ANYBODY ELSE THAT MIGHT BE INTERESTED IN IT. THE
24	QUESTION IS HOW DO WE HANDLE THAT.
25	SO IN THE TOP IT SAYS THE DEBTOR MUST ALSO
	156
	150

1AGREE TO TERMS FOR FULL OR PARTIAL REPAYMENT. AND I2SUGGEST THAT WE STAY WITH FULL REPAYMENT THERE AND3THEN MODIFY THREE OR FOUR SENTENCES DOWN, THAT THE4FI NANCE SUBCOMMITTEE SHALL HAVE THE RIGHT TO MAKE5THOSE MODIFICATIONS. BUT I DON'T WANT TO GIVE THE6IMPRESSION THAT YOU COULD ABANDON AS A WAY TO COME7BACK AND ASK US TO MODIFY THE TERMS.8MR. SWEEDLER: DUANE AND I SPOKE ABOUT9THI S. SO HERE ARE THE ACTUAL DETAILS FOR THAT10AMENDMENT. IN THE FIRST LINE ON PAGE 11 WHERE IT11SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS12"FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR13THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION14OF REPAYMENT. "WE'D ADD THE WORDS "AND AMOUNT"15AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT16OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY17FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY18DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT19THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT20WOULD ONLY BE PARTIAL.21MR. ROTH: THANKS. I THINK THAT ADDRESSES22THAT.
3THEN MODIFY THREE OR FOUR SENTENCES DOWN, THAT THE4FINANCE SUBCOMMITTEE SHALL HAVE THE RIGHT TO MAKE5THOSE MODIFICATIONS. BUT I DON'T WANT TO GIVE THE6IMPRESSION THAT YOU COULD ABANDON AS A WAY TO COME7BACK AND ASK US TO MODIFY THE TERMS.8MR. SWEEDLER: DUANE AND I SPOKE ABOUT9THIS. SO HERE ARE THE ACTUAL DETAILS FOR THAT10AMENDMENT. IN THE FIRST LINE ON PAGE 11 WHERE IT11SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS12"FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR13THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION14OF REPAYMENT." WE'D ADD THE WORDS "AND AMOUNT"15AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT16OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY17FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY18DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT19THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT20WOULD ONLY BE PARTIAL.21MR. ROTH: THANKS. I THINK THAT ADDRESSES
 FINANCE SUBCOMMITTEE SHALL HAVE THE RIGHT TO MAKE THOSE MODIFICATIONS. BUT I DON'T WANT TO GIVE THE IMPRESSION THAT YOU COULD ABANDON AS A WAY TO COME BACK AND ASK US TO MODIFY THE TERMS. MR. SWEEDLER: DUANE AND I SPOKE ABOUT THIS. SO HERE ARE THE ACTUAL DETAILS FOR THAT AMENDMENT. IN THE FIRST LINE ON PAGE 11 WHERE IT SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS "FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION OF REPAYMENT. "WE'D ADD THE WORDS "AND AMOUNT" AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT WOULD ONLY BE PARTIAL. MR. ROTH: THANKS. I THINK THAT ADDRESSES
 THOSE MODIFICATIONS. BUT I DON'T WANT TO GIVE THE IMPRESSION THAT YOU COULD ABANDON AS A WAY TO COME BACK AND ASK US TO MODIFY THE TERMS. MR. SWEEDLER: DUANE AND I SPOKE ABOUT THIS. SO HERE ARE THE ACTUAL DETAILS FOR THAT AMENDMENT. IN THE FIRST LINE ON PAGE 11 WHERE IT SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS "FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION OF REPAYMENT. "WE'D ADD THE WORDS "AND AMOUNT" AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT WOULD ONLY BE PARTIAL. MR. ROTH: THANKS. I THINK THAT ADDRESSES
 6 IMPRESSION THAT YOU COULD ABANDON AS A WAY TO COME BACK AND ASK US TO MODIFY THE TERMS. 8 MR. SWEEDLER: DUANE AND I SPOKE ABOUT 9 THIS. SO HERE ARE THE ACTUAL DETAILS FOR THAT 10 AMENDMENT. IN THE FIRST LINE ON PAGE 11 WHERE IT 11 SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS 12 "FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR 13 THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION 14 OF REPAYMENT. "WE'D ADD THE WORDS "AND AMOUNT" 15 AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT 16 OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY 17 FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY 18 DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT 19 THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT 20 WOULD ONLY BE PARTIAL. 21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
 BACK AND ASK US TO MODIFY THE TERMS. MR. SWEEDLER: DUANE AND I SPOKE ABOUT THIS. SO HERE ARE THE ACTUAL DETAILS FOR THAT AMENDMENT. IN THE FIRST LINE ON PAGE 11 WHERE IT SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS "FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION OF REPAYMENT." WE'D ADD THE WORDS "AND AMOUNT" AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT WOULD ONLY BE PARTIAL. MR. ROTH: THANKS. I THINK THAT ADDRESSES
8MR. SWEEDLER: DUANE AND I SPOKE ABOUT9THIS. SO HERE ARE THE ACTUAL DETAILS FOR THAT10AMENDMENT. IN THE FIRST LINE ON PAGE 11 WHERE IT11SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS12"FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR13THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION14OF REPAYMENT." WE'D ADD THE WORDS "AND AMOUNT"15AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT16OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY17FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY18DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT19THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT20WOULD ONLY BE PARTIAL.21MR. ROTH: THANKS. I THINK THAT ADDRESSES
 9 THIS. SO HERE ARE THE ACTUAL DETAILS FOR THAT 10 AMENDMENT. IN THE FIRST LINE ON PAGE 11 WHERE IT 11 SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS 12 "FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR 13 THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION 14 OF REPAYMENT." WE'D ADD THE WORDS "AND AMOUNT" 15 AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT 16 OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY 17 FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY 18 DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT 19 THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT 20 WOULD ONLY BE PARTIAL. 21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
 AMENDMENT. IN THE FIRST LINE ON PAGE 11 WHERE IT SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS "FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION OF REPAYMENT." WE'D ADD THE WORDS "AND AMOUNT" AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT WOULD ONLY BE PARTIAL. MR. ROTH: THANKS. I THINK THAT ADDRESSES
 11 SAYS FULL OR PARTIAL REPAYMENT, STRIKE THE WORDS 12 "FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR 13 THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION 14 OF REPAYMENT." WE'D ADD THE WORDS "AND AMOUNT" 15 AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT 16 OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY 17 FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY 18 DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT 19 THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT 20 MR. ROTH: THANKS. I THINK THAT ADDRESSES
 12 "FULL OR PARTIAL." AND THEN ON THE FIFTH LINE NEAR 13 THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION 14 OF REPAYMENT." WE'D ADD THE WORDS "AND AMOUNT" 15 AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT 16 OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY 17 FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY 18 DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT 19 THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT 20 WOULD ONLY BE PARTIAL. 21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
 13 THE END OF THAT LINE, IT SAYS "TERMS FOR RESUMPTION 14 OF REPAYMENT. "WE'D ADD THE WORDS "AND AMOUNT" 15 AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT 16 OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY 17 FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY 18 DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT 19 THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT 20 WOULD ONLY BE PARTIAL. 21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
 OF REPAYMENT. "WE'D ADD THE WORDS "AND AMOUNT" AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT WOULD ONLY BE PARTIAL. MR. ROTH: THANKS. I THINK THAT ADDRESSES
 AFTER RESUMPTION. TERMS FOR RESUMPTION AND AMOUNT OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT WOULD ONLY BE PARTIAL. MR. ROTH: THANKS. I THINK THAT ADDRESSES
 16 OF REPAYMENT. SO IT PRESERVES THE SAME FLEXIBILITY 17 FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY 18 DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT 19 THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT 20 WOULD ONLY BE PARTIAL. 21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
 17 FOR THE FINANCE COMMITTEE AS IT WAS ORIGINALLY 18 DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT 19 THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT 20 WOULD ONLY BE PARTIAL. 21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
 18 DRAFTED, BUT THERE'S A SHIFT OF EMPHASIS SO THAT 19 THERE ISN'T AN INHERENT EXPECTATION THAT REPAYMENT 20 WOULD ONLY BE PARTIAL. 21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
 19 THERE I SN' T AN I NHERENT EXPECTATION THAT REPAYMENT 20 WOULD ONLY BE PARTIAL. 21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
 20 WOULD ONLY BE PARTIAL. 21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
21 MR. ROTH: THANKS. I THINK THAT ADDRESSES
22 THAT.
23 AND THE SECOND DEALS WITH SUBHEADING H
24 RIGHT BELOW. AND I WOULD ASK, IAN, THAT WE TRY TO
25 FIND LANGUAGE THAT COVERS BOTH RECOURSE AND
157

1	NONRECOURSE LOANS WHERE AN EXTENSION MAY BE NEEDED
2	AND GIVE THE SUBCOMMITTEE, AGAIN, THE FLEXIBILITY ON
3	EITHER. AND THE REASON I ASK FOR THAT IS I THINK
4	SOME SMALL COMPANIES MAY, IN FACT, TAKE A RECOURSE
5	LOAN, AND THEN THERE'S A LONG INTERRUPTION, A DELAY
6	WITH FDA OR SOMETHING LIKE THAT, WHERE WE'D LIKE TO
7	HAVE THE FLEXIBILITY, INSTEAD OF CALLING THE LOAN,
8	TO ADJUST THOSE TERMS. THAT WOULD JUST GIVE US THAT
9	FLEXIBILITY. SO IF YOU COULD FIND A WAY TO DO THAT,
10	OR IF YOU THINK IT'S ALREADY COVERED AND WE DON'T
11	NEED TO DO IT, BUT I WANT TO MAKE SURE WE HAVE THAT
12	FLEXI BI LI TY.
13	MR. SWEEDLER: I THINK THAT THERE'S A
14	BASIC LEVEL OF FLEXIBILITY BUILT INTO EVERYTHING
15	ABOUT HOW THESE LOANS WILL BE ADMINISTERED OVER THE
16	YEARS. AS WITH ANY CONTRACT, THERE'S ROOM FOR
17	RENEGOTIATION. THIS PROVISION ABOUT EXTENDING THE
18	LOAN PERIOD IF THERE'S A DELAY IN THE PROJECT TIES
19	IN WITH THE CONCEPT OF A NONRECOURSE LOAN AS BEING
20	SOMETHING TIED TO THE PROJECT. THERE'S NO INHERENT
21	PROBLEM WITH ADDING THAT OPTION IN THERE FOR
22	RECOURSE LOANS AS WELL IF THAT'S SOMETHING THAT THE
23	BOARD WANTS TO DO, BUT IT IS IT MAY CHANGE THE
24	EXPECTATIONS ABOUT WHAT A RECOURSE LOAN IS UNDER THE
25	PROGRAM.

158

-	
1	MR. ROTH: THAT'S WHY I'D LIKE THE WORDING
2	TO BE BROAD ENOUGH TO ALLOW THAT WITHOUT MAKING IT
3	APPEAR THERE IS AN EXPECTATION THAT CAN HAPPEN. BUT
4	WHAT WE DON'T WANT TO HAVE TO DO IS HAVE JAMES TELL
5	US THAT OUR POLICY REALLY DOESN'T ALLOW US TO MAKE
6	AN ADJUSTMENT THAT WE FEEL WE NEED TO MAKE SIX,
7	SEVEN YEARS FROM NOW.
8	CHAIRMAN KLEIN: I THINK THIS IS PRUDENT
9	IN THE CURRENT FINANCIAL ENVIRONMENT WE HAVE OUT
10	THERE, WHICH MAY EXTEND FOR SEVERAL YEARS, TO HAVE
11	THAT DISCRETION WITH A CLEAR MESSAGE THAT IT'S
12	RESERVED AS A TRUE EXCEPTION.
13	MR. SWEEDLER: SO THE WAY THAT WOULD BE
14	IMPLEMENTED, IF THAT'S SOMETHING THAT THE BOARD
15	WANTS TO DO, WOULD REALLY JUST BE A CHANGE IN THE
16	TITLE OF THAT SECTION ON PAGE 11, ADDING THE WORDS
17	"RECOURSE OR. " SO EXTENSION OF LOAN PERIOD FOR
18	RECOURSE OR NONRECOURSE LOANS.
19	MR. ROTH: OR TAKE NONRECOURSE OUT OF THE
20	TITLE, THE HEADER.
21	MR. SWEEDLER: I THINK IT'S BETTER TO BE
22	EXPLICIT THAT IT'S AVAILABLE TO BOTH.
23	MR. GOLDBERG: CHAIRMAN KLEIN, YOU HAD A
24	POINT WITH REGARD TO THE WARRANT COVERAGE, IN
25	PARTICULAR FOR THE NONRECOURSE LOANS.
	159

1 CHAIRMAN KLEIN: SINCE WE STARTED THIS 2 PROGRAM, STOCK PRICES HAVE FALLEN. THEY' VE RECOVERED IN BIOTECH SECTORS IN SOME CASES, BUT IT'S 3 NOT CONSISTENT. IT'S VERY SPOTTY. SO I JUST 4 SUGGEST THAT WE MONITOR THIS SITUATION BECAUSE AT 5 THE CURRENT STOCK PRICES AND VALUATIONS OF THESE 6 7 COMPANIES, WE CAN HAVE A MUCH LARGER PERCENTAGE OWNERSHIP THAN WAS INTENDED OUT OF THIS HUNDRED 8 9 PERCENT WARRANT COVERAGE.

10 DUANE PROPERLY INDICATES THAT WE CAP THIS OUT A 20-PERCENT MAXIMUM VALUATION. I JUST BELIEVE 11 WE SHOULD KEEP OUR EARS OPEN, MONITOR IT, AND SEE IF 12 13 ON AN INDIVIDUAL RFA WE SHOULD TEST ANOTHER PERCENTAGE. THIS IS A NEW PROGRAM. WE'RE GOING TO 14 NEED TO BE RESPONSIVE. WE'RE GOING TO NEED TO LOOK 15 16 AT THIS PROGRAM, WHICH HAS HAD A GREAT DEAL OF 17 THOUGHT IN IT, ON AN ORGANIC BASIS AS WE RESPOND PARTICULARLY IN THE CONTEXT OF CURRENT ECONOMIC 18 19 CONDITIONS. MR. ROTH: I AGREE WITH THAT. AND THAT'S 20

20 MR. ROTH: T AGREE WITH THAT. AND THAT S 21 WHY WE PUT THE 20-PERCENT CAP IN. IF THERE'S 22 DILUTED FINANCING SUBSEQUENT TO OUR WARRANT ISSUE, 23 WE'RE GOING TO BE DILUTED WITH THAT. SO WE SHOULD 24 BE OKAY WITH A 20-PERCENT CAP. 25 MR. GOLDBERG: ARE THERE ANY QUESTIONS

160

FROM MEMBERS OF THE BOARD? 1 2 MR. SHEEHY: I MAY HAVE MISSED THIS, BUT WHEN WE WERE TALKING ABOUT THE LOAN FUNDING FOR 3 NONPROFIT APPLICANTS, DID WE TALK ABOUT ON PAGE 3, 4 NUMBER D, PART 4, WHERE WE COULD REQUIRE A NONPROFIT 5 APPLICANT TO TAKE A LOAN? 6 7 MR. SWEEDLER: RIGHT. THAT WAS THE SLIDE ABOUT COLLABORATIONS. SO I CAN GO THROUGH THAT WITH 8 9 A LITTLE MORE DETAIL. IT WOULD BE -- LET'S SAY THAT 10 THERE'S AN REA IN WHICH THE RULE IS THAT NONPROFIT APPLICANTS GET GRANTS AND FOR-PROFIT APPLICANTS GET 11 LOANS. AND THAT REFLECTS A BASIC POLICY DECISION 12 13 THAT WHERE A SIGNIFICANT BENEFICIARY OF THAT FUNDING IS A COMPANY, THAT WE THINK WE SHOULD GET OUR 14 REPAYMENT IN THE FORM OF THE LOAN REPAYMENT RATHER 15 16 THAN THE REVENUE SHARING PROVISIONS. 17 IT WOULD BE POSSIBLE FOR, IN THE CASE OF A COLLABORATION, THEY CONTROL WHO THEY WANT TO BE THE 18 19 APPLICANT INSTITUTION AND WHICH WOULD BE THE CO-PI INSTITUTION. AND WE WOULD RATHER SEE THAT DECISION 20 21 BE DRIVEN BY SCIENTIFICALLY WHO'S THE RIGHT PERSON 22 TO BE THE PI RATHER THAN AN ATTEMPT TO MANIPULATE THE FUNDING MECHANISM. 23 24 SO AS IT'S WRITTEN IN THE POLICY, IF THE 25 ICOC ADOPTS THAT APPROACH, THEN IF THE FOR-PROFIT IS 161

1	RECEIVING MORE THAN 40 PERCENT OF THE RESEARCH
2	FUNDING UNDER THAT PROPOSAL, THEN IT CAN ONLY BE
3	FUNDED IN THE FORM OF A LOAN.
4	MR. SHEEHY: SO I JUST WANT PEOPLE TO BE
5	CLEAR. WE'RE TALKING ABOUT FOR DISEASE TEAMS, WE'RE
6	GOING TO REQUIRE COMPANIES TO TAKE LOANS. THEY
7	CANNOT APPLY FOR A GRANT. SO FOR INSTITUTIONS, THEY
8	COULD BE IN A POSITION WHERE THEY ARE REQUIRED TO
9	TAKE LOANS IF THEY HAVE A COMPANY COLLABORATOR WHO
10	HAS OVER 40 PERCENT. SO BEFORE WE PUT THIS INTO
11	STONE, I THINK EVERYONE SHOULD BE COMFORTABLE WITH
12	THE IDEA THAT THEY
13	MR. SWEEDLER: BUT I DO WANT TO CLARIFY
14	SOMETHING THERE. THE FUNDING MECHANISM IN A
15	SITUATION LIKE THAT OVERALL IS A LOAN, BUT THE
16	NONPROFIT TAKES ON NO LOAN REPAYMENT OBLIGATIONS OR
17	ANY OBLIGATION THAT IS IN ANY WAY DIFFERENT FROM
18	WHAT THEY TAKE ON IN A GRANT CIRCUMSTANCE. THE
19	FOR-PROFIT IS TAKING ON THE REPAYMENT OBLIGATION AND
20	THE WARRANT.
21	SO YOU HAVE CORRECTLY SUMMARIZED THE
22	SITUATION, BUT I JUST WANT TO MAKE SURE PEOPLE
23	UNDERSTAND THAT WE'RE NOT SUGGESTING THAT NONPROFITS
24	TAKE ON DEBT OR AN OBLIGATION TO REPAY ANYTHING.
25	MR. SHEEHY: WE DID NOT DISCUSS THIS
	162

1	HAS NOT BEEN DISCUSSED THIS ACTUAL ITEM HAS NOT
2	BEEN HEARD AT FINANCE SUBCOMMITTEE.
3	MR. SWEEDLER: THAT'S RIGHT.
4	MR. SHEEHY: NOT TO THIS DEGREE OF DETAIL.
5	WE TALKED ABOUT THE ISSUE, BUT WE HAVE NOT HAD THIS
6	ACTUAL LANGUAGE BEFORE US.
7	CHAIRMAN KLEIN: I THINK HE'S RIGHT. I'D
8	LIKE TO EMPHASIZE HERE, SO THAT THE PUBLIC
9	UNDERSTANDS, THAT SCIENTIFICALLY WE WANT TO DRIVE
10	WHO THE PI IS. YOU CAN HAVE A NONPROFIT PI; AND MY
11	UNDERSTANDING UNDER OUR LANGUAGE NOW IS THAT, IF
12	THERE'S A NONPROFIT PI AND THE FOR-PROFIT HAS LESS
13	THAN 40 PERCENT, THEY CAN STILL ELECT FOR IT TO BE A
14	LOAN. AND THE LOAN IS PICKED UP NOT BY THE
15	NONPROFIT, BUT BY THE FOR-PROFIT BECAUSE THEY'RE
16	GETTING THE FULL BENEFIT OF THE PRODUCT THAT'S BEING
17	DEVELOPED WITH THIS RESEARCH. AND THAT LOAN IS
18	ONLY, IN FACT, IN EFFECT IF THAT PRODUCT IS
19	SUCCESSFUL. SO THE FOR-PROFIT IS NOT ASSUMING A
20	LOAN OBLIGATION FOR SOMETHING THAT FAILS.
21	NOW, IT'S ONLY IF IT'S SUCCESSFUL THAT
22	THIS ACTUALLY BECOMES AN ACTUAL FINANCIAL OBLIGATION
23	TO REPAY.
24	DR. HAWGOOD: ONE POINT OF CLARIFICATION
25	AND ONE QUESTION. IF THE FOR-PROFIT IS UNDER
	163
	105

1	OBLIGATION FOR THE WARRANTIES AND THE PAYBACK OF THE
2	LOAN, IS IT JUST FOR THAT COMPONENT OF THE FUNDING
3	THAT WAS USED BY THE LOAN?
4	MR. SWEEDLER: THAT'S A GOOD QUESTION.
5	NO. IT'S FOR THE FULL AMOUNT, WHICH IS PREMISED ON
6	THE RATIONALE THAT CHAIRMAN KLEIN JUST GAVE, WHICH
7	IS THAT IT'S A UNIFIED PROJECT IN WHICH THE PARTIES
8	PRESUMABLY HAVE ARRANGED THE COMMERCIALIZATION PARTS
9	OF IT. THE BENEFITS OF THAT GO TO THE COMPANY. SO
10	IT'S APPROPRIATE FOR THEM TO BE REPAYING THE COST OF
11	THE PROJECT.
12	DR. HAWGOOD: MY QUESTION, HAS
13	PARTICULARLY THIS PARTICULAR CONCEPT BEEN VETTED
14	THROUGH ANY OF THE MAJOR INSTITUTIONAL COUNSELS,
15	UNIVERSITY OF CALIFORNIA OR ANY OF THE OTHER MAJOR
16	INSTITUTIONS THAT MAY BE TAKING ADVANTAGE OF THIS
17	CONCEPT, TO MAKE SURE IT'S CONSISTENT WITH REGENTIAL
18	POLICY OR OTHER?
19	MR. SWEEDLER: WE HAVEN'T HAD THOSE
20	CONVERSATIONS, BUT I WANT TO MAKE SOMETHING VERY
21	CLEAR. THE OBLIGATIONS, PROMISES, COMMITMENTS,
22	RIGHTS AND RESPONSIBILITIES OF THE NONPROFIT ARE TO
23	THE LETTER IDENTICAL TO A GRANT. SO IT CAN'T HAVE A
24	LEGAL IMPACT BECAUSE IT'S NOT ANY DIFFERENT. IT'S
25	ALMOST AS IF SO I UNDERSTAND YOUR CONCERN, BUT I

1	JUST WANT TO MAKE SURE PEOPLE UNDERSTAND THAT AS FAR
2	AS THE NONPROFIT IS CONCERNED, THE RELATIONSHIP WITH
3	CIRM AND THE OBLIGATIONS ARE IDENTICAL TO THOSE OF A
4	GRANT.
5	DR. HAWGOOD: I GUESS I'M PARTICULARLY,
6	AND AGAIN THIS IS OUT OF MY AREA OF EXPERTISE, BUT
7	WOULD PARTICULARLY WANT TO BE SURE THAT WE WEREN'T
8	GETTING INTO ADDITIONAL DIFFICULTIES WITH
9	INTELLECTUAL PROPERTY AND OTHER ISSUES IF THE
10	FOR-PROFIT IS, IN FACT, RESPONSIBLE FOR PAYBACK OF
11	THE ENTIRE GRANT THAT WAS GOING TO THE
12	NOT-FOR-PROFIT, WHO OWNS WHAT.
13	MR. SWEEDLER: I DON'T THINK THAT WOULD BE
14	A PROBLEM.
15	MR. ROTH: JEFF, IF I COULD MAYBE JUST ON
16	THIS ITEM NO. 4, AND DON'T THINK ABOUT DISEASE TEAMS
17	HERE, THIS IS MORE IN TRANSLATIONAL WHERE YOU HAVE
18	PRODUCTS INVOLVED, AND SOMEBODY WOULD TRY TO USE A
19	UNIVERSITY AS A WAY TO AVOID A LOAN PAYMENT. AND SO
20	WE PUT THE WORD "MAY" IN HERE SO THAT IF WE SUSPECT
21	THAT THE ARRANGEMENT IS INAPPROPRIATE FOR A GRANT,
22	WE COULD ASK THEM TO TAKE IT AS A LOAN.
23	MR. SWEEDLER: ACTUALLY THE MAY IN THERE
24	REFERS TO AN ELECTION THAT YOU WOULD MAKE ON AN
25	RFA-BY-RFA BASIS AT THE ICOC.
	165

165

1	MR. ROTH: THE OTHER POINT I WAS GOING TO
2	MAKE IS THIS WILL BE COVERED IN THE RFA.
3	MR. SHEEHY: I GUESS WHAT I'M AFRAID OF IS
4	THAT A VERY INTERESTING SCIENCE PROJECT COULD BE
5	WOULD NEVER COME TO US BECAUSE THE UNIVERSITIES OR
6	THE UNIVERSITY PI WOULD BE UNABLE TO NEGOTIATE WITH
7	THE COMPANY TO HAVE THIS. BASICALLY WE'RE TELLING
8	THE UNIVERSITY THAT YOU CAN ONLY COME IN FOR THIS
9	MONEY WITH SUBSTANTIAL
10	CHAIRMAN KLEIN: DR. FRIEDMAN, I NEED YOU
11	TO HOLD ON FOR A COUPLE MINUTES.
12	DR. FRIEDMAN: I CAN'T.
13	CHAIRMAN KLEIN: COUPLE MINUTES.
14	DR. FRIEDMAN: NO. I'M SERIOUS. I'VE
15	GOT TO GO BECAUSE THE CONVERSATION IS GOING TO TAKE
16	LONGER THAN A COUPLE OF MINUTES, BOB.
17	CHAIRMAN KLEIN: CAN WE CALL THE QUESTION?
18	THIS IS AN INTERIM REG THAT'S GOING OUT FOR PUBLIC
19	COMMENT. IT'S GOING TO GO OUT FOR LOTS OF INPUT FOR
20	120 DAYS; IS THAT CORRECT?
21	MR. SWEEDLER: YES. THERE WILL BE
22	OPPORTUNITIES. THIS IS WHAT WILL TAKE EFFECT NOW,
23	BUT THERE WILL BE MANY OPPORTUNITIES TO MODIFY IT AS
24	THIS GOES ALONG.
25	MR. GOLDBERG: SO WE'E READY TO HAVE A
	166

1	MOTION ON ADOPTING THE LOAN ADMINISTRATION POLICY AS
2	AMENDED BY
3	MR. SHEEHY: I'M SORRY. I HAVE TO OBJECT.
4	WE HAVE NEVER DISCUSSED EITHER IN SUBCOMMITTEE OR AT
5	THIS BOARD THIS ITEM, AND THIS IS INAPPROPRIATE TO
6	PUT THIS THROUGH.
7	DR. FRIEDMAN: I APOLOGIZE TO EVERYBODY.
8	I DON'T MEAN TO BE THE PERSON WHO RUINS THE QUORUM.
9	MR. SHEEHY: IF YOU WANT TO APPROVE IT
10	MINUS THIS SECTION AND WE CAN COME BACK TO THIS
11	SECTION, I WOULD BE HAPPY TO VOTE FOR THE REST OF IT
12	AND URGE DR. FRIEDMAN
13	MR. GOLDBERG: JEFF, WE HAVE AN
14	OPPORTUNITY TO REVIEW THE WHOLE THING IN ITS
15	ENTIRETY BEFORE IT'S ADOPTED BY VIRTUE OF IT GOING
16	OUT AS AN INTERIM DOCUMENT. LET'S FIND OUT WHETHER
17	PEOPLE HAVE PROBLEMS WITH THIS.
18	MR. ROTH: THAT'S ALL RIGHT. LET'S SEE IF
19	IT'S AN ISSUE AND THEN WE'LL COME BACK TO IT.
20	CHAIRMAN KLEIN: VERY QUICKLY BECAUSE WE
21	NEED TO GET SOMETHING OUT THERE SO THAT THERE'S AN
22	UNDERSTANDING IN THE DISEASE TEAMS WHAT THEY'RE
23	GOING TO BE FACED WITH. I WOULD ASK IF WE COULD
24	HAVE IT'S THE 40-PERCENT ISSUE?
25	MR. SHEEHY: I DON'T THINK WE CAN REQUIRE
	167

A NONPROFIT TO TAKE A LOAN. 1 2 MR. SWEEDLER: LET ME JUST POINT OUT THIS GIVES THE I COC THE OPTION TO DO THAT. THERE WILL BE 3 ANOTHER AGENDA I TEM WHERE YOU DECIDE WHAT THE TERMS 4 WILL BE FOR THE DISEASE TEAMS IN PARTICULAR WHERE 5 THERE ARE VARIABLES IN HERE. 6 7 CHAIRMAN KLEIN: WHAT I'D LIKE TO DO HERE, 8 SINCE THIS IS AN INTERIM REG, AS THE CHAIRMAN OF THE 9 FINANCE COMMITTEE POINTS OUT, IS SEE IF WE CAN GET A 10 MOTION WITHOUT THE 40-PERCENT VERSION, WHICH WE CAN COME BACK AND ADD LATER BECAUSE THAT'S THE ONLY NEW 11 THING THAT I KNOW SPECIFICALLY THAT HAS BEEN ADDED. 12 13 MR. SHEEHY: NO. IT'S TO REQUIRE LOAN FUNDING. THAT IS NEW. WE HAVE NOT EVER SAID THAT 14 WE WOULD REQUIRE LOAN FUNDING FOR AWARDS GIVEN TO A 15 16 NONPROFIT APPLICANT. 17 CHAIRMAN KLEIN: THIS IS ONLY IF THEY HAVE MORE THAN 40 PERCENT GOING TO A FOR-PROFIT. 18 19 MR. SHEEHY: IT'S NOT A QUESTION OF PERCENTAGE. IT'S A QUESTION OF THE REQUIREMENT, AND 20 21 I DON'T THINK WE SHOULD REQUIRE INSTITUTIONS. 22 DR. POMEROY: AS A CLARIFICATION OF THAT, CAN THE FINANCE COMMITTEE TELL US IF THEY'VE CHECKED 23 WITH THE USUAL, THE LIKELY NONPROFITS TO FIND OUT 24 25 HOW THEY WOULD REACT?

168

1	CHAIRMAN KLEIN: THERE HAVE BEEN A NUMBER
2	OF DISCUSSIONS THAT HAVE OCCURRED. IT'S GOING TO BE
3	A CONTINUING PROCESS. WE'RE GOING TO LOSE DR.
4	FRIEDMAN. WE'RE GOING TO HAVE TO PUT OUT DISEASE
5	TEAM FOR THE ORIGINAL PRELIMINARY APPLICATION IF THE
6	BOARD SO DECIDES ON A LATER ITEM. I NEED TO KNOW IF
7	THERE'S A MOTION ELIMINATING THE REQUIREMENT FOR
8	NONPROFIT APPLICANTS TO BE A TO ACCEPT A LOAN
9	UNDER THIS PROGRAM, BUT ADOPTING EVERYTHING ELSE.
10	MR. SHEEHY: I WOULD MAKE A MOTION TO
11	ADOPT THIS AS WRITTEN STRIKING SECTION 4 (D)(4) ON
12	PAGE 3.
13	CHAIRMAN KLEIN: IS THERE A SECOND?
14	MR. ROTH: I'LL SECOND. JEFF, INCLUDE MY
15	AMENDMENTS EARLIER.
16	MR. SHEEHY: PLUS YOUR AMENDMENTS.
17	CHAIRMAN KLEIN: PLUS HIS AMENDMENTS. I'D
18	LIKE TO ASK THE PUBLIC, GIVEN TIME, GIVEN THAT THIS
19	IS INTERIM, CAN WE GO FORWARD WITHOUT ADDITIONAL
20	COMMENTS AT THIS MOMENT? I'D LIKE TO CALL THE
21	QUESTION. VOICE VOTE. ALL IN FAVOR? OPPOSED?
22	THANK YOU VERY MUCH.
23	MS. KING: CHAIRMAN KLEIN, IF I COULD MAKE
24	A POINT ABOUT THE QUORUM. I KNOW THAT THERE ARE
25	OTHERS THAT HAVE TO LEAVE IN THE 2:30 TIMEFRAME.
	169

1	I'D LIKE TO ASK THAT NOBODY ELSE LEAVE BEFORE THEN.
2	I'M TRYING TO GET DR. ROME BACK ON THE PHONE, AND
3	WE'RE HOPING THAT LEEZA WILL BE ABLE TO JOIN US.
4	MR. SWEEDLER: WE ALSO NEED ONE MORE VOTE
5	TO GET DISEASE TEAMS OUT, AND THAT IS WE NEED TO
6	APPLY THIS POLICY TO THE DISEASE TEAMS RFA BY
7	SETTING THE INTEREST RATE AND A COUPLE OF OTHER
8	ITEMS. WE DO NEED TO FIND A QUORUM BEFORE THE END
9	OF THE DAY TODAY.
10	CHAIRMAN KLEIN: I WANT YOU, PLEASE, TO
11	PROCEED WITH THAT DISCUSSION ON ITEM IS THIS ITEM
12	10? DR. OLSON, IF YOU COULD PROCEED, PLEASE.
13	DR. OLSON: SO WHAT I'D LIKE TO DO IS
14	ADDRESS, AS IAN STATED, AS MR. SWEEDLER
15	CHAIRMAN KLEIN: WE NEED TO JUST FOCUS THE
16	DISCUSSION HERE IF WE COULD, PLEASE.
17	DR. OLSON: MR. CHAIRMAN, MEMBERS OF THE
18	BOARD AND THE PUBLIC, I'D LIKE TO ADDRESS THE
19	RFA-SPECIFIC ITEMS WITH RESPECT TO THE LOAN POLICY
20	INSOFAR AS THEY APPLY TO DISEASE TEAMS.
21	SO IF WE CAN NEXT. SO I THINK WE CAN
22	SKIP THIS SLIDE AS WELL. SO WHAT I WANT TO DO IS
23	JUST, AS WE SAID, THE SPECIFIC FEATURES THAT ARE
24	RELEVANT ON AN RFA-BY-RFA BASIS. SO FOR DISEASE
25	TEAMS, WHAT WE WOULD LIKE TO SAY IS A FOR-PROFIT
	170
	170

1	APPLICANT ORGANIZATION, SO THIS IS WHEN THE PI IS
2	FROM A FOR-PROFIT ORGANIZATION, OUR RECOMMENDATION
3	WOULD BE THAT THE LOAN AWARD MECHANISM BE THE
4	OPERABLE MECHANISM IN THIS CASE.
5	I THINK, GIVEN THE PRECEDING DISCUSSION,
6	WE CAN DELETE, STRIKE THE NEXT ITEM BECAUSE WE'VE
7	TAKEN THAT OUT OF THE LOAN ADMINISTRATION POLICY.
8	SO IF WE COULD PLEASE GO TO THE NEXT SLIDE.
9	FOR THE LOAN TERM, WE WOULD LIKE TO MAKE
10	EITHER SIX OR TEN YEARS AN OPTION FOR THE DISEASE
11	TEAM. THE INTEREST RATE THAT WE ARE RECOMMENDING IS
12	FOR A SIX-YEAR LOAN, AND THIS WOULD APPLY TO BOTH
13	THE RECOURSE AND NONRECOURSE. AND I SHOULD MAKE THE
14	POINT THAT THE INTEREST RATE WAS DEVELOPED WITH
15	MEMBERS OF THE FINANCE COMMITTEE. SO IT WAS WITH
16	THEIR INPUT. AND WE'RE RECOMMENDING PRIME RATE PLUS
17	300 BASIS POINTS FOR THE SIX-YEAR LOAN, AND FOR THE
18	TEN-YEAR LOAN, PRIME RATE PLUS 500 BASIS POINTS.
19	THE RATE WOULD BE SET AT THE TIME THE ICOC APPROVES
20	THE AWARD.
21	NOW, I THINK WE'RE GOING TO HAVE TO
22	PERHAPS LOOK AT THAT LANGUAGE IN TERMS OF WHAT IT
23	MEANS TO APPROVE THE AWARD VERSUS APPROVE FUNDING.
24	BUT I THINK PROBABLY APPROVE FUNDING MAY BE THE MOST
25	RELEVANT THING, BUT I'LL LEAVE MR. GOLDBERG OR
	171

171

AND SO BASICALLY WE ARE REQUESTING THAT
APPROVE THE LOAN TERMS AS RECOMMENDED FOR
SE TEAM RESEARCH WITH THE EXCEPTION OF THE
LY LARGE MINORITY, THE ONE THAT YOU DELETED
LOAN POLICY, AND THEN FOR CLARIFICATION, ON
INTEREST RATE WOULD BE SET UP, WHEN IT'S
R WHEN FUNDS ARE AWARDED.
MR. GOLDBERG: THANK YOU, DR. OLSON. JUST
IFICATION, WITH RESPECT TO THE INTEREST, IT
UE OR BE CAPITALIZED AT THE ELECTION OF THE
TEE, FINANCE SUBCOMMITTEE.
DR. PIZZO: JUST FOR CLARIFICATION, I
E THE STRIKING OF SECTION 4 PREVIOUSLY, BUT
NT TO BE SURE THAT I REALLY DO UNDERSTAND
E THE WAY I HEARD IT WAS THAT WE WERE
IT. THE WAY IT'S SPECIFICALLY WRITTEN IS
AYS MAY REQUIRE. SO IT'S NOT AS IF IT'S A
N THIS IN ANY EVENT.
DR. PENHOET: WE'RE TALKING TWO DIFFERENT
W. THE FIRST WAS THE POLICY. WE ARE NOW
PECIFICALLY ABOUT THE DISEASE TEAM RFA.
DR. OLSON: THAT'S RIGHT.
DR. PENHOET: SO THE MAY REQUIRE IS
UT TO BE A REQUIRE. IT'S A DIFFERENT
172

BARRISTERS' REPORTING SERVICE 1 CONVERSATION. 2 CHAIRMAN KLEIN: ON THE POLICY, MAY 3 REQUIRE. DR. PIZZO: IT'S STILL A MAY. YOU KNOW, 4 IT'S SOFTER THAN, I THINK, WE WERE THINKING. 5 DR. PENHOET: WITH RESPECT TO WHAT WE'RE 6 7 DISCUSSING NOW, WE ARE ACTING ON THE "MAY," SO TO 8 SPEAK. 9 CHAIRMAN KLEIN: WE DELETED THAT. 10 MR. SHEEHY: BUT WE ARE REQUIRING FOR-PROFITS TO TAKE A LOAN. 11 DR. OLSON: FOR-PROFIT APPLICANTS. 12 MR. SHEEHY: AND WE COULD HAVE HAD A 13 DECISION POINT FOR NOT-FOR-PROFITS WHERE WE SAID IF 14 YOU WERE RECEIVING 40 PERCENT, YOU WOULD ALSO HAVE 15 16 TO APPLY FOR A LOAN. 17 DR. PIZZO: CAN YOU GO BACK TO THAT SLIDE? NO, THE ONE BEFORE IT. 18 19 MR. SHEEHY: WE'VE STRICKEN --DR. PIZZO: RIGHT THERE. 20 21 DR. OLSON: THAT'S THE ONE IT WAS, AS YOU 22 RIGHTLY POINTED OUT, DR. PIZZO, IT WAS ON A RFA-BY-RFA BASIS. IT WAS A MAY. IN THIS CASE, 23 24 AGAIN, BECAUSE OF THE MAGNITUDE OF THESE AWARDS, AND 25 WERE THERE A FOR-PROFIT SIGNIFICANT BENEFICIARY, WE 173

1	WERE RECOMMENDING TO THE BOARD THAT THAT AWARD BE
2	THE SUBJECT OF A LOAN MECHANISM.
3	MR. ROTH: WHAT IT REALLY SAYS IS IT CAN
4	BE 80 PERCENT GOING TO THE NONPROFIT. ANYTHING
5	80 PERCENT OF THE MONEY COULD GO TO THE NONPROFIT,
6	BUT IT WILL NOT BE A LOAN.
7	MR. SHEEHY: AGAIN, THIS IS A
8	PHILOSOPHICAL QUESTION. WE DON'T KNOW THAT THE
9	UNIVERSITIES WILL BE ABLE TO NEGOTIATE THESE
10	ARRANGEMENTS. THE WHOLE POINT OF THESE DISEASE
11	TEAMS IS TO HAVE THESE COLLABORATIONS BETWEEN
12	UNIVERSITIES AND FOR-PROFITS. THERE ARE DIFFERENT
13	IP ARRANGEMENTS IN PLACE AND DIFFERENT BENEFICIARIES
14	FOR THOSE IP, AND THE UNIVERSITIES MIGHT ACTUALLY
15	HAVE TO SACRIFICE IP IN ORDER TO GET THE COMPANIES
16	TO TAKE THE LOAN EXPOSURE WITH THE WARRANTS THAT
17	THEN WOULD ACCRUE TO US. SO WE MAY BE TRANSFERRING
18	IP FROM THE UNIVERSITIES TO US, AND IP THAT ACTUALLY
19	ALSO COULD POTENTIALLY GO TO THE STATE AS A WHOLE TO
20	US BECAUSE THE PAYBACK REQUIREMENTS WITHIN OUR GRANT
21	ADMINISTRATION PROGRAM, IF YOU LICENSE THAT IP, 25
22	PERCENT OF THE LICENSING FEE COMES BACK TO THE
23	STATE.
24	SO IT'S NOT JUST IT'S A MORE COMPLEX
25	ISSUE THAT I THINK WE JUST NEED TO BE EXTREMELY
	174

1	THOUGHTFUL ABOUT AND UNDERSTAND THE IMPLICATIONS OF.
2	CHAIRMAN KLEIN: TO SUGGEST THAT COULD GO
3	THE OTHER WAY BECAUSE UNDER A LOAN PROGRAM WITH MORE
4	CERTAINTY, THE UNIVERSITIES OR RESEARCH INSTITUTIONS
5	MAY BE ABLE TO NEGOTIATE BETTER DEALS WITH THE
6	FOR-PROFIT ORGANIZATIONS. ECONOMIC CERTAINTY COMES
7	AT A PREMIUM IN THESE NEGOTIATIONS ON THE FOR-PROFIT
8	SIDE ON THEIR EXPOSURE. DR. HAWGOOD.
9	DR. HAWGOOD: JUST, AGAIN, A POINT OF
10	CLARIFICATION. IF UNDER SCENARIO 1 UP HERE WHERE
11	IT'S A FOR-PROFIT PI AND, THEREFORE, THE ENTIRE
12	THING IS A LOAN AND THE PIECE THAT'S IN THE
13	NOT-FOR-PROFIT IS A GRANT, ARE THE INDIRECT IT'S
14	MANAGED AS A GRANT.
15	DR. OLSON: THE INDIRECTS ARE SET BY THE
16	RESPECTIVE POLICIES, THE GRANTS ADMINISTRATION
17	POLICY FOR EITHER THE FOR-PROFIT OR THE NONPROFIT.
18	SO IF THE NONPROFIT ORGANIZATION IS THE PI, YOUR
19	INDIRECTS ARE SET PER YOUR NORMAL PROCEDURES. FOR
20	THE PI FOR THE CO-PI WHO IS A FOR-PROFIT, THE
21	INDIRECTS, YOU WILL RECALL, THAT WE ARE GOING TO SET
22	UP SEPARATE BUDGETS FOR CO-PI'S WITH THE INDIRECTS
23	DEPENDENT ON THE TYPE OF ORGANIZATION THEY ARE.
24	MR. SHEEHY: I JUST WANT TO RESPOND TO
25	BOB'S POINT. A NOT-FOR-PROFIT CAN STILL ELECT TO
	175

175

1 TAKE A LOAN, BUT THEY HAVE A CHOICE AS OPPOSED TO 2 BEING REQUIRED TO DO SO. SO IF THERE IS A SCENARIO 3 WHERE THE COMPANY WOULD PREFER TO HAVE THE CERTAINTY 4 OF THE IP POLICY FOR A LOAN, THEY CAN WORK WITH THE 5 NOT-FOR-PROFIT TO HAVE THAT BE THE CASE. I JUST 6 DON'T WANT US TO STRAIGHTJACKET THE NOT-FOR-PROFITS 7 AND TELL THEM THAT IF THEY HAVE SUBSTANTIAL COMPANY 8 INVOLVEMENT FOR DISEASE TEAMS, THAT THEY MUST TAKE A 9 LOAN WHEN WE DON'T KNOW THEY CAN NEGOTIATE THAT. 10 MR. SWEEDLER: CAN I MAKE A SUGGESTION, 11 WHICH IS THAT THIS IS A VALUABLE DISCUSSION, BUT 12 IT'S NOT SPECIFIC TO DISEASE TEAMS. AND IT LOOKS 13 LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS 14 VOTE TO MOVE AHEAD. 15 CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, 16 THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE 17 OUR OWN LIVES, CAN'T WE? 20 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A 21 OUORUM. 22 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? 23 CHAIRMAN KLEIN: WITH THE MODIFICATIONS 24 SUGGES		
 WHERE THE COMPANY WOULD PREFER TO HAVE THE CERTAINTY OF THE IP POLICY FOR A LOAN, THEY CAN WORK WITH THE NOT-FOR-PROFIT TO HAVE THAT BE THE CASE. I JUST DON'T WANT US TO STRAIGHTJACKET THE NOT-FOR-PROFITS AND TELL THEM THAT IF THEY HAVE SUBSTANTIAL COMPANY INVOLVEMENT FOR DISEASE TEAMS, THAT THEY MUST TAKE A LOAN WHEN WE DON'T KNOW THEY CAN NEGOTIATE THAT. MR. SWEEDLER: CAN I MAKE A SUGGESTION, WHICH IS THAT THIS IS A VALUABLE DISCUSSION, BUT IT'S NOT SPECIFIC TO DISEASE TEAMS. AND IT LOOKS LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS VOTE TO MOVE AHEAD. CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE QUORUM. MS. GIBBONS: WE CAN ALL BE THE HERO IN OUR OWN LIVES, CAN'T WE? CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	1	TAKE A LOAN, BUT THEY HAVE A CHOICE AS OPPOSED TO
 OF THE IP POLICY FOR A LOAN, THEY CAN WORK WITH THE NOT-FOR-PROFIT TO HAVE THAT BE THE CASE. I JUST DON'T WANT US TO STRAIGHTJACKET THE NOT-FOR-PROFITS AND TELL THEM THAT IF THEY HAVE SUBSTANTIAL COMPANY INVOLVEMENT FOR DISEASE TEAMS, THAT THEY MUST TAKE A LOAN WHEN WE DON'T KNOW THEY CAN NEGOTIATE THAT. MR. SWEEDLER: CAN I MAKE A SUGGESTION, WHICH IS THAT THIS IS A VALUABLE DISCUSSION, BUT IT'S NOT SPECIFIC TO DISEASE TEAMS. AND IT LOOKS LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS VOTE TO MOVE AHEAD. CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE QUORUM. MS. GIBBONS: WE CAN ALL BE THE HERO IN OUR OWN LIVES, CAN'T WE? CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	2	BEING REQUIRED TO DO SO. SO IF THERE IS A SCENARIO
5NOT-FOR-PROFIT TO HAVE THAT BE THE CASE. I JUST6DON'T WANT US TO STRAIGHTJACKET THE NOT-FOR-PROFITS7AND TELL THEM THAT IF THEY HAVE SUBSTANTIAL COMPANY8INVOLVEMENT FOR DISEASE TEAMS, THAT THEY MUST TAKE A9LOAN WHEN WE DON'T KNOW THEY CAN NEGOTIATE THAT.10MR. SWEEDLER: CAN I MAKE A SUGGESTION,11WHICH IS THAT THIS IS A VALUABLE DISCUSSION, BUT12IT'S NOT SPECIFIC TO DISEASE TEAMS. AND IT LOOKS13LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS14VOTE TO MOVE AHEAD.15CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA,16THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE17QUORUM.18MS. GIBBONS: WE CAN ALL BE THE HERO IN19OUR OWN LIVES, CAN'T WE?20CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A21QUORUM.22MR. SHEEHY: CAN I MOVE TO ADOPT THIS?23CHAIRMAN KLEIN: WITH THE MODIFICATIONS24SUGGESTED. WE DELETED THAT SECTION.25MR. SHEEHY: WITH THAT DELETION OF THAT	3	WHERE THE COMPANY WOULD PREFER TO HAVE THE CERTAINTY
 bon't want us to straightjacket the not-for-profits AND TELL THEM THAT IF THEY HAVE SUBSTANTIAL COMPANY INVOLVEMENT FOR DISEASE TEAMS, THAT THEY MUST TAKE A LOAN WHEN WE DON'T KNOW THEY CAN NEGOTIATE THAT. MR. SWEEDLER: CAN I MAKE A SUGGESTION, WHICH IS THAT THIS IS A VALUABLE DISCUSSION, BUT IT'S NOT SPECIFIC TO DISEASE TEAMS. AND IT LOOKS LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS VOTE TO MOVE AHEAD. CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE QUORUM. MS. GIBBONS: WE CAN ALL BE THE HERO IN OUR OWN LIVES, CAN'T WE? CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	4	OF THE IP POLICY FOR A LOAN, THEY CAN WORK WITH THE
 AND TELL THEM THAT IF THEY HAVE SUBSTANTIAL COMPANY INVOLVEMENT FOR DI SEASE TEAMS, THAT THEY MUST TAKE A LOAN WHEN WE DON'T KNOW THEY CAN NEGOTIATE THAT. MR. SWEEDLER: CAN I MAKE A SUGGESTION, WHI CH IS THAT THIS IS A VALUABLE DI SCUSSION, BUT IT'S NOT SPECIFIC TO DI SEASE TEAMS. AND IT LOOKS LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS VOTE TO MOVE AHEAD. CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE QUORUM. MS. GI BBONS: WE CAN ALL BE THE HERO IN OUR OWN LIVES, CAN'T WE? CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	5	NOT-FOR-PROFIT TO HAVE THAT BE THE CASE. I JUST
 INVOLVEMENT FOR DI SEASE TEAMS, THAT THEY MUST TAKE A LOAN WHEN WE DON'T KNOW THEY CAN NEGOTI ATE THAT. MR. SWEEDLER: CAN I MAKE A SUGGESTION, WHI CH I S THAT THIS I S A VALUABLE DI SCUSSION, BUT IT'S NOT SPECIFIC TO DI SEASE TEAMS. AND IT LOOKS LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS VOTE TO MOVE AHEAD. CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE QUORUM. MS. GI BBONS: WE CAN ALL BE THE HERO IN OUR OWN LIVES, CAN'T WE? CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	6	DON'T WANT US TO STRAIGHTJACKET THE NOT-FOR-PROFITS
 LOAN WHEN WE DON'T KNOW THEY CAN NEGOTIATE THAT. MR. SWEEDLER: CAN I MAKE A SUGGESTION, WHICH IS THAT THIS IS A VALUABLE DISCUSSION, BUT IT'S NOT SPECIFIC TO DISEASE TEAMS. AND IT LOOKS LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS VOTE TO MOVE AHEAD. CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE QUORUM. MS. GIBBONS: WE CAN ALL BE THE HERO IN OUR OWN LIVES, CAN'T WE? CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	7	AND TELL THEM THAT IF THEY HAVE SUBSTANTIAL COMPANY
 MR. SWEEDLER: CAN I MAKE A SUGGESTION, WHI CH IS THAT THIS IS A VALUABLE DI SCUSSION, BUT IT'S NOT SPECIFIC TO DI SEASE TEAMS. AND IT LOOKS LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS VOTE TO MOVE AHEAD. CHAI RMAN KLEIN: THAT'S RIGHT. SO, LEEZA, THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE QUORUM. MS. GI BBONS: WE CAN ALL BE THE HERO IN OUR OWN LIVES, CAN'T WE? CHAI RMAN KLEIN: SO, JAMES, WE DO HAVE A QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAI RMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	8	INVOLVEMENT FOR DISEASE TEAMS, THAT THEY MUST TAKE A
 11 WHICH IS THAT THIS IS A VALUABLE DISCUSSION, BUT 12 IT'S NOT SPECIFIC TO DISEASE TEAMS. AND IT LOOKS 13 LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS 14 VOTE TO MOVE AHEAD. 15 CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, 16 THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE 17 QUORUM. 18 MS. GIBBONS: WE CAN ALL BE THE HERO IN 19 OUR OWN LIVES, CAN'T WE? 20 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A 21 QUORUM. 22 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? 23 CHAIRMAN KLEIN: WITH THE MODIFICATIONS 24 SUGGESTED. WE DELETED THAT SECTION. 25 MR. SHEEHY: WITH THAT DELETION OF THAT 	9	LOAN WHEN WE DON'T KNOW THEY CAN NEGOTIATE THAT.
 12 IT'S NOT SPECIFIC TO DISEASE TEAMS. AND IT LOOKS 13 LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS 14 VOTE TO MOVE AHEAD. 15 CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, 16 THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE 17 QUORUM. 18 MS. GIBBONS: WE CAN ALL BE THE HERO IN 19 OUR OWN LIVES, CAN'T WE? 20 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A 21 QUORUM. 22 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? 23 CHAIRMAN KLEIN: WITH THE MODIFICATIONS 24 SUGGESTED. WE DELETED THAT SECTION. 25 MR. SHEEHY: WITH THAT DELETION OF THAT 	10	MR. SWEEDLER: CAN I MAKE A SUGGESTION,
 LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS VOTE TO MOVE AHEAD. CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE QUORUM. MS. GIBBONS: WE CAN ALL BE THE HERO IN OUR OWN LIVES, CAN'T WE? CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	11	WHICH IS THAT THIS IS A VALUABLE DISCUSSION, BUT
 14 VOTE TO MOVE AHEAD. 15 CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, 16 THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE 17 QUORUM. 18 MS. GIBBONS: WE CAN ALL BE THE HERO IN 19 OUR OWN LIVES, CAN'T WE? 20 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A 21 QUORUM. 22 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? 23 CHAIRMAN KLEIN: WITH THE MODIFICATIONS 24 SUGGESTED. WE DELETED THAT SECTION. 25 MR. SHEEHY: WITH THAT DELETION OF THAT 	12	IT'S NOT SPECIFIC TO DISEASE TEAMS. AND IT LOOKS
 15 CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA, 16 THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE 17 QUORUM. 18 MS. GIBBONS: WE CAN ALL BE THE HERO IN 19 OUR OWN LIVES, CAN'T WE? 20 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A 21 QUORUM. 22 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? 23 CHAIRMAN KLEIN: WITH THE MODIFICATIONS 24 SUGGESTED. WE DELETED THAT SECTION. 25 MR. SHEEHY: WITH THAT DELETION OF THAT 	13	LIKE WE VERY BRIEFLY HAVE A QUORUM. SO WE NEED THIS
 16 THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE 17 QUORUM. 18 MS. GIBBONS: WE CAN ALL BE THE HERO IN 19 OUR OWN LIVES, CAN'T WE? 20 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A 21 QUORUM. 22 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? 23 CHAIRMAN KLEIN: WITH THE MODIFICATIONS 24 SUGGESTED. WE DELETED THAT SECTION. 25 MR. SHEEHY: WITH THAT DELETION OF THAT 	14	VOTE TO MOVE AHEAD.
 17 QUORUM. 18 MS. GIBBONS: WE CAN ALL BE THE HERO IN 19 OUR OWN LIVES, CAN'T WE? 20 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A 21 QUORUM. 22 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? 23 CHAIRMAN KLEIN: WITH THE MODIFICATIONS 24 SUGGESTED. WE DELETED THAT SECTION. 25 MR. SHEEHY: WITH THAT DELETION OF THAT 	15	CHAIRMAN KLEIN: THAT'S RIGHT. SO, LEEZA,
 18 MS. GIBBONS: WE CAN ALL BE THE HERO IN 19 OUR OWN LIVES, CAN'T WE? 20 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A 21 QUORUM. 22 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? 23 CHAIRMAN KLEIN: WITH THE MODIFICATIONS 24 SUGGESTED. WE DELETED THAT SECTION. 25 MR. SHEEHY: WITH THAT DELETION OF THAT 	16	THANK YOU VERY MUCH FOR BEING HERE. YOU ARE THE
 19 OUR OWN LIVES, CAN'T WE? 20 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A 21 QUORUM. 22 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? 23 CHAIRMAN KLEIN: WITH THE MODIFICATIONS 24 SUGGESTED. WE DELETED THAT SECTION. 25 MR. SHEEHY: WITH THAT DELETION OF THAT 	17	QUORUM.
 CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	18	MS. GIBBONS: WE CAN ALL BE THE HERO IN
 QUORUM. MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	19	OUR OWN LIVES, CAN'T WE?
 MR. SHEEHY: CAN I MOVE TO ADOPT THIS? CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	20	CHAIRMAN KLEIN: SO, JAMES, WE DO HAVE A
 CHAIRMAN KLEIN: WITH THE MODIFICATIONS SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	21	QUORUM.
 SUGGESTED. WE DELETED THAT SECTION. MR. SHEEHY: WITH THAT DELETION OF THAT 	22	MR. SHEEHY: CAN I MOVE TO ADOPT THIS?
25 MR. SHEEHY: WITH THAT DELETION OF THAT	23	CHAIRMAN KLEIN: WITH THE MODIFICATIONS
	24	SUGGESTED. WE DELETED THAT SECTION.
176	25	MR. SHEEHY: WITH THAT DELETION OF THAT
		176

1	SECTION.
2	CHAIRMAN KLEIN: I'LL MAKE A SECOND.
3	DISCUSSION OF THE BOARD? FOR THE BENEFIT OF LEEZA
4	GIBBONS IN PARTICULAR AND THE PUBLIC, MR. HARRISON,
5	COULD YOU RESTATE THE SUBJECT OF THE MOTION?
6	MR. HARRISON: YES. THE SUBJECT OF THE
7	MOTION ARE THE LOAN TERMS FOR THE DISEASE TEAM
8	AWARDS, INCLUDING INTEREST RATE AND THE REQUIREMENT
9	THAT FOR-PROFIT APPLICANTS TAKE A LOAN.
10	CHAIRMAN KLEIN: IN ADDITION TO ANY OF THE
11	OTHER MATERIAL THAT THE STAFF HAS RECOMMENDED?
12	MR. HARRI SON: YES.
13	CHAIRMAN KLEIN: WITH THE AMENDMENT THAT
14	WAS REFERENCED BY THE MAKER OF THE MOTION. SO ARE
15	THERE PUBLIC COMMENTS? SEEING NO PUBLIC COMMENTS,
16	I'D LIKE A VOICE VOTE. ALL IN FAVOR? OPPOSED?
17	VERY QUICKLY, I'D LIKE TO KNOW, SHERRY
18	LANSING, WE HAVE BEFORE US RECOMMENDATIONS OF
19	PERSONNEL FOR THE SCIENTIFIC AND MEDICAL RESEARCH
20	FUNDING WORKING GROUP. WE HAVE THE BIOS. I DON'T
21	THINK THERE IS A NEED TO DISCUSS THEM. THEY'RE
22	PUBLICLY AVAILABLE.
23	MS. LANSING: MOVE APPROVAL.
24	MR. GOLDBERG: SECOND.
25	CHAIRMAN KLEIN: SECOND? BOARD COMMENT?
	177

	BARRISTERS' REPORTING SERVICE
1	ASKING FOR PUBLIC COMMENT. SEEING NONE, ALL IN
2	FAVOR?
3	MS. KING: DR. ROME?
4	DR. ROME: YES, I'M HERE.
5	MS. KING: EXCELLENT. THANK YOU SO MUCH.
6	YOU ARE OUR QUORUM, AND SHERRY CAN WALK OUT THE DOOR
7	AND NOBODY ELSE.
8	CHAIRMAN KLEIN: COME BACK FOR A MOMENT IF
9	YOU CAN.
10	DR. ROME: I CAN HEAR YOU.
11	CHAIRMAN KLEIN: THANK YOU VERY MUCH. CAN
12	YOU HEAR US?
13	DR. ROME: I'M OKAY.
14	CHAIRMAN KLEIN: SO, STAFF, IF, STAFF, YOU
15	COULD ADVISE ME ON THE PRIORITIES OF THE REMAINING
16	ITEMS FOR THE STAFF.
17	ITEM 14 IS AN ITEM THAT WE PREVIOUSLY HAVE
18	DISCUSSED, BUT IT WAS NOT ADOPTED. THAT WAS THE
19	ITEM RELATED TO PRIOR NEW FACULTY I AND II GRANTS
20	WHERE WE SPECIFICALLY DISCUSSED THE ABILITY TO HAVE
21	LOAN REPAYMENT CONCESSIONS FOR, I BELIEVE IT'S,
22	MEDICAL FACULTY.
23	DR. OLSON: OR PHYSICIAN-SCIENTISTS THAT
24	WERE APPROVED IN NEW FACULTY I AND II AWARDS.
25	CHAIRMAN KLEIN: RIGHT. SO THIS IS AN
	178

1	I TEM THAT THERE SHOULD HAVE BEEN A SEPARATE
2	RESOLUTION ON. THE ITEM WAS PREVIOUSLY DISCUSSED.
3	DR. OLSON, COULD YOU SUMMARIZE IT?
4	DR. OLSON: JUST BRIEFLY, AT BOTH THE
5	CONCEPT APPROVAL FOR NEW FACULTY I AND NEW FACULTY
6	II, WE BROUGHT UP THE NOTION THAT IN ORDER TO
7	ENCOURAGE PHYSICIAN-SCIENTISTS TO MOVE INTO STEM
8	CELL RESEARCH, THAT WE WERE GOING TO OFFER THE
9	INCENTIVE OF A MEDICAL SCHOOL LOAN REPAYMENT
10	PROGRAM. AT OUR MOST RECENT CONCEPT APPROVAL FOR
11	THIS AT NEW FACULTY II, THIS BOARD DID, IN FACT,
12	APPROVE UP TO \$4 MILLION IN LOAN REPAYMENT FUNDS FOR
13	THIS PROGRAM.
14	WE ARE ACTUALLY GETTING AT THE FIRST YEAR
15	ANNIVERSARY OF OUR NEW FACULTY I. THIS PROGRAM,
16	UNLIKE THE GRANT PROGRAMS, IS PAID IN ARREARS. YOU
17	HAVE TO HAVE DONE EVERY YEAR BEFORE YOU APPLY FOR
18	IT. WE HAVE UP TO SIX PHYSICIAN-SCIENTISTS IN OUR
19	NEW FACULTY I PROGRAM WHO WOULD THEORETICALLY BE
20	ELIGIBLE FOR THIS. SO A MAXIMUM LIABILITY FOR US
21	THIS YEAR WOULD BE, IF ALL SIX OF THEM TOOK THE
22	MAXIMUM AMOUNT AND I WOULD REMIND YOU THE TERMS
23	OF THIS. IT'S UP TO 35,000 A YEAR.
24	LET ME REMIND YOU OF THE TERMS. THE TERMS
25	ARE THAT WE WOULD PAY DOWN A LOAN UP TO 35,000 A
	179

1	YEAR FOR EACH OF UP TO FIVE YEARS, WHICH IS THE TERM
2	OF THE NEW FACULTY AWARDS. SO THE MAXIMUM THAT ANY
3	ONE PHYSICIAN APPLICANT COULD COLLECT WOULD BE 35
4	TIMES FIVE, WHICH IS 175,000. BUT THIS YEAR IN
5	PARTICULAR, IF ALL SIX OF THE PHYSICIAN-SCIENTISTS
6	TOOK ADVANTAGE OF THE MAXIMUM AMOUNT, IT WOULD BE
7	210, 000.
8	SO WHAT I'M ASKING IS WHAT WE ACTUALLY
9	NEED. SINCE THE BOARD HAS, IN FACT, APPROVED THE
10	NEW FACULTY, THEY APPROVED SPECIFIC AWARDS THAT
11	COVERED THE RESEARCH, BUT WHAT THEY HAVE NOT
12	APPROVED IS ESSENTIALLY THE AUGMENTATION OF THIS
13	MEDICAL SCHOOL LOAN REPAYMENT PROGRAM.
14	IF YOU WILL JUST GO TO THE LAST SLIDE.
15	WHAT WE ARE ASKING OF YOU IS THAT THE ICOC VOTE TO
16	AUGMENT THE FOLLOWING AWARDS TO MAKE MEDICAL SCHOOL
17	LOAN REPAYMENT WITHIN THE TERMS PROPOSED. AND SO
18	THAT'S THE UP TO 35,000 A YEAR FOR UP TO FIVE YEARS.
19	BY THE WAY, I SHOULD SAY THAT WE HAVE ACTUALLY
20	CALCULATED NOW, GIVEN THAT WE HAVE 17
21	PHYSICIAN-SCIENTISTS, ASSUMING THEY ALL QUALIFIED
22	FOR THE FULL 35,000 A YEAR FOR THE FULL FIVE YEARS,
23	THE MAXIMUM LIABILITY WOULD BE \$2.98 MILLION OVER
24	THE COURSE OF FIVE YEARS. RECOGNIZE THIS IS FIVE
25	YEARS.

180

 AS I'VE ALREADY INDICATED, IT'S 210,00 MAXIMUM THIS YEAR. THESE ARE THE AWARDS, THE 17 AWARDS. SO WE WOULD LIKE TO REQUEST YOUR APPROV FOR SUPPLEMENTAL UP TO 170,000 PER AWARD FOR THE ONES. CHAIRMAN KLEIN: DR. OLSON, THIS WHOLE CONCEPT WAS PART OF THE CONCEPT ORIGINALLY PRESE TO US; IS THAT CORRECT? 	AL SE NTED	
 3 AWARDS. SO WE WOULD LIKE TO REQUEST YOUR APPROV 4 FOR SUPPLEMENTAL UP TO 170,000 PER AWARD FOR THE 5 ONES. 6 CHAIRMAN KLEIN: DR. OLSON, THIS WHOLE 7 CONCEPT WAS PART OF THE CONCEPT ORIGINALLY PRESE 	AL SE NTED	
 4 FOR SUPPLEMENTAL UP TO 170,000 PER AWARD FOR THE 5 ONES. 6 CHAIRMAN KLEIN: DR. OLSON, THIS WHOLE 7 CONCEPT WAS PART OF THE CONCEPT ORIGINALLY PRESE 	SE NTED	
 5 ONES. 6 CHAIRMAN KLEIN: DR. OLSON, THIS WHOLE 7 CONCEPT WAS PART OF THE CONCEPT ORIGINALLY PRESE 	NTED	
6 CHAIRMAN KLEIN: DR. OLSON, THIS WHOLE 7 CONCEPT WAS PART OF THE CONCEPT ORIGINALLY PRESE	NTED	
7 CONCEPT WAS PART OF THE CONCEPT ORIGINALLY PRESE	NTED	
8 TO US; IS THAT CORRECT?	D TO	
	D TO	
9 DR. OLSON: IT WAS ORIGINALLY PRESENTE		
10 YOU AT BOTH THE NEW FACULTY II AND THE NEW FACUL	YOU AT BOTH THE NEW FACULTY II AND THE NEW FACULTY	
11 II, AND, IN FACT, UP TO 4 MILLION WAS AUTHORIZED	II, AND, IN FACT, UP TO 4 MILLION WAS AUTHORIZED FOR	
12 THE JOINT PROGRAM FOR BOTH AT THE NEW FACULTY II	THE JOINT PROGRAM FOR BOTH AT THE NEW FACULTY II	
CONCEPT.		
14 CHAIRMAN KLEIN: SO THIS IS AN		
15 IMPLEMENTATION OF A PRIOR AGREED PROGRAM. AND D	R.	
16 ROBSON, MY UNDERSTANDING IS THAT THESE DOLLARS A	RE	
17 IN OUR EXISTING OBLIGATIONS CASH FLOW WE PREVIOU	IN OUR EXISTING OBLIGATIONS CASH FLOW WE PREVIOUSLY	
18 PRESENTED; IS THAT CORRECT?		
19 DR. ROBSON: (DR. ROBSON NODS.)		
20 DR. PIZZO: I THINK WITHOUT QUESTION		
21 ANYTHING THAT WE CAN DO TO ENRICH OUR SUPPLY OF		
22 PHYSICIAN-SCIENTISTS IS CRITICALLY IMPORTANT, SO	I	
23 CLEARLY SUPPORT THAT. BUT I JUST WONDER, JUST		
24 REMIND ME BECAUSE I DON'T REMEMBER THIS ASPECT O	F	
25 IT, WHAT ARE THE HOOKS THAT WE HAVE TO KEEP PEOP	LE	
181		

1	WHO KEEP INDIVIDUALS WHO BENEFITED FROM THIS IN,
2	IF YOU WILL, THE ROLE OF PHYSICIAN-SCIENTISTS.
3	CHAIRMAN KLEIN: IN THE RESEARCH FIELD.
4	DR. PIZZO: THAT'S RIGHT.
5	CHAIRMAN KLEIN: DR. OLSON.
6	DR. OLSON: I DO NOT I MEAN ASIDE FROM
7	THE FACT THAT WE MONITOR, WE HAVE THE PROGRESS
8	REPORTS EVERY YEAR, BUT WE DO NOT MONITOR
9	DR. PIZZO: I DON'T KNOW WHETHER WE
10	HAVE
11	CHAIRMAN KLEIN: WE HAVE A FIVE-YEAR
12	PROGRAM
13	DR. OLSON: WE HAVE A FIVE-YEAR PROGRAM.
14	CHAIRMAN KLEIN: THAT THEY ARE
15	OBLIGATED TO, BUT WHAT YOU ARE ASKING IS BEYOND THE
16	FIVE-YEAR PROGRAM.
17	DR. PIZZO: YEAH. I THINK THIS IS JUST
18	GIVEN WHERE WE ARE IN LIFE, I THINK THIS IS JUST
19	SOMETHING THAT WE SHOULD DO OR AT LEAST LOOK AT
20	DOING TO HAVE SOME EXPECTATION THAT IF YOU RECEIVE
21	THIS MONEY, YOU'RE ACTUALLY GOING TO DO WHAT YOU
22	SAID WERE GOING TO DO; AND IF PEOPLE OPT OUT, THEY
23	HAVE THE OPPORTUNITY TO PAY BACK OR NOT ACCEPT IT.
24	BUT JUST MAKING IT A FREEBIE AND THEN HAVING PEOPLE
25	GO OFF AND DO OTHER THINGS IS NOT TO ME A GOOD USE,

182

1	IN THIS CASE, OF THE TAXPAYERS' MONEY.
2	DR. TROUNSON: DO YOU MEAN DURING THE
3	PERIOD OF TIME OF THEIR GRANT OR AFTER THAT?
4	DR. PIZZO: I MEAN AFTER THAT. I WOULD
5	HAVE SOME EXPECTATION. OF COURSE, THEY'RE GOING TO
6	DO IT DURING THEIR GRANT, OTHERWISE THEY WOULDN'T BE
7	THERE. BUT I'M TALKING ABOUT SOME EXPECTATION THAT
8	FOR X YEARS AFTER THIS YOU ACTUALLY DO IT.
9	DR. TROUNSON: WE WOULD BECAUSE THE
10	GRANTS ARE TO THE UNIVERSITY, WE WOULD HAVE TO HAVE
11	A LOOK AT WHETHER WE REALLY HAVE ANY PARTICULAR
12	DR. PIZZO: SO IT MAY BE A BROADER
13	DISCUSSION, AND MAYBE WE DON'T WANT TO HAVE THAT
14	DISCUSSION TODAY, BUT I WOULD ARGUE THAT WE TAKE A
15	LOOK AT THIS AND MAYBE YOU COME FORWARD AT SOME
16	POINT WITH SOME DEFINED CRITERIA.
17	DR. TROUNSON: RI GHT.
18	DR. PRIETO: JUST RESPOND TO THAT. A
19	LITTLE BIT OF INFORMATION ON PRECEDENT. FOR WHAT
20	IT'S WORTH, I FUNDED MY MEDICAL EDUCATION THROUGH
21	THE NATIONAL HEALTH SERVICE CORPS. AND THE TERMS AT
22	THE TIME WERE IF I DID NOT FULFILL MY SERVICE YEAR
23	FOR YEAR AS ONE YEAR FOR EVERY YEAR I WAS PAID IN
24	PRIMARY CARE, THAT I WOULD HAVE HAD TRIPLE PAYBACK
25	OF THE AMOUNT SPENT ON MY BEHALF.

183

1	DR. PIZZO: THERE ARE THINGS LIKE THAT.	
2	THOSE WHO TAKE MILITARY PATHS HAVE TO DO PAYBACKS.	
3	SO I THINK WE SHOULD HAVE SOME ACCOUNTABILITY THAT	
4	PEOPLE ARE ACTUALLY ACHIEVING WHAT WE SAY.	
5	MR. ROTH: MR. CHAIRMAN, COULD I MAKE A	
6	QUESTION. IF WE WERE TO GO AHEAD AND JUST FUND THIS	
7	YEAR AS OPPOSED TO THE FIVE-YEAR COMMITMENT, COULD	
8	WE REVISIT THIS AND THEN MAKE SURE THE POLICY'S	
9	WHERE WE WANT IT TO BE? THIS IS A VOTE ON FIVE	
10	YEARS.	
11	CHAIRMAN KLEIN: I WANT TO ASK DR. OLSON	
12	WHAT WE REPRESENTED TO THE FACULTY I AND FACULTY II	
13	RECIPIENTS. WHAT DID THEY REPRESENT TO THE FACULTY	
14	I AND FACULTY II RECIPIENTS RELATED TO THIS PROGRAM?	
15	DR. OLSON: WE REPRESENTED WELL, WHAT	
16	WE HAVE SAID, THAT WE WOULD REPAY OUTSTANDING	
17	MEDICAL SCHOOL LOANS, THAT ELIGIBLE AND ELIGIBILITY	
18	IS DEFINED BY BEING A PHYSICIAN-SCIENTIST RECIPIENT	
19	OF THE NEW FACULTY I OR II AWARD. WE DID NOT GO	
20	INTO SPECIFICS, SO THAT I THINK WE WOULD HAVE THE	
21	OPTION, AT THE BOARD'S DISCRETION, OF REQUIRING SOME	
22	SORT OF REPAYMENT OBLIGATION.	
23	I WOULD STATE THAT THIS IS MODELED ON AN	
24	NIH PROGRAM THAT I DO NOT BELIEVE REQUIRES ANY	
25	REPAYMENT OBLIGATION OR ANY SERVICE OBLIGATION, BUT	
	184	

1	THAT DOESN'T MEAN WE DON'T HAVE THAT OPTION.
2	CHAIRMAN KLEIN: ALL RIGHT.
3	DR. REED: I'D JUST LIKE TO AT LEAST ONE
4	OF THE VOICES OF THE OPINION THAT I DON'T THINK THIS
5	IS THE WISEST OR HIGHEST PRIORITY USE OF OUR LIMITED
6	FUNDS. AND I WOULD SUGGEST WE HOLD IT ABEYANCE AT
7	LEAST UNTIL WE KNOW A LITTLE BIT MORE ABOUT HOW
8	THINGS ARE GOING TO SHAKE OUT FOR US AND WOULD EVEN
9	SUGGEST OF COURSE, I WASN'T HERE TO BENEFIT FROM
10	THE DISCUSSION THAT WENT AROUND ON THIS BEFORE, BUT
11	I THINK IT'S SOMETHING THAT OUGHT TO BE REEVALUATED.
12	CHAIRMAN KLEIN: CERTAINLY IF IT WERE A
13	NEW PROGRAM. OUR PROBLEM IN THIS CASE IS WE MADE
14	REPRESENTATIONS TO THE FACULTY I AND FACULTY II. IT
15	WAS PRESENTED CONCEPTUALLY TO THE BOARD AS A PART OF
16	THOSE PROGRAMS, AND THERE'S BEEN REPRESENTATIONS TO
17	THE RECIPIENTS. SO DR. PIZZO.
18	DR. PIZZO: WITH ALL DUE RESPECT, JOHN,
19	I'D LIKE TO OFFER AN ALTERNATIVE POSITION BECAUSE IF
20	YOU LOOK AT THE DATA, THE AVERAGE DEGREE OF
21	INDEBTEDNESS OF GRADUATES OF MEDICAL SCHOOLS TODAY
22	IS ABOUT \$150,000. AND IF YOU LOOK AT DETRACTORS
23	THAT IMPACT ON CAREER CHOICE, THE DEGREE OF
24	INDEBTEDNESS IS ONE OF THE SIGNIFICANT VARIABLES
25	THAT DRIVES PEOPLE TO CHOOSE AREAS LIKE DERMATOLOGY

185

1	OR ANESTHESIA, NOT THAT THERE'S ANYTHING WRONG WITH
2	THOSE, CERTAINLY NOT ANESTHESIA, BUT IT DOES IMPACT
3	ON PEOPLE'S CHOICE ABOUT GOING INTO WHAT MAY BE
4	LOWER REVENUE PRODUCING AREAS.
5	AND BEING A PHYSICIAN-SCIENTIST IS REALLY,
6	YOU KNOW, IT IS WE TALK ABOUT THE SHORTAGE OF
7	PEOPLE IN PRIMARY CARE. WELL, I WOULD PUT
8	PHYSICIAN-SCIENTISTS IN THE SAME CATEGORY, AND I
9	WOULD PUT MEDICAL SCHOOL INDEBTEDNESS AS A
10	SIGNIFICANT FACTOR THAT CONTRIBUTES TO THAT.
11	DR. TROUNSON: I THINK WE CAN COME BACK TO
12	YOU WITH SOME KIND OF REASSURANCE IF WE LOOK AT WHAT
13	OUR LEGAL POSITION IS. BUT I THINK THE COMMITMENT
14	TO THESE YOUNG PEOPLE, HAVING MADE THE DECISION TO
15	APPLY, HAVING WORKED INTO THE PROGRAM WITH THOSE
16	EXPECTATIONS, I THINK WE NEED TO UNDERTAKE THAT
17	COMMITMENT; BUT WE WILL COME BACK TO YOU ON WHAT IS
18	WHAT IS A REASONABLE OPTION IN ENSURING THAT THEY
19	REMAIN IN THE RESEARCH AREA.
20	CHAIRMAN KLEIN: LET ME ASK. MY
21	UNDERSTANDING OF THE STATEMENT YOU JUST MADE, DR.
22	TROUNSON, IS THAT IF WE HAD A MOTION TO APPROVE
23	THIS, THAT THE STAFF WOULD BE DIRECTED TO SEE WHAT
24	REASONABLE PROVISIONS WE COULD PUT INTO THESE TERMS
25	TO ACCOMPLISH THE CONCEPTUAL GOAL DR. PIZZO OUTLINED
	106

186

	BARRISTERS' REPORTING SERVICE	
1	AND REPORT BACK TO US ON THAT, BUT WE WOULD PROCEED	
2	TO APPROVE THIS ITEM AT THIS TIME. DR. PIZZO, DOES	
3	IT MAKE SENSE TO YOU?	
4	DR. PI ZZO: YES.	
5	CHAIRMAN KLEIN: I'D LIKE TO GET DR. GILL	
6	AND DR. AZZIZ.	
7	DR. GILL: WELL, AS A FEW OF YOU KNOW, THE	
8	PHYSICIAN-SCIENTIST AS AN ENDANGERED SPECIES HAS	
9	BEEN A PASSION OF MINE FOR MORE THAN 30 YEARS.	
10	DR. PIZZO: AND YOU'RE STILL AROUND.	
11	DR. GILL: UNFORTUNATELY, IT'S STILL QUITE	
12	AN ENDANGERED SPECIES, MAYBE MORE SO THAN WHEN I	
13	STARTED. SO I THINK ANYTHING WE CAN DO TO ENCOURAGE	
14	CAREERS OF PHYSICIAN-SCIENTISTS, PARTICULARLY WHEN	
15	WE'RE LOOKING TO TRANSLATE DISCOVERIES INTO THE	
16	CLINIC, IS ABSOLUTELY ESSENTIAL. AND SO I WOULD	
17	STRONGLY URGE APPROVAL OF THIS MOTION AS THE STAFF	
18	PRESENTS IT.	
19	IN RESPONSE TO PHIL, I WOULD SORT OF BEG	
20	TO DISAGREE THAT WE PUT ANY HOOKS BEYOND THE	
21	CONTRACTUAL TIME OF THE GRANT BECAUSE THE BIG	
22	CRITICISMS OF THE NIH REPAYMENT PROGRAMS WERE THAT	
23	THIS WAS THE LAST VESTITUDE OF INDENTURED SERVITUDE.	
24	I THINK THAT IS SOMETHING WE WANT TO AVOID. I MEAN	
25	IF THEY CHOOSE TO LEAVE AFTER FIVE YEARS BECAUSE	

187

THEY'RE UNSUCCESSFUL, SO BE IT. IF WE SUPPORT THEM	
FOR FIVE YEARS, THAT GIVES THEM A WONDERFUL SHOT.	
IF THEY'RE NOT INTERESTED AFTER THAT, LET'S DON'T	
PUNI SH THI S.	
DR. PIZZO: JUST I WOULD SAY LET'S HAVE	
FURTHER DISCUSSIONS ABOUT THAT. WE DON'T NEED TO DO	
IT NOW, BUT I'M HAPPY TO HAVE THAT DIALOGUE.	
MR. SWEEDLER: I WOULD APPRECIATE JUST A	
LITTLE CLARIFICATION, CHAIRMAN KLEIN. ARE YOU	
PROPOSING THAT THE BOARD APPROVE THIS AND THAT STAFF	
BE ABLE TO THEN GO AHEAD AND IMPLEMENT IT, AT THE	
SAME TIME COME BACK TO YOU FOR AN ITEM TO TALK ABOUT	
HOW WE MIGHT IMPLEMENT ANOTHER PROGRAM FOR FUTURE	
RFA'S THAT WOULD BE DIFFERENT? IS THAT YOUR INTENT?	
CHAIRMAN KLEIN: I THINK WELL, I THINK	
THAT THE INTENT WAS TO REPORT BACK ON HOW, WITH THIS	
ITEM, LEGALLY HOW YOU MAY BE ABLE TO HAVE INCENTIVES	
OR HOW YOU MAY ENCOURAGE PEOPLE TO REMAIN IN THE	
FIELD, BUT	
MR. SWEEDLER: IF I COULD PROVIDE A LITTLE	
BIT OF CONTEXT. THIS VERSION OF THE APPROACH IS	
WHAT WAS PRESENTED TO THE ICOC TWICE AS PART OF	
CONCEPT APPROVAL. AND THEN FOLLOWING THAT, ALTHOUGH	
WE DIDN'T PROVIDE DETAILS, WE MADE THIS PROMISE TO	
THE PEOPLE WHO APPLIED. AND THE WAY THE PROGRAM	
188	

188

1	WORKS IS THAT IT MAKES LOAN REPAYMENTS ON BEHALF OF	
2	THESE INDIVIDUALS. IT DOESN'T REIMBURSE PRIOR	
3	STUDENT LOANS, WHICH MEANS THAT EACH MONTH THAT WE	
4	DELAY BEING ABLE TO IMPLEMENT THIS MEANS A CERTAIN	
5	AMOUNT OF REPAYMENT THAT THESE PHYSICIAN-SCIENTISTS	
6	WILL SIMPLY MISS OUT ON FOREVER.	
7	DR. TROUNSON: LOOK, MR. CHAIRMAN, I	
8	RESPECTFULLY DI SAGREE WI TH MY COLLEAGUE HERE. I	
9	THINK WE CAN ACTUALLY COME BACK TO YOU WITH A RANGE	
10	OF OPTIONS. I DON'T THINK WE HAVE TO HAVE THE	
11	PROGRAM START BEFORE THE NEXT MEETING. BUT CLEARLY	
12	WE'D WANT THAT TO HAPPEN AS SOON AS POSSIBLE FOR	
13	THESE PEOPLE. THAT WOULD BE THE REASONABLE THING.	
14	BUT I THINK WE SHOULD BE ABLE TO EXPLORE FOR YOU	
15	WHAT THE OPTIONS ARE.	
16	I THINK IT WOULD BE IMPORTANT FOR US TO	
17	INDICATE WE'RE IN SUPPORT OF THESE YOUNG PEOPLE AS	
18	GORDON HAS PUT. AND IN A WAY, I'M VERY MUCH WITH	
19	HIM IN THAT RESPECT. IF YOU FORCE SOMEBODY TO WANT	
20	TO DO SOMETHING AFTER THEY'RE FINISHED THAT THEY	
21	DON'T WANT TO DO, THEY'RE NOT LIKELY TO BE A VERY	
22	USEFUL PERSON. BUT NEVERTHELESS, LET US EXPLORE	
23	WHAT IS POSSIBLE AND REASONABLE.	
24	CHAIRMAN KLEIN: I THINK LEEZA HAD A	
25	POI NT.	
	100	
	189	

1	MS. GIBBONS: I ACTUALLY JUST HAD A	
2	QUESTION THAT YOU HAD BROUGHT UP EARLIER. IS IT THE	
3	UNDERSTANDING THAT THIS AUGMENTATION, THIS MONEY,	
4	WAS SET ASIDE WHEN WE HAD THIS COME BEFORE US	
5	EARLI ER?	
6	CHAIRMAN KLEIN: IT WAS DESCRIBED AND IT	
7	WAS REPRESENTED TO THE RECIPIENTS, BUT THE MOTION	
8	DID NOT CAPTURE THE ACTUAL APPROPRIATION OF FUNDS TO	
9	MATCH THE DESCRIPTION OF THE PROGRAM. THIS IS NOT A	
10	NEW ITEM.	
11	MR. SWEEDLER: ACTUALLY THE NATURE OF THE	
12	CONCEPT APPROVAL WAS SUCH THAT IN RETROSPECT WHAT WE	
13	SHOULD HAVE DONE WAS SIMPLY INCLUDED THIS IN THE	
14	APPLICATION BUDGET, AND IT WOULD HAVE BEEN PART OF	
15	THE AWARD. SO	
16	CHAIRMAN KLEIN: WE'RE NOT DISAGREEING.	
17	MR. SWEEDLER: WHAT I'M SAYING IS IT WAS	
18	NOT ANTICIPATED THAT WE WOULD BE COMING BACK TO YOU	
19	FOR ADDITIONAL APPROVAL; BUT BECAUSE THE AWARDS HAVE	
20	BEEN MADE, WE NEED TO SUPPLEMENT THEM TO IMPLEMENT	
21	THEM. THAT'S ALL.	
22	CHAIRMAN KLEIN: WE UNDERSTAND THAT. SO	
23	WE HAVE SOME LIMITED TIME HERE.	
24	DR. AZZIZ: I'D LIKE TO EITHER WE DON'T	
25	ACTUALLY HAVE A MOTION ON THE TABLE TO APPROVE.	
	100	
	190	

1	CHAIRMAN KLEIN: I'M ASKING IF THERE IS A		
2	MOTION.		
3	DR. AZZIZ: I DON'T KNOW IF I HAVE A		
4	CONFLICT TO MAKE A MOTION. OTHERWISE, I'D LIKE TO		
5	MAKE A MOTION TO APPROVE THIS PROGRAM AS PRESENTED.		
6	I'LL SIMPLY ADD THAT I FULLY AGREE WITH PHIL THAT WE		
7	NEED TO MAKE ACCOUNTABILITY, BUT THIS IS PROBABLY		
8	NOT THE TIME TO MAKE THIS MORE ACCOUNTABLE THAN WHAT		
9	IS CURRENTLY AVAILABLE THROUGH THE NIH. IT WILL		
10	TAKE SOME DEEP THOUGHT.		
11	DR. PIZZO: I AGREE WITH THAT. I WAS NOT		
12	SUGGESTING WE DO IT TODAY.		
13	DR. AZZIZ: WHAT I DON'T ALSO THINK WE		
14	SHOULD DO IS DELAY THIS APPROVAL, WHICH IS A		
15	RELATIVELY SMALL ITEM.		
16	DR. PIZZO: I AGREE WITH THAT. I WASN'T		
17	SUGGESTING WE DO THAT.		
18	DR. AZZIZ: TO GIVE FURTHER THOUGHT. IN		
19	THE FUTURE WE SHOULD THINK ABOUT THAT; BUT AS YOU		
20	ALL KNOW, MAKING YOUNG SCIENTISTS ACCOUNTABLE AND		
21	MAKING THEM STAY IN THE FIELD IS PROBABLY ONE OF THE		
22	MORE COMPLEX ITEMS THAT WE'LL EVER DEAL WITH. I		
23	WOULD LIKE TO MOTION.		
24	CHAIRMAN KLEIN: LET ME ASK. CAN HE MAKE		
25	THE MOTION?		
	191		
	171		

BARRISTERS'	REPORTING SERVICE
--------------------	--------------------------

-	
1	MR. HARRISON: HE CAN. THESE PAYMENTS
2	WOULD BE MADE DIRECTLY TO THE LENDERS, NOT TO ANY OF
3	THE INSTITUTIONS, SO THERE ARE NO CONFLICTS.
4	DR. AZZIZ: I MAKE THE MOTION.
5	DR. PIZZO: SECOND THE MOTION.
6	CHAIRMAN KLEIN: SO DR. GILL AND DR. PIZZO
7	ARE SECONDS. PUBLIC COMMENT? SEEING NO, I'D LIKE A
8	VOICE VOTE. ALL IN FAVOR? OPPOSED?
9	DR. REED: NO.
10	CHAIRMAN KLEIN: MOTION PASSES. THANK
11	YOU.
12	SO I WOULD LIKE SOME AGAIN, IN TERMS OF
13	WHAT WE HAVE TO DO TODAY, I'D LIKE TO GO TO THE
14	STRATEGIC PLAN.
15	MR. HARRISON: MR. CHAIR, COULD I MAKE ONE
16	REQUEST? WE DO NOW HAVE LEEZA GIBBONS PRESENT.
17	CHAIRMAN KLEIN: VERY FAIR. LEEZA, WHEN
18	YOU WERE OUT, THERE WERE SOME ITEMS THAT PASSED
19	EXCEPT FOR SUBCATEGORY GRANTS WITHIN THOSE ITEMS
20	THAT THEY'RE SHORT A VOTE FOR A QUORUM. SO I'D LIKE
21	MR. HARRISON TO WALK THROUGH EACH OF THOSE, EXPLAIN
22	THE MOTION, EXPLAIN THE GRANT THAT IS AT ISSUE, AND
23	THEN ON THE RECORD ASK WHAT YOUR VOTE WOULD BE.
24	MR. HARRISON: I'LL ASK GIL SAMBRANO TO
25	PULL UP THE CHART SO YOU CAN SEE IT. BUT THIS IS
	192

1	WITH RESPECT TO THE BRIDGES PROGRAM, AND THERE WERE
2	TWO APPLICATIONS IN THE FUNDING CATEGORY THAT HAVE
3	BEEN APPROVED BY THE BOARD, BUT WE DIDN'T HAVE A
4	SUFFICIENT QUORUM IN YOUR ABSENCE TO PASS THEM. AND
5	THEY ARE APPLICATIONS 1190 AND 1194. AND THEN WE
6	HAVE ONE APPLICATION THAT WAS THE SUBJECT OF AN
7	OMNIBUS MOTION NOT TO FUND FOR WHICH WE DIDN'T HAVE
8	A SUFFICIENT QUORUM. AND THAT'S APPLICATION 1187.
9	AND WE'LL PULL UP THE DISTRIBUTION SO YOU
10	CAN SEE WHERE THESE APPLICATIONS FALL. AGAIN, IN
11	THE TO FUND, WE'RE REFERRING TO APPLICATIONS 1190
12	AND 1194.
13	CHAIRMAN KLEIN: AGAIN, THESE ARE IN THE
14	BRIDGES TO STEM CELL PROGRAM.
15	MR. SHEEHY: CAN I ASK A QUESTION, JAMES?
16	FOR PURPOSES OF QUORUM, A YES, NO, OR ABSTENTION ARE
17	OPTIONS FOR LEEZA?
18	MR. HARRI SON: YES.
19	MR. SHEEHY: WOULD A YES OR NO MATERIALLY
20	AFFECT THE OUTCOME OF THE VOTE?
21	MR. HARRISON: NO, IT WOULD NOT.
22	CHAIRMAN KLEIN: OKAY. AN ABSTENTION IS
23	AN OPTION, DOESN'T AFFECT OUR QUORUM?
24	MR. HARRISON: CORRECT. IN OTHER WORDS,
25	WE HAVE A SUFFICIENT NUMBER OF YES VOTES FOR BOTH
	100
	193

1	MOTIONS SO THAT AN EXTENSION WOULD NOT MAKE A
2	DI FFERENCE.
3	MS. GIBBONS: SO YOU ASKING ME ABOUT THEM
4	TOGETHER?
5	CHAIRMAN KLEIN: IDENTIFY THE NUMBERS
6	AGAIN FOR HER, PLEASE.
7	MR. HARRISON: YES. THEY ARE APPLICATIONS
8	1190 AND 1194, AND THE MOTION WAS TO APPROVE THE
9	FUNDING OF THOSE TWO APPLICATIONS AS PART OF THE
10	BRIDGES PROGRAM.
11	MS. GIBBONS: YES. I VOTE IN FAVOR.
12	MR. HARRISON: AND THE OTHER MOTION WAS
13	WITH RESPECT TO APPLICATION 1187, AND THE MOTION WAS
14	NOT TO FUND THAT APPLICATION AS PART OF THE BRIDGES
15	PROGRAM.
16	CHAIRMAN KLEIN: COULD YOU SHOW HER THE
17	SCORE ON THAT, PLEASE.
18	MS. GIBBONS: THAT ONE I'M NOT PREPARED TO
19	VOTE ON RIGHT NOW.
20	DR. YAFFE: 1187 HAD A SCORE OF 43.
21	MS. GIBBONS: AND THE MOTION WAS NOT TO
22	VOTE FOR FUNDING?
23	MR. HARRISON: YES, NOT TO FUND.
24	MS. GIBBONS: I AGREE.
25	MR. HARRISON: THANK YOU, MR. CHAIR.
	194
	Т / Т

	BARRISTERS' REPORTING SERVICE
1	CHAI RMAN KLEI N: THANK YOU. STRATEGI C
2	PLAN, ITEM NO. 12, DR. TROUNSON.
3	DR. TROUNSON: I'LL BE BRIEF, IF I MAY,
4	CHAIR, BECAUSE WE'VE HAD BERNIE LO WAITING ALL DAY
5	TO MAKE A PRESENTATION TO YOU. SO I WON'T USE ALL
6	THE SLIDES. MELISSA, IF YOU GO TO THE NEXT ONE.
7	WHAT WE WERE ASKED TO BRING BACK IS A
8	PROCEDURE FOR THE PUBLIC TO BE INVOLVED WITH LOOKING
9	AT THE REVISIONS OF THE 2006 STRATEGIC PLAN. THESE
10	ARE THE ISSUES THAT WE WANT TO PROPOSE TO YOU, THAT
11	THERE BE TWO INDUSTRY INPUTS, AND THEY WOULD WE
12	HAVE SUGGESTED THAT THEY COULD BE AT SOUTH SAN
13	FRANCISCO ON THE 3D OF FEBRUARY AND IN SOUTHERN
14	CALIFORNIA AT CARLSBAD, I UNDERSTAND, ON THE 20TH OF
15	FEBRUARY. BUT INDEPENDENTLY OF THAT, THERE WOULD BE
16	TWO COMMUNITY INPUTS, TWO FORUMS IN LATE FEBRUARY,
17	EARLY MARCH IN LOS ANGELES AND SAN FRANCISCO.
18	I HAVE SPOKEN TO ED PENHOET, WHO AGREED TO
19	CHAIR THE INDUSTRY SESSIONS, AND WE HAVE TED LOVE,
20	DUANE ROTH, AND BOB KLEIN INVOLVED IN THOSE INDUSTRY
21	MEETINGS. THERE'S A VERY STRONG DESIRE BY INDUSTRY,
22	AS INDICATED, THAT WOULD LOVE TO COME TO THOSE
23	MEETINGS IN LARGE NUMBERS. AND I'VE ALSO TALKED TO
24	SEVERAL OF THE BOARD MEMBERS ABOUT CHAIRING ONE OF
25	THE SESSIONS IN SAN FRANCISCO AND ONE IN LOS

195

ANGELES.

1

IF I JUST SHOW YOU THE NEXT SLIDE, WE WERE 2 SET TO REVIEW BY OUTSIDE PANEL IN OUR 2006 STRATEGIC 3 PLAN AT YEAR THREE AND AT YEAR SEVEN. SO IF YOU SET 4 YEAR ONE TO BEGIN 2007, SO THAT THREE-YEAR REVIEW 5 WOULD BE IN 2010. WE'RE AT THE HALFWAY POINT TO THE 6 7 THREE-YEAR REVIEW. AS I SHOWED YOU A SLIDE IN MY 8 PRESIDENT'S PRESENTATION, YOU ACTUALLY AGREED IN 9 CONCEPT AT LEAST TO A BILLION DOLLARS ALREADY. SO I 10 THINK IT'S TIME FOR US TO HAVE A GOOD, HARD LOOK TO SEE IF THE DIRECTIONS WE'RE GOING ARE REALLY THE 11 ONES THAT OPTIMIZE, SHOULD I SAY OPTIMIZE. IT IS 12 13 ALSO STATED THAT THE STRATEGIC PLAN IS A LIVING DOCUMENT TO BE REVISED BY CIRM PERIODICALLY. 14 15 THE GOALS OF THE UPDATE THAT WE WILL SET, 16 AND PART OF THOSE DOCUMENTS WHICH WILL BE REVISED 17 THAT YOU SAW LAST TIME, IS TO ASSESS PROGRESS TO DATE, ACKNOWLEDGE OPERATIONAL CHANGES FROM THE '06 18 19 PLAN BECAUSE THERE HAVE BEEN THOSE MADE SINCE THE BEGINNING, ASSESS THE STATE OF THE FIELD, WHICH HAS 20 21 CHANGED DRAMATICALLY IN SOME PLACES; BUT, 22 IMPORTANTLY, THESE PUBLIC MEETINGS WILL CONSIDER STRATEGIC ADJUSTMENTS. 23 24 I THINK THAT'S PROBABLY ALL YOU NEED AT THE MOMENT. I CAN GO INTO SOME OF THE AREAS THAT WE 25

1	THINK ARE WORTHY OF DISCUSSION IF YOU WISH, BUT I
2	THINK THAT WAS THE INTENT OF WHAT YOU REQUIRED FROM
3	US AT THIS MEETING.
4	CHAIRMAN KLEIN: ALL RIGHT. THANK YOU
5	VERY MUCH. THANK YOU FOR THE REAL SUBSTANTIVE
6	PUBLIC INPUT YOU'VE MADE AN OPPORTUNITY FOR IN THIS
7	PROCESS. ANY BOARD COMMENT? ANY PUBLIC COMMENT?
8	MR. SIMPSON: JOHN SIMPSON FROM CONSUMER
9	WATCHDOG. AT THE LAST MEETING WHEN THIS WAS
10	DISCUSSED, THERE WAS A FEELING, I THINK, ON SOME
11	PEOPLE'S PART THAT THERE DIDN'T AT THAT POINT SEEM
12	TO BE GOOD PROVISIONS FOR PUBLIC INPUT AND INDUSTRY
13	INPUT. AND BASED ON WHAT WE SEE HERE AND SO ON, IT
14	SEEMS TO BE EXACTLY ON THE RIGHT TRACK. AND THANK
15	YOU VERY MUCH, DR. TROUNSON.
16	CHAIRMAN KLEIN: OKAY. ANY ADDITIONAL
17	BOARD DISCUSSION? VOICE VOTE. ALL IN FAVOR?
18	OPPOSED? WE'VE LOST A QUORUM. THE SENSE OF THE
19	GROUP IS APPROPRIATE.
20	I'D LIKE TO CALL ON DR. BERNIE LO.
21	DR. LO: I'M GOING TO ASK FOR PASSAGE OF
22	SEVERAL ITEMS, SO IF YOU HAVE NO QUORUM, PERHAPS YOU
23	SHOULD MOVE ON TO OTHER THINGS.
24	CHAIRMAN KLEIN: I THINK WE SHOULD PRESENT
25	THE ITEM. I'M GOING TO, WHILE WE TRY AND FIGURE OUT
	197

1	HOW WE'RE GOING TO GET A QUORUM NOTHING IS
2	IMPOSSIBLE, JAMES WHILE WE TRY AND FIGURE OUT HOW
3	WE'RE GOING TO GET A QUORUM, I THINK IT IS IMPORTANT
4	THAT WE CREATE THE PUBLIC RECORD AND PROVIDE
5	OPPORTUNI TY HERE FOR DI SCUSSI ON.
6	DR. LO: THANK YOU FOR GIVING ME THE
7	CHANCE TO PRESENT ON BEHALF OF THE STANDARDS WORKING
8	GROUP. FIRST, I WANT TO SAY YOU CAN ALL TAKE A DEEP
9	BREATH. THIS SHOULD BE RELATIVELY EASY FOR YOU, I
10	THINK. THIS IS PROBABLY NONCONTROVERSIAL AND IT
11	WON'T COST YOU A PENNY. JUST LISTENING IN THE BACK,
12	I KNOW THERE'S BEEN SOME VERY TOUGH DECISIONS YOU'VE
13	BEEN FACING.
14	SO WHAT I'M GOING TO PROPOSE TO YOU ARE
15	TWO THINGS. FIRST, NEW RECOMMENDATIONS TO, FIRST,
16	CLARIFY THE CIRM REQUIREMENTS FOR OVERSIGHT OF
17	RESEARCH WITH INDUCED PLURIPOTENTIAL CELLS, IPS
18	CELLS, IN TERMS OF WHAT KIND OF OVERSIGHT DOES THE
19	INSTITUTIONAL SCRO, STEM CELL RESEARCH OVERSIGHT
20	COMMITTEE, HAVE TO DO? AND SECONDLY, TO SUGGEST
21	SOME MEASURES THAT WOULD FACILITATE THE COLLECTION
22	AND USE OF SOMATIC CELLS FOR IPS RESEARCH TO DERIVE
23	NEW CELL LINES.
24	WE'VE HAD A LOT OF COMMENTS FROM
25	UNIVERSITIES AND INVESTIGATORS WHO ARE VERY
	198
	170

1	INTERESTED IN PURSUING THIS VERY PROMISING LINE OF
2	STEM CELL RESEARCH TO CLARIFY SEVERAL AMBIGUITIES IN
3	OUR CIRM REGULATIONS.
4	AND SECONDLY, WE'RE ASKING YOU TO MAKE TWO
5	INTERIM REGULATIONS WHICH WERE PREVIOUSLY DISCUSSED
6	AND APPROVED ON EMBRYONIC STEM CELL RESEARCH
7	DERIVATION USING, QUOTE, GRANDFATHERED,
8	GRANDPARENTED EMBRYOS, MAKE THOSE PERMANENT
9	REGULATIONS AND PUT THEM THROUGH THE REGULATORY
10	PROCESS.
11	OUR CURRENT CIRM GUIDELINES FOR IPS
12	DERIVATION ARE MORE RESTRICTIVE THAN THE NATIONAL
13	ACADEMY OF SCIENCE 2008 RECOMMENDATIONS AND FOR
14	FEDERAL REGULATIONS, THE COMMON RULE THAT GOVERNS
15	HUMAN SUBJECTS RESEARCH. SO INVESTIGATORS WHO WANT
16	TO ENTER THIS EXCITING FIELD TO DERIVE NEW IPS LINES
17	ARE CAUGHT BETWEEN HAVING TO LIVE WITH MORE
18	RESTRICTIVE CIRM GUIDELINES. AS YOU KNOW, MANY
19	CALIFORNIA INSTITUTIONS ARE APPLYING OUR CIRM
20	GUIDELINES TO ALL STEM CELL RESEARCH AT THEIR
21	INSTITUTION.
22	THE STANDARDS WORKING GROUP MET AND
23	SUGGESTED THAT THERE IS NO ETHICAL CONCERN REGARDING
24	IPS CELLS THAT WARRANTS A MORE RESTRICTIVE APPROACH
25	IN THE CIRM GUIDELINES. SO WE THINK THIS IS AN
	199

1	AMBIGUITY, A HISTORICAL SORT OF ANACHRONISM, BUT IT
2	IS CAUSING SOME CONCERNS AMONG INSTITUTIONS AND
3	RESEARCHERS. SO WE'RE ASKING YOU TO CLARIFY AND
4	REMOVE THOSE AMBIGUITIES.
5	SPECIFICALLY, THE ISSUES ARE HOW MUCH
6	OVERSIGHT DOES THE INSTITUTIONAL SCRO HAVE TO DO FOR
7	A DERIVATION PROJECT OF NEW IPS CELLS AND, SECONDLY,
8	THE CONSENT TO DONATE SOMATIC CELLS. OUR GUIDELINES
9	ACTUALLY EXCLUDE SOME SOMATIC CELLS THAT WOULD BE
10	PERMITTED UNDER IRB APPROVED PROTOCOLS AND THE
11	FEDERAL COMMON RULE.
12	NEXT SLIDE. I'LL TRY AND SHOW THIS
13	GRAPHICALLY. ON THE ISSUE OF OVERSIGHT, WE'RE
14	SUGGESTING THAT IF A RESEARCHER WANTS TO DERIVE A
15	NEW IPS LINE, THEY MERELY NEED TO NOTIFY THE SCRO
16	THAT THIS IS HAPPENING. THEY WOULD STILL BE SUBJECT
17	TO ANY IRB REQUIREMENTS FOR DONATION OF CELLS, BUT
18	WE DON'T WANT TO PUT THEM THROUGH A FULL SCRO
19	REVIEW. AND, INDEED, THE NAS GUIDELINES DO NOT
20	REQUIRE FULL SCRO REVIEW.
21	SECOND ISSUE IS CONSENT FROM THE SOMATIC
22	CELL DONOR, THAT WE'RE ASKING THAT GENERAL CONSENT
23	FOR RESEARCH OR A WAIVER OF CONSENT FROM THE IRB
24	WOULD SUFFICE FOR IPS DERIVATION. OUR REASONING IS
25	THIS IS NOT OBTAINING THESE CELLS IS NOT

200

1	MEDICALLY OR PHYSICALLY DANGEROUS. IT DOESN'T RAISE
2	THE KINDS OF ETHICAL CONCERN THAT COLLECTING OOCYTES
3	OR EMBRYOS DOES. AND THE RESEARCHERS IN OTHER
4	FIELDS ARE COLLECTING MATERIALS WITHOUT SPECIAL
5	SPECIFIC CONSENT.
6	WE DO, HOWEVER, SAY THAT, AS OPPOSED TO
7	THE DERIVATIONAL LINES, IF YOU ARE GOING TO HAVE A
8	PROTOCOL ACTUALLY TRANSPLANTING IPS CELLS INTO
9	HUMANS, YOU NEED CONSENT FOR THAT TRANSPLANTATION
10	FROM THE DONORS.
11	SO SWITCHING TO THE DO YOU WANT TO DO
12	THEM ONE AT A TIME, CHAIRMAN KLEIN? SO LET'S GO
13	BACK TO THE LAST SLIDE. SO FOR IPS RESEARCH, WE'RE
14	ASKING YOU TO CLARIFY IN INTERIM REGULATIONS THAT
15	THE SCRO ONLY NEEDS TO BE NOTIFIED FOR IPS
16	DERIVATION, AND THE GENERAL CONSENT FOR RESEARCH,
17	UNSPECIFIED RESEARCH, OR WAIVER OF CONSENT SUFFICES
18	FOR IPS DERIVATION. THESE CHANGES WOULD MAKE US
19	CONSISTENT WITH THE COMMON RULE AS IS ENFORCED BY
20	IRB'S THROUGHOUT CALIFORNIA AND WITH THE NAS
21	STANDARDS AS AMENDED IN MAY 2008.
22	CHAIRMAN KLEIN: SO WITH THAT, AND THIS
23	HAS GONE THROUGH THE STANDARDS COMMITTEE?
24	DR. LO: YES. WE UNANI MOUSLY SUGGEST YOUR
25	APPROVAL.
	201
	201

	CHAIRMAN KLEIN: SO WHAT I WOULD ASK HERE,
2	UNLESS THERE FIRST OF ALL, IF THERE'S ANY
3	DISCUSSION OF THIS; BUT ALSO IN YOUR DISCUSSION, I'D
4	ASK THAT IF THERE IS NO OBJECTION, I WOULD LIKE TO
5	PUT THIS ON THE CONSENT CALENDAR FOR THE MARCH
6	MEETING AFTER TAKING THE SENSE OF THIS GROUP TO SEE
7	IF THERE'S GENERAL CONSENT GENERAL SUPPORT FOR
8	THI S.
9	IS THERE ANY OBJECTION TO PUTTING THIS ON
10	THE CONSENT CALENDAR FOR THE MARCH MEETING?
11	DR. HAWGOOD: I HAVE JUST ONE QUESTION
12	THAT MAYBE BERNIE OR MAYBE ALAN. THE COMMON CELL
13	FOR THIS IS A FIBROBLAST AND THAT'S EASY. YOU
14	PRESENTED A OR SHOWED US A PAPER WHERE KERATI NOCYTES
15	WERE BECOMING A TARGET PERHAPS PREFERRED. DO YOU
16	SUSPECT THAT ANY MORE DIFFICULT TO OBTAIN CELL MAY
17	BECOME A TARGET FOR IPS, AND DOES IT INFLUENCE WHAT
18	WE'RE THINKING HERE?
19	DR. TROUNSON: YES. AND ALSO I THINK WE
20	EXPLORED THAT WITH THE COMMITTEE. BUT, FOR EXAMPLE,
21	THERE ARE PUBLICATIONS SAYING THAT LIVER CELLS ARE
22	MUCH MORE EFFECTIVE AS CANDIDATE CELLS FOR COMPLETE
23	REPROGRAMMING. SO IT IS POSSIBLE, SAM, THAT A LIVER
24	CELL MAY BE A PREFERRED CELL OR MAYBE ANOTHER CELL
25	COULD BE PREFERRED IN THE LONGER TERM. SO WE

202

1	COULDN'T BE CERTAIN ABOUT THAT. BUT LET'S IMAGINE
2	THAT A LIVER CELL MIGHT BE PREFERRED, ALTHOUGH I
3	DON'T THINK THAT IS THE SENSE OF THE FIELD RIGHT AT
4	THE MOMENT.
5	DR. LO: IF I COULD SORT OF TAKE THE
6	ETHICAL TWISTS ON THAT QUESTION. THAT PROTOCOL
7	WOULD BE REVIEWED BY THE IRB FOR DONATION OF HUMAN
8	MATERIALS. THEY, I ASSUME, WOULD LOOK VERY CLOSELY
9	AT THE MEDICAL RISK AND THE CONSENT PROCESS. WE'RE
10	JUST SAYING WE DON'T WANT TO ADD ON ANY ADDITIONAL
11	SPECIAL REVIEW BECAUSE IT'S GOING TO BE USED FOR IPS
12	RESEARCH AS OPPOSED TO CANCER RESEARCH OR GENETICS
13	RESEARCH. SO WE'RE NOT TAKING AWAY OVERSIGHT.
14	WE'RE JUST NOT ADDING TO WHAT IS IN PLACE AND WHICH
15	WE FEEL AND THE NAS FELT WAS ADEQUATE FOR THIS KIND
16	OF RESEARCH.
17	DR. AZZIZ: JUST A PROCESS QUESTION, AND I
18	MAY HAVE LOST TRACK. DO WE OR DO WE NOT HAVE A
19	QUORUM?
20	CHAIRMAN KLEIN: WE DO NOT HAVE A QUORUM.
21	THE QUESTION IS IF THERE'S ANY OBJECTION, IT WOULD
22	NOT GO ON THE CONSENT CALENDAR. IF THERE'S NO
23	OBJECTION, AND THERE APPEARS TO BE GENERAL OVERSIGHT
24	GIVEN IT UNANIMOUSLY WENT THROUGH STANDARDS, AND IF
25	THERE'S NO PUBLIC OBJECTION, I'M GOING TO ASK FOR

203

PUBLIC COMMENT, WE'D THEN PUT IT ON THE CONSENT
CALENDAR FOR MARCH, THEREFORE, SAVING TIME IN MARCH
SINCE IT'S BEEN REVIEWED THOROUGHLY AT THE STANDARDS
LEVEL AND THERE DOESN'T APPEAR TO BE OBJECTION.
DR. LO: CHAIRMAN KLEIN, COULD I MAKE A
CORRECTION? I MISSPOKE. THAT IT WAS UNANIMOUS, BUT
WE DID NOT HAVE A QUORUM AT THE SWG, BUT IT WAS THE
UNANIMOUS SENSE OF OUR COMMITTEE.
CHAIRMAN KLEIN: WE LOVE THE SPIRIT OF
DISCLOSURE. THANK YOU. ANY PUBLIC COMMENT ON THIS
ITEM? SEEING NO PUBLIC COMMENTS AND NO OBJECTION, I
THINK THE QUESTION HAS BEEN ANSWERED. AND THANK
YOU, DR. LOMAX, FOR ALL THE WORK THAT GOES IN BEHIND
THE STANDARDS MEETINGS AND WORKING THROUGH THE VERY
TECHNICAL ISSUES IN THIS SUBAREA.
DR. LOMAX: COULD I JUST STATE FOR THE
RECORD, MR. CHAIRMAN, THAT IT WAS A SENSE OF THE
ICOC THAT ALL THE RECOMMENDED LANGUAGE PERTAINING TO
THE REGULATIONS THAT DR. LO DESCRIBED IN SECTIONS
100070 AND 100090 WAS THE SENSE THAT WE SHOULD MOVE
FORWARD. THOSE WERE WHAT YOU APPROVED. I JUST
WANTED TO MAKE CLEAR THAT WE'RE DEALING WITH TWO
SETS OF REGULATIONS AND HAVE THAT IN THE RECORD.
AND YOU HAVE THAT LANGUAGE BEFORE YOU.
CHAIRMAN KLEIN: DOES ANYONE OBJECT TO
204

1	THAT WORDING? SEEING NO OBJECTION, THAT APPEARS TO
2	BE THE PROPER COURSE.
3	DR. LOMAX: THANK YOU.
4	DR. LO: SO IF I COULD GO TO THE SLIDE,
5	THE ONE AFTER THE ARROW DIAGRAM. SO THE SECOND ITEM
6	IS THAT WE'RE ASKING YOU TO TAKE ITEMS THAT YOU HAD
7	PREVIOUSLY APPROVED AS INTERIM REGULATIONS AT THE
8	MARCH MEETING, MOVE THEM INTO THE REGULATORY PROCESS
9	AS PROPOSED PERMANENT REGULATIONS. AND THESE
10	REGULATIONS PERTAIN TO EMBRYOS THAT A CIRM
11	RESEARCHER PROPOSES TO USE IN CIRM-FUNDED RESEARCH,
12	BUT THEY WERE ORIGINALLY CREATED FOR IVF PURPOSES,
13	FOR REPRODUCTIVE PURPOSES, BEFORE A CUTOFF DATE,
14	WHICH I'LL SHOW YOU ON A TIMELINE ON THE NEXT SLIDE.
15	THE TWO SPECIFIC ISSUES IS, FIRST, TO
16	AUTHORIZE THE USE OF EMBRYOS CREATED FROM A GAMETE
17	FOR WHICH THE DONOR WAS PAID IN AN IVF CONTEXT. SO
18	THAT THE GAMETE DONOR GAVE AN EGG OR AN OOCYTE IN AN
19	IVF CONTEXT, SUBSEQUENTLY AN EMBRYO THAT WAS FROZEN
20	WAS DEEMED NOT NECESSARY FOR REPRODUCTIVE PURPOSES
21	BY THE WOMAN OR COUPLE IN IVF, AND THEY WANTED TO
22	GIVE IT TO RESEARCH. THE IDEA WAS THAT BECAUSE THE
23	PAYMENT HAD TAKEN PLACE IN AN IVF CONTEXT AND WAS
24	NOT A PAYMENT FOR DONATION IN A RESEARCH CONTEXT,
25	THAT THE LEGAL OPINION WAS THAT THAT DID NOT

205

1	CONTRAVENE PROP 71. AND IT WAS THE DECISION OF THE
2	ICOC, ACTING ON THE RECOMMENDATION OF THE SWG, THAT
3	THIS BE PERMITTED AS AN INTERIM REGULATION.
4	THE SECOND ISSUE WAS, AS YOU RECALL, WE
5	PUT IN VERY STRINGENT AND CAREFUL REGULATIONS FOR
6	OOCYTE DONATION SPECIFICALLY FOR THE PURPOSE OF
7	RESEARCH. AND, AGAIN, WE WANT TO DRAW A DISTINCTION
8	BETWEEN THAT SITUATION AND THE SITUATION OF DONATING
9	OOCYTES FOR IVF, BUT LATER, USUALLY YEARS LATER, THE
10	EMBRYO THAT WAS CREATED, NOT BEING NEEDED FOR
11	REPRODUCTIVE PURPOSES AND THE COUPLE WANTING TO
12	DONATE IT TO RESEARCH, THAT WE NOT REQUIRE THE
13	HEIGHTENED CIRM CONSENT REQUIREMENTS FOR OOCYTE
14	DONATION IN THAT CONTEXT BECAUSE IT OCCURRED NOT IN
15	A REPRODUCTIVE CONTEXT.
16	SO IN THE NEXT SLIDE, I'LL SHOW YOU THE
17	TIMELINE. SO WE'RE SAYING THAT BEFORE THE CUTOFF
18	DATE ESTABLISHED AT THE LAST MEETING, 8/13/08, IVF
19	EMBRYOS FROM PAID DONORS MAY BE USED FOR RESEARCH.
20	BECAUSE THE PAYMENT WAS IN THE REPRODUCTIVE CONTEXT,
21	IT COULD NOT HAVE BEEN AN UNDUE INDUCEMENT, IT COULD
22	NOT HAVE LED TO ANY ADVERSE OUTCOMES FOR THE DONOR,
23	PRESUMABLY IN THE IVF CONTEXT THAT CONSENT WAS FULLY
24	OBTAINED. SO THAT'S ONE TIME, 8/13/08, YOUR LAST
25	MEETING, WHEN THAT WAS AN INTERIM REGULATION.

206

1	ON THE NEXT SLIDE, FOR THE CONSENT, WE
2	ACTUALLY HAVE TWO DIFFERENT GRANDFATHER TIME
3	DEADLINES. UP UNTIL THE ACCEPTANCE OF THE NAS
4	REGULATIONS AS CIRM INTERIM GUIDELINES, WE SAY ANY
5	EMBRYOS CREATED BEFORE THAT TIME, IF A DONOR EGG OR
6	SPERM WAS USED, THAT DONOR ONLY NEEDED TO HAVE
7	CONSENTED TO RESEARCH IN GENERAL. THEY DID NOT
8	SPECIFICALLY NEED TO CONSENT TO EMBRYO RESEARCH OR
9	EMBRYONIC STEM CELL RESEARCH BECAUSE THAT REALLY
10	WASN'T, WE BELIEVE, THE STANDARD OF CARE AT THE
11	TIME.
12	NOW, GOING FORWARD THE SAME TIMELINE
13	WITH THE GREEN ARROWS. SHOULD BE MY VERY LAST
14	SLIDE. THE TIME PERIOD BETWEEN THAT DEADLINE AND
15	THE 8/13/08 DEADLINE, WE DO REQUIRE THAT THERE BE
16	CIRM-SPECIFIC RESEARCH CONSENT BECAUSE AT THAT TIME
17	OUR GUIDELINES HAD ALREADY BEEN ADOPTED. NOW, THIS,
18	AGAIN, CAME THROUGH SWG. IT WAS PRESENTED TO ICOC.
19	YOU APPROVED THIS WITH PUBLIC INPUT AS INTERIM
20	REGULATION. WE'RE NOW PROPOSING, ASKING YOU AT YOUR
21	MARCH MEETING TO MOVE THIS THROUGH AS A PERMANENT
22	REGULATION, AND THEN START THE REGULATORY PROCESS
23	WITH PUBLIC COMMENT AND FURTHER APPROVAL.
24	CHAIRMAN KLEIN: OKAY. LET ME CLARIFY THE
25	STATEMENT YOU JUST MADE. YOU'RE ASKING US TO
	207

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

	BARRISTERS' REPORTING SERVICE
1	APPROVE IT AS A PERMANENT REGULATION?
2	DR. LO: RIGHT. WHAT YOU APPROVED AS AN
3	INTERIM REGULATION AT THE LAST MEETING.
4	CHAIRMAN KLEIN: AND START THE COMMENT
5	PERI OD.
6	DR. LO: RIGHT. START THE PUBLIC COMMENT
7	PERI OD.
8	CHAIRMAN KLEIN: OKAY.
9	DR. LO: SO, AGAIN, YOU'LL HAVE A CHANCE
10	TO COME BACK TO THIS IN THE CONTEXT.
11	CHAIRMAN KLEIN: SO WITHOUT OBJECTION, I'D
12	LIKE TO PUT THIS ON THE CONSENT CALENDAR FOR MARCH.
13	ANY PUBLIC OBJECTION? WE KNOW THIS IS A TREMENDOUS
14	AMOUNT OF EFFORT TO PROCESS THESE VERY IMPORTANT
15	RULES.
16	WE DO HAVE ONE MORE ITEM AFTER THIS THAT'S
17	VERY IMPORTANT AS A DISCUSSION ITEM, BUT I'D LIKE TO
18	THANK REALLY DR. BERNIE LO AND GEOFF LOMAX FOR ALL
19	THE WORK THEY PUT INTO THIS. THANK YOU.
20	(APPLAUSE.)
21	DR. LO: I WANT TO AGAIN THANK THE SWG
22	MEMBERS, SEVERAL OF WHOM ARE MEMBERS OF THE ICOC,
23	AND PARTICULARLY TO SHERRY LANSING, MY CO-CHAIR.
24	THANK YOU.
25	CHAIRMAN KLEIN: SO THE LAST ITEM FOR
	208

1	DISCUSSION, WHICH IS REALLY CRITICAL TO OUR MISSION,
2	IS THERE'S BEEN A WE HAVE AN RFA TO BE POSTED ON
3	DISEASE TEAMS. NOW, IT'S IMPORTANT TO BE ABLE ON
4	THIS RFA TO MAKE SURE THAT THE BOARD, IN THE CONTEXT
5	OF THE FINANCIAL SITUATION, THAT I THINK WE MAKE A
6	DECISION THAT THE STAFF CAN GO FORWARD WITH THAT
7	POSTING. THIS IS A DISCUSSION. THIS IS NOT AN
8	ACTION ITEM, BUT IT'S IMPORTANT FOR THEM TO
9	UNDERSTAND THE SENSE OF THE BOARD, THAT WE'RE IN
10	BUSI NESS.
11	AS YOU RECALL, THIS IS GOING THROUGH
12	TRIAGE, SO THERE IS A LIMITED APPLICATION UP FRONT;
13	BUT IF WE DON'T HAVE THAT PIPELINE IN DEVELOPMENT,
14	WE WILL NOT BE IN A POSITION TO, IF WE HAVE THE
15	FUNDS, TO FUND DISEASE TEAMS. IN ADDITION, HAVING
16	THAT PIPELINE IN PROCESS, IF THERE IS A STRONG
17	PARTICIPATION IN CALIFORNIA IN THE DISEASE TEAMS
18	PRELIMINARY SCREENING PROGRAM, IT GIVES US A
19	TREMENDOUS ARGUMENT FOR URGENCY ON THE PRIVATE
20	PLACEMENT OF TAXABLE BONDS.
21	SO IT'S A MISSION CRITICAL ISSUE,
22	IMPORTANT TO PROVIDE FEEDBACK. DR. CSETE, WOULD YOU
23	LIKE TO ADDRESS THIS ITEM?
24	MS. KING: CAN I JUST CLARIFY? WHAT
25	AGENDA ITEM ARE WE REFERRING TO?
	209
	207

	Briting TERS ALL ON THIS SERVICE
1	CHAIRMAN KLEIN: THIS IS A DISCUSSION.
2	MS. KING: I UNDERSTAND. SO IT'S NO. 8.
3	CHAIRMAN KLEIN: THIS IS A DISCUSSION
4	WITHIN THE CONTEXT OF NO. 8.
5	DR. CSETE: MR. CHAIRMAN, MEMBERS OF THE
6	BOARD, I REALLY DO WANT TO GET YOUR ATTENTION. I
7	KNOW EVERYBODY IS TIRED AND DRAINED, BUT THIS IS A
8	VERY IMPORTANT ISSUE FOR US TO BE UPDATED ABOUT.
9	AND IT WAS REQUESTED BY SEVERAL MEMBERS OF THE BOARD
10	AT THE LAST MEETING THAT WE UPDATE THEM ON OUR
11	COLLABORATI VE FUNDI NG PARTNERSHI PS.
12	I WANT TO REPORT THAT WE HAVE MADE GREAT
13	STRIDES IN EXECUTING ONE OF THE GOALS OF THE
14	STRATEGIC PLAN, WHICH WAS GOAL 10, TO ESTABLISH
15	NATIONAL AND INTERNATIONAL COLLABORATIONS IN STEM
16	CELL RESEARCH THAT ALLOW US TO LEVERAGE OUR
17	COMPARATIVE ADVANTAGE IN CALIFORNIA AND ADVANCE
18	TOWARDS THERAPIES.
19	SO THESE COLLABORATIONS ARE, FIRST AND
20	FOREMOST, FOR THE SCIENCE. CALIFORNIA IS NOW, AS A
21	CONSEQUENCE OF YOUR INCREDIBLE EFFORTS AND THE
22	EFFORTS OF THE SCIENCE STAFF AND/OR GRANTEES, A
23	CENTER OF STEM CELL RESEARCH. AND ESPECIALLY WITH
24	TRANSLATIONAL PROGRAMS OUTSIDE THE UNITED STATES,
25	WE'RE GOING TO HAVE TO USE THAT TO REACH OUT TO

1	MAJOR STRENGTHS OUTSIDE OF CALIFORNIA BECAUSE STEM
2	CELL RESEARCH IS NOW BEING SEEN IN THE LARGER
3	CONTEXT OF REGENERATIVE MEDICINE.
4	AND MEDICINE IS SUCH THAT DISEASES DO NOT
5	STOP AT BOUNDARIES. AS WE GET INTO MORE AND MORE
6	CLINICAL, TRANSLATIONAL KINDS OF RESEARCH PROJECTS
7	AND TRIALS, WE HAVE TO HAVE MULTICENTER,
8	MULTIMEDICAL CULTURE TRIALS TO REALLY STRENGTHEN
9	THEM. AND THE CAPACITY FOR CLINICAL TRIALS IN
10	CALIFORNIA MAY, IN FACT, LIMIT SOME OF THE
11	APPLICATIONS THAT WE'LL LIKELY SEE COMING TO US IN
12	THIS NEXT YEAR.
13	IN ADDITION, IF WE LOOK PAST LOOK TO
14	THE PAST, OUR VISTA HAS REALLY CHANGED. IN ADDITION
15	TO ALL THE ECONOMIC CHANGES THAT WE'VE TALKED ABOUT
16	IN THE LAST COUPLE OF YEARS, IF WE THINK BACK TO THE
17	TIME OF THE ORIGINAL PASSAGE OF PROP 71 WHEN REALLY
18	WHAT WE WERE TALKING ABOUT WERE USING HUMAN
19	EMBRYONIC STEM CELL-DERIVED CELL THERAPIES TO CREATE
20	PRODUCTS FOR THE CLINIC, THE SCIENCE HAS NOW
21	EXPANDED. AND CIRM HAS REALLY EMBRACED THE NEW
22	SCIENCE AS A WAY TO GET TO THE END GAME. BUT WITH
23	THIS LARGER OPPORTUNITY ALSO COMES THE NEED FOR
24	LARGER RESOURCES. AND THIS IS EXACTLY WHERE THESE
25	KINDS OF COLLABORATIONS WILL BE IMPORTANT TO DRIVE

211

1	THE KIND OF RESEARCH WE'D LIKE TO SEE.
2	SO HOW HAVE WE DONE THIS? THIS WAS THE
3	QUESTION THAT WAS RAISED BY THE BOARD. IT'S A VERY
4	DELIBERATE PROCESS. USUALLY AGENCIES HAVE COME TO
5	US RATHER THAN US GOING TO THEM. BUT WITH THE
6	ASSISTANCE OF NANCY KOCH, WE FIRST SIGNED AN
7	AGREEMENT AT A VERY HIGH LEVEL, A MEMORANDUM OF
8	UNDERSTANDING, JUST TO TALK TO EACH OTHER, TO OPEN
9	OUR PROCESSES TO EACH OTHER SO THAT WE CAN FIGURE
10	OUT HOW TO INTEGRATE THEM WELL, ALWAYS KEEPING IN
11	MIND THAT WE KEEP COMPLETE COMPLIANCE WITH THE CIRM
12	STATUTORY AND POLICY FRAMEWORK, AND ALL FUNDS WILL
13	STAY IN CALIFORNIA WITH THESE RELATIONSHIPS.
14	THEN WE GO ABOUT THE DETAILS. AND NANCY
15	WORKS WITH THE COLLABORATIVE FUNDING PARTNERS LEGAL
16	SYSTEMS TO INTEGRATE OUR PROCESSES ON OUR VARIOUS
17	LEGI SLATI VE CONSTRAINTS. AND IMPORTANTLY, THESE
18	MEMORANDA OF UNDERSTANDING ALLOW THE SCIENTISTS AT
19	THE GROUND LEVEL TO START WORKING WITH EACH OTHER
20	AND TALKING TO EACH OTHER ABOUT WHERE THE SCIENTIFIC
21	SYNERGIES ARE. AND WE'VE DONE THAT THROUGH A
22	VARIETY OF MECHANISMS, INCLUDING WORKSHOPS AND VIDEO
23	CONFERENCING WITH THE AUSTRALIANS, WHERE IT'S
24	PARTICULARLY HARD TO GET TO.
25	AND THEN WE HAVE ALSO MADE IT VERY, VERY
	212

1072 SE BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CLEAR TO OUR PARTNERS THAT BECAUSE OF THE WAY THE
2	LEGISLATION IS WRITTEN, WE CANNOT CHANGE OUR BASIC
3	PROCESSES. WE WRITE THE RFA'S AND, OF COURSE, WE
4	CONSULT WITH AND GET IDEAS FROM OUR COLLABORATIVE
5	FUNDING PARTNERS, BUT THESE ARE THE RFA'S THAT WE
6	HAVE INTERNALLY DECIDED ARE THE BEST SCIENTIFIC
7	PROGRAMS TO GET TO OUR GOALS. OUR REVIEW PROCESS IS
8	ALSO NOT CHANGED.
9	AND IT'S IMPORTANT TO KNOW THAT THE
10	REVIEWERS WILL BE AGNOSTIC WHEN THEY REVIEW
11	APPLICATIONS IN ANY CYCLE AS TO WHETHER THE TEAMS
12	ARE ALL CALIFORNIA OR IF THEY ARE HYBRID TEAMS OF
13	CALIFORNIA AND NON-CALIFORNIA SCIENTISTS.
14	SO WHAT I'M GOING TO DESCRIBE TO YOU ARE
15	THE DETAILS OF SOME OF OUR ARRANGEMENTS WITH OTHER
16	JURISDICTIONS. BUT, IN GENERAL, WHO ARE THESE
17	PEOPLE? THESE ARE THE MAJOR PLAYERS IN REGENERATIVE
18	MEDICINE FROM AROUND THE WORLD. WE'VE BEEN
19	SELECTIVE BECAUSE WE REALLY ARE REACHING OUT AND
20	EXTENDING OUR CONVERSATIONS ONLY WITH PEOPLE WHO CAN
21	HELP OUR CALIFORNIA SCIENTISTS WITH EXTRA
22	INTELLECTUAL RESOURCES, FINANCIAL RESOURCES,
23	INFRASTRUCTURE.
24	AND IT'S BEEN IMPORTANT IN GOING THROUGH
25	THESE CONVERSATIONS WITH OTHER COLLABORATIVE
	213
	215

1	PARTNERS THAT WE'VE ALSO BEGUN TO UNDERSTAND HOW IT
2	IS WHAT KIND OF DETAILS ARE NECESSARY FOR US TO
3	INTEGRATE OUR VARIOUS PROCESSES.
4	ONE OF THE THINGS THAT DOESN'T APPEAR ON
5	THE LIST FOR DISEASE TEAMS AS A PARTNER IS A
6	DISEASE-SPECIFIC FOUNDATION. HOWEVER, WE HAVE
7	SIGNED AN AGREEMENT WITH THE JUVENILE DIABETES
8	RESEARCH FOUNDATION. AND THEY WILL BE WORKING WITH
9	US IN THE FUTURE; BUT, AS YOU KNOW, FOUNDATIONS ARE
10	VERY, VERY SHORT OF FUNDS RIGHT NOW. WE ALSO THINK
11	THAT THESE COLLABORATION WILL SET THE GROUNDWORK FOR
12	US TO CONTINUE OUR DIALOGUE WITH THE NIH AS THE
13	POLICIES AND LEADERSHIP AT NIH CHANGE. AND WE FULLY
14	EXPECT TO BE WORKING WITH NIH DOWN THE ROAD.
15	SO OUR PARTNERSHIPS NOW INCLUDE, FIRST,
16	THE STATE OF VICTORIA IN AUSTRALIA. THIS WAS
17	INITIATED WHEN NANCY KOCH AND I MET WITH GOVERNMENT
18	REPRESENTATIVES AT THE BIO MEETING HERE IN JUNE OF
19	2008. AND THERE'S MANY, MANY REASONS TO COLLABORATE
20	WITH VICTORIA. AS WE ALL KNOW THROUGH ALAN, THEY
21	BRING ENORMOUS STRENGTHS IN STEM CELL BIOLOGY; BUT
22	FOR MY PARTICULAR BIAS, I THINK THEY BRING IMPORTANT
23	STRENGTHS IN TRANSPLANT IMMUNOLOGY.
24	SO THEY HAVE PARTICIPATED IN THE EARLY
25	TRANSLATION REVIEW GRANTS WHICH ARE UNDER REVIEW
	214

1	RIGHT NOW, AND NINE OF THE 71 TEAMS WERE HYBRID
2	TEAMS BETWEEN CALIFORNIA AND VICTORIA. I THINK THE
3	VICTORIAN GOVERNMENT WAS ACTUALLY SURPRISED AT THE
4	ENTHUSIASM OF THEIR SCIENTISTS FOR THIS. AND WE'RE
5	REALLY LOOKING FORWARD TO AN ONGOING RELATIONSHIP
6	WITH THEM. THEY HAVE COMMITTED A TOTAL OF \$5
7	MILLION SO FAR TO THIS COLLABORATION.
8	THE CANADIAN STEM CELL CONSORTIUM HAS MADE
9	AN ENORMOUS CONTRIBUTION TO OUR ONGOING
10	COLLABORATION IN THAT IN TOTAL THEY HAVE A SET ASIDE
11	OF \$200 MILLION SPECIFICALLY FOR CALIFORNIANS AND
12	CANADIANS TO WORK ON CANCER STEM CELLS. THIS
13	COLLABORATION BUILT ON, FIRST, A VISIT MADE BY THE
14	GOVERNOR AND OUR CHAIRMAN IN CANADA, FOLLOWED BY
15	WORKSHOPS AND, AGAIN, INTERACTIONS BETWEEN THE
16	SCIENTISTS, ONCE THE ANNOUNCEMENT WAS MADE IN JUNE,
17	THAT WE WERE GOING TO PROCEED WITH THIS
18	COLLABORATION. IN AUGUST WE CALLED TOGETHER THE
19	THOUGHT LEADERS IN CALIFORNIA TO HELP US TRY TO
20	DECIDE HOW WE SHOULD PROCEED WITH THIS
21	COLLABORATI ON.
22	AND IN THAT WORKSHOP, ONE OF THE THINGS
23	THAT FELL OUT WAS THIS VERY IMPORTANT LEVERAGE THAT
24	THE CANADIANS BRING TO US BECAUSE THEIR MEDICAL
25	SYSTEM IS NETWORKED IN A WAY THAT OURS ISN'T. AND
	215

1	IN THE AREA OF CANCER STEM CELLS, THE CANADIANS HAVE
2	MUCH GREATER ACCESS TO FRESH SURGICAL MATERIAL FOR
3	THE ISOLATION OF STEM CELLS FROM FRESH MATERIAL THAN
4	WE CAN EVER POSSIBLY HAVE IN CALIFORNIA.
5	SO THERE ARE LOTS OF UNEXPECTED BENEFITS
6	OF THIS COLLABORATION. AND I THINK IT'S ALSO BEEN
7	GREAT FOR THE SCIENCE OFFICE BECAUSE AN EXPERIENCED
8	SCIENCE OFFICER ON THE OTHER SIDE, ESPECIALLY IN THE
9	CANADIAN CONTEXT WHERE THEY'RE USED TO MANAGING VERY
10	LARGE-SCALE INTERNATIONAL COLLABORATIONS, HAS
11	ALLOWED US TO LEARN FROM THEIR EXPERIENCE. AND THEY
12	HAVE COMMITTED FOR THIS ROUND OF DISEASE TEAMS A
13	TOTAL OF \$40 MILLION IN FUNDS, AND THEY WOULD
14	IDEALLY LIKE THAT DISTRIBUTED TO TWO DISEASE TEAM
15	GRANTS FOCUSED ON CANCER.
16	WE HAD OFFICIAL WORD JUST THIS MORNING
17	THAT THE MRC, THE NIH EQUIVALENT IN THE UK, HAS
18	SIGNED ON FOR DISEASE TEAMS AS WELL WITH A
19	COMMITMENT OF \$5 MILLION. THIS DECISION FOLLOWS
20	CLOSELY ON A JANUARY WORKSHOP IN WHICH THERE WAS A
21	LOT OF TEAM FORMATION GOING ON BY THE SCIENTISTS ON
22	THE GROUND. AND YOU SHOULD NOTE THAT THE UK HAS THE
23	LARGEST EUROPEAN STEM CELL PORTFOLIO.
24	THE SPANISH HAVE BEEN VERY INVOLVED
25	DR. PENHOET: MARIE, IF I COULD, WE WERE
	01/
	216

1	EXPECTING TO DISCUSS THE DISEASE TEAM RFA, AND THIS
2	IS A VERY INTERESTING PRESENTATION, BUT ARE YOU
3	NEARING THE END OF THIS PRESENTATION?
4	DR. CSETE: ABSOLUTELY. THE SPANISH HAVE
5	BEEN VERY INVOLVED IN STEM CELL RESEARCH FOR A LONG
6	TIME, AND THEIR GOVERNMENT JUST THIS YEAR MADE
7	REGENERATIVE MEDICINE A MAJOR PRIORITY. AS A
8	CONSEQUENCE OF THEIR INTEREST IN WORKING WITH
9	CALIFORNIA SCIENTISTS, THEY ALSO ARE COMMITTED TO
10	PARTICIPATING IN DISEASE TEAMS WITH A COMMITMENT OF
11	13 MILLION EURO.
12	DR. PIZZO: CAN I ASK ONE QUESTION? BOTH
13	WITH THE UK AND THE FIRST ONE, ARE THEY CONTINGENT
14	UPON ACTUALLY GETTING THE GRANT?
15	DR. CSETE: ABSOLUTELY.
16	DR. PIZZO: SO IT'S NOT THAT THEY'RE
17	GIVING YOU 5 OR 13. IT'S IF THEY GET THE GRANT.
18	DR. CSETE: RIGHT. THEY GET THE GRANT.
19	SO THE JAPANESE RECENTLY CAME TO US. THEY
20	ARE THE CLEAR LEADERS IN IPS TECHNOLOGIES AND ALSO
21	IN SYSTEMS BIOLOGY WORLDWIDE. AND THEY WANTED TO
22	MAKE IT A BALANCED PORTFOLIO IN THEIR GOVERNMENT
23	THAT NECESSARY HUMAN EMBRYONIC STEM CELL AND IPS
24	WORK WENT ON IN PARALLEL. AND WE'RE REALLY LOOKING
25	FORWARD TO WORKING OUT THE DETAILS. WE HAVE SIGNED

-	
1	AN MOU WITH THEM, AND THE DETAILS OF HOW OUR
2	SCIENTISTS WILL GET TOGETHER ARE BEING WORKED OUT
3	THIS MONTH.
4	SO OVERALL, THE MAJOR POINTS I WANTED TO
5	BRING HOME, BECAUSE THEY SEEM TO BE THE MAJOR
6	CONCERN OF THE BOARD, IS THAT WE ARE SELECTIVE. WE
7	ARE RESPONDING TO REQUESTS FROM PEOPLE WHO ARE
8	COMING FROM A POSITION OF STRENGTH TO BRING US
9	ENORMOUS INTELLECTUAL RESOURCES AND SYNERGIES TO OUR
10	SCIENTIFIC PROGRAMS. OUR SCIENTISTS ARE UNIVERSALLY
11	ENTHUSIASTIC ABOUT THIS, AND WE WILL CONTINUE TO, OF
12	COURSE, HAVE ONGOING EVALUATION THROUGH OUR USUAL
13	PROGRESS AND MILESTONE REPORTING. AGAIN, IT'S
14	CRITICALLY IMPORTANT AS WE GO INTO MORE
15	TRANSLATIONAL AND CLINICAL PROGRAMS THAT THESE KINDS
16	OF COLLABORATIONS HAPPEN BECAUSE CLINICAL PROJECTS
17	THAT ARE DEFINED IN TWO PLACES THAT ARE VERY
18	DIFFERENT ARE MUCH STRONGER IN ACCELERATING
19	THERAPIES TO THE CLINIC.
20	AND, FINALLY, THIS GIVES US AN OPPORTUNITY
21	FOR KEEPING OUR LEADERSHIP POSITION IN STEM CELL
22	BIOLOGY AND HARMONIZING REGENERATIVE MEDICINE
23	APPROACHES AROUND THE WORLD.
24	CHAIRMAN KLEIN: THANK YOU VERY MUCH.
25	THIS IS A VERY IMPORTANT PROGRAM. DR. PIZZO, COULD
	218

1	WE DO SOME AN ITEM VERY QUICKLY AND THEN HAVE
2	SOME GENERAL COMMENTS ON THIS?
3	DR. PIZZO: CAN YOU DO SOMETHING VERY
4	QUI CKLY?
5	CHAIRMAN KLEIN: YES.
6	DR. PI ZZO: SURE.
7	CHAIRMAN KLEIN: WHAT I'D LIKE TO DO IS
8	THIS IS A THIS COLLABORATIVE PROGRAM I AM A GREAT
9	BELIEVER IN. THERE'S A TREMENDOUS AMOUNT OF EFFORT
10	IN IT. I WANT TO HOLD THE COMMENTS ON IT BEFORE WE
11	LOSE SOME MEMBERS HERE VERY QUICKLY BECAUSE I WANT
12	DR. OLSON TO ADDRESS THE FACT THAT WE'RE ABOUT TO
13	PUT OUT THE RFA FOR DISEASE TEAMS. AND WHAT'S
14	CRITICAL HERE IS THAT THIS IS GOING THROUGH TRIAGE.
15	THIS IS A SHORT-FORM APPLICATION, BUT WE HAVE TO
16	MAINTAIN THIS MOMENTUM TO HAVE THE PIPELINE FOR
17	MISSION CRITICAL PROGRAMS. THIS IS THE MOTIVATION,
18	IN FACT, FOR PLACING MAJOR PRIVATE PLACEMENT. THIS
19	IS A MAJOR MOTIVATION FOR ANY FUNDS FROM THE FEDERAL
20	GOVERNMENT. IT IS A MAJOR POINT. AND I'D LIKE TO
21	ASK DR. OLSON, GIVEN THIS CONDITIONS, GIVEN WE HAVE
22	TRANSPARENCY, DO WE FEEL THAT WE CAN MOVE FORWARD
23	AND MAINTAIN THIS PIPELINE? AND I'D LIKE TO MAKE
24	SURE THAT WE HAVE THE BOARD'S SUPPORT FOR THIS AS A
25	VITAL PROGRAM.

219

	BARRISTERS' REPORTING SERVICE
1	DR. OLSON: I DON'T HAVE TO SAY A WORD.
2	CHAIRMAN KLEIN: FOR THE RECORD, DR.
3	OLSON, BECAUSE THIS TRANSCRIPT IS GOING TO BE LOOKED
4	AT BY A LOT OF PEOPLE.
5	DR. OLSON: I THINK I JUST WANT TO GET A
6	SENSE FROM THE BOARD THAT THE BOARD WANTS US TO
7	CONTINUE ON THE TIMELINE WE CURRENTLY HAVE
8	CONTEMPLATED FOR THE DISEASE TEAM RFA; THAT IS,
9	RELEASE OF THE RFA WITHIN THE NEXT COUPLE OF WEEKS.
10	WE WOULD DO PREAPPLICATION AND REVIEW OF SCREENING.
11	SO THIS WOULD BE A SHORT FOUR TO FIVE PAGES, I THINK
12	YOU' VE HEARD. AND THAT THE INVITATION FOR FULL
13	APPLICATIONS WOULD NOT HAPPEN UNTIL LATE APRIL,
14	EARLY MAY. SO THAT'S WHEN THE SIGNIFICANT AMOUNT OF
15	EFFORT WOULD GO IN ON THE PART OF THOSE APPLICANTS
16	WHO ARE INVITED TO APPLY.
17	CHAIRMAN KLEIN: DUANE AND DR. REED
18	DR. OLSON: DO WE HAVE A SENSE?
19	CHAIRMAN KLEIN: ARE YOU SUPPORTIVE OF
20	THI S? DR. REED.
21	DR. REED: YES.
22	CHAIRMAN KLEIN: DR. AZZIZ?
23	DR. AZZI Z: YES.
24	CHAIRMAN KLEIN: THANK YOU.
25	DR. OLSON: THANK YOU.
	220

1	CHAIRMAN KLEIN: DR. PIZZO.
2	DR. PIZZO: SO CLEARLY I'M ALSO SUPPORTIVE
3	TO THIS. I WANT TO MAKE TWO COMMENTS BOTH WITH
4	REGARD TO THIS AND THE AFOREMENTIONED PRESENTATION.
5	IS THERE AN INTENT WHEN WE GO FORWARD TO
6	MAKE IT CLEAR IN THE RFA THAT THE FUNDING ISSUES ARE
7	ALSO NOT FULLY DETERMINED? I REALIZE EVERYBODY IS
8	APPLYING.
9	CHAIRMAN KLEIN: THERE ARE CHALLENGES.
10	DR. PIZZO: THERE MAY NOT BE FUNDING. WE
11	SHOULD MAKE IT CLEAR ALONG THE LINES OF WHERE WE ARE
12	TODAY.
13	CHAIRMAN KLEIN: I THINK WE SHOULD POST A
14	GENERAL STATEMENT.
15	DR. PIZZO: A GENERAL STATEMENT. THAT
16	WOULD BE FINE. I'M PERFECTLY FINE WITH THAT. I
17	THINK THAT'S GOOD.
18	SO THE SECOND STATEMENT THAT I WANTED TO
19	MAKE IS I WAS ONE OF THE PEOPLE WHO RAISED THE
20	CONCERNS ABOUT THE INTERNATIONAL COLLABORATIONS AT
21	OUR LAST MEETING. AND THANKS TO SOME ADDITIONAL
22	DISCUSSIONS AND I THINK THE PRESENTATION THAT MARIE
23	GAVE TODAY, I WANT TO SAY THAT MY CONCERNS HAVE BEEN
24	FULLY MET. I THINK THAT THIS IS A GOOD PLAN,
25	PARTICULARLY BECAUSE OF THE WAY IT'S BEEN

221

FORMULATED.

1


2 WHAT WAS NOT CLEAR TO ME EARLIER WAS WHETHER THIS WAS HAPPENING IN A HAPHAZARD WAY, 3 WHETHER IT WAS A LITTLE BIT OF JUST COINCIDENTAL, 4 MAYBE EVEN SOME PREDATORY, BUT IT IS SOMETHING THAT 5 IS STARTING FROM THE GROUND UP TO A GREAT DEGREE, 6 7 NOT SIMPLY BECAUSE A COUNTRY SAYS, GEE, I'D LIKE TO 8 JOIN THIS, AND THAT IT'S BASED ON GOOD -- ULTIMATELY 9 WILL BE BASED ON GOOD SCIENCE THAT'S PEER REVIEWED 10 AND DOESN'T HAVE A LIEN BASED UPON THE INTERNATIONAL COLLABORATION OR THE MONEY, BUT RATHER ON WHAT'S THE 11 12 BEST QUALITY. 13 THAT'S WHAT I HEARD FROM YOU TODAY. SO IF I HAD RESERVATIONS THAT WERE EXPRESSED LAST TIME, 14 I'D LIKE IT TO BE CLEAR THAT I DON'T HAVE THOSE AT 15 16 THIS POINT. 17 CHAIRMAN KLEIN: THANK YOU VERY MUCH. AS TO COMMENTS FROM THE OTHER MEMBERS OF THE BOARD ON 18 19 PROCEEDING ON THE DISEASE TEAM RFA, IS IT CONSISTENT WITH THE REST OF THE BOARD THAT WE FEEL THIS IS A 20 21 CRITICAL PROGRAM WE NEED TO MOVE FORWARD ON THROUGH 22 THIS PRESCREENING PROCESS? SEEING GENERAL AGREEMENT 23 THROUGHOUT THE BOARD. THIS IS MISSION CRITICAL. WE 24 APPRECIATE THE STAFF'S WORK ON IT. WE KNOW IT WILL 25 BE VERY CHALLENGING.

222

1	AND, DR. PIZZO, I WOULD ASSUME THAT WHEN
2	WE POST A STATEMENT ON OUR WEBSITE, WE SHOULD STATE
3	THE CHALLENGE AND STATE THE THINGS WE'RE DOING TO
4	WORK ON ADDRESSING THE CHALLENGE.
5	DR. PIZZO: ABSOLUTELY. YOU COULD HAVE IT
6	FLASHING.
7	CHAIRMAN KLEIN: OKAY. DR. TROUNSON,
8	ADDITIONAL ITEMS YOU'D LIKE TO HAVE ADDRESSED?
9	DR. TROUNSON: NO. LOOK, I THINK YOU' VE
10	DONE A MARVELOUS JOB, CHAIR AND BOARD. AND WE
11	REALLY DO THANK YOU. WE COULD BRING ANOTHER TWO
12	DOZEN MATTERS IF YOU REALLY WANT IT NEXT TIME, BUT I
13	THINK YOU'VE BEEN THROUGH SOME REALLY DIFFICULT
14	DISCUSSIONS, AND PARTICULARLY THE FINANCES. AND
15	WHILE THEY HAVE BEEN AN ISSUE FOR US FOR QUITE SOME
16	TIME, I THINK YOU'VE GOT THE ENTIRE MESSAGE. AND
17	WE'RE VERY HAPPY TO RESPOND TO ANY MEMBER OF THE
18	BOARD WHO WANTS ANY PARTICULAR INFORMATION THAT THEY
19	THOUGHT WASN'T TOTALLY CLEAR OR THEY WANTED TO REASK
20	THE QUESTION AGAIN.
21	I WOULD SAY WE WOULD THANK THE BOARD FOR
22	THE CONFIDENCE THAT YOU PLACE IN THE WHOLE AREA OF
23	RESEARCH. AND FOR THE SCIENTISTS OUT THERE AND
24	THOSE PEOPLE WHO NOW ARE PLOWING IN TRANSLATION
25	TOWARDS THE CLINIC OR HEADING INTO THE CLINIC, THIS

1	IS A VERY GOOD TIME FOR THEM. AND I THINK YOU'VE
2	DONE THE ABSOLUTE VERY BEST ON THEIR BEHALF. AND I
3	THINK IT WILL BE RECORDED HISTORICALLY THAT THE ICOC
4	AND CIRM DIDN'T TAKE A BACKWARD STEP, BUT KEPT THE
5	MOMENTUM GOING FORWARD. I THINK THAT'S A VERY
6	IMPORTANT MESSAGE TO GO TO THE WHOLE WIDE WORLD.
7	AND THANK YOU, BOARD, VERY, VERY MUCH FOR YOUR
8	SUPPORT OF EVERYTHING THAT WE'VE PUT TO YOU OVER
9	THESE LAST TWO DAYS.
10	CHAIRMAN KLEIN: OKAY. THANK YOU. THANK
11	ALL THE BOARD MEMBERS. AND, YOU KNOW, LET IT BE
12	SAID THAT EVEN SICKNESS DOES NOT KEEP AWAY DEDICATED
13	BOARD MEMBERS. THANK YOU, LEEZA, FOR RALLYING FOR
14	OUR QUORUM. IT IS DEEPLY APPRECIATED.
15	DR. PIZZO: THANK YOU, LEEZA. I'M GLAD NO
16	ONE IS SITTING AROUND YOU THOUGH.
17	(APPLAUSE.)
18	CHAIRMAN KLEIN: THANK YOU FOR THE STAFF
19	FOR THEIR TREMENDOUS EFFORT AS ALWAYS. HUGE
20	DEDICATION. I'D LIKE TO SAY IN THE FIRST TWO
21	WEEKS AGO IN THE FIRST, COUNTING SUNDAY, IN THE
22	FIRST FIVE DAYS OF THE WEEK, STARTING WITH SUNDAY, I
23	THINK MELISSA PUT IN ABOUT 85 HOURS. BY THE END OF
24	THE WEEK, I THINK SHE WAS AT A HUNDRED HOURS. SO
25	WE'RE TALKING ABOUT EXTRAORDINARY COMMITMENT. IN

-	
1	WASHINGTON, D.C., SHE WAS WORKING TILL ELEVEN OR
2	MIDNIGHT EVERY NIGHT WITH STAFF AT THE CAPITOL GOING
3	BACK AND FORTH CONSTANTLY. SO, MELISSA, THANK YOU
4	FOR YOUR EXTRAORDINARY CONTRIBUTION.
5	(APPLAUSE.)
6	DR. PIZZO: WE'RE GOING TO PAY YOU ON AN
7	HOURLY BASIS.
8	CHAIRMAN KLEIN: OKAY. THANK YOU ALL.
9	THANK THE SCIENTIFIC STAFF. IT IS AN EXTRAORDINARY,
10	EXCITING PERIOD. WE'RE LOOKING FORWARD TO
11	TRANSLATION AND DISEASE TEAMS, AND WE'RE LOOKING
12	FORWARD TO FINDING UNIQUE, CREATIVE, AND DYNAMIC
13	WAYS TO MEETING THE FINANCIAL CHALLENGES WE HAVE
14	BEFORE US. THANK YOU. WE ARE ADJOURNED.
15	(THE MEETING WAS THEN ADJOURNED AT
16	03:09 P.M.)
17	
18	
19	
20	
21	
22	
23	
24	
25	
	225
	1072 SF BRISTOL STREFT, COSTA MESA, CALIFORNIA 92626
	THE A STREET AND A TRACTOR AND A TRACTAGE A STREET A



I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

> CROWNE PLAZA HOTEL SFO 1177 AI RPORT BOULEVARD BURLI NGAME, CALI FORNI A ON FRI DAY, JANUARY 30, 2009

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

Inaux

BEIH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100

226